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Summary.
Genetic toxicology assesses the genotoxic potential o f chemicals in consumer 
products, pharmaceuticals and from agricultural and industrial processes. Such 
assessment is integral in hazard identification and risk assessment to prevent 
unnecessary human exposure and limit cancer risk. Human risk assessments for 
genotoxic alkylating agents were based upon linear dose-response models where 
genotoxicity accrues proportionally with dose. Evidence is accumulating to support a 
non-linear dose-response at low doses of ethyl methanesulfonate (EMS), a model 
alkylating agent. For acceptance of non-linear dose responses, a strong explanatory 
mechanism of action needs to be elucidated. In the following work, low dose 
mutagenic effects of methyl nitorosurea (MNU), the most potent alkylating agent, 
have been examined in AHH-1 human lymphoblastoid cells using the HPRT assay. 
An increase in mutant frequency was not observed until 0.01pg/ml MNU (LOGEL, 
Lowest Observed Genotoxic Effect Level) with a No-Observed Genotoxic Effect 
Level (NOGEL) at 0.0075pg/ml MNU. O f interest, is the apparent hormesis induced 
at 0.0025pg/ml MNU. The principle adduct responsible for MNU mutagenesis is 
0 6Methylguanine (0 6MeG) that miscodes during replication and becomes fixed as 
GC->AT transitions. Accordingly, the non-linear increase in mutant frequency is 
accompanied by a non-linear increase in GC->AT transitions. Furthermore, evidence 
is provided that implicates methlyguanine methyltransferase (MGMT) in protecting 
DNA from MNU induced mutagenesis by repairing 0 6MeG at low doses, thereby 
creating the NOGEL. AHH-1 cells treated with 0 6Benzylguanine (0 6BG), to 
inactivate MGMT, were hypersensitive to low dose MNU mutagenesis. At 
0.0075pg/ml MNU, there was a three-fold increase in mutant frequency and an 
increase in proportion of GC-^AT transitions, from 28% to 48% in MGMT 
inactivated cells. This thesis presents a non-linear dose-response for MNU with a 
strong biological mechanism of action involving DNA repair.
Table of contents
Summary iii
List o f  Tables and Figures xiii
Abbreviations xxi
Chapter 1
1.1. The need for genotoxicolgy testing: chemicals cause mutations, mutations cause cancer.
2
1.1.2. Micro-mutations affecting DNA sequence. 2
1.1.3. Macro-mutations affecting chromosomes. 3
1.2. Genetic toxicology in risk assessment. 5
1.3. Hazard identification and characterisation 7
1.4. Regulatory genotoxicity. 8
1.4.1. Regulatory genotoxicity testing strategies. 8
1.4.2. Stage 1; a battery o f in vitro genotoxicity tests. 9
1.4.3. Stage 2: in vivo testing. 10
1.4.4. Reduce, refine and replace animal usage in genotoxicology. 11
1.4.5. In vitro to in vivo, high dose to low dose and animal to human extrapolation. 12
1.5. Dose-response relationships for genotoxicty. 14
1.5.1. Supralinear and sublinear dose responses. 15
1.5.2. J-shaped dose-response. 16
1.5.3. Linear dose-response 18
1.5.4. Threshold dose-response. 19
1.5.4.1. Genotoxic thresholds for indirect genotoxins. 22
1.5.4.2. Genotoxic thresholds for direct genotoxins. 22
1.5.4.3. Potential mechanisms behind threshold dose response to genotoxins. 24
1.5.4.4. Implications o f thresholds in risk assessment o f  genotoxic impurities. 26
1.6. Methyl-N-nitrosourea (MNU), a potent mutagen. 27
1.7. MNU induced carcinogenesis. 27
1.8. Mode o f carcinogenic action. 28
1.9. Reaction with DNA; mode o f genotoxic action. 29
1.10. The mutagenicity o f N7MeG. 30
1.10.1. 0 6MeG is a highly mutagenic lesion. 30
1.11. Repair o f  Q6MeG by MGMT prevents GC-> AT transitions. 31
1.12 Transcriptional regulation o f MGMT 33
1.13. Cellular processing o f 0 6MeG:Thymine mispairs. 34
1.14. Mutation spectra o f MNU 36
1.15. MNU dose-response for mutation induction. 37
1.16. This thesis. 37 
Chapter 2
2.1. General materials and methods. 40
2.2. AHH-1 cell culture. 40
2.2.1 Cell culture procedure. 40
2.2.2 AHH-1 growth media. 40
2.2.3 Cell freezing for storage. 41
2.2.4 Dilution o f cells 41
2.3. Preparation o f chemical stocks for testing 42
2.3.1. MNU 42
2 .3 .2 .6-Thioguanine. 43
2.4. Cytotoxicity assessment using relative population doubling (RPD). 44
2.5. HPRT Forward mutation assay. 45
2.5.1. Mutant purification; establishing a HPRT mutant free stock. 45
2.5.2. Treatment protocol. 45
2.5.3. Calculating Mutant frequency 46
2.5.4. Enumeration o f mutant colonies for sufficient RNA yields. 47
2.6. RNA extraction. 47
2.7. cDNA synthesis for end point PCR. 48
2.8. Calculation o f 1 pg RNA for use in cDNA synthesis. 48
2.9. End-point PCR. 49
2.10. 6% PAGE. 52
2.11. Silver nitrate staining. 53
2.12. Preparation o f samples for sequencing. 53
2.13. Construction o f mutation spectrum 54
2.14. Two step real-time PCR. 54
2.14.1. cDNA synthesis for real time PCR 54
2.14.2. Real time PCR. 55
2.15. Protein extraction. 56
v
2.16. Protein quantitation. 56
2.17. Western Blotting 57
2.18. SDS-PAGE. 58
2.19. Protein blotting. 59
2.20. Membrane blocking and antibody dilutions. 59
2.21. Protein detection. 60
2.22. Western blot reagents. 60
Chapter 3
3.1. Introduction 62
3.1.1. HPRT as a mutation sensor 62
3.1.2. HPRT function in wildtype cells. 63
3.1.2.1 Intracellular purine biochemistry: the salvage pathway involves HPRT 63
3.1.2.2. De novo purine synthesis 64
3.1.3. Exploiting HPRT for mutation analysis. 66
3.1.4. Selection procedures for isolation o f mutant or wildtype HPRT. 66
3.1.4.1. Using HAT supplement to select for HPRT+/o wildtype cells. 66
3.1.4.2. Counter selection; toxic analogues are used to select for HPRT -/o mutants. 67
3.1.5. Mechanism o f 6-Thioguanine toxicity in wildtype HPRT cells. 68
3.1.6. Alternative HPRT proficiency selection strategies. 70
3.1.7. Outline o f HPRT assay methodology. 70
3.1.7.1. Stage 1-mutant cleansing, Reducing the background HPRT-/o mutants. 72
3.1.7.2. Stage 2-treatment with test article and subculturing. 72
3.1.7.3. Stage 3-selection for mutants and quantitation. 73
3.1.8. Why use the HPRT assay? 73
3.1.8.1. Alternative in vitro mutation assays. 73
3.1.9. HPRT assay in mutation research. 75
3.1.10. HPRT assay has been used to determine the dose-response o f alkylating agents. 76
3.2. Results. 77
3.2.1. MNU dose-response 77
3.2.2. Statistical analysis 79
3.3. Discussion. 82
3.3.1. HPRT assay methodology. 82
vi
3.3.2. MNU treatment strategy 84
3.3.3. MNU dose-response 85
3.3.4. Hormetic dose-response for MNU. 86
3.3.5. Biology behind hormesis. 87
3.3.6. Hypothesised mechanism to explain hormesis. 88
3.3.7. MNU mechanism o f action (MOA). 90
Chapter 4
4.1. Introduction. 93
4.1.1. Adduct formation is a critical carcinogenic event. 93
4.1.2. Electrophile chemistry. 94
4.1.3. Some genotoxins require activation into an electrophile to cause DNA damage. 95
4.1.4. Endogenous electrophiles cause adducts that contribute to spontaneous 
mutagenesis. 96
4.1.4.1. Endogenous methylation regulates gene expression and can be mutagenic. 97
4.1.4.2. Endogenous levels o f 0 6MeG, N7MeG and N3MeA. 99
4.1.5. Exogenous electrophiles. 101
4.1.5.1. Exogenous adducts have a linear dose-response. 102
4.1.6. Adducts as biomarkers o f exposure 104
4.1.7. Biological effect o f adducts is determined by cellular processing. 105
4.1.7.1. DNA repair plays a crucial role in adduct removal which prevents mutation.
106
4.1.8. Analytical methods for measuring DNA adducts. 107
4.1.9. Mass spectrometry in DNA adduct analysis. 109
4.1.9.1. Liquid chromatography electrospray ionization tandem mass spectrometry 
multiple reaction monitoring (LC-ESI-MS/MS-MRM). 109
4.1.10. Measuring N7MeG as a biomarker for MNU exposure. 111
4.2. Materials and method. 112
4.2.1. Treatment o f AHH-1 cells with MNU. 112
4.2.2. Isolation o f  genomic DNA from AHH-1 cells. 112
4.2.3. Preparation o f the internal standard [15N 5]N7MeG. 113
4.2.4. Preparation o f the positive control. 114
4.2.5. Preparation o f DNA for LC-ESI/MS-MS-MRM analysis. 114
4.2.6. Measuring N7MeG using LC-ESI/MS-MS-MRM. 115
4.2.7. Calculation o f DNA adduct levels. 116
4.2.8. Conversion o f mole DNA adduct to adducts/108 nucleotides. 116
4.3. Results. 116
4.3.1. Purity o f  the internal standard [15N 5]N7MeG. 117
4.3.2. DNA extraction. 117
4.3.3. LC-ESI-MS/MS-MRM chromatograms. 118
4.3.4. N7MeG levels below and above the mutation NOAEL for MNU. 120
4.4. Discussion. 121
4.4.1. Assay methodology. 121
4.4.2. Postulating a no observed effect level for adducts. 123
4.4.2.1. Assay sensitivity. 124
4.4.2.2. Biological mechanism to prevent DNA reaction. 124
4.4.3. Adducts and HPRT mutant frequency. 126
4.4.4. Concluding remarks. 127
Chapter 5
5.1. Introduction. 130
5.1.1. Establishing a mutation spectrum. 130
5.1.2. Point mutations caused by MNU induced adducts. 131
5.1.2.1.0 6MeG is miscoding. 132
5.1.2.2. N7MeG and N3MeG are not miscoding. 132
5.1.3. HPRT mutation spectra database. 135
5.1.4. M ethod s for m utati on detecti on. 135
5.1.5. DNA sequencing. 137
5.1.6. Experimental approaches to sequence HPRT. 138
5.1.7. PCR and sequencing method optimisation. 141
5.1.7.1. Nested PCR. 141
5.1.7.2. Overlapping PCR primers. 143
5.1.8. Optimization strategy. 144
5.2. Materials and methods. 148
5.2.1. Principal component analysis. 148
viii
5.2.2. Adam-Skopek test. 148
5.3. Results. 149
5.3.1. Proportion of mutations identified. 149
5.3.2. Mutation spectra 151
5.3.3. Principle component analysis (PCA) of mutation spectra 154
5.3.4. Measuring the effect of MNU treatment on MGMT. 155
5.3.4.1. MGMT activity in AHH-1 cells. 155
5.3.4.2. Expression analysis of MGMT in AHH-1 cells. 155
5.3.4.3. MGMT promoter methylation analysis. 156
5.4. Discussion. 157
5.4.1. Mutagenesis at the HPRT locus. 157
5.4.2. Spontaneous mutagenesis at the HPRT locus. 157
5.4.3. Comparison of mutation spectra. 161
5.4.4. Real time PCR methodology. 163
5.4.5. Method of expression quantitation. 165
5.4.6. Promoter methylation analysis. 166
5.4.7. Concluding remarks: Mechanism for the observed dose-response. 167
Chapter 6
6.1. Introduction. 170
6.1.1. Methods of MGMT knockdown. 170
6.1.1.2. Gene knockdown. 171
6.1.1.3. MGMT has a broad range of affinity for structures at the O6 position of guanine.
172
6.1.2. Effective inhibition of MGMT by 0 6BG. 174
6.1.3. How MGMT inactivation is achieved. 175
6.1.4. Measuring the inactivation of MGMT. 176
6.1.5. Cellular influences on 0 6BG efficacy. 177
6.1.5.1. Polymorphism within MGMT can modify affinity for 0 6BG. 178
6.1.6. 0 6BG in chemotherapy. 180
6.1.7. 0 6BG and low dose alkylating agent. 181
6.2. Materials and method. 181
6.2.1. Preparation of 0 6Benzylguanine stock. 181
6.2.2. 0 6BG pre-treatment. 182
6.2.3. HPRT assay. 182
6.2.4. Cytotoxicity. 1 ^
6.2.5. Negative controls for 0 6BG and MNU in the HPRT assay and cytotoxicity studies.
183
6.2.6. Calculation o f the RPD and RPE for the negative controls. 184
6.2.7. Calculating the RPD o f treated control cultures 184
6.2.8. Preparation o f cells for MGMT activity analysis. 184
6.2.9. siRNA oligonucleotides 185
6.2.9.1. MGMT siRNA oligonucleotides. 185
6.2.9.2. siRNA controls. 185
6.2.9.3. Reconstitution o f MGMT siRNA. 185
6.2.9.4. Transfection optimisation. 186
6.2.9.5. Real time analysis o f siRNA treated cells. 186
6.3. Results. 186
6.3.1. siRNA and 0 6BG in creating a MGMT deficient phenotype. 187
6.3.1.2. siRNA trial. 187
6 .3 .2 .0 6BG. 190
6.3.2.1. Assessing the cellular presence o f 0 6BG through increased toxicity by MNU.
190
6.3.2.2. Does 0 6BG render low dose MNU toxic? 190
6.3.3. The effect o f MGMT inactivation the shape o f the dose-response. 192
6.3.4. Comparisons o f dose-response with MGMT active AHH-1 cells in Chapter 3.
194
6.3.5. Comparison o f benchmark dose (BMD). 195
6.3.6. Fold difference in MF. 197
6.3.7. Fraction o f lesions unrepaired by MGMT. 198
6.3.8. Real time analysis o f MGMT transcripts over MNU dose range with 0 6BG. 199
6.3.9. Mutation spectra at the HPRT locus. 200
6.4. Discussion. 203
6.4.1. siRNA as a method for MGMT knockdown. 203
6.4.2. 0 6BG as a method o f MGMT inhibition. 204
6.4.2.1. Assessing the toxicity o f  MNU with 0 6BG. 204
6.4.2.2. Ensuring the experiment was appropriately controlled. 204
6.4.2.3. Assessing the cellular presence o f 0 6BG through increased MNU toxicity. 205
6.4.3. 0 6MeG toxicity. 206
6.4.4. Effect o f MGMT inactivation on HPRT mutant frequencies. 206
6.4.4.1. Comparing background mutant frequency + /-0 6BG. 206
6.4.4.2. 0 6BG sensitises AHH-1 cells to (below LOEL doses) MNU mutagenesis. 208
6.4.5. Real time MGMT analysis. 209
x
6.4.6. Spontaneous mutant spectra + /-0 6BG.
6.4.7. The effects o f MGMT inactivation on MNU induced mutations.
6.4.8. Conclusion: Evidence for the role o f MGMT.
209
210 
211
Chapter 7
7.1. General Discussion. 214
7.2. Findings o f this thesis. 214
7.2.1. NOAEL for MNU induced point mutations (Chapter 3). 215
7.2.2. Hormesis o f low dose MNU on mutation induction (chapter 3). 215
7.2.3. MNU interacts with DNA at doses blow the NOAEL (Chapter 4 and Chapter 5).
216
7.2.4. MNU induced 0 6MeG causes GC-> AT transitions that are increased above the 
NOAEL (Chapter 5). 217
7.2.5. MGMT protects DNA from GC->AT changes below the NOAEL (Chapter 6). 218
7.3. Linear dose-response model challenged; implications in hazard identification
219
7.4. Concluding remarks. 222
7.5. Future work. 223
Appendices
List o f appendices. 224
Appendix 1 :Speicification sheet for methyl-A-nitrosourea 225
Appendix 2:Raw HPRT data (Chapter 3) 226
Appendix 3:Raw HPRT plating efficiency data (Chapter 3). 227
Appendix 4:Instructions for dose-response modeling (Chapter 3 and Chapter 6) 227
Appendix 5:Raw N7MeG adduct levels 231
Appendix 6:Raw sequence data (Chapter 5) 231
Appendix 7: Coding for Principle component analysis (Chapter 5) 232
Appendix 8:Raw real time data (Chapter 5) 233
Appendix 9: Real time PCR statistics (Chapter 5) 236
Appendix 10:Raw data for real time validation o f siRNA 237
Appendix 11 :Raw relative population doubling data +/-06B G  (Chapter 6). 240
Appendix 12:Raw HPRT data (Chapter 6). 243
Appendix 13:Raw HPRT plating efficiency data. 245
Appendix 14:Fraction o f unrepaired adducts (Chapter 6) 245
Appendix 15: Raw real time data + 0 6BG (Chapter 6) 246
Appendix 16: Accepted abstract for poster at UKEMS 2009 and ICEM, 2009. 250
Appendix 17: Poster at UKEMS 2009 (Prize awarded) and ICEM 2009. 251
Appendix 18: Accepted abstract for poster at UKEMS 2010. 252
Appendix 19: Poster at UKEMS 2010. 253
Appendix 20: Accepted abstract for oral presentation (UKEMS, 2011) and poster (EEMS, 
2011) 254
Appendix 21: poster at EEMS 2011 (prize awarded) and EMS (2012) 255
Appendix 22: Published literature. 256
Glossary
References
260
262
List of Tables and Figures
Chapter 1
Figure 1.1. Macro-mutations affecting chromosome structure including deletion
(A), Duplication (B), inversion (C) and translocation (D). 4
Figure 1.2. The process of current genotoxicity testing to identify and 
characterise chemical hazards. Image taken from COM (2011). 11
Figure 1.3. Theoretical dose-response models. (A) Sublinear, linear and 
supralinear taken from Swenberg et al (2008). (B) Horemtic/J-shaped model 
taken from Gaylor, Lutz and Connolly (2004). (C) Threshold dose-response 
taken from Lovell (2000). 15
Figure 1.4. The differences in threshold definitions (pragmatic v absolute) as 
defined by COM (2009). Image adapted from Lovell (2000) based on definetions 
by Kirsch-Vodlers et al (2000). 19
Figure 1.5. Representation of the “broken stick” statistical modeling of non­
linear threshold dose-response to determine the threshold dose (td) with NOEL 
and LOEL identified. LLC1 td=lower confidence interval of the td. Image 
adapted from Lutz and Lutz (2009) and Johnson et al (2009). 21
Figure 1.6 (overleaf). Conclusions drawn from analysis of genotoxic endpoints 
in the carcinogenesis caused by MelQx. Is this indicative of MO A or due to 
differences in sensitivity of endpoint detection. Taken from Fukishima et al 
(2002). 23
Figure 1.7. The process of mutagenesis from chemical exposure (solid lines) and 
cytoprotective mechanisms (dashed lines) that would account for a NOEL.
Taken from Jenkins et al (2005) 25
Figure 1.8. Structure of MNU (A), which decomposes into a DNA reactive 
methyldiazonium ion (B) in aqueous solution. Details from (Golding et al,
1997). 27
Figure 1.9. Schematic representation of SnI and Sn2 reaction mechanisms. 
R=methyl group, X=leaving group, Y=DNA. Taken from Colvin (2000). 29
Figure 1.10. Repair of 0 6MeG by methylgaunine methyltransferase (MGMT) 
prevents mutagenesis by 0 6methylating agents. MMR=mismatch repair. Image 
taken from Kaina et al (2007). 32
Figure 1.11. The current model o f processing 0 6MeG:Thymine mispairs to 
explain the various mutations observed following treatment with MNU and other 
O methylating agents. Taken from Kaina et al (2007). 35
Figure 1.12. Layout of the results chapters in this thesis. 38
Chapter 2
Table 2.1. Preparation of chemical stocks. 42
Table 2.2. Dilution series for low dose MNU treatments. 43
Table 2.3. Components per sample for cDNA synthesis. 48
Table 2.4. Components of the master mix for amplifying |3-actin mRNA to 
clarify the success of each cDNA reaction. 49
Table 2.5. Sequences of the primers used for successful amplification of HPRT
cDNA. 49
Figure 2.1. Sequence of HPRT mRNA and the locations of D primers 
(underlined) and K primers (bold). 50
Table 2.6. Constituents of each master mix to amplify HPRT mRNA. 51
Table 2.7. The conditions for amplification with D and K mastermixes. The 
numbers in brackets specify conditions used to amplify (3-actin mRNA. 51
Table 2.8. Reagents of 6% PAGE gels. 52
Table 2.9. Volumes of silver stain reagents used to visualize PCR products on 
PAGE gels. 53
Table 2.10. Constituent reagents for elimination of genomic DNA from RNA 
samples. 54
Table 2.11. cDNA synthesis reaction mixture for real time PCR. 55
Table 2.12. Components of the each well of a 96 well plate for real time PCR. 55 
Table 2.13. Conditions for two step real time PCR using Taqman® probes. 56
Table 2.14. Dilution of BSA protein standard. 57
Table 2.15. Constituents of SDS-PAGE for separation of extracted protein. 58
Chapter 3
Figure 3.1. Purine recycling through the salvage pathway, HPRT (Hypoxanthine 
phosphoribosyl transferase) is circled. Adapted from Stout and Caskey (1985). 64 
Figure 3.2. Purine biosynthesis via the de novo pathway. PRPP, the ribosyl 
donor in the salvage pathway initiates the process. Increased PRPP concentration 
in HPRT deficiency syndromes increases de novo throughput. 10- 
formyltetrahydrofolte (circled in red) acts as a formyl (CHO) donor for two 
reactions. Without this donor this pathway does not function. This forms the 
basis o f selection for HPRT+/o cells that use the salvage pathway to overcome 
loss of nucleotide synthesis through de novo pathway. Image manipulated from 
Ashihara and Suzuki (2004). 65
Figure 3.3. Part of the human folate metabolism pathway, the enzyme DHFR 
(dihydrofolate reductase) is inhibited by aminopterin. The end product, 10- 
formylTHF donates formyl (CHO) groups to intermediates of the de novo purine 
biosynthetic pathway (Figure 3.2) without this, purine biosynthesis can only 
occur through HRT and the salvage pathway. DHF; dihydrofolate, THF; 
tetrahydrofolate, FTL; formate-tetrahydrofolate ligase. Constructed from 
Lightfoot et al (2005) and Vickers et al (2009). 67
Figure 3.4. Metabolism of 6-thioguanine (6-TG) in HPRT wildtype cells. 6-TG 
is converted into its monophosphate form, 6-TGMP, that inhibits de novo purine 
synthesis and is incorporated into DNA leading to cell death. Cells deficient in 
HPRT will not metabolise 6-TG and will survive. Modified from Aubrecht et al 
(1997). 69
Figure 3.5. A schematic of the selective agents used to unify a population based 
on the cells HPRT proficiencies. 69
Figure 3.6. Representation of the method employed in the HPRT assay to 
quantify the mutagenic potential o f a test article based on frequency of HPRT 
mutants in a treated population. 71
Table 3.1. Alternative assays to the HPRT assay available for genotoxicity
testing. 74
xiv
Figure 3.7. Plating efficiency relative to control was used to assess the ability of 
cells to grow in 96 well plates alongside plates to assess mutant frequency. The 
solvent control (DMSO) is shown here. In comparison, the untreated control 
showed 92.3+/-18.2% PE. Therefore, DMSO had no great effect on PE. n=3, 
error bars signify standard deviation (SD), * p=<0.01. 78
Figure 3.8. A J-shaped curve is evident at low doses of MNU in wildtype human 
AHH-1 lymphoblastoid cells in the HPRT assay. There was a significant 
decrease in mutant frequency (MF) at 0.0025pg/ml (p=0.003), the 
NOGEL=0.0075pg/ml (p=0.07) and LOGEL=0.01pg/ml (p=0.001) as adjudged 
by a t test which was in agreement with a post host Dunnetf s test. n=3, error 
bars indicate SD, * p=<0.001. 79
Figure 3.9. Initial regression analysis of HPRT data over 0.00075pg/ml to
0.075pg/ml MNU suggested a linear dose-response. 80
Figure 3.10. The dose-response up to the NOGEL (0.0075pg/ml MNU) shows a 
quadratic relationship. The gradient of the slope is negative indicative of 
hormesis. 81
Table 3.2 (overleaf). Frequency of spontaneous mutants in various populations 
of cells at the HPRT locus. The values reported in this study are quite 
comparable. 84
Figure 3.11. A reduction in the number of HPRT mutant colonies was observed 
at 0.0025pg.ml (dm). n=3. Error bars=SD. * p=<0.05, ** p=<0.001 as compared 
to solvent (DMSO) control. 89
Chapter 4
Figure 4.1. Sites of alkylation in double stranded DNA. O f importance to this 
study are the sites circled in red. Methylation at Oxygen and Nitrogen causes 
0 6Methlyguanine (0 6MeG) N7-Methylgaunine (N7MeG), respectively.
Adapted from Jenkins et al (2005). 93
Table 4.1. Comparative adduct spectra between two model methylating agents.
A low s value (MNU) shows higher propensity for alkylation at exocyclic 
oxygen of guanine (06G) a potent miscoding adduct responsible for GC->AT 
transitions. Taken from Beranek (1990). 95
Table 4.2. Levels of endogenous alkylation damage. It is considered that 0 6MeG 
is naturally formed at lower levels than N7MeG. 100
Figure 4.2. The levels of exogenous adducts (diamonds) from 2 to lOppm do not 
exceed the endogenous level (square) and do not cause a linear increase under 
the “addition to background” hypothesis at low doses. Data taken from Lu et al, 
2011). 102 
Figure 4.3. N7MeG adducts induced by MMS (solid diamonds) show a linear 
dose response. Mutation induction by this agent is non-linear with a NOEL at 
1 pg/ml (empty circles). At the NOEL there are approximately 300 more adducts 
compared to Opg/ml without an increase in mutant frequency. Taken from 
Swenberg et al (2008). 103
Figure 4.4. The strucutre of N7MeG base (precursor ion) and product ion 
following CID (collission-induced dissociation). With thanks to Dr Ed Dudley. 
Structures drawn using freeware at www.emolecules.com. 110
xv
Figure 4.5. HPLC-UV chromatogram of the internal standard preparation. The 
peak represents [15N5]N7MeG showing absorbance at 250nm as a function of 
elution time using a solvent gradient at a flow rate of lml/min. Kindly 
reproduced from Jodie Sandhu with permission from Dr Rajinder Singh. 117
Table 4.3. DNA yields from lx l0 7cells using Qiagen. Each letter represents a 
different replicate for the specified treatment group. For each treatment, sample 
A and B were pooled into one and so was C and D. The amount of DNA on 
column is shown. This was the final amount of DNA used for analysis. Values 
were calculated after the samples were pooled and accounted for the unavoidable 
loss of sample. This occurred following filtration of adduct from unwanted DNA 
(15pl was retained in the filter) and on injection into the LC system (15pl of 
20[a1 was used). These values were also used for equation 1.1. An absorbance 
ratio of 1.8-2.2 for 260/280 indicates no protein contamination and for 260/230 
indicates no ethanol or solvent carryover. 118
Figure 4.6. Quantifying N7MeG from DNA treated with MNU using a 
Phenomenex Synergi Fusion RP 80A column (4pM, 2.0mm x 250mm) eluted at 
120, Typical LC-MS/MSpl/min with 0.1% formic acid/5% methanol. 
Chromatograms for A.) 0.1% DMSO B.) 0.00075|xg/ml MNU and C.)
0.025 p,g/ml MNU with respective internal standards. The numerical output for 
each DNA sample is shown in Table 2. 119
Table 4.4. The area under the peaks and retention time for each sample is given. 
The peak area for N7MeG was normalised against the corresponding peak area 
of the internal standard (equation 1.0). The retention time for N7MeG is 
typically O.lmin behind that for [15Ns]7MeG. The mass spectrometer 
preferentially identifies higher mass ions first. 120
Figure 4.7. Threshold dose-response observed for N7MeG following lhr MNU 
exposure. Results show average of two replicates with standard deviation 
displayed. 121
Figure 4.8. 50pg genomic DNA was assessed for the quantity of N7MeG 
adducts in AHH-1 cells treated with MNU for 24hr. This allowed time for repair, 
DNA replication and spontaneous depurination of chemically unstable N7MeG, 
which reduces the level of N7MeG. n=2. 122
Figure 4.9. The adduct-dose relationship mimics that for mutation induction by 
MNU this suggests that the NOAEL is dependent upon adduct formation. 127
Chapter 5
Figure 5.1. Mutations are biomarkers of effect, a combination of adduct formation 
and cellular processing. Image is taken from Swenberg et al, 2008). 131
Figure 5.2. Fixation of 0 6MeG into GC->AT transitions is a well-understood 
mechanism requiring two rounds of replication. Image adapted from O’Neill 
(2000). 132
Figure 5.3. Enzymatic removal and unstable properties of methylpurines (as well 
as other mechanisms) lead to apurinic sites that are substrates for repair to restore 
the original DNA sequence or can lead to point mutations and chromosome 
aberrations. Image taken from Boiteux and Guillet (2004). 133
Table 5.1. Mutation induction at the HPRT locus from three alkylators. The 
differences in proportions of substitutions likely reflect different mechanisms of 
action and adduct spectra. Taken from Jenkins et al (2005). 134
xvi
Figure 5.4. Theory of restriction site mutagenesis (RSM) assay. Image taken from 
Jenkins et al, (1999). 136
Figure 5.5 HPRT schematic showing intron/exon organisation. Adapted from 
http://www.ncbi.nlm.nih.gov/nuccore/NG_012329.1 ?from=l &to=51601 &report 
=graph&content=5. Values taken from O’Neill et al (1998). 139
Table 5.2. Details of the nested PCR primers. 141
Figure 5.6. Temperature gradient for PCR reaction number 1 (A) and PCR 
reaction number 2 (B). Left most lane is 100bp-1500bp DNA ladder. 142
Figure 5.7. Concentration gradient. Optimal volume of product from PCR reaction 
1 (template) is 5pl for use in PCR reaction 2. Right most lane is 300-1500bp. 143
Figure 5.8. Schematic of the technique that splits HPRT mRNA into two 
overlapping oligos to shorten the length o f amplicon and improve PCR success.
Red primers are designated “D” and green are designated “K”. 143
Figure 5.9. Optimal concentration of primers (A) a temperature gradient with 2pM 
primers was too concentrated (B) 1 in 10 dilution was sufficient. Leftmost lanes are 
1 OObp-1500bp DNA ladder. 145
Figure 5.10. Optimal temperature for D and K primer sets is 52.6°C. 146
Figure 5.11. Magnesium chloride (MgCk) concentration gradients for D (A) and K
(B) primer sets. 146
Figure 5.12 . To increase yield, the number of cycles were increased to 40 and 
tested with RNA extracted from 4 HPRT mutant colonies. Once optimised, all 
RNA samples were tested for DNA contamination by using RNA in PCR (-RT 
(without reverse transcription) control) and the PCR reagents were tested for 
contamination by using water as a control (no template control, NTC). 147
Figure 5.13. Halving the extension time to lOseconds reduced the appearance of 
high molecular weight bands. 147
Figure 5.14. For convenience, both primer sets were added to one reaction tube to 
mimic multi-plex PCR. However, primer dimmers were evident that interfered with 
downstream sequencing and so D and K reactions were performed in separate 
tubes. 148
Figure 5.15. Data from Chapter 3 showing the doses (outlined in red) selected for 
sequence analysis at the HPRT locus. 149
Table 5.3. Proportions of the substitutions at the HPRT locus observed at 
increasing concentrations of MNU. The values in bold represent the most 
predominant substitution at each dose. n=40 per dose. *= <1x1 O'60. 150
Figure 5.16. The proportion of GC->AT changes increases in concordance with 
the increase in HPRT mutant frequency observed in chapter 3. 151
Figure 5.17. Summation of all the mutations found along the HPRT mRNA 
sequence from 40 HPRT mutants for each treatment. Spectra were composed using 
iMARS software (Morgan and Lewis, 2006). 153
Figure 5.18. Scatterplot to visualise the differences in mutable sites between the 
spectra of different treatment. 154
Table 5.4. MGMT activity in AHH-1 cells was not detected but the positive 
controls were successful. It is possible that MGMT in AHH-1 cells is below the 
limit of detection. 155
Figure 5.19. Real time PCR analysis of MGMT transcripts showed no statistically 
significant increase in expression in response to MNU exposure. 156
Figure 5.20. Methylation specific PCR (MS-PCR) suggests that MGMT promoter 
in AHH-1 is methylated. MZ160 is the unmethylated control and MZ227 is the 
methylated control. 156
xvii
Figure 5.21. Base substitution along the protein coding region of HPRT gene 
(black) shows substantial spread in the location of deleterious mutations, (taken 
from Jinnah et al, 2000). 157
Figure 5.22. Comparison of spontaneous mutation spectra in different cells taken 
from Mammalian Gene Mutation Database (MGMD). Top to bottom: AHH-1 (own 
data), Chinese Hamster Ovary cell line (CHO), Human T lymphocyte, Cynomolgus 
Monkey T lymphocyte, Murine macrophage, Murine splenic T lymphocyte, TK6 
and Chinese Hamster Lung cell lines (CHL). Axes are described in Figure 5.17.
160
Table 5.5. Analysis of the strand specificity of GC->AT transitions. The number of 
G->A transitions occurring on the non-transcribed strand (mRNA) are higher in 
presence of MNU which is indicative of the mechanism of action (MO A) of MNU.
161
Table 5.6. Comparison of two fluorescence technologies for use in Real time PCR.
163
Figure 5.23. Amplification efficiencies of one-step PCR varied between samples
164
Figure 5.24. Low abundance of MGMT mRNA in AHH-1 cells means dilutions 
for a standard curve for use in the Pfaffl method are impossible. 165
Figure 5.25. Western blot using 40pg protein from various cell types was analysed 
for MGMT protein. There is clear evidence of inter-cellular variation in MGMT 
levels. 166
Chapter 6
Figure 6.1. Schematic of siRNA mediated gene knockdown. siRNA molecules 
associate with proteins such as TRBP (transactivating response binding protein) 
forming RISC (RNA induced silencing complex) that degrades homologous mRNA 
sequences. Taken from Peek and Behlke (2007). 172
Figure 6.2. Examples of mononucleotide substrates acted upon by MGMT. Each a 
guanine base with different adducts at O6 A.) 0 6Methylguanine (0 6MeG). B.)
f \  ( \ f \O Benzylguanine (O BG). C.) Allylguanine. D.) O (p-methylbenzyl)guanine. From 
Moschel et al (1992). Structures drawn using freeware at www.emolecules.com 173 
Figure 6.3. The inactivation of human AGT (MGMT) with low dose 0 6BG. The 
difference in intra-species inactivation is explained through bioinformatics by 
Daniels et al (2000) which suggests that 0 6BG is unable to bind at the active site of 
the respective species specific MGMT. Graph taken from Pegg et al (1993). 174
Figure 6.4. Reaction of 0 6BG with MGMT. Direct transfer of alkyl group from 
0 6BG to cysl45 restores guanine but inactivates the protein and targets it for 
degradation. Adapted from Kaina, Margisson and Christmann (2010). 175
Figure 6.5. Time course showing more rapid degradation of MGMT post 0 6BG 
treatment in tumour biopsies (diamonds) compared to peripheral blood 
mononucleocytes (PBMC’s, circles). Taken from Liu et al (2001). Expressing the 
data as % control circumvents well-documented inter-tissue differences in MGMT 
levels (Gerson et al, 1986). 177
xviii
Figure 6.6. A schematic of the primary structure of MGMT. The coloured circles 
represent published mutations that desensitise cells to 0 6BG. They all fall into the 
active site preventing 0 6BG from binding and inactivating the enzyme (Daniels et 
al, 2000). The colours correspond to the mutations in table 1. Other documented 
mutations affect sensitivity but those shown cause the most drastic difference. 178
Table 6.1. Fold change is given to negate differences in the ED50 for inhibition of 
wildtype MGMT in different cell types. See text for potential causes of the inter­
cellular differences. 179
Table 6.2. Dilutions of MNU used to cause cytotoxicity in AHH-1 cells. 183
Table 6.3. The sequences of the siRNA used in MGMT knockdown from Kato 
et al, (2010) including overhangs necessary for efficient transfection and silencing 
(Bellemin et al, 2007). 185
Figure 6.7. The first attempt at GPADH knockdown using siRNA. 20pmol siRNA 
with 1.5 pi Lipofectamine ™ RNAiMAX showed greatest fold decrease. n=3. Error 
bars represent standard deviation (SD), **p=<0.01*** p=<0.001, ****p=<0.0001, 
* * * * * p = < 0 0 0 0 0 1  187
Figure 6.8. Fold change in GAPDH at higher concentrations of siRNA reagents. 
n=3. Error bars are SD *p=<0.05, ***p=<0.001, ****p=<0.0001. 188
Figure 6.9. There was no decrease in MGMT mRNA level following siRNA 
transfection. n=3, error bars are SD. 189
Table 6.4. Pre-treatment with 0 6BG reduces the dose of MNU needed to achieve 
50% cytotoxicity at both time points. n=2. 190
Figure 6.10. Toxicity curves for the dose of MNU used in the HPRT assay in 
absence and presence of 0 6BG showing that 0 6BG does not significantly potentiate 
toxicity at low dose MNU. Key; M NU-06BG (Dashed line), M NU+06BG (solid
line), 24hr (squares) 48hr (circles). n=3. 191
Table 6.5. The contribution of the respective solvent controls to the observed 
toxicity o f MNU and 0 6BG are shown in table. It can be seen that the solvent 
treatments did not cause a substantial reduction in RPD. n=2. 191
Figure 6.11. Plating efficiency as a measure o f AHH-1 cell viability following 
MGMT inactivation with 0 6BG at increasing concentrations of MNUover the 
HPRT assay. The solvent control represents DMSO+methanol compared to 
untreated controls. n=3 error bars represent standard deviation. 192
Table 6.6. The effects of solvent controls and 0 6BG on mutant frequency and 
plating efficiency compared to untreated cultures as calculated using equations in 
materials and method. n=3. 193
Figure 6.12. Linear increase (p=0.15) in HPRT mutant frequencies following 24hr 
exposure to MNU in AHH-1 cells pre-treated with 0 6BG. The solvent control 
represents the MF of cells treated with Methanol and DMSO. n=3. 193
Figure 6.13. HPRT data comparing the dose-response at sub-NOEL MNU doses in 
presence (A) and absence (B) of 0 6BG. 195
Table 6.7. Numerical values for the slopes o f Figure 6.13. 196
Table 6.8. The benchmark dose (BMD) that marks the critical event in a dose- 
response, analogous to the NOGEL/LOGEL approach. 90% confidence limits are 
given either side of the BMD. 197
Figure 6.14. The fold difference in MF between + 0 6BG and -0 6BG is greatest at 
doses below the statistical LOGEL of 0.01 pg/ml. Plotted on Log-Linear axis. 197 
Table 6.9. A two tailed t test compared each dose for significance to see the effect 
of 0 6BG on MF. Significance was only achieved at doses below the NOGEL show 
in bold. p=<0.05 except 0.005pg/ml where p=<0.01. 198
xix
Figure 6.15. Fewer adducts are unrepaired at doses below the LOGEL of
0.01 fig/ml. values approaching 1 at higher doses suggest that all adducts are 
unrepaired. Plotted on Log-Linear axis. 199
Figure 6.16. MGMT mRNA was analysed at different time points following 
treatment with MNU in MGMT inactivated cells. 200
Table 6.10. A comparison of the mutation spectra at the HPRT locus in AHH-1 
cells following treatment with 0.0075pg/ml MNU, with and without pre-treatment 
with 0 6BG and the spontaneous mutation spectra following pre-treatment of 0 6BG 
which has been shown to inactivate MGMT. 201
Figure 6.17 (overleaf). Spontaneous mutation spectra (A) and mutations induced 
by 0.0075pg/ml MNU without 0 6BG treatment (B) and with 0 6BG pre-treatment, 
a potent inducer of MGMT inactivation (C). 202
Figure 6.18. Mutation spectra for 0.0075pg/ml M NU+06BG (A) and 0.025pg/ml 
MNU (B). Similarities unique to these spectra are circled. 211
Figure 6.19. Inactivation of MGMT by 0 6BG causes increases in MF (A) and 
GC->AT transitions (B). Error bars in A) represent standard deviation,
* p=<0.05. 212
Chapter 7
Figure 7.1. Representation of the conclusions of this thesis. 219
Figure 7.2. Current thinking in genotoxicology distinguishes carcinogens based on 
their MOA (non-genotoxic/genotoxic potential) as to the mathematical model for low 
dose extrapolations. LNT=linear no threshold, ALARA=As Low As Reasonably 
Achievable, NOAEL=no observed adverse effect level. 220
Figure 7.3. Schematic of a decision tree to evaluate the most appropriate method to 
deal with a genotoxic impurity, this is heavily dependent upon perceived risk. 
Abbreviations: PDE=Permitted Daily Exposure, UF=Uncertainty Factors, 
TTC=Threshold of Toxicological Concern. Taken from EMEA (2006). 221
xx
Abbreviations.
MNU-Methyl nitrosourea
ENU-Ethyl nitrosourea
MMS-Methyl methanesulfonate
EMS-Ethyl methanesulfonate
0 6M eG -06Methylguanine
N7MeG -N7-Methy lguanine
MGMT-Methy lguanine methyltransferase
0 6B G -06Benzylguanine
MMR-Mismatch repair
DNA-Deoxyribonucleic acid
RNA-Ribonucleic acid
HPRT-Hypoxanthine phosphoribosy ltransferase
NO(G)EL-No observed (genotixc) effect level
LO(G)EL-Lowest observed (genotoxic) effect level
BMD-Benchmark dose
Td-Threshold dose
G-Guanine
A-Adenine
C-Cytosine
T-Thymidine
WOE-Weight of evidence
Chapter 1.
General Introduction.
Introduction To 
Genetic Toxicology
1.1. The need for genotoxicology testing: chemicals cause mutations, mutations 
cause cancer.
The deoxyribonucleic acid (DNA) sequence within genes and their arrangement 
within chromosomes in the genome are often evolutionary conserved. Permanent 
changes to DNA sequence or structure (mutation) can have catastrophic consequences 
to the organism or its offspring (if the changes occur in germline cells). Heritable 
mutations in the germline are required for genetic diversity and evolutionary success 
o f a species. However, mutations in critical genes such as tumour suppressor genes or 
proto-oncogenes of somatic cells lead to unregulated cell division and cancer (Loeb 
and Loeb, 2000). Mutations arise through indirect DNA damage (e.g. perturbations in 
the spindle apparatus during nuclear division) or directly by, for example, 
unavoidable mistakes by the replication machinery during DNA replication, or 
induced by pre-mutagenic adducts. Adducts are chemical groups covalently added to 
nucleophilic centres within cellular macromolecules (e.g. DNA and proteins) by 
electrophiles. In DNA, adducts can be efficiently repaired. However, replication of 
unrepaired adducts “fixes” the damage into mutations (Miller and Miller, 1971). 
Mutations can be grouped into micro-mutations to the sequence of a gene or macro­
mutations affecting chromosome structure or number.
1.1.2. Micro-mutations affecting DNA sequence.
There are three classes of mutations that affect the sequence of DNA. These are:
1. Point mutations, of which there are three types:
• Silent (synonymous). Due to the redundancy of the genetic code, a 
nucleotide, often the third (wobble) base of the triplet codon, can be 
substituted for another without changing the amino acid and with no 
consequence to the phenotype.
• Missense. A base is substituted for another that subsequently changes 
the amino acid upon transcription then eventual translation. If the 
amino acids have similar chemical properties there may be no effect. 
Protein function can be altered if a chemically different amino acid is 
coded for, leading to loss of protein function or gain of an abnormal 
function either to the benefit or, often, detriment to the cell/organism.
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• Nonsense. A base substitution that changes the triplet codon to a stop 
codon leading to a non-functional truncated protein.
2. Insertions, The insertion of one or more nucleotides into DNA is often the 
result of polymerase slippage in repeated sequences (microsatellites), 
integration of viral genomes or insertion of transposable elements. Frameshift 
insertions alter the open reading frame (ORF) thereby changing all amino 
acids in the polypeptide.
3. Deletions, deletion o f DNA through, for example, exon skipping during 
mRNA maturation that results in the loss of information for protein 
translation, could also cause frameshifts resulting in disruption to the ORF.
Gene mutations are well documented as cancer initiating events (Knudson, 1971).
1.1.3. Macro-mutations affecting chromosomes.
Chromosomal mutations can change the ploidy of loci that alters gene dosage. There 
are two types:
Changes to chromosome number (Aneuploidy). Gain/loss o f an entire 
chromosome. Aneuploidy (the failure o f the chromosomes to separate equally into the 
daughter cells) results from non-disjunction during meiosis in gametocytes and during 
mitosis in somatic cells. Additionally, exposure to indirect genotoxins (aneugens) 
disrupts the spindle apparatus leading to improper chromosome segregation resulting 
in the loss or gain of chromosome in the daughter cell. This imbalance of genetic 
information is a well-documented cause of reproductive failure (Boue, Boue and 
Lazer, 1975), cancer (Boveri, 1914) and hereditary genetic defects (Korenberg, 1991) 
such as Down’s syndrome, largely caused by the gain of chromosome 21 (trisomy 
21). To regain balance of gene expression, cells modify the epigenome, which may 
cause dysregulation (Scheid et al, 1996).
Changes to chromosome structure. Gain/loss or alteration of fragment of a 
chromosome. There are many types of structural rearrangements, the most notable 
being:
• Deletion- A portion of the chromosome is lost causing haploinsufficiency at 
an affected locus, whereby the single, remaining functional allele is 
insufficient for normal function (Figure 1.1 A).
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• Duplication- During m itosis, m isaligned hom ologous chrom osom es are at 
risk o f  unequal crossover. A chrom osom al fragm ent is rem oved from one 
chrom osom e and given to the other. This duplicates the fragm ent in the second 
chrom osom e (Figure 1.1 B).
• Inversion-A fragm ent o f  chrom osom e is reversed in orientation (Figure 
1.1C).
• Translocation-A portion o f  a chrom osom e is exchanged for another. A well- 
docum ented m echanism  is the reciprocal translocation. This occurs, for 
exam ple, in form ation o f  the Philadelphia chrom osom e. Part o f  chrom osom e 9 
is translocated to chrom osom e 22, form ing a fusion gene (bcr/abl) at the 
chrom osom e 22/chrom osom e 9 junction. This has shown to be a cause o f 
chronic m yelogenous leukaem ia (Daley. Van Etten and Baltim ore, 1990) 
(Figure 1.1D).
Structural aberrations result in a m ultitude o f  diseases depending on the genes in the 
fragm ent.
D
Figure 1.1. M acro-m utations affecting chrom osom e structure including deletion (A), 
duplication (B), inversion (C) and translocation (D). Taken from 
http ://w w w .bioscience.org/2012/v4s/af/302/fulltext.asp?bfram e=figures.htm & doi=yes
Point m utations are causal events in tum ourigenesis responsible for creating a 
“m utator phenotype” that has increased propensity for genom e instability and cell 
cycle dysregulation (Loeb, 1991; Shibata and Lieber. 2010; Fox et al, 2010). 
H ow ever, it is uncertain w hether aneuploidy is a cause or consequence o f  genom e 
instability and tum origenesis (Ganem . Storchova and Pellm an, 2007). Surprisingly,
4
Weaver et al (2007) note the role of anueploidy as a tumour suppressor. However, 
aneuploid cells are found in an array of malignancies (Dey, 2004) and was found in 
65% of patients with non-small-cell lung cancer (Choma et al, 2001).
The realisation that environmental or occupational chemicals cause point mutations 
and chromosome damage through adducts (Hemminki, 1983) or aneuploidy through 
perturbation of the cell division machinery, served as the impetus to develop genetic 
toxicology. This field of study aims to test chemicals for their genotoxic, mutagenic 
and carcinogenic potential in order to limit human risk (Ames, 1979).
1.2. Genetic toxicology in hazard identification/characterisation.
Genetic toxicology in mammalian cells (in vitro) and in animal models (in vivo) is 
used in hazard identification and characterisation. The exposure scenario is then 
extrapolated to the human condition forming a four-step risk assessment framework 
detailed below:
1. Hazard identification. Identifies the nature of adverse effects through an 
increase in genotoxic end-points such as DNA lesions, mutation and 
chromosomal anomalies in genotoxicity assays. Often merged with hazard 
characterisation.
2. Hazard characterisation. Quantifies consequences of exposure (response) to 
molecular dosimetry in a dose-response relationship, used to inform 
mechanism and mode of action. This is of importance in the following work 
and will be discussed further under section 1.3.
3. Exposure assessment. Estimates the level of hazard in the external 
environment through direct measurement of concentration. This can be at the 
source of exposure and also the internal or biologically effective dose 
following exposure by determining levels of macromolecular adducts as 
biomarkers of exposure (this is further detailed in chapter 4).
4. Risk characterisation. The summation of all available data to predict 
likelihood and consequence of human exposure.
Unregulated exposure to known or potential carcinogens represents a significant 
cancer risk (National Cancer Institute at the U.S. Department of Health and Human 
Services, 2010). Before the realisation of endogenous damage, exogenous agents were
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thought to account for 85% of human cancers (Wood, 1969). Occupational hazards 
represent a significant risk because workers are exposed to higher than normal levels 
o f hazardous substances for prolonged periods of time. Since the discovery of other 
carcinogens such as viruses and endogenous processes, Boffetta and Kogevinas 
(1999) more accurately estimate that occupational exposures account for 13-18% of 
lung cancers, 2 to 10% of bladder cancers and 2-8% of laryngeal cancers. Early 
epidemiological observations of exposed individuals highlighted the risk of exposure 
to hazardous substances. For example, Percivall Pott noted the increase in scrotal 
cancers in chimney sweeps following exposure to soot in 1775 (Androutsos, 2006). 
Whereas soot is a complex mixture of chemicals, contemporary studies in hazard 
identification and characterisation aim to identify carcinogenic potential and mode of 
action (Sonich-Mullin et al, 2001) of each chemical on a case-by-case basis through 
controlled dosimetry studies in cell culture and animal models. Nevertheless, 
epidemiology still plays an important part in hazard identification and characterisation 
(Wogan et al, 2004). If available epidemiological and mode of action data (EPA, 
2005) suggest that exposure to a certain chemical will increase incidence of human 
cancer, it is categorised by the International Agency for Research on Cancer (IARC) 
as group 1-carcinogenic to humans. Other categories are:
• Group 2A-Probably carcinogenic to humans
• Group 2B-Possibly carcinogenic to humans
• Group 3-Not classifiable as to its carcinogenicity to humans
• Group 4-Probably not carcinogenic to humans
IARC’s monographs are used here as an example, monographs published by other 
agencies exist and their robustness can be debated (Dr Paul Fowler, personal 
communication). These monographs detail the risk of a variety of chemicals including 
those in pesticides, diet, lifestyle factors (smoking and tanning devices), 
pharmaceuticals, general environment (plant extracts) and industry as well as the 
carcinogenicity of viruses (Hepatitis B virus, group 1), bacteria {Helicobacter pylori, 
group 1), radiation (Gamma, group 1) and surgical implants (cardiac pacemakers, 
group 3). With legislative action, exposure to group 1 carcinogens can be limited to 
better public health. Such exposure limitation is crucial in preventing an increase 
cancer risk over the pre-existing, natural level of cancer incidence.
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1.3. Hazard identification and characterisation.
Hazard identification and characterisation requires in vitro bacterial and mammalian 
cell based assays and in vivo studies to assess genotoxicity, and 2-year bioassays in 
animal models to assess carcinogenicity. The following work discusses genotoxicity 
tests and so carcinogenicity bioassays will not be considered. Carcinogens cause 
cancer through either direct DNA interaction (genotoxins e.g. alkylating agents) or 
through interaction with other cellular components via a non-genotoxic mode of 
action (MOA). Aneugens and topoisomerase inhibitors are the exception as they are 
indirect genotoxins because they cause mutations (aneuploidy and double strand 
breaks, respectively) through interaction with the DNA replication machinery and not 
directly with DNA. It is understood that aneugens have an adverse effect threshold, 
whereby a sufficiently high concentration of chemical is needed to cause adverse 
effects (Kirsch-Volders, Aardema and Elhajouji, 2000) this is further discussed under 
section 1.5.4.1. Genotoxins, however, are thought not to have a threshold and are 
damaging at low levels, although this is under contention (Jenkins et al, 2005; Doak et 
al, 2007; Gocke and Muller, 2009). Therefore, distinguishing the mode of 
carcinogenic action has important implications in risk assessment. A number of 
genotoxicity assays are employed to distinguish MOA as genotoxic or non-genotoxic 
by assessment of numerous endpoints:
1. DNA adducts through highly sensitive physical chemistry methods like mass 
spectrometry (positive for DNA reactive genotoxins)
2. Point mutations that cause loss of function of an easily assayable protein 
(positive for mutagens)
3. Aberrations in chromosomal structure as examined under microscopy 
(positive for clastogens and agents with other MOA such as cytostatic drugs)
4. Changes in chromosome number under fluorescence microscopy using pan 
centromeric probes (positive for aneugens such as nocodazole)
A positive result is defined as a statistically significant increase in endpoint over 
respective solvent control. If all endpoints are negative it is assumed that the 
carcinogen is not genotoxic but causes cancer by other methods such as increased cell 
proliferation in hormone-induced carcinogenesis (Liehr, 2000a). However, in this 
instance, caution is urged as the chemical may show tissue specificity or require 
metabolic activation into a mutagenic product before genotoxicity can be seen.
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1.4. Regulatory genotoxicity.
Specific guidelines are used in genotoxicity testing to ensure the standardisation of 
assay methodology. During drug development, pharmaceutical companies adhere to 
guidelines proposed by the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH). Their 
mission statement is “to achieve greater harmonisation to ensure that safe, effective, 
and high quality medicines are developed and registered in the most resource-efficient 
manner.” Genotoxicity testing for other purposes, such as the regulation of food by 
European Food Standards Agency (EFSA), consults strategy documents (e.g. COM, 
2011) proposed by Committee o f Mutagenicity in Food, Consumer Products and the 
Environment. This advisory panel o f experts from scientific societies reference 
guidelines from the Organisation for Economic Cooperation and Development 
(OECD) for well-established and validated genotoxicity tests. Genotoxicity assays 
performed at Swansea University adhere and contribute to these guidelines for inter­
laboratory comparisons (Johnson et al, 2010) necessary for the global standardisation 
o f assays.
1.4.1. Regulatory genotoxicity testing strategies.
There is a general consensus that the strategy for testing consists o f stage 1; basic in 
vitro genotoxicity tests and stage 2  follow up in vivo genotoxicity tests on equivocal 
or positive stage 1 findings (COM, 2000). COM 2011 guidelines also state a stage 0. 
This involves prior consideration of physico-chemical properties of the test chemical 
with emphasis on solvent/vehicle interactions (Fischer et al, 2008), solubility, stability 
and volatility as well as consideration for possible artifactual positive results through 
cell stress by pH changes in cell culture media. For the assessment of genotoxic 
impurities, recent validations permit the in silico evaluation of quantitative structure 
activity relationships (QSAR) (Benigni and Bossa et al, 2008). Designated as 
computational toxiocology, programs like DEREK (Cariello et al, 2002) are used to 
identify structural moieties responsible for the chemical’s mutagenicity (Ashby and 
Paton, 1993). COM 2011 also recommends the use of high throughput pre-screens 
such as GADD45-GFP assay (Walmsley, 2008).
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1.4.2. Stage 1; a battery of in vitro genotoxicity tests.
A number o f OECD validated in vitro assays are available, with debate as to the most 
suitable (Kirkland et al, 2005). Since there are a number of genotoxic endpoints that 
need to be assessed, a battery of assays is required. Due to the research by Kirkland et 
al (2005), the guidelines recommend that a battery of two “core” assays are used to 
detect mutagenicity, clastogenicity and aneugenicity. The authors found that 
sensitivity and predictability of three commonly used assays (Ames, in vitro 
micronucleus assay (MNvit) and chromosome aberration) were highest when used in 
combination to identify rodent carcinogens. Although, the assays had poor specificity; 
the rate o f false positives (known non-carcinogens to be wrongly classified as positive 
genotoxins) was high (75-95%). Addition of more assays to the battery reduced 
specificity and caused more misleading false positives. COM 2011 suggests the use of 
Ames in combination with MNvit, since MNvit (coupled with kinetochore staining) 
can more accurately detect aneuploidy than chromosome aberration tests (Lorge et al, 
2007). O f relevance to this thesis is the hypoxanthine phosphoribosyltransferase 
(HPRT) gene mutation assay (chapter 3), which is used as a stage 1 test to assess a 
chemical’s ability to cause small DNA sequence changes, predominantly point 
mutations. The HPRT assay can also be used as an in vivo mutation sensor. According 
to OECD, for full evaluation, the tests should be performed under a variety of 
exposure concentrations and times and in the absence and presence of metabolic 
activating enzymes provided by rat liver extracts, S9, to identify any mutagenic 
products. However, S9 is a potent inducer of mutagenic reactive oxygen species 
(ROS). Tweats et al (2007) identified a number of chemicals positive in vivo but not 
in vitro. Although the majority of chemicals show the same response, meaning that in 
vitro models are highly predictive of in vivo genotoxicity (Tennant, 1987). If stage 1 
negative results agree with published literature and QSAR analysis, the chemical is 
considered not mutagenic, only requiring in vivo testing if  prolonged human exposure 
is anticipated. Positive results in any stage 1 assay are further investigated in stage 2 
in vivo tests although the biological relevance of in vitro positives must be considered 
before stage 2 tests are performed (Kirkland and Muller, 2000).
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1.4.3. Stage 2: in vivo testing.
Stage 2 evaluates in vivo genotoxicity of a given chemical that shows in vitro 
genotoxicity in stage 1. This includes; germ cell genotoxicity for heritable genetic 
effects, site of exposure genotoxicity and tissue specificity. Testing strategy is decided 
on a case-by-case basis, depending on, for example, the genotoxic mode of action 
identified in stage 1 and SAR information (Thybaud et al, 2007). COM (2011) 
recommends the use of three assays. These being; rodent bone marrow chromosome 
aberration assay for clastogenicity, transgenic rodent mutation (TGR) assay for gene 
mutations and a rodent comet assay able to detect a wide range of low level DNA 
damage such as strand breaks, cross links and repair induced alkali labile sites. A 
small number of positive in vitro mutagens are negative in vivo. The question exists as 
to whether it is a false (in vitro) positive or true (in vivo) negative. A lack of 
absorption, rapid elimination or detoxification in vivo (true negative) or 
physiologically irrelevant testing conditions in vitro (false positive) could cause this 
disparity. Distinguishing false positives, due to non-physiological conditions in vitro, 
from true in vivo negatives relies on a WOE approach (Kirkland et al, 2005; Kirkland 
et al, 2007) often requiring more animal tests. The complete process is shown in 
Figure 1.2.
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POSITIVE result in any 
test
NEGATIVE results in all 
tests
Stage I: Bacterial gene mutation test (Ames test)
Clastogenicity and aneugenicity (in vitro micronucleus test)
Substance is not 
mutagenic
NEGATIVE after full 
assessment
Insufficient evidence to 
assess the mutagenicity of 
the substance 
Review available data and 
make pragmatic 
conclusions based on 
weight of evidence
POSITIVE: if  data is 
robust consider substance 
to be in vivo somatic cell 
mutagen and possible 
germ cell mutagen
Stage 0:
Structure Activity Relationships (SAR), screening tests and physico-chemical properties 
(of substances and impurities)
Undertake one or more of the following recommended 
assays:
1 .Micronucleus assay or chromosome aberration test
2. Transgenic mutation test
3. Comet assay
Stage 2:
Consider rational for in vivo study selection; may include:
- Mutagenic endpoints identified in Stage 1 in vitro tests
- Tumour target tissues in carcinogenicity studies
- Potential for germ cell genotoxicity
- Where exposure is high, or moderate and prolonged
- Site of contact tissues
Figure 1.2. The process o f  current genotoxicity testing to identify and characterise 
chemical hazards. Image taken from COM  (2011).
1.4.4. Reduce, refine and replace animal usage in genotoxicology.
The use o f  animals in genotoxicity testing is contentious. The European Union (EU) 
7th Amendment to the Cosmetics Directive in March 2009 banned the testing o f
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cosmetics on animals in the EU, so efforts are in place to improve in vitro tests to 
reduce, refine and replace animals in research. Increasing the reliability of in vitro 
methods would reduce the high level of false positives and reduce the need for stage 2  
follow up testing in animals. Cosmetics Europe, formerly the EU Cosmetics 
Association (COLIPA), has funded research into improving in vitro methodology to 
reduce false positive results. Sources of false positives were highlighted by Kirkland 
et al (2007) and Blakey et al (2008) which included; unstable or sensitive (e.g. p53 
deficient) mammalian cell lines; CHO, CHL and V79 (Pfuhler et al, 2011; Fowler et 
al, 2012a), unnecessarily high (lOmM, OECD) top concentrations (Kirkland and 
Fowler, 2010) and cytotoxicity assessment methods (relative population doubling 
(RPD), relative increase in cell counts (RICC), relative cell counts (RCC), and 
cytokinesis-blocked proliferation index (CBPI)) that underestimate toxicity leading to 
selection of an unnecessarily high LD50, a dose to give 50% toxicity, that 
subsequently gives misleading positive genotoxicity data (Johnson et al, 2010; 
Whitwell et al, 2010; Fowler et al, 2012). Another avenue of COLIP A funded 
research is to develop other in vitro assays (Pfuhler et al, 2010) such as the 
development of the Epiderm™ 3D human skin based micronucleus assay (Aardema et 
al, 2010). The advantage of such assays, over existing in vitro assays, is that the route 
o f exposure is considered. Reader is directed to www.alttox.org for further 
information.
1.4.5. In vitro to in vivo, high dose to low dose and animal to human 
extrapolation.
Predicting the genotoxic and carcinogenic response in humans relies on cell culture 
and animal models. Therefore, risk assessment relies on inter-species extrapolation. 
Extrapolating risk from inbred laboratory animals to a genetically diverse human 
population is difficult as some individuals are more susceptible than others. Genetic 
polymorphisms in genes encoding phase I and phase II metabolic enzymes involved 
in absorption, distribution, metabolism and excretion of carcinogens coupled with 
variations in dietary detoxifying agents have been shown to alter individual cancer 
risk (Ratnasinghe et al, 2000). These unknowns exist due to a deficiency in data and 
are known as uncertainty factors (UF) (WHO, 2001; IGHRC, 2003). UF’s introduce a
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10- to 100-fold safety margin around a “safe dose” of chemical (Lehman and 
Fitzhugh, 1953). Obtaining a “safe dose” requires extrapolation from high doses, 
which are required to achieve a statistically significant increase in measured endpoint 
over background levels. Methods of extrapolation depend on genotoxic potency of the 
given carcinogen (Bolt et al, 2004). Non-genotoxic carcinogens and those observing 
thresholds (aneugens, discussed later under section 1.5.5.1) are perceived as less 
potent than direct genotoxins (Perera, 1991). For non-genotoxic carcinogens, animal 
carcinogenicity assays determine a threshold dose at which no adverse effects are 
seen, i.e. there is no increase in tumours at a particular dose of carcinogen. No 
observed effect level NOEL, or the more robust, benchmark dose (BMD) models are 
used to extrapolate this dose to a lower level applicable to human exposure (Guess, 
Crump and Peto, 1977). On the other hand, genotoxic carcinogens are perceived to be 
mutagenic at all doses. Therefore, without evidence o f a threshold, it is precautionary 
to assume a linear extrapolation from high to low doses (USEPA, 2000). This 
assumption of low dose linearity is challenged in this thesis and will be discussed 
under section 1.5.5.2. Under a linear hypothesis, the mathematical models used to 
determine a safe level are more cautionary (Bolt, 2004). Models include threshold of 
toxicological concern (TTC) or a more conservative risk assessment; as low as 
reasonably practicable (ALARP), to limit the concentration of chemical to as low as 
reasonably possible. The reader is referred to Muller et al (2009) for an example of 
risk assessment of likely exposure to the genotoxic impurity, ethyl methanesulfonate
(EMS), in Viracept . It can be said that in vivo studies are useful for dose
extrapolations to humans. However, dosage extrapolations from in vitro toxicology 
are seldom used (Bemauer et al, 2005). Recently, there is interest in in vitro (and in 
vivo) dose-response relationships at low doses to establish potency (Pottenger and 
Gollapudi, 2009) and biological relevance (Kirkland and Muller, 2000) at low dose, 
mechanism of action and to better inform risk assessments if linear high dose to low 
dose extrapolation is assumed correctly for genotoxins (Lutz, 1990).
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1.5. Dose-response relationships for genotoxicity.
The dose-response quantifies a given genotoxic endpoint at increasing doses of 
chemical, thus giving an idea of potency. The shape of the dose-response has 
implications in safety assessment. A variety of dose-response models are postulated 
for different genotoxic endpoints (Lutz, 1990).
These are:
1. Supralinear and Sublinear
2. J-shaped
3. Linear
4. Threshold
Each model is shown in Figure 1.3. It may be imprudent to assume a linear 
extrapolation from high to low doses (Lutz, 1998) if  an alternative dose-response can 
be sufficiently supported. Each dose-response will be explained in turn with emphasis 
on J-shaped, linear and threshold.
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Figure 1.3. Theoretical dose-response models. (A) Sublinear. linear and supralinear 
taken from Swenberg et a l (2008). (B) Hormesis/J-shaped model taken from Gay lor, 
Lutz and Connolly (2004). (C) Threshold dose-response taken from Lovell (2000).
1.5.1. Supralinear and sublinear dose responses.
Supralinearity and sublinearity occur towards higher doses o f  chemical, with linearity 
assumed at low doses. These models have been shown for various DNA adducts 
(Swenberg et al, 1987). A supralinear dose-response can be explained by saturation o f  
metabolic enzymes necessary for pro-carcinogen activation into a DNA reactive 
electrophile, capable o f  adduct formation. This would limit activated carcinogen and 
as a result would limit adduct formation. For example, a supralinear dose-response 
was observed for 0 6-methylguanine (OhMeG) adducts present in DNA o f  rodent 
respirator}' mucosa following increasing doses o f  tobacco-specific. 4-
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(methylnitrosamino)-l-(3-pyridyl)-l-butanone (NNK). Higher concentrations were 
less effective at causing 0 6MeG adducts (Swenberg et al, 1995). Although, it could 
be postulated that repair of adducts at these concentrations is upregulated and 
improves the removal of adducts, this hypothesis has yet to be substantiated. At 
higher concentrations, the effect of toxicity cannot be ignored. Cell death is an 
effective way of removing heavily damaged and mutated cells from the population 
and could account for a plateau in dose-response. Sublinear dose-responses, in 
contrast, show disproportionally higher potency for adduct and mutation at higher 
doses. This is hypothesised to occur following saturation of protective mechanisms 
such as detoxification and DNA repair. Sublinearity has been shown for DNA-protein 
cross links following increasing concentrations of formaldehyde, the result of 
intracellular glutathione depletion (Casanova et al, 1987). Mutations have been 
hypothesised to show sublinearity due to increased adduct fixation caused by 
regenerative hyperplasia (increased cell division following neighbouring cell death) in 
response to cytotoxic doses of genotoxin (Lutz, 1990).
1.5.2. J-shaped dose-response.
The J-shaped relationship is an example of hormesis, a biphasic dose-response 
ubiquitous in biomedical literature (Calabrese, 2006). In most instances, hormesis 
refers to an inverted-U shaped dose-response, depicting low dose stimulation and high 
dose inhibition of for example, growth or cell proliferation. In toxicology, hormesis is 
illustrated by a J-shaped curve, referring to “low dose reduction and high dose 
enhancement” of endpoint such as cancer incidence (Calabrese, 2009), which may 
reflect low dose stimulation and high dose inhibition of cytoprotective mechanisms. 
Hormesis states that low doses of substances can be beneficial. Rozman (2005) insists 
that all substances are beneficial at low doses. The hormesis hypothesis was used to 
explain low dose stimulatory effects on cell division following radiation exposure in 
algae as early as 1898. Since then, evidence of radiation hormesis has accumulated 
(Calabrese and Baldwin, 2000). However, stimulatory effects were not reproducible 
or considered true, but the result of overcompensation following insult (Calabrese, 
2005). Further criticism came from prominent statisticians, including R.A. Fischer, 
who dismissed hormetic effects as variation in data. Many US regulatory bodies
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maintain that radiation hormesis has not been proven in humans. As a result, the 
hormetic dose-response was overlooked in favour of linear models (Calabrese, 2009). 
Recently, robust data showing hormesis, has increased interest in its predictability of 
low dose effects in toxicology. Calabrese and Baldwin (2001) report that citations of 
hormesis have increased from 1 in 1945-1954 to 485 citations in 1995-2004 with 
publications in respected scientific journals including Nature (Calabrese, 2004) and 
Science (Kaiser, 2003). Publications by US department of agriculture (USDA) refer 
to hormesis and have incorporated the model into risk assessments but not for human 
health. Calabrese (2006; 2007), Scott (2008) and Tubiana et al (2009) suggest that 
hormesis better predicts low dose effects than threshold and linear models, 
particularly for radiation exposure. For chemical agents, the hormetic concept has 
been described for many carcinogenic endpoints such as tumour incidence, 
glutathione 5-transferase (GST-P) hepatic foci and bladder hyperplasia (Calabrese, 
2005) and for many non-genotoxic carcinogens including phenobarbitol, a tumour 
promoter that inhibited tumour promotion in low concentration (Kinoshita et al, 
2003). A report by Calabrese and Baldwin (2001) showed that 1600 dose-response 
relationships for toxicity endpoints displayed hormesis in microbial, plant and animal 
systems. Hormesis has also been observed for genotoxicity endpoints in response to 
direct acting genotoxins such as MNNG. Conolly and Lutz (2004) proposed a 
mechanism to explain hormesis for adducts. They postulate that exogenous adducts 
formed from exposure to genotoxin, can activate or upregulate expression of genes 
whose products remove endogenously and exogenously generated adducts. The 
authors also postulate that low dose genotoxin causes a low level of adducts that slow 
cell cycle progression allowing sufficient time for repair. Both mechanisms support 
low dose linearity that is well accepted for exogenous adducts (Zito, 2001; Swenberg 
et al, 2008). Calabrese and Baldwin (2001) recognise that hormesis is dependent on 
time, as time increases the hormetic effect becomes more pronounced, potentially 
owing to the time to upregulate DNA repair proteins. Since changes to the DNA 
repair transcriptome are rapid, we can hypothesise that hormesis would be evident by 
24 hours (Sandrini et al, 2009). Analogies have been made between hormesis and the 
adaptive response to environmental changes, which has been a long known event in 
bacteria in response to alkylating agents which relies on upregulation o f DNA repair 
enzymes through expression of inducible promoters (Lindahl et al, 1988). The 
adaptive response “pre-conditions” the cell to better withstand higher doses in future
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exposures (Calabrese et al, 2009) and so hormesis may be more evident in chronic 
exposures and repeated dosing regimes.
1.5.3. Linear dose-response.
As previously mentioned, regulatory bodies favoured the linear (no threshold) model 
as a default prediction of low dose adverse effects in response to genotoxic 
carcinogens. One of the advantages of the linear model was that it could be generally 
applied to all chemical and physical genotoxins, however, it does not apply to 
aneugens or non-genotoxic carcinogens (Calabrese, 2009). The “additivity to 
background” hypothesis (Crump et al, 1976) gave justification for this assumption of 
linear low dose extrapolation. It states that if a carcinogen adds to a naturally 
occurring carcinogenic process, responsible for spontaneous tumour incidence, then 
only linearity could be accepted. Considering that DNA damage is unavoidable 
(Gupta and Lutz, 1999), exposure to exogenous genotoxins would add to the already 
formed damage. Therefore, all genotoxins, until recent publications, were assumed to 
be linear. This assumption was substantiated by the “single hit-single target” theory 
based on historical work with ionising radiation (UNSCEAR, United Nations 
Scientific Committee on the Effects of Atomic Radiation, 1958). The theory supposes 
that a single hit (damage) to DNA is sufficient to cause a mutation and subsequently 
cancer (Knudson, 1971). It is now known that not all DNA damage is fixed as 
mutations (Swenberg et al, 2008). However, there are some instances where 
mutagenicity is proportional to DNA damage induced in cases of poor adduct repair 
or its increased mispairing potential during DNA replication e.g. Aflatoxin B1 
(Morris et al, 1999). Where data to support other dose-response relationships is 
lacking, low dose linearity is the most appropriate hypothesis for the protection of 
public health (USEPA, 2000). However, this model is likely to overestimate risk. 
Therefore, Conolly and Lutz (2004) conclude that “cost compliance...may be greater 
than is actually needed” for protection. Through the use o f assays with ever increasing 
sensitivity the true low dose effect can be established.
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1.5.4. Threshold dose-response.
Thresholds are well known in toxicology (Cox, 1987). A threshold dose-response, 
referring to Paracelsus “the dose makes the poison,” states that there is no increase  in 
adverse effects at low doses compared to the untreated control. This differs from 
hormesis, which states low doses reduces endpoint to below the background level. 
Current opinion states that threshold dose-responses for genotoxic endpoints are 
accepted but need to be proven on a case-by-case basis (COM, 2011). The 
International Commission for Protection against Environmental Mutagens and 
Carcinogens define thresholds as “a range o f  sub-critical doses incapable o f  producing 
the specific response; as dose increases, the minimal dose that can elicit the response 
is the threshold dose" (ICPEMC, 1983). A threshold may be the result o f  poor assay 
resolution, which imparts an artificially high background level, meaning the assay is 
insensitive to increases in specific response until sufficiently high number o f  events 
have occurred. There are many definitions o f  a threshold dose (reviewed in Kirsch- 
Volders et a l , 2003; Slob. 1999) as a result; thresholds in genotoxicologv are confused 
by “semantic ambiguity” (Zito. 2001). The differences in absolute and pragmatic 
threshold are given in Figure 1.4.
Absolute threshold. 
Slope=0
—I Background  
—J variability
Pragmatic
threshold.
Effect hidden in
background
variability
Figure 1.4. The differences in threshold definitions (pragmatic v absolute) as 
defined by COM (2009). Image adapted from Lovell (2000) based on definitions 
by Kirsch-Vodlers et al (2000).
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The European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) 
defines an absolute threshold as a concentration that does not interact with cellular 
machinery, the point in the dose response where slope 0 changes to slope >0 (Lutz, 
1998). Experimentally determining an absolute threshold dose is difficult 
(Schneiderman et al, 1979). Therefore, of interest here are pragmatic thresholds, 
where low dose linearity is hidden within the background variability of the untreated 
control (Lutz, 1998). To define a pragmatic threshold, the use of statistics identifies a 
No Observed Effect Level (NOEL) defined as the highest concentration that is not 
statistically significantly different from the control and Lowest Observed Effect Level 
(LOEL) defined as the lowest concentration that produces a statistically significant 
increase in the endpoint in a well designed experiment (Waddell, 2005) with 
sufficient statistical power (Lovell, 2000). NO(G)ELs and LO(G)ELs are determined 
by a priori Dunnets and post hoc analysis of variance (ANOVA) (Doak et al, 2007). 
A more robust stepwise approach as recommended by Gocke and Wall (2009) are 
now employed. This involves:
1. Comparison of untreated and solvent controls by one-way ANOVA
2. Best of fit modeling between the null hypothesis of linearity and quadratic, the 
simplest non-linear curve over the entire dose-range (Johnson et al, 2009)
3. Determining the NOEL and LOEL using post hoc Dunnett’s
4. Linear vs quadratic curve estimation at below NOEL doses
5. Application of “Broken stick” model to determine the threshold dose (td) 
(Lutz and Lutz, 2009) defined as an inflection point where the curve departs 
from slope 0 to a slope greater than 0 (Figure 1.5).
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Figure 1.5. Representation of the “broken stick” statistical modelling of non-linear 
threshold dose-response to determine the threshold dose (td) with NOEL and LOEL 
identified. LLC1 td=lower confidence interval of the td. Image adapted from Lutz and 
Lutz (2009) and Johnson et al (2009).
The acceptance of thresholds depends on statistical inference and “sound theoretical 
understanding” of the underlying biological mechanism of genotoxicity (ICPEMC, 
1983). Thresholds have been observed in genotoxiciology to explain false positive in 
vitro results that may not be relevant in vivo, if  the LOEL dose has not been exceeded 
in vivo (Henderson, Albertini and Aardema, 2000). Threshold identification relies 
upon:
1. The number of (redundant) targets
2. The mode of interaction with target
3. The type and sensitivity o f endpoint e.g adduct versus mutation detection
4. Physiological cytoprotective mechanisms that prevent observable adverse 
effects at low dose (Speit et al, 2000; Kirsch-Volders et al, 2000).
According to the above criteria, thresholds have been accepted for aneugens, 
topoisomerase and polymerase inhibitors.
I.5.4.I. Genotoxic thresholds for indirect genotoxins.
The one hit theory has been applied to genotoxins targeting a single target, i.e. DNA 
and linearity has been assumed. For non-DNA targeting carcinogens, effect is
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observed once multiple targets have been hit. The multiple target theory is generalised 
across all genotoxins and forms the theory behind the threshold dose-response for 
indirect genotoxins. The chemical must be in sufficient concentrations to interact with 
and damage all (or majority of) targets before an adverse effect is seen. A threshold 
has been shown for induction of indirect clastogenicity by topoisomerse II inhibitors, 
e.g. etoposide (Lynch et al, 2003) and induction of aneuploidy by spindle poisons 
(Parry, Fielder and McDonald, 1994; Elhajouji et al, 1995). For aneugens, since 
alterations in chromosome number are the first observable endpoint, a lack of 
sensitivity in being able to detect initial damage to individual spindles (referring to 
point 3 on the previous page) may account for the threshold. Damage to spindle 
apparatus may be linear; this is the emerging case with genotoxins when adducts are 
assessed as the genotoxic endpoint, a question of assay resolution (discussed in the 
following section).
1.5.4.2. Genotoxic thresholds for direct genotoxins.
Arguing that a threshold dose-response is more predictive than the favoured linear 
model is difficult for genotoxic carcinogens (Gehring and Blau, 1978). Genotoxic 
carcinogens are said to abide by the “one hit” theory, which has been interpreted to 
mean that there is no safe level of DNA damage, thereby assuming a linear dose 
response. With recent advancements in assay sensitivity, low dose effects can be 
ascertained. Increasing evidence challenges the “one hit” theory particularly when 
mutations are measured as the genotoxic endpoint; stipulating that one hit does not 
necessarily cause one mutation. Koana et al (2004) showed a threshold for mutation 
induction by ionising radiation attributed to protection by DNA repair mechanisms. 
Ever increasing evidence substantiates NOELs for mutation and chromosome break 
induction by direct acting genotoxins. In vitro and in vivo data by Doak et al (2007), 
Pottenger et al (2009), Gocke et al (2009), Lutz (2009), Bryce et al, (2010) and Lynch 
et al (2011) provide evidence in support of NOELs for mutagenic and clastogenic 
alkylating agents; methyl-A-nitrosourea (MNU), methyl methanesulfonate (MMS), 
ethyl methanesulfonate (EMS) and ethyl-A-nitrosourea (ENU). NOEL’s have also 
been found for induction of hepatocarcinogensis by food-derived genotoxins, 2 - 
amino-3,8-dimethylimidazo[4,5-y]quinoxaline (MelQx) and TV-nitrosodiethylamine
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(Fukushima et al, 2002; Waddell, Fukushima and Williams, 2006). This is logical 
given the “number of targets” criteria (specified on page 2 1 ) and the multistage 
progression of cancer. The shape of the dose-response for genotoxins depends on the 
genotoxic endpoint being assessed. This is in support of Waddell et al (2006) and 
Fukushima et al (2002) where, “different NOELs may exist for different parameters” 
(Figure 1.6).
Figure 1.6. Conclusions drawn from analysis of genotoxic endpoints in the 
carcinogenesis caused by MelQx. Taken from Fukushima et al (2002).
For example, quantifying adducts as the genotoxic endpoint reveals a linear dose- 
response at low doses of exogenous chemical suggesting that all doses are capable of 
adduct formation whereas mutation curves observe thresholds (Perera, 1988; 
Swenberg et al, 2008). It is reasonable to hypothesise a NOEL for adducts at 
extremely low doses where the chemical fails to interact with DNA either through 
detoxification or cellular membrane/nuclear envelope exclusion (Speit et al, 2000). 
The discrepancy in dose-response shapes for mutations and adducts could reflect the 
enhanced sensitivity of methods used in adduct quantitation (Jenkins et al, 2005). 
Mutational assays typically detect one non-synonymous mutation in 105/106 
nucleotides (Rossiter and Caskey, 1990). Quantitative adduct detection is capable of 
detecting 1 adduct in 1 0 1 °/1 0 11 nucleotides with the advent of accelerator mass 
spectrometry (Swenberg et al, 2000; Farmer, 2004). Swenberg et al (2008) concludes 
that adducts can be detected at doses below the mutagenic NOEL, thus questioning 
the biological relevance of adducts if not all are fixed as mutations and questioning 
the “one-hit” postulations (Jenkins et al, 2005). The resulting NOEL for mutation will 
depend upon the adduct’s propensity for mutation. Highly mutagenic adducts will
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shift the NOEL to the left, in some instances eliciting a linear mutation dose-response. 
This reflects:
• Half-life of the adduct depending upon proficiency of its repair process.
• Miscoding potential during replication.
• Location for adducts within the genome. Adducts in exons are likely to disrupt 
protein sequence if they are converted into missense/nonsense(non- 
synonymous) mutations, since it will only be non-synonymous changes that 
will be detected in mutation assays.
This is exemplified by Doak et al (2007). The authors report mutational NOELs for 
alkylsulfonates (MMS and EMS) but not for alkylnitrosoureas (MNU and ENU). The 
alkylnitrosoureas are 2 0  times more mutagenic than alkylsulfonates due to a higher 
level of 0 6alkylguanine (0 6AlkG) induced which has a high propensity for miscoding 
(Beranek, 1990). Lower doses of alkylnitrosoureas would be required to determine 
NOELs (Pottenger et al, 2009). The presence of adducts at doses which do not cause 
mutations implicate DNA repair as a potential mechanism behind mutation induction 
curves observed for DNA damaging genotoxins, i.e the NOEL must involve a post- 
adduct mechanism of action as found for ENU (Zair et al, 2011).
1.5.4.3. Potential mechanisms behind threshold dose response to genotoxins.
Many authors recognise the possible contribution of cytoprotective mechanisms 
behind the threshold dose-response for mutation induction by genotoxins (Speit et al, 
2000). These include:
• Plasma membrane exclusion from cells and/or nuclear envelope exclusion 
from nucleus
• Metabolic inactivation of xenobiotics
• DNA repair of induced lesions
• Removal of heavily damaged cells by apoptosis and/or necrosis 
These are shown in Figure 1.7.
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Figure 1.7. The process of mutagenesis from chemical exposure (solid lines) and 
cytoprotective mechanisms (dashed lines) that would account for a NOEL. Taken 
from Jenkins et al (2005)
Of interest to the following work is the hypothesised role of DNA repair in the 
removal of pre-mutagenic adducts prior to DNA replication in creating a NOEL for 
mutation induction. DNA repair deficiency sensitises cells to mutagenic and cytotoxic 
effects of high dose alkylating agents, highlighting the protective effect of DNA 
repair (Glassner et al, 1999) even in reducing the efficacy of alkylating agent 
chemotherapy (Shiraishi, Sakumi and Sekiguchi, 2000; Frosina 2009). If the linear 
hypothesis holds true, alkylating chemotherapy would be damaging at all doses. This 
is not the case. Furthermore, there is an established correlation between DNA repair 
gene expression and low dose genotoxin exposure. This has been shown for 
upregulation o f 0 6-methylguanine-DNA methyltransferase (MGMT) 4 hours post low 
dose MMS treatment (Doak et al, 2008) and immediate upregulation of N- 
methylpurine-DNA glycosylase (MPG) following EMS treatment (Zair et al, 2011). 
The upregulation did not reduce the level of adverse effects below the control level 
and so it is not considered as hormesis. The role o f DNA repair in protection of low 
dose clastogen has been determined by Zair et al (2011). By utilising cells deficient in 
N7-Ethylguanine repair (MPG deficient cells), the authors have removed the NOEL 
for clastogenicity caused by EMS induced N7-Ethylguanine or N3-Ethyladenine 
adducts giving a linear dose-response. Additionally, there was no change to the dose- 
response of mutation induction by EMS in MPG deficient cells, since N7-
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Ethylguanine is not a major miscoding adduct and inducer of point mutations. 
Therefore, the authors clarified that NOELs are mechanism of action specific and so 
these experiments can help generalise thresholds to genotoxins of similar 
mechanisms. Polymorphisms within DNA repair genes that exist in a human 
population would influence the shape of the dose-response. Susceptible individuals 
may be less tolerant to low level genotoxins and may not display a NOEL. Risk 
estimates to a population would be difficult (Jenkins, 2010).
I.5.4.4. Implications of thresholds in risk assessment of genotoxic impurities.
Throughout the manufacturing o f pharmaceuticals, substances can be contaminated 
with genotoxic impurities. McGovern and Jacobson-Kram (2007) suggest that 
genotoxic impurities “carry only risk” and that pharmaceuticals should “strive to 
achieve the lowest levels of genotoxic impurities that are technically feasible or that 
carry no significant increase in cancer risk.” While this is logical for a positive 
chemical assumed to be under the linear hypothesis of no safe level, if substantial 
evidence suggests an impurity causes no appreciable risk, precautionary measures 
would be an unnecessary cost. In situations where it is not possible to remove the 
genotoxic impurity, the Food and Drug Administration’s (FDA) Centre for Drug 
Evaluation and Research (CDER) guidelines permit the re-evaluation of genotoxic 
potential of positive impurities (FDA, 2006). If a lack of genotoxic hazard can be 
concluded, using a WOE approach and mechanism of action data, “clinical studies 
could proceed” without need for further evaluation. The European Medicines Agency 
(EMEA) published guidelines on the limit of genotoxic impurities (EMEA, 2006). 
The guidelines state the calculation of a permitted daily exposure (PDE) from the 
experimentally determined NOEL. Whereas, without sufficient threshold data, levels 
should be controlled according to ALARP or threshold o f toxicological concern 
(TTC). Therefore the determination of NOELs have implications in risk assessment 
but require substantial experimental evidence for justification.
1.6. Methyk/V-nitrosourea (MNU), a potent mutagen.
This thesis examines the low dose effects o f MNU. The structure is shown in Figure
1.8. The monofunctional alkylating agent, MNU (Cas No; 684 93 5), is a direct acting
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genotoxin that adds methyl groups (-CH3) to nucleic acids and proteins. In DNA, 
methyl adducts show propensity for mutation but can be efficiently repaired without 
consequence. MNU is classified by IARC as a “group 2A probable carcinogen”. 
MNU is used widely in mutagenesis research as a model alkylating agent, most 
extensively for the induction of rat mammary tumours, although MNU has broad 
tissue specificity (Tsubura et al, 2011). Compared to other alkylating agents, MNU is 
a potent transplacental mutagen (Donovan and Smith, 2010) and at equitoxic doses, 
MNU is more proficient at inducing HPRT  mutants in V79 cells (Suter et al, 1980). 
This is attributed to the higher level of 0 6-methylguanine ( 0 6MeG) induced by MNU 
(Beranek, 1990). Due to this, at the doses tested, MNU is linear for mutation 
induction (Doak et al, 2007).
A). B). C).
\ L - H H\H I \  + H— 0 — C~— N
\  I .  H — C — N = N  L
I S L  y N  v  , 0
0
Figure 1.8. Structure of MNU (A), which decomposes into a DNA reactive 
methyldiazonium ion (B) and cyanic acid (C) and a hydroxide ion in aqueous 
solution. Details from (Golding et al, 1997).
1.7. MNU induced carcinogenesis.
Given the multistage model of cancer progression (Kirsch-volders et al, 2003), MNU 
is a tumour initiator in skin tumourigenesis (Brown, Buchmann and Balmain, 1990; 
Mukhtar et al, 1988) and also in thyroid tumours (Ohshima and Ward, 1986), in both 
situations requiring application of a tumour promoter. However, a single dose of 1 
milligram (mg) MNU was sufficient to cause murine epidermal tumours by 
regenerative hyperplasia after 38 weeks (Kirkhus, Hilmar and Kristensen, 1987). 
Additionally, administration of a single high dose or multiple low dose of MNU 
caused murine lymphomas after a 4-week latency period, which was accelerated by 
female hormones (Romach et al, 1994). Swenberg et al (1975) conclude that various 
tissues are susceptible to MNU induced oncogenic transformation particularly at the
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site of exposure. The authors also note differential tissue sensitivity to the effects of 
MNU. It seems that MNU alone is sufficient to initiate tumorigenesis.
1.8. Mode of carcinogenic action.
Evidence for DNA reactivity came from Swann and Magee (1968). The authors 
detected DNA methylation in various tissues following administration of 
radioactively labeled MNU. The critical initiating event seems to be MNU induced 
transformation of ras proto-oncogenes (Newcomb, Bayona and Pisharody, 1995). Of 
the three Ras genes (H-ras, K-ras and N-ras) a point mutation at codon 12, 13 or 61 
of any of the isoforms is a known initiating mutation in carcinogenesis (Bos, 1989). 
MNU induced mutations have been found in all codons (Mariyama et al, 1989; 
Sukumar, 1989). It is well established that MNU induces a GC->AT transition at the 
middle base of codon 12 (GGA->GAA) of the ras proto-oncogenes resulting in an 
aspartic acid to glutamic acid change sufficient for oncogenic transformation (Jacoby 
et al, 1992). Methylation of 0 6Guanine by MNU forms 0 6-methylguanine (0 6MeG), 
which has miscoding potential during replication resulting in the G C ^A T transition. 
0 6MeG is removed by MGMT however at codon 12 of K-ras, MGMT’s activity is 
hindered, increasing the probability of mutation, which accounts for this mutation 
hotspot (Engelbergs, Thomale and Rajewsky, 2000). As will be discussed, 0 6MeG 
causes double strand breaks (DSBs) through mismatch repair (MMR) processing, 
forming a substrate for recombination. This can lead to chromosome aberrations and 
oncogene activation (Jackson, 2002). 0 6MeG can also be converted into a toxic lesion 
capable of killing the cell, however, in a tissue this would cause neighbouring cells 
with sub-lethal damage to undergo regenerative hyperplasia contributing to 
tumourigenesis; a common carcinogenic MOA of many toxic chemicals.
1.9. Reaction with DNA; mode of genotoxic action.
The intracellular biochemistry of MNU under physiological conditions is complex 
(Anderson and Burdon, 1970). There is greater extent of DNA alkylation at higher 
intracellular thiol (glutathione) concentration due to increased decomposition of MNU 
into its DNA reactive metabolite, methyldiazonium ion (Lawley and Thatcher, 1970)
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(Figure 1.8B). The rate of MNU decomposition is solvent and pH dependent and this 
influences the genotoxic potential of MNU (McCalla, Reuvers and Kitai, 1968; 
Golding et al, 1997). Nevertheless, MNU induced DNA alkylation is well understood. 
According to Ingold’s concept of nucleophilic substitution (Spratt et al, 1997), 
alkylating agents abide by either SnI or Sn2  reaction kinetics upon reaction with 
DNA. MNU is a SnI alkylating agent, which shows first order kinetics, and the rate of 
reaction depends on the degradation into a carbocation intermediate 
(methyldiazonium for MNU). MMS, for example, is a SN2 alklyating agent (Figure 
1.9). Sega, Wolfe and Owens (1981) report that DNA was l.*5 times more methylated 
after 4 hr MNU treatment than following MMS treatment showing a faster rate of 
reaction for Sn 1 alkylating agents.
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Figure 1.9. Schematic representation of SnI and Sn2 reaction mechanisms. R=methyl 
group, X=leaving group, Y=DNA. Taken from Colvin (2000).
A number of nucleophilic sites are susceptible to alkylation. The location and 
proportion of alkyl adducts in DNA, termed adduct spectra, is determined by the 
agents’ electrophilic potential, governed by the swain-scott constant (s value) (Swain 
and Scott, 1953). MNU has a low s value of 0.42. Due to this it is able to methylate 
sites of low nucleophilicity such as 0 6G. MMS and agents with higher s values, 
approaching 1 of methylbromide, react with sites of higher nucleophilicty such as 
N7guanine (N7G), to a greater extent, forming a larger proportion of 
N7Methylguanine (N7MeG) (Beranek, Weis and Swenson, 1980). Each adduct in the 
spectra can theoretically contribute to the biological effect of exposure. However, the 
consequences of 0 6MeG and N7MeG have been well characterised. 0 6MeG is a 
highly mutagenic adduct due to its propensity for miscoding during replication. 
N7MeG, is relatively innocuous since it is present at naturally high levels in genomic
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DNA. However, it can cause point mutations and chromosome breaks due to 
spontaneous depurination and erroneous repair. The ratio of 0 6alkylG:N7alkylG is 
predictive of an alkylator’s mutagenic potential. Referring to the adduct spectra of 
MNU, 0 6MeG constitutes 5.9-8.2% and 65.0-70.0% N7MeG. MMS, however forms 
only 0.3% 0 6MeG (high 5  value) and 81.0-83.0% N7MeG. MNU therefore has a 
higher ratio of 0 6alkylG:N7alkylG and is more mutagenic.
1.10. The biological relevance of N7MeG.
N7MeG, the major adduct upon exogenous DNA alkylation, does not have miscoding 
properties but its formation weakens the glycosidic bond leaving an apurinic site 
following spontaneous depurination or removal by its repair enzyme (MPG). 
Processing of the apurinic site by error prone base excision repair (BER) and bypass 
translesion synthesis (TLS) renders the lesion mutagenic (Boiteux and Guillet, 2004). 
If left unrepaired, apurinic sites can cause eventual chromosome breaks and is the 
hypothesised lesion responsible for the induction of micronuclei (Zair et al, 2011). 
The apurinic site can also lead to point mutations. Due to the “A-rule” (Ide et al, 
1995), the preferential incorporation of adenine opposite the apurinic site may result 
in a GC~>TA transversion. It is postulated that TLS polymerases and MMR may 
incorporate a variety of bases opposite an abasic site to account for the high level of 
GC->AT transitions and other transversions seen following treatment of MMS that 
are not compatible with its adduct spectra (Glaab et al, 1998; Glaab, Tindall and 
Skopek, 1999; Kokoska, McCulloch and Kunkel, 2003).
1.10.1. The biological relevance of 0 6MeG.
The biological relevance of 0 6MeG in carcinogenicity, cytotoxicity and mutagenicity 
was first noted by Loveless (1969) who noted the predominance of GC->AT 
transitions following exposure of bacteriophages to 0 6-methylating agents. 
Methylation of exocyclic oxygen in 0 6MeG disrupts a hydrogen bond held with 
exocyclic nitrogen at the fourth position of cytosine so that only two groups capable 
of hydrogen bonding remain on guanine. The structure of 0 6MeG therefore resembles 
adenine and has significant miscoding potential (Baranek, 1983). Upon replication,
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the polymerase inserts a thymine opposite 0 6MeG forming 0 6MeG:Thymine mispair 
in the first post-treatment cell cycle. During the second cell cycle, there are two 
eventualities:
1. Repair of 0 6MeG in the mispair leaving a G/T mispair. MMR can either insert 
an adenine opposite the thymine causing the GC->AT transition or it can 
incorporate cytosine opposite guanine restoring the original DNA sequence 
(Kaina et al, 2007).
2. 0 6MeG is not repaired and remains in the mispair. MMR processing of 
0 6MeG:Thymine mispair can cause DSBs and in turn initiate apoptosis, this is 
regarded as the mechanism for 0 6MeG cytotoxicity (Discussed under section 
1.13).
0 6MeG is therefore not only mutagenic but can be clastogenic and cytotoxic in MMR 
proficient cells (Shiravstav, Li and Essigman, 2010). To a lesser extent, mutations are 
caused by other MNU induced methyl adducts. Another miscoding lesion is 
0 4Methylthymine (0 4MeT) that constitutes 0.1-0.7% of total alkylation events by 
MNU (Baranek, 1990). 0 4MeT causes TA->CG transitions (Klein et al, 1994). 
0 6MeG and 0 4MeT adducts have been shown to cause transitions in vitro and in vivo 
(Singer et al, 1985; Singer et al, 1989). Palombo et al (1991) found 20 GC->AT 
transitions and 1 TA->CG transitions at the human gpt gene following MNU 
exposure, attributable to 0 6MeG and 0 4MeT, respectively. Furthermore, GC->AT 
transitions account for 98% of mutations induced by MNU (Sledziewska-Gojska and 
Torzewska, 1997). Even though a number of mutagenic adducts are produced, it is 
recognised that 0 6MeG is the most mutagenic as it is readily mispaired. This is 
further discussed in chapter 5.
1.11. Repair of 0 6MeG by MGMT prevents GC-> AT transitions.
MGMT efficiently repairs 0 6MeG, restoring guanine without consequence to DNA 
(Figure 1.10). The protective effects are evident in studies which show a reduction in 
MNU induced thymomas and skin carcinogenesis in transgenic murine models 
expressing human MGMT (Dumenco et al, 1993), MGMT mediated inhibition of 
MNU induced malignant progression (Becker et al, 2003), resistance of CHO cells 
over-expressing MGMT to the genotoxic and cytotoxic effects o f 0 6-methylating
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agents (Kaina et a l, 1991). perturbation o f  skin tumour initiation in transgenic mice 
(Becker et a l, 1996) and increased sensitivity to alkylating agent induced mutagenesis 
and cytotoxicity in M G M T deficient cells (termed Mer-/Mex-) (Fritz and Kaina, 
1992; Tsuzuki et a l , 1996). Despite the importance o f  M GM T to DNA repair, little is 
known about transcriptional regulation and protein turnover within human cells, 
which is the current topic o f  interest (Professor Bernd Kaina, personal 
communication). Ishibashi et al (1994) provide immunohistochemical evidence to 
suggest that the majority o f  M G M T  molecules reside in the cytoplasm and are 
actively transported into the nucleus to replace inactivated nuclear molecules. The 
signalling pathway responsible has not been identified. However, the mechanisms o f  
removal o f  0 6MeG by M G M T are well understood.
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Figure 1.10. Repair o f  Cf-methylguanine ( 0 6MeG) by 0 6-methylguanine-DNA 
methyltransferase (M G M T) prevents mutagenesis by 0 (1-methylating agents. 
M M R=mismatch repair. Image taken from Kaina et al (2007).
In a suicide reaction that inactivates M GM T. the methyl adduct is irreversibly 
transferred to an internal cysteine residue in the active site o f  the protein. The reaction 
is stoichiometric i.e the number o f  adducts that can be repaired is equal to the num ber 
o f  active M GM T molecules, which has been shown to differ between cell types. 
Therefore the cell has limited capacity to repair 0 (1MeG, depending on basal levels o f  
M GM T, which can be depleted (reviewed by Pegg and Byers, 1992). Depletion o f  
M GM T leaves the cell sensitive to alkylation damage (Hirose et a l , 2003). The rate o f  
M GM T regeneration is cell type specific. Repletion occurred faster in mitogen
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stimulated T cells (Gerson, 1988) suggesting that cell division is important (Sklar et 
al, 1981).
1.12 Transcriptional regulation of MGMT.
It is well established that in rats, MGMT has an expression induction system in 
response to alkylation and X-ray induced damage (Fritz et al, 1991; Grombacher, 
Mitra and Kaina 1996). The mechanics are not well understood, possibly involving 
p53 and transcription factors (Activator Protein-1, AP-1 and Specificity Protein-1, 
SP1 (Rafferty et al, 1996; Grombacher, Eichhom and Kaina, 1998) although this is 
controversial (Harris et al, 1996). There is very little evidence for the same induction 
system in humans in response to genotoxins (Doak et al, 2008). However, 
upregulation has been observed following treatment with corticosteroids, phorbol-1 2 - 
myristate-13-acetate (TPA) and other Protein Kinase C activators in HeLa S3 cells 
(Boldogh et al, 1998; Grombacher, Mitra and Kaina, 1996). Humans have a higher 
level of basal MGMT activity than rodent cells (Dunn et al 1986). Bacteria have 
MGMT at two loci. The ogt gene shows a constitutive basal level of MGMT 
expression, and upon insult, a second gene, ada, is expressed. This is the well- 
documented adaptive response that seems to be lacking in humans. Due to its unique 
inactivation reaction with 0 6MeG, structural analogues such as 0 6Benzylguanine 
(0 6BG) have been used to inactivate MGMT as a knockout strategy in chemotherapy 
to sensitise MGMT proficient gliomas and other malignancies to alkylating 
chemotherapy. The point of the cell cycle where damage is induced is important in 
allowing sufficient time for 0 6MeG to be repaired by MGMT (Meikrantz et al, 1998). 
Tong, Fazio and Williams (1980) concluded that cells in S phase are most sensitive to 
alkylation damage given the increased mutant frequency of cells exposed when in S 
phase. Replication of 0 6MeG adducts that have failed to be repaired in the first cell 
cycle cause 0 6MeG/Thymine mispairs during S phase that enter the second cell cycle. 
Here, MMR processing of mispairs cause second cell cycle delay by G2 arrest with 
possible apoptosis.
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1.13. Cellular processing of 0 6MeG:Thymine mispairs.
0 6MeG:Thymine mispairs are formed during the first S phase and are substrate for 
MMR processing which can cause a variety of mutations and eventual cytotoxicity 
(Figure 1.11). “Methylation tolerant” cells are defective in MMR proteins, most 
commonly; M utSa (composed of MSH2 and MSH6 ) or M utLa (composed of MLH 1 
and PMS2). They are resistant to alkylation-induced cytotoxicity at the expense of 
0 6MeG mediated GC->AT point mutations and a high cancer incidence. Conversely, 
there are reports of MMR deficiency causing cytotoxicity following alkylation 
damage (Aquilina et al, 1998). This was attributable to increased genomic instability 
like that observed in MMR deficient human non-polyposis colorectal cancer 
(HNPCC) (Fishel et al, 1993). It is recognised that MMR is essential for converting 
0 6MeG into a clastogenic lesion and is essential for 0 6MeG induced chromosomal 
aberrations (Galloway et al, 1995), sister chromatid exchanges (SCE’s) (Vemole, 
Pepponi and D ’Atri, 2003) and apoptosis (Morris et al 1994) in the second cell cycle. 
Triggering apoptosis is achieved by direct MMR signalling or from MMR induced 
secondary lesions (O’Brien and Brown, 2006). Yoshioka, Yoshioka and Hsieh (2006) 
provide evidence that MMR directly initiates apoptosis by interaction with ATR 
(ataxia telangiectasia related) upon recognition of 0 6MeG:Thymine mispairs. ATR is 
a phosphoinositide 3-kinase related kinase (PIKK) DNA damage sensor that relays 
the DNA damage signal to eventual effector molecules such as p53 to bring about cell 
cycle arrest for DNA repair or apoptosis. Hickman and Samson (1999) suggest that 
MMR can also activate apoptosis independent of p53 following p53 independent G2 
arrest, where a decision to enter mitosis or apoptosis is made (McNamee and 
Brodsky, 2009). Chromatin associated MMR proteins can also cause direct apoptosis 
by triggering S phase arrest immediately after the formation o f 0 6MeG/Thymine 
mispairs (Schroering et al, 2009). Another method of apoptosis is through secondary 
DNA lesions caused by MMR processing of mispairs. Futile cycling produces single 
strand gaps in DNA that are too small to attract recombinogenic foci (RAD51) and 
fail to trigger checkpoints (Mojas, Lopes and Jiricny, 2007). They enter the second S 
phase leading to DSBs that can either be repaired by Brca2/Xrcc2 dependent 
homologous recombination giving SCE’s (Roos et al, 2009) or lead to second cell 
cycle G2 arrest and apoptosis by ATR/ATM (ataxia telangiectasia mutated) mediated
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recognition o f  the lesion or resulting stalled replication forks (Bohgaki, Bohgaki and 
Hakem, 2010; Quiros, Ross and Kaina, 2010). This would trigger the observed 
upregulation o f  p53 and Fas/CD95/Apo-l, triggering the death response in T cells 
(Roos, Baumgartner and Kaina, 2004). Additionally, Hirose et a l (2003) provide a 
link between M M R and G2 arrest via p38, possibly representing another pathway o f  
0 6MeG induced G2 arrest. Schroering et al (2009) investigated cell cycle effects 
following alkylation exposure in M GM T deficient/M M R proficient HeLa M R cells. 
The authors show a lack o f  second cell cycle delay, the cells traverse into the third 
cell cycle with high level o f  DSBs that result in multinucleation, which serves as a 
trigger for apoptosis. In mutation assays, cells that undergo apoptosis as a result o f  
M M R processing in the first few post-treatment cell cycles will not be recovered. 
However, the mutational event will persist since G C ->A T transitions would occur in 
half  o f  the viable daughter cells upon replication o f  thymine and not Cf’M eG in the 
template strand, unless the damage at other sites trigger apoptosis (Morris et a l , 1994). 
Therefore, with the "dilution o f  0 6MeG during cell cycle (divisions), a decline in the 
level o f  cell kill is to be expected" (Quiros, Roos and Kaina et a l, 2010). These 
investigations are important in alkylating chemotherapy to distinguish m ethods o f  
sensitising alkylation-resistant tumours (Heacock et al. 2010).
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Figure 1.11. The current model o f  processing 0 6M eG:Thymine mispairs to explain 
the various mutations observed following treatment with M NU and other O6" 
methylating agents. Taken from Kaina et al (2007).
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1.14. Mutation spectra of MNU.
The mutation spectrum identifies the frequency and location of mutations across a 
locus to identify non-random mutational hotspots. Hotspots are useful “to infer 
mechanisms of mutagenesis contributing to tumourigenesis” (Glazko et al, 2006). 
Since GC->AT transitions constitute the majority o f MNU induced point mutations, 
sequence specificity has only been considered for this transition. It is noted that 
guanines preceded by a purine (5’-PuG-3’) are particularly susceptible to mutation in 
E.coli (Glickman et al, 1987) and mammalian cells (Palombo, Bignami and Dogliotti, 
1992). Glickman et al (1987) state “the distribution of the initial DNA damage” is 
responsible. The nearest neighbour effect of the flanking purine enhances the 
molecular electrostatic potential of the O6 site for alkylation (Pullman and Pullman, 
1981). This explains why it is the second guanine o f GGA (codon 12 of K-ras) that is 
methylated by MNU. Another explanation would be reduced adduct repair by MGMT 
at sites preceded by a purine (Dolan, Oplinger and Pegg, 1988) and chemical 
involvement in alkylation by the preceding purine (Horsfall et al, 1990). Palombo et 
al (1992) demonstrated that MNU induced mutations predominantly occurred on the 
non-transcribed strand, and was independent of transcriptional status. The mutation 
spectra therefore, cannot be attributed to transcription-coupled repair. This could 
reflect the accessibility of DNA within the nucleus. Furthermore, Jack and Brooks 
(1981) state that DNA damage is heterogeneous throughout the genome, 
predominantly occurring at sites that are accessible to the genotoxin. In vitro mutation 
spectra for alkylating agents used a mutation sensor gene such as HPRT on an extra- 
chromosomal vector (Dogliotti et al, 1991) and so may not reflect mutational patterns 
on genomic DNA. Mutation spectra can identify hotspots, with additional multivariate 
statistical analysis; the mutation spectra can identify commonalities between 
treatments or treatment groups. It is a reliable tool for analysis of mutation spectra to 
understand mutation induction by alkylating agents (Benigni, Palombo and Dogliotti, 
1992). The authors found that SnI agents have markedly different spectra than Sn2 
agents. Two such methods of multivariate statistics are principle component analysis 
(PCA) and cluster analysis (CA) (Lewis and Parry 2002). At the HPRT  locus, 
Bouwens-Rombouts et al (1993) identified two hotspots of exon 3 these being a 
GC->AT transition at 16676 and a GC->TA transversion at 16680 one in each of two
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families. These were also sites for mutation following MMS treatment (Jenkins et al, 
2005). Furthermore, Tomita-Mitchell et al (2003) state that the mutation spectra 
determined following alkylation exposure in vitro is reflective of the mutational 
pathways in vivo.
1.15. MNU dose-response for mutation induction.
Linearity has long been assumed for MNU induced mutations at low doses. Doak et al 
(2007) found that MNU elicited chromosomal aberrations and gene mutations in 
proportion to dose. However, the authors postulate that a threshold could exist at 
doses lower than those tested. This has been substantiated by Pottenger et al (2009). 
The authors report a NOEL of 0.69pM (0.71 pg/ml) MNU at the thymidine kinase 
(TK) locus in L5178Y mouse lymphoma cells. It is clarified that the dose-response 
curve does not correlate to N7MeG levels which is not mutagenic. Since 0 6MeG is 
the major mutagenic adduct, a potential threshold would be dependent upon repair of 
this adduct by MGMT. It is possible that previously tested doses have caused 
sufficient 0 6MeG to saturate the repair enzyme, inhibiting the cell’s ability to prevent 
mutations. Doak et al (2007) found a linear low dose-response but attributed the 
linearity to other adducts and mutations that result from MNU exposure and erroneous 
repair mechanisms such as translesion synthesis. The following work further tests the 
repair mediated threshold hypothesis by using a dose range 10-fold lower than that of 
Doak et al (2007).
1.16. Thesis aims and objectives.
A study by Zair et al (2011) that characterised a biological mechanism behind the 
mutagenic NOEL of EMS is emulated in the following work to assess the role of 
MGMT in the prevention of GC->AT point mutations at low doses of MNU. This 
study has critical importance because:
1. MNU is the most mutagenic o f the four alkylators discussed previously 
(MNU, ENU, EMS and MMS), therefore, describing low dose effects for 
MNU sets precedence for lesser mutagenic alkylating agents.
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2. Point mutations have a better defined role in carcinogenesis than chromosomal 
aberrations. Therefore, there is real impetus for defining the mechanism of 
mutation induction.
This evidence together with in vivo substantiation will provide a strong biological 
WOE for low dose protection to alkylating agents, which may be applicable to 
genotoxins of similar mechanisms of action. This thesis is an all-encompassing report 
into the characterisation of low dose MNU from dose-response modelling, adduct 
detection, mutation analysis and DNA repair. The layout of the results chapters are 
shown in Figure 1.12.
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m utations at low 
dose MNU?
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ADDUCT ANALYSIS
Does MNU cause 
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Figure 1.12. Layout of the results chapters in this thesis.
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Chapter 2.
General Materials 
And Methods.
2.1. General materials and methods.
The following account is of the materials and methods that are common to at least two 
results chapters.
2.2. AHH-1 cell culture.
AHH-1 (TK+/-) cells were purchased from American Type Culture Collection 
(ATCC) (Middlesex, UK). AHH-1 cells are Epstein-Barr virus transformed human B 
lymphoblastoid cells expressing cytochrome p4501Al (Crespi and Thilly, 1984). 
Originally derived from RPMI-1788, AHH-1 also has aryl hydrocarbon hydroxylase 
(AHH) activity (Freedman et al, 1979) for xenobiotic metabolism. Corso and Parry 
(2004) showed that AHH-1 maintained a stable karyotype for five weeks in culture. 
AHH-1 cells harbour a heterozygous mutation at codon 282 (CGG->TGG) of p53. 
This is a hotspot for spontaneous 5’methylcytosine deamination in p53 gene (Guest 
and Parry, 1999). It may act in a dominant negative way to cause the loss of G1 arrest 
(Morris et al, 1996) but AHH-1 are capable of apoptosis (Zair et al, 2011) and G2 
arrest (Morris et al, 1996; Guest and Parry, 1999) in response to alkylating agent 
exposure.
2.2.1 Cell culture procedure.
All cell culture was performed using aseptic techniques in Scanlaf Mars Pro class 2 
hoods pre-cleaned with 70% ethanol with routine UV sterilisation. All centrifugation 
steps were performed in an Eppendorf 581 Or centrifuge with a radius of 173mm 
unless otherwise stated.
2.2.2 AHH-1 growth media.
AHH-1 cells were grown, mycoplasma free, in growth media composed of RPMI 
1640 (GIBCO, Paisley, UK) supplemented with 10% horse serum (BioSer, Sussex, 
UK) and 1% L-Glutamine (GIBCO, Paisley, UK) in humidified atmosphere at 37°C,
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5% CO2 . Mycoplasma testing was carried out routinely using MycoAlert® 
mycoplasma detection kit (Lonza, Slough, UK). Between experiments, cells were 
maintained at 1.25xl05cells/ml in 50ml cultures and sub-cultured every 2 days (at 
confluency) with microscopic examination under xlOO objective on a Ziess Axiovert 
25 light microscope.
2.2.3 Cell freezing for storage.
25ml of 50ml confluent culture was centrifuged at 1500rpm for 3 minutes (min), the 
supernatant discarded and the pellet re-suspended in 1ml freeze down media (12% 
DMSO in horse serum). The cells were left to cool at -80°C overnight at a rate of 
l°C/min in a Nunclon cell freezer. After this time, the cells were transferred to liquid 
nitrogen for long-term storage. Upon resurrection cells were thawed rapidly at 37°C 
and transferred to 50ml growth media.
2.2.4 Dilution of cells.
For an experiment, the appropriate concentration of cells was obtained by using 
equation 2.1:
Equation 2.1 V2= (CjxVj)
“C2 “
Derived from, C ] xV i =C2XV2
Where;
C ^ Concentration needed (cell/ml)
V]=Volume needed (ml)
C2=Concentration o f culture (cells/ml)
V2=Volume of stock required (ml).
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For example; diluting a cell stock o f 1.5x106 cells/ml to 50ml at 1.25x105cells/ml.
V2= q .25xl0sx50t 
1.5xl06
V2=4.2. Therefore 4.2ml+45.8ml growth media (50-4.2) will give 50ml at 
1.25xl05cells/ml.
All calculations were checked using equation 2.2.
Equation 2.2 (C2/Ci)xV2=Vi
2.3. Preparation of chemical stocks for testing.
Chemical handling took place inside Scanlaf Mars Pro class 2 hoods under aseptic 
techniques with the necessary safety precautions. All equipment was sterilised by UV. 
To prevent leaching of plastics, stocks were diluted in glass vials (Sigma, Gillingham, 
UK) with appropriate solvents (Table 2.1).
Table 2.1. Preparation of chemical stocks.
Chemical
name
Cas
number Solvent
Reconstituted
stock
concentration
(pg/ml)
Final 
concentration 
in media 
(Hg/ml)
Storage 
temperature 
of powder 
(°C)
Storage once 
reconstituted 
(°C)
M ethyl-A- 
, nitrosourea 
!(MNU)
684-93-
5 DMSO 1000
Refer to 
Table 2.2 4
Discarded 
after use
o 6-
benzylguanine
(0 6BG)
19916-
73-5
100%
Methanol 10 2.4 26
Discarded 
after use
6-thioguanine
(6-TG)
154-42-
7
1M
sodium
hydroxide
(NaOH)
1.5 0.6 4 -20
2.3.1. MNU.
Pottenger et al (2009) reported the purity of MNU (Sigma Aldrich, USA) as 69%. We 
have used an alternative product (MNU ISOPAC®, Cat number: N1517 Sigma- 
Adrich, Gillingham, UK), which has previously been used to induce mammary 
tumours in rodents (Bhat and Lacroix, 1989). Unfortunately the manufacturers do not
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state purity, the specification sheet presented as appendix 1. For each replicate and 
treatment with MNU a new stock was ordered. 10ml DM SO reconstituted MNU to 
O.lg/ml. 1 pil of this was added to 10ml DMSO in a 1/10000 dilution to give a 
O.Olmg/ml stock. 200pl of O.Olmg/ml stock was further diluted 1/10 in 1.8ml DMSO 
to yield a stock of 0.001 mg/ml. These stocks were further diluted to the desired 
concentration using equation 2.1 (Table 2.2).
Table 2.2. Dilution series for low dose MNU treatments.
Volume (nl)
Final DMSO O.OOlmg/ml O.Olmg/ml
0.00075 185 15 -
0.001 180 20 -
0.0025 150 50 -
0.005 100 100 -
0.0075 185 - 15
0.01 180 - 20
0.025 150 - 50
0.05 100 - 100
0.075 50 - 150
lOOpl of MNU at appropriate concentration was added to 10ml cell culture; this xlOO 
dilution factor was accounted for. These concentrations were nominal without exact 
purity of MNU and should only be compared to studies of the same methodology. 
Experimental determination of dose is achievable according to the solvent extraction 
method of Mirvish and Chu (1973). However, this was not undertaken. The 
manufacturers estimate that 13% of MNU ISOPAC® is made up of water and acetic 
acid necessary to maintain stability o f MNU. It must be noted that when comparing to 
studies that use MNU of 100% purity, the concentrations shown here should be 
adjusted.
2.3.2. 6-thioguanine.
To minimise freeze/thaw cycles, 5ml single use working stocks at 0.15mg/ml (lx) 
were prepared, lx  stock was prepared from a 30x stock of 6-thioguanine (6-TG, 
4.5mg/ml) by addition of 29ml 0.1M sodium hydroxide (NaOH) to 1ml 30x 6-TG, 
filter sterilized by use of 0.2pM filters and kept at -20°C for storage. Dissolving lg  
NaOH (Sigma, Gillingham, UK) in 250ml distilled water gave 0.1M NaOH, which
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was autoclaved. For every 25ml of culture media, addition of lOOpl lx  6-TG gave a 
final concentration of 0.6pg/ml. One stock of 6-TG was used through all HPRT 
assays. The quality of stock was checked by determining the absorbance ratio of 
320/260nm (Fenwick, 1985). A ratio >2.5 is a reliable stock. The stock used here had 
a ratio o f 4.8 (0.708/0.149).
2.4. Cytotoxicity assessment using relative population doubling (RPD).
Toxicity of MNU+/-06BG was determined by counting the number of cells before 
and after treatment, used to calculate relative population doubling (RPD). 
1.5x105 AHH-1 cells/ml were set up as 10ml cultures per dose o f MNU and incubated 
for 24hr at 37°C, 5% CO2 . Five additional 10ml cultures were established, for pre­
treatment (baseline) counts. After 24hr, the baseline flasks were gently shaken and 
lOOpl sampled and mixed with 10ml Isoton (Beckman) and cell number counted 
using a Beckman coulter counter set to count cells between 5-17pM. These counts 
were averaged and used for calculating relative population doubling (RPD) in 
equation 2.3. lOOpl of MNU at the appropriate dose was added to the treatment
flasks and incubated for 24hr at 37°C, 5% CO2 . At this time, the flasks were washed
twice in phosphate buffered saline (PBS. Lonzo, Blackley, UK) and re-suspended in 
10ml growth media. lOOpl was sampled and counted to obtain 24hr post treatment 
counts. The flasks were incubated for a further 24hr and sampled to obtain 48hr post 
treatment counts.
Equation 2.3
RPD = number of population doubling (PD) in treated cultures 
number of population doubling (PD) in control cultures
Where,
PD= Rog(24 or 48hr oost-treatment cell number/baseline counts)!
log2
Taken from Fellows et al (2008).
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2.5. HPRT Forward mutation assay.
2.5.1. Mutant purification; establishing a HPRT mutant free stock.
To purify AHH-1 cell populations of existing hypoxanthine 
phosphoribosyltransferase (HPRT) mutants, 5x l05 AHH-1 cells/ml were grown in a 
50ml culture for 3 days in hypoxanthine, aminopterin and thymidine (HAT) 
supplemented growth media. 1ml 50x HAT supplement (Invitrogen, Paisley, UK) was 
added to 49ml growth media. The final concentration was 2xlO'4mol/L hypoxanthine, 
8xlO‘7mol/L aminopterin and 3.5xl0*5mol/L thymidine. After this time, the cells were 
centrifuged at 1500rpm for 3min washed with PBS and re-suspended in 100ml HT 
supplemented media (HAT media without aminopterin) for appropriate cell sub 
culturing. 2ml 50x HT supplement (Invitrogen, Paisley, UK) was added to 98ml 
growth media. Cells were grown in presence of HT for 24hr washed with PBS and re­
suspended in 200ml normal growth media to culture for 2 days. Cells were then 
frozen according to method outlined in section 2.2.3.
2.5.2. Treatment protocol.
Following mutant purification, AHH-1 cells were revived and grown in normal 
growth media for 2 days. 10ml culture was established at a concentration of 5xl05 
AHH-1 cells/ml and exposed to:
• 1 OOpl of the appropriate dose of MNU
• lOOpl DMSO (final concentration o f 0.1% DMSO) for solvent control
• 1 OOpl growth media for the untreated control
• 0.075pg/ml MNU as the positive control (LOEL in Doak et al, 2007)
For 24hr at 37°C, 5% CO2 . Cells were then washed in PBS and re-suspended in 50ml 
growth media for a total o f 13 days to remove residual wildtype HPRT activity and 
allow expression of a mutant HPRT phenotype. Treatment wash off was counted as 
day 0 and sub-culturing, as described, took place on days 1,3,5,7,9,11. Due to the high 
number of 96 well plates needed for statistical power on day 13, incubator space was 
limited. To overcome this, all doses were frozen during the mutant expression period 
on day 7 and 2 doses were revived at a time. Upon revival, cells were designated day 
7 and sub-cultured 2 days later (day 9). To account for the effect of freezing/thawing
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on recovery of wildtype and mutant cells, a control culture should have been removed 
from storage at the same time as dosed cultures. This was not performed as the 
positive control gave the expected increase in mutant frequency, indicating that the 
assay was working. On day 9, cells were sub-cultured to 1.25xl05 cells/ml in 80ml. 
Upon day 11, 80ml was divided into 4 x 125cm2 flasks with the addition of 60ml 
growth media for sufficient number o f cells on day 13. On day 13, 96 well plates were 
loaded with lOOpl of AHH-1 cells at 4x l05 cells/ml (4xl04 cells/well) in selective 6- 
thioguanine (6-TG) supplemented media (lOOpl 0.15mg/ml 6-TG stock per 25ml of 
media) at a final concentration of 0.6pg/ml 6-TG. This caused efficient removal of 
HPRT wildtype cells but allowed sensitive selection of HPRT mutants. For threshold 
analysis, 10000 wells were required per dose. In addition, 60 plates per dose 
containing 200cells/ml (20 cells/well) in non-selective media were used for 
measurements of colony forming ability (plating efficiency). All plates were 
incubated at 37°C, 5% CO2 for 14 days and the number of wells with colonies scored. 
60 wells per plate were scored and the perimeter wells were excluded because the 
media partially evaporated. Colonies were identified as being <20 cells in diameter 
and were light in colour.
2.5.3. Calculating Mutant frequency.
Equation 2.4 Percentage Plating Efficiency (% PE) = -Ln (X0/N0) x 100
Equation 2.5 Cell Viability (%) = PE x 100
PE of control
Equation 2.6 Mutant frequency (MF) = -Ln (Xg/Ng) x DF
-Ln ( X “0/ N o )
DF = Dilution factor = "TNo. o f initial cells per well) Non-selective conditions 
(No. o f initial cells per well) Selective conditions
Xs= No. of wells without colonies T
Ns = Total no. of wells J  Selective conditions
X0= No. of wells without colonies "1
N0 = Total no. of wells \  Non-selective conditions
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2.5.4. Enumeration of mutant colonies for sufficient RNA yields.
At the end of the HPRT assay, colonies were aspirated and transferred to a 24 well 
plate (Nunc, ThermoScientific, Loughborough, UK) containing 2ml of growth media 
per well and left to grow at 37°C, 5% CO2 . After 5 days, cells were carefully aspirated 
using a 300pl pipette and mixed with 5 volumes (1.5ml) RNA protect® cell reagent 
(Qiagen, Sussex, UK) and stored at -20°C for RNA extraction.
2.6. RNA extraction.
Total RNA extraction was performed using RNeasy kit® (Qiagen, Sussex, UK). All 
centrifugation took place at 25°C for 15sec at lOOOOrpm in Heraeus Biofuge Fresco 
centrifuge with a radius of 85mm. Surfaces and equipment were wiped with 
RNAzap® (Applied Biosystems, Warrington, UK) to remove RNAses. Cells in RNA 
protect® cell reagent were defrosted at room temperature and pelleted by centrifuging 
at 1800rpm for 3mins and re-suspended in 350pl RLT cell lysis buffer. Cells were 
homogenised by passing through a narrow gauge needle. To help bind RNA to the 
spin column, equal volume (350jnl) of 70% ethanol was added, mixed thoroughly and 
applied to the spin column. To bind RNA, the column was centrifuged and the flow 
through discarded. The column was washed with 350pl wash buffer RW1 with repeat 
centrifugation. Genomic DNA was digested using RNase-free DNA set (Qiagen, 
Sussex, UK). For each column, 80pl DNase mix (lOpl DNase+70pl RDD buffer) was 
applied and incubated at room temperature for 15mins. 350pl of wash buffer RW1 
was added and centrifuged. 500pl buffer RPE was added and centrifuged. This was 
repeated but centrifuged for 2min to dry the column of ethanol present in buffer RPE. 
30pl of water was applied directly to the column, incubated at room temperature for 
lOmins and centrifuged for lmin to elute RNA. RNA was kept on ice once eluted. 
The concentration was determined by use of nanodrop 1000 spectrophotometer. The 
samples were divided into two aliquots and stored at -80°C. For endpoint PCR and 
sequencing in mutation detection, the first RNA aliquot was used to find mutations 
and the process repeated with the second aliquot to confirm mutations.
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2.7. cDNA synthesis for end-point PCR.
cDNA synthesis reactions were set-up on ice using RETRO script® (Applied 
Biosystems, Warrington, UK) in a purifier vertical clean bench (Labconco, USA) pre­
cleaned with RNAzap\ Volumes of reagents are given in (Table 2.3). Oligo (dT) 
primers were used over random decamers to preferentially target mRNA from other 
RNA species (tRNA and rRNA). The reaction ran at 44°C for 60min followed by 
lOmin at 90°C to inactivate reverse transcriptase enzymes using an icycler (Biorad, 
Hemel Hempstead, UK). 2pi of completed reaction mixture was immediately used in 
each master mix for end-point PCR.
Table 2.3. Components (per sample) for cDNA synthesis.
Reagent Volume (pi)
Buffer 1
Oligo (dT) 1
dNTP 2
RNase inhibitor 0.5
MMLV-reverse transcriptase enzyme 0.5
RNA template lOOOng
Nuclease-free water =5-volume of RNA
Total 10
2.8. Calculation of lp g  RNA for use in cDNA synthesis.
Equation 2.7 Volume (pi) of sample to give lpg. lpg  RNA = lOOO(ng)
Amount of RNA (ng) per pi
For example, for a RNA sample of 250ng/pl, 4pl of sample would give lpg  for 
cDNA synthesis.
The use of Oligo(dT) primers targeted all mRNA transcripts from the total RNA 
extracted from cells, p-actin is an abundant target with optimised primers. Therefore, 
P-actin primers were used to amplify P-actin mRNA to clarify the success of the 
cDNA reaction. The reaction was set-up according to Table 2.4.
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Table 2.4. Components of the master mix for amplifying |3-actin mRNA to clarify the
success of each cDNA reaction.
Reagent Volume in B-actin master mix Final
5x Buffer 5 IX
lOmM dNTP mix 0.5 0.2mM each
25mM Magnesium Chloride 1.5 2mM
3-actin forward primer 0.5 0.2 pM
B-actin reverse primer 0.5 0.2pM
GoTaq DNA polymerase (5u/pl) 0.15 1.5U
cDNA template 1 -
Water 15.85 -
Total 25 -
2.9. End-point PCR.
HPRT mRNA was amplified by use of two pairs of overlapping primers (D and K) to 
obtain 83% gene coverage. The oligonucleotide sequence for each primer is shown in 
Table 2.5. The location of each primer is shown in Figure 2.1.
Table 2.5. Sequences of the primers used for successful amplification of HPRT 
cDNA.
Primer Name Sequence
D Forward 5'-GAACCTCTCGGCTTTCCC-3'
D Reverse 5'-TGCCAGTGTCAATTATATCTTCC-3'
K Forward 5'-GATGATCTCTCAACTTTAACTGG-3'
K Reverse 5 '-CTT ACTTTT CT AAC AC ACGGT GG-3'
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GGCGGGGCCTGCTTCTCCTCAGCTTCAGGCGGCTGCGACGAGCCCTCAGG 
CGAACCTCTCGGCTTTCCCGCGCGGCGCCGCCTCTTGCTGCGCCTCCGCCT 
CCTCCTCTGCTCCGCCACCGGCTTCCTCCTCCTGAGCAGTCAGCCCGCGCG 
CCGGCCGGCTCCGTTATGGCGACCCGCAGCCCTGGCGTCGTGATTAGTGA 
T GAT G AACC AGGTT AT G ACCTT G ATTT ATTTT GC AT ACCT AAT C ATT AT GC 
T G AGG ATTT GG A A AGGGT GTTT ATTCCT C ATGG ACT A ATT AT GG AC AGG A 
CT G AACGT CTT GCTCG AG AT GT GAT G AAGG AG AT GGG AGGCC AT C AC ATT 
GT AGCCCT CT GT GT GCT C A AGGGGGGCT AT AA ATT CTTT GCT G ACCT GCTG 
GATT AC AT C A AAGC ACT G A AT AG AAAT AGT GAT AG ATCC ATT C CT AT G AC 
T GT AG ATTTT AT C AG ACT G AAG AGCT ATT GT AAT G ACC AGT C AAC AGGGG 
AC AT AAA AGT AATT GGTGG AG ATG ATCTCTC A ACTTT A ACTGG AA AG AA 
T GT CTT GATT GT GG A AG AT AT A ATT G AC ACTGGC A AA AC AAT GC AG ACTT 
T GCTTTCCTT GGTC AGGC AGTAT AAT CC AAAG AT GGT C AAGGTCGC A AGC 
TT GCTGGT G A A AAGG ACCCC ACG AAGT GTT GG AT AT AAGCC AG ACTTT GT 
T GG ATTT G AAATTCC AG AC AAGTTT GTT GTAGGAT AT GCCCTT G ACT AT A A 
T G A AT ACTTC AGGG ATTT G AAT CAT GTTT GT GT C ATT AGT G A AACT GG A A A 
AGC A A A AT AC A A AGCCT A AG AT G AG AGTTC A AGTT G AGTTT GGAAAC AT C 
T GG AGTCCT ATT G AC ATCGCC AGT AAAATT AT C A AT GTT CT AGTTCT GT GG 
C CAT CTGCTT AGT AG AGCTTTTT GC AT GT AT CTT CT A AG A ATTTT AT CT GTT 
TT GT ACTTT AG AAAT GTC AGTT GCT GC ATTCCT AAACTGTTT ATTT G C ACT 
AT G AGCCT AT AG ACT AT C AGTT CCCTTT GGGCGG ATT GTT GTTT A ACTT GT 
AAAT G AAAA AATTCTCTT A AACC AC AGC ACT ATT G AGT G A A AC ATT G A AC 
TC AT AT CT GT A AG AAAT A A AG AG AAG AT AT ATT AGTTTTTT AATT GGT ATT 
TT A ATTTTT AT AT AT GC AGG A AAG AAT AG AAGT GATT G AAT ATT GTT AATT 
ATACCACCGTGTGTTAGAAAAGTAAGAAGCAGTCAATTTTCACATCAAA 
GACAGCATCTAAGAAGTTTTGTTCTGTCCTGGAATTATTTTAGTAGTGTTT 
C AGT AAT GTT G ACT GT ATTTTCC A ACTT GTTC AAATT ATT ACC AGT G A AT C 
TTT GT C AGC AGTTCCCTTTT AAAT GC AAAT C A AT AAATTCCC AAAA ATTT A 
AAAAAAAAAAAAAAAAAAAAA
Figure 2.1. Sequence of HPRT mRNA and the locations of D primers (underlined) 
and K primers (bold).
Primers were designed using Beacon 2 software (Premier Biosoft) and synthesised by 
MWG Eurofins (Germany) with instructions for reconstitution of lyophilized primers 
to lOOpM (pmol/pl) in nuclease free water. This master stock was further diluted 1:10 
to lOpM working stock in nuclease free water and frozen as single use (1 Ojul) 
aliquots. To prevent primer dimers, two master mixes (designated D and K) were 
established for each primer pair, according to the volumes in Table 2.6.
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Table 2.6. Constituents of each master mix to amplify HPRT mRNA.
D Master 
mix
K Master 
mix
Reagent Supplier Volume (pi) Volume (pi) Finalconcentration
5x Buffer Promega, Southampton, UK 10 10 IX
' lOmM dNTP 
i mix Promega, Southampton, UK 1 1
0.2mM each 
dNTP
I 25mM 
I Magnesium 
Chloride
Promega, Southampton, UK 4 4 2mM
! D forward primer MWG Eurofins, Germany 1 0 0.2pM
! D reverse primer MWG Eurofins, Germany 1 0 0.2pMi
K Forward 
! primer MWG Eurofins, Germany 0 1 0.2pM
K reverse primer MWG Eurofins, Germany 0 1 0.2pM
QoTaq DNA
polymerase
(5u/pl)
Promega, Southampton, UK 0.3 0.3 1.5U
cDNA template - 2 2 -
Water - 30.7 30.7 -
Total - 50 50 -
Both master mixes ran simultaneously under the conditions given in Table 2.7 using 
an icycler (Biorad, Hemel Hempstead, UK). Upon reaction completion, samples were 
stored at -20°C awaiting purification for DNA sequencing.
Table 2.7. The conditions for amplification with D and K master mixes. The numbers 
in brackets specify conditions used to amplify j3-actin mRNA.
Stage Temperature (°C) Time (sec) Number of cycles
Initial 93 120 1denaturation
Denaturation 93 10
Annealing 52.6 (60) 20 40 (25)
Extension 72 10
Preservation 4 Infinity 1
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2.10. 6% PAGE.
To verify the success of PCR amplification, 1 Ojul aliquot of reaction mixture was 
loaded onto vertical 6% PAGE (polyacrylamide gel electrophoresis) gels. The 
constituents and respective volumes used for 6% PAGE are given in Table 2.8 which 
are sufficient for two 7.5cm x 9cm gels.
Table 2.8. Reagents of 6% PAGE gels.
Reagent Supplier Volume
Distilled water - 16ml
lOx TBE (Tris/Borate/EDTA) - 2.3ml
10% APS (ammonium per sulphate) Sigma llO pl
30% Acrylamide/Bis acrylamide Biorad 4ml
N, N, N \N '-T  etramethy lethy lenediamine 
(TEMED) Sigma 22.5pl
For 1L of lOx TBE; 108g of Tris (Sigma, Gillingham, UK), 55g boric acid (Sigma, 
Gillingham, UK), and 40ml of 0.5M EDTA (ethyldiamine tetraacetic acid). For 500ml
0.5M EDTA, 93.05g of EDTA (Sigma, Gillingham, UK) was dissolved in 400ml of 
water, the pH adjusted with 2M sodium hydroxide and the final volume increased to 
500ml with water. Gel construction was as follows; 1.5mm glass plates (Biorad, 
Hemel Hempstead, UK) were washed with 70% ethanol and assembled in the casting 
stand supplied. The reagents in Table 2.8 were premixed and added to the cast. A 15 
well comb was inserted and the gel allowed to polymerise for 30min at room 
temperature. Following successful polymerisation, the comb was removed and the 
samples pipetted into the wells. lOpl of each sample was premixed with 2pl loading 
dye supplied with the RETROscript® cDNA syntheis kit. 1 pi of 100 base pair (bp) 
DNA ladder (Promega, Southampton, UK) was mixed with 2pi loading dye and ran 
on the gel. The gel ran at 170V for 30min using a mini protean® 3 cell kit and a 
power pac 300 (Biorad, Hemel Hempstead, UK). D primers gave a product of 537bp 
and K primers gave a product of 715bp. The product bands were visualised by silver 
nitrate staining.
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2.11. Silver nitrate staining.
The stain and developing solution were made up according to Table 2.9. Gels were 
immersed in silver nitrate for 8mins at room temperature, washed twice with distilled 
water and incubated at room temperature in developing solution with gentle agitation 
until the bands were visible. A photographic record was kept using a Biorad universal 
hood II (Biorad).
Table 2.9. Volumes of silver stain reagents used to visualize PCR products on PAGE 
gels.
Reagent Amount Supplier
Silver stain
0.1 % Silver nitrate 
(A gN 03) lg Sigma
Distilled water 1L -
Developer
Sodium hydroxide 
(NaOH) 13.5g Sigma
37% formaldehyde 
(CH20 ) 3.6pl Sigma
Distilled water 0.9L -
2.12. Preparation of samples for sequencing.
The remaining 40pl of PCR product (50pl-10pl for gel analysis) was purified using 
PCR purification kit® (Qiagen, Sussex, UK). 5x volume (200pl) of buffer PE, with 
pH indicator, was added to the reaction mixture. None of the samples needed pH 
adjustments. The solutions were applied to the provided Qiaquick spin columns and 
centrifuged for lmin at 13000rpm in a Heraeus Biofuge Fresco centrifuge with a 
radius of 85mm and the flow through discarded. 750pl of wash buffer was added with 
repeat centrifugation and the flow through discarded. The columns were centrifuged 
to remove ethanol, present in the wash buffer. 30pi of nuclease free water was added, 
incubated for lmin at room temperature and eluted by centrifugation. The samples 
were sent to Genome Enterprise Limited (Norwich, UK) for sequencing. To prevent 
DNA contamination, all equipment used to package samples were wiped with
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DNAaway™ wipes (Molecular Bioproducts, USA). Under the instruction of Genome 
Enterprise Limited, 20pl of each sample was put into PCR tubes (Fisher Scientific, 
Loughborough, UK) in supplied sequencing boxes for shipment. 1.5pM D forward 
and K forward primers were also included in separate tubes in sufficient volume for 
5 pi per sequencing reaction. Sequencing data were analysed using mutation surveyor
3.3. Any mutations found were confirmed by repeat processing of the second aliquot 
ofRNA.
2.13. Construction of mutation spectrum.
Mutation spectra were constructed using iMARS software, kindly provided by Dr 
Paul Lewis at Swansea University (Morgan and Lewis, 2006).
2.14. Two step real time PCR.
2.14.1. cDNA synthesis for real time PCR.
cDNA synthesis was performed under the same precautions used in end-point PCR. 
1 pg of RNA was used in cDNA synthesis using Quantitect reverse transcription kit 
(Qiagen, Sussex, UK) according to manufacturers instructions. Firstly, RNA was 
subject to genomic DNA (gDNA) elimination using the reagents in Table 2.10.
Table 2.10. Constituent reagents for elimination of genomic DNA from RNA 
samples.
Reagent Volume per sample (pi)
gDNA elimination buffer 2
RNA lOOOng
Nuclease-free water Make up to total volume
Total 14
The reagents were vortexed and centrifuged and incubated on an icycle (Biorad, 
Hemel Hempstead, UK) at 42°C for 2mins, then returned to ice. 6pl of the reverse 
transcription master mix was added (Table 2.11), the tube vortexed, centrifuged 
briefly and incubated for 15mins and at 42°C.
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Table 2.11. cDNA synthesis reaction mixture for real time PCR.
Reagent Volume per sample (pi)
Reverse transcriptase enzyme 1
Quanti script buffer 4
Primer mix 1
gDNA elimination step 14
Total 20
2 pi o f the completed reaction mixture was added to one well of the real time PCR 
plate. Note, equation 2.8 was used in scaling up the reverse transcription master mix.
Equation 2.8. Volume of reagent = (n+1) (where n=number of samples).
2.14.2. Real time PCR.
Real time PCR was performed immediately after cDNA synthesis under the same 
laboratory practice. Expression analysis was performed using QuantiFast Probe PCR 
+ROX Vial Kit (Qiagen, Sussex, UK) and inventoried FAM conjugated Taqmam 
gene expression assays (Applied Biosystems, Warrington, UK) for MGMT (assay ID; 
Hs01037698_ml), TBP (assay ID; Hs00427620_ml); an appropriate house keeping 
gene and GAPDH (assay ID; Hs99999905_ml) for siRNA validation (Chapter 6). 
The reaction was set up according to instructions provided in the QuantiFast kit. The 
volumes o f reagents in the master mix are given in Table 2.12.
Table 2.12. Components of each well of a 96 well plate for real time PCR.
Reagent Volume per sample well (pi)
Taqman probe 1
QuantiFast buffer 10
Nuclease-free water 7
cDNA sample 2
Total 20
To scale the reaction, equation 2.9 was used.
Equation 2.9. Volume of reagent (n+5) (where n=number of samples).
Real time PCR for each cDNA template was performed in triplicate in separate wells.
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To minimise pipetting errors between triplicates, 59.4pl of the master mix was 
premixed with 6.6pl cDNA sample (allowing 10% excess), vortexed and centrifuged, 
20 j l x 1 was then pipetted into each of three wells. The plates were sealed using 
microseal B film (Biorad Hemel Hempstead, UK), centrifuged and placed in a MY iQ 
icycler single colour real time PCR detection system. Thermocycling conditions are 
shown in Table 2.13.
Table 2.13. Conditions for two step real time PCR using Taqman® probes.
Stage
Temperature
(°C)
Time
(sec)
Number of 
cycles
PCR initial activation 
step 95 180 1
Denaturation 95 3
40Combined
annealing/extension 60 30
2.15. Protein extraction.
A total of lx l0 6 AHH-1 cells gave approximately 1 mg/ml protein yield using RIPA 
buffer (Sigma, Gillingham, UK). Upon harvest, cells were centrifuged at 1500rpm for 
5mins at room temperature, washed twice in PBS to remove inhibitory media 
components and the pellet re-suspended in 200pl RIPA buffer by brief vortex. The 
sample was incubated on ice for 5min, vortexed briefly and frozen at -80°C for long 
term storage. Once defrosted, the samples were centrifuged at 8000rpm for lOmin at 
4°C in a Heraeus Biofuge Fresco centrifuge, the supernatant was carefully removed 
and the pelleted insoluble aggregate discarded. The samples were then quantified by 
use o f the Bicinchoninic acid (BCA) assay.
2.16. Protein quantitation.
The BCA assay is colorimetric, measuring absorbance at 562nm (blue/purple), which 
signifies the reduction of Cu2+ to Cu+ in the presence of alkaline proteins. A standard 
curve was constructed (Table 2.14) for determination of protein concentration. The 
maximum concentration of bovine serum albumin (BSA) supplied was 1 mg/ml, 
therefore, dilutions of samples in RIPA buffer were sometimes necessary to fit onto 
the standard curve. The BCA working reagent was made up of 1ml Reagent A mixed
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with 20|ul Reagent B until precipitate dissolved. 160pl of the BCA working reagent 
was added to 20pl sample or 20pl standard per well of a 96 well plate (Nunc, 
ThermoScientifc, Loughborough, UK).
Table 2.14. Dilution of BSA protein standard.
Concentration of 
BSA standard 
(pg/ml)
Volume of protein 
standard (pi)
Volume of RIPA 
buffer (pi)
1000 20 0
800 16 4
600 12 8
400 8 12
200 4 16
0 0 20
The plate was sealed using nescofilm and incubated at 37°C for 30min. Absorbance 
was measured using a polarstar luminometer. The concentration of protein in each 
sample was determined from the standard curve using equation 2.10.
Equation 2.10 y=mx+c re-arranged for x, x=(y-c)/m
Where,
y=absorbance of sample 
m=gradient of graph 
x=concentration of sample (pg/ml) 
c=y-axis intersect.
2.17. Western blotting.
Investigations into MGMT protein levels were made by western blot. All antibodies 
were purchased from Abeam (Cambridge, UK). These were;
• Mouse monoclonal antibody to MGMT (ab39253)
• Mouse monoclonal antibody to p-actin loading control (mAbcam 8226)
• Rabbit polyclonal secondary antibody to mouse IgG-HRP (horse radish
peroxidsase) conjugated (ab6728).
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2.18. SDS-PAGE.
1.5mm glass plates were washed with 70% ethanol and assembled vertically in a 
casting stand. The constituents of the resolving gel (Table 2.15) were premixed and 
added to the cast leaving ~2cm for the stacking gel. 1ml o f propan-2-ol 
(ThermoScientific, Loughborough, UK) was added immediately to the top of the 
resolving gel and left to polymerise at room temperature for 30mins. The layer of 
propan-2-ol was removed and the stacking gel applied (Table 2.15). A 10 well comb 
was inserted and the gel left to polymerise for 30min at room temperature. After 
which time, the comb was removed and the gel removed from the casting stand and 
assembled in the electrode assembly kit filled with running buffer at 4°C. The 
optimum amount of protein loaded per well was found to be 40pg. The volume of 
sample required for 40pg protein was mixed in a 1:1 ratio with Laemmli buffer 
(Sigma, Gillingham, UK), vortexed, centrifuged and incubated at 95°C for 5min using 
heatblock. 5 pi Western C molecular weight marker (Biorad, Hemel Hempstead, UK) 
was added to the first lane, lOpl Dual Colour standard (Biorad, Hemel Hempstead, 
UK) was added to the second and tenth lane. 40pg of protein was added to respective 
wells and the gel run at 120V for 90min at 4°C.
Table 2.15. Constituents of SDS-PAGE for separation of extracted protein.
Volume (ml)
Reagent Stacking Gel 10% Resolving Gel
30% Acrylamide 0.65 5
Distilled water 3 6
1.5M Tris (pH8.8) - 3.75
1M Tris (pH6.8) 1.25 -
10% sodiumdodecylsulfate (SDS) 0.05 0.15
10% ammonium persulfate (APS) 0.025 0.075
N,N,N',N'-
T etramethylethy lenediamine 
(TEMED)
0.005 0.015
2.19. Protein blotting.
Proteins separated by SDS-Page were transferred to Immuno-blot Polyvinylidene 
fluoride (PVDF) membrane (Biorad, Hemel Hempstead,UK) pre-soaked in 100%
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methanol (ThermoScientific, Loughborough,UK). The stacking gel was separated 
from the resolving gel and discarded. The gel, PVDF membrane, 2x fibre pads and 2x 
blot paper were soaked in transfer buffer pre-cooled to 4°C. The transfer cassette was 
assembled ensuring there were no air bubbles between the gel and membrane. The 
cassette was put into the electrode assembly and run at 400mA for 90min at 4°C. 
Upon completion, the membrane was washed in TBS/T buffer (see section 2.22) and 
the membrane cut to separate the Western C ladder in the first lane for separate 
antibody incubations. The membrane was cut according to the bands o f Dual colour 
standard. MGMT has a molecular mass of 22KDa and so the membrane was cut either 
side of lOKDa and ~30KDa. (3-actin is 44 KDa and the membrane was cut either side 
of 37KDa and 75KDa.
2.20. Membrane blocking and antibody dilutions.
To reduce background noise, 0.5% milk in TBS/T was used as the blocking buffer. 
Membranes were immersed in blocking buffer and left for lhr at room temperature 
with gentle agitation. Blocking buffer was removed and membranes probed with 
1:1000 of respective primary antibody in dilution blocking buffer. The Western C 
membrane remained in blocking buffer. The membranes were left overnight at 4°C 
with gentle agitation. The primary antibody was removed and the membranes washed 
four times with vigorous shaking for 5min in TBS/T. HRP-conjugated secondary 
antibody, diluted 1:1000 in blocking buffer, was added to MGMT and |3-actin sample 
membranes and incubated with gentle shaking for lhr at room temperature. Western 
C membranes were incubated under the same conditions with StrepTactin-HRP 
(Biorad, Hemel Hempstead, UK) conjugate diluted in blocking buffer. The secondary 
antibody was removed following repeated washing with TBS/T as described.
2.21. Protein detection.
Protein bands were detected using Immun-Star Western C chemiluminescent kit 
(Biorad, Hemel Hempstead) according to manufacturers instructions. 
Luminol/enhancer solution was mixed with equal volume of peroxide buffer and kept
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out of light. The membranes were immersed for lmin with vigorous shaking, the 
excess removed and visualised using a ChemiDoc XRS (Biorad, Hemel, Hempstead, 
UK). On manual exposure, 2sec was sufficient to detect |3-actin whereas MGMT 
required up to 3min.
2.22. Western blot reagents.
10% (W/V) Ammonium persulfate (APS)-lg APS diluted in 8ml distilled H20 , 
volume adjusted to 10ml by addition of dH20 .
10%(w/v) sodium dodecylsulfate (SDS)-25g SDS dissolved in 200ml dH20  and the 
volume increased to 250ml by distilled H20 .
1.5M Tris (pH 8.8)-45.4g Tris dissolved in 150ml water adjusted to pH 8.8 by 
addition of 10M hydrochloric acid (HC1) and the volume increased to 250ml by 
distilled H20 .
1M Tris (pH 6.8)-30.3g Tris dissolved in 150ml water adjusted to pH 6.8 by addition
of 10M HC1 and the volume increased to 250ml by distilled H20 .
lOx Running buffer-30.3g Tris, 144.1 g Glycine, 100ml 10% (w/v) SDS in 800ml
water adjusted to 1L by addition of distilled H20 .
lx  running buffer-100ml of lOx buffer and 900ml distilled H20 .
Transfer buffer-100ml lOx running buffer, 200ml 100% methanol, 700ml distilled 
H20 .
lOx TBS-24.2g Tris, 80. lg  NaCl dissolved in 800ml dH20 , pH adjusted to 7.6 by 
10M HC1 and volume increased to 1L by distilled H20 .
TBS/T wash buffer-100ml lOx TBS, 10ml 10% (v/v) Tween20 and distilled H20  to 
1L.
0.5% milk blocking buffer-0.5g Semi skimmed milk powder dissolved in 80ml 
TBS/T adjusted to 100ml once dissolved.
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Chapter 3.
Dose-response
Modeling.
Dose-response For 
Mutation Induction 
By Low Dose MNU 
In Human Cells.
3.1. Introduction.
The following chapter highlights the hypoxanthine (guanine) phosphoribosyl 
transferase [H(G)PRT] forward mutation assay as an important sensitive test system 
used for assessing mutation induction at low doses of exposure to mutagens. The 
HPRT assay has well-established guidelines (OECD 476, 1997). The end result of the 
assay is the mutant frequency (MF), which dictates the frequency of HPRT mutants in 
a population of cells. A mutagen gives a positive result, which is observed as a 
statistically significant increase in MF over the untreated and solvent control (OECD 
476, 1997). The assay is specific enough to correctly identify a wide range of 
mutagens. The assay can identify agents that cause base substitutions or small 
deletions at the HPRT gene, whereas major changes in the X chromosome, where 
HPRT gene is located, are lethal and cannot be detected. The assay can be run in a 
number of mammalian cell lines including hamster V79 and CHO cells. However, 
with considerable impetus for the use of human cell lines as a model of hazard 
identification in human populations (Hawksworth, 1994), the HPRT assay is used in 
human cell lines such as TK6 and AHH-1 and in isolated lymphocytes in bio­
monitoring studies. Fowler et al (2012a) provide impetus for using human cell lines 
for specific and sensitive assessment of genotoxic potential over rodent cell lines.
3.1.1. HPRT as a mutation sensor.
Located on the X chromosome in mammalian cells, Xq26-27 (Pai et al, 1980), the 
HPRT gene is hemizygous; it is present as only one allelic copy in male cells, whereas 
in female cells, due to imprinted silencing of the second X chromosome (Ahn and 
Lee, 2008), only one functional copy exists. Therefore, it is designated HPRT+/o. 
This means that, unlike autosomal genes, a second allele does not compensate for 
recessive changes in the first allele. As a result, this locus is more sensitive to 
phenotypic alteration. The HPRT locus has been used as a surrogate mutation sensor 
for other important loci like p53 (Dobrovolsky, Shaddock and Heflich, 2005). Caution 
is urged as different loci may have different mutation rates (Hodgkinson and Eyre- 
Walker, 2011). Impaired HPRT protein function, through non-synonymous mutations 
within the protein coding region, will confer resistance to a toxic agent (a toxic
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analogue o f guanine). This means HPRT mutants gain a growth advantage (DeMarini 
et al, 1989). Therefore, use o f simple selective media allows the differentiation of 
HPRT deficient (-/o) from HPRT proficient (+/o) cells and vice versa. An inherent 
disadvantage o f this and other mutation assays, which select for loss of protein 
function, is that synonymous/silent mutations that change DNA sequence but not 
protein function will be missed.
3.1.2. HPRT function in wildtype cells.
Functional HPRT is a housekeeping enzyme (EC 2.4.2.8) found in the cytoplasm 
where it contributes to the salvage pathway, one of two biosynthetic pathways that 
produce purines for RNA and DNA biosynthesis. The pathways are;
1. De novo synthesis (synthesis from simple molecules)-A metabolically 
expensive, 10 enzyme pathway that synthesises purines from the sugar 
5’phosphoribosyl-l-pyrophosphate (PRPP).
2. Salvage pathway-HPRT recycles degraded DNA bases into usable purine 
nucleotides. 90% of free purines in mammalian cells are recycled (Rossiter 
and Caskey, 1995). The salvage pathway is the main purine biosynthetic 
pathway in erythrocytes because they are deficient in the de novo pathway for 
synthesis o f purines, such as adenosine triphosphate, ATP used as an energy 
source (Fontelle and Henderson, 1969).
3.1.2.1 Intracellular purine biochemistry: the salvage pathway involves HPRT.
The role of HPRT in the condensation of PRPP and guanine or hypoxanthine into 
guanosine monophosphate (GMP) and inosine monophosphate (IMP) is shown in 
Figure 3.1. The reaction, featuring the ribosylation o f guanine where PRPP acts as a
I
ribosyl donor, is influenced by magnesium (Mg ). HPRT binds to PRPP and then 
guanine or hypoxanthine, forming a temporary intermediate. Following the transfer o f 
phosphoribosyl to guanine; pyrophosphate is released as a by-product, giving IMP or 
GMP for DNA or RNA synthesis.
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De novo synthesis
Uric Acid
Figure 3.1. Purine recycling through the salvage pathway, HPRT' (Hypoxanthine 
phosphoribosyl transferase) is circled. Adapted from Stout and Caskey (1985).
3.1.2.2. De novo purine synthesis.
PRPP serves as the starting point for the main purine biosynthetic de novo  pathway. 
This involves 10 steps, culminating in the production o f  IMP that can form adenosine 
monophosphate (AMP) or GM P (Figure 3.2). This is the default pathway in most 
mammalian cells but it is energetically expensive. The salvage pathway compensates 
when the de novo  synthesis pathway is inhibited (see section 3.1.4.1). Purine 
metabolism and its influence on DNA synthesis is a target for chemotherapy (Riscoe 
et al, 1989).
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Figure 3.2. Purine biosynthesis via the de novo pathway. PRPP. the ribosyl donor in 
the salvage pathway initiates the process. Increased PRPP concentration in HPRT 
deficiency syndromes increases de novo throughput. 10-formyltetrahydrofolate 
(circled in red) acts as a formyl (CHO) donor for two reactions. Without this donor 
this pathway does not function. This forms the basis o f  selection for HPRT+/o cells 
that use the salvage pathway to overcome loss o f  nucleotide synthesis through de 
novo pathway. Image manipulated from Ashihara and Suzuki (2004).
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3.1.3. Exploiting HPRT for mutation analysis.
The use of readily available media supplements can distinguish HPRT mutants from 
wildtype cells allowing easy quantitation of mutant frequency and mutagenic potency. 
Commonly used supplements are;
1. HAT, a combination of Hypoxanthine, Aminopterin and Thymidine that 
allows HPRT+ / 0  wildtype cells to survive. Used to remove existing mutants 
from the population at the start of the assay
2. 6-Thioguanine, a toxic purine analogue that allows HPRT-/o cells to survive.
3.1.4. Selection procedures for isolation of mutant or wildtype HPRT.
3.I.4.I. Using HAT supplement to select for HPRT+/o wildtype cells.
Media supplemented with HAT will block de novo purine synthesis (Figures 3.2 and 
3.3). This forces cells to use the salvage pathway to provide purines for DNA 
synthesis. Cells deficient in HPRT (through loss of heterozygosity (LOH) mutations) 
will be unable to synthesise purines, when grown in HAT media and undergo 
apoptosis through an unknown mechanism possibly involving c-myc proto-oncogene 
expression (Chung et al, 2001). At the start o f the HPRT assay HPRT mutants are 
removed, increasing the sensitivity of the assay to chemical mutagenesis, an 
advantage held over other loci such as lacl in transgenic mice (Skopek, Kort and 
Marino, 1995). Aminopterin, present in HAT supplement, was used as an 
antileukemic drug (Farber and Diamond 1948). Like other chemotherapeutic 
antimetabolites such as methotrexate (Kinsella, Smith and Pickard, 1997), it targets 
enzymes to inhibit synthesis of DNA building blocks thereby limiting a cell’s 
capacity to divide. Aminopterin competes with folic acid for the active site of 
dihydrofolate reductase (DHFR, Figure 3.3), an enzyme that converts folic acid into 
cofactors essential for enzymes in de novo biosynthesis (Huennekens et al, 1963). 
Once bound to the active site, aminopterin will inhibit this enzyme and deplete 
intracellular pools o f nucleotides, affecting DNA strand synthesis during S phase of 
the cell cycle, ultimately limiting cell division (Tsurusawa et al, 1990). The end 
product is 10-formyltetrahydrofolate that serves as a formyl (CHO) donor at two steps 
of the 10 steps of the de novo synthesis pathway (Figure 3.2). Without 10- 
formyltetrahydrofolate, de novo synthesis shuts down and only cells proficient in
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HPRT will be able to synthesise nucleotides and proliferate. DHFR inhibition also 
leads to the loss o f  thymidine/deoxythymine. a pyrimidine nucleotide whose loss is 
toxic to all cells. This is provided in HAT as thymidine. Incidentally hypoxanthine in 
HAT is supplied as a substrate for HPRT mediated purine synthesis. Both additives 
maintain the growth o f  HPRT+/0 cells.
AMINOPTERIN
A\\
Key:
INHIBITION
DHFR 
Folic Acid — >
DHFR 
D H F  ► THF
FTL
10-formylTHF
Figure 3.3. Part o f  the human folate metabolism pathway. The enzyme DHFR 
(dihydrofolate reductase) is inhibited by aminopterin. The end product. 10- 
formylTHF donates formyl (CHO) groups to intermediates o f  the de novo  purine 
biosynthetic pathway (Figure 3.2). Without this, purine biosynthesis can only occur 
through HPRT and the salvage pathway. DHF: dihydrofolate, THF; tetrahydrofolate, 
FTL; formate-tetrahydrofolate ligase. Constructed from Lightfoot et a l (2005) and 
Vickers el al (2009).
3.1.4.2. Counter selection; toxie analogues are used to select for HPRT -/o 
mutants.
A particular attraction to this locus is the ability to select for HPRT mutants as well as 
wildtype cells, as previously discussed. When selecting for mutants, only cells 
deficient in HPRT will survive. This is achieved through use o f  a guanine analogue; it 
is converted into a toxin only if  HPRT is functional, thereby killing wildtype cells. 8- 
azaguanine was commonly used as a guanine analogue for selecting HPRT mutants 
(Arlett et al. 1975). However, van Diggelen et al (1979) report that 8-azaguanine is a 
poor substrate for HPRT. Wildtype HPRT shows higher affinity for 6-TG over 8- 
azaguanine (Cellela et a l , 1983) offering a more stringent mutant selection. Therefore.
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the assay featured in the following work uses 6-thioguanine (6-TG) as the most 
stringent selective agent.
3.1.5. Mechanism of 6-Thioguanine toxicity in wildtype HPRT cells.
Once 6-TG enters the cell it is firstly converted to 6-thioguanine monophosphate (6- 
TGMP), which inhibits purine biosynthesis by;
1. Pseudo feedback inhibition of amidophosphoribosyl transferase, the first 
enzyme of de novo purine biosynthesis
2. IMP dehydrogenase inhibition.
These effects shutdown all sources of purine nucleotides, meaning a higher 
probability that 6-TGMP will be incorporated into nucleic acids. 6-TGMP is then 
phosphorylated and is incorporated into DNA (Nelson et al, 1975) (Figure 3.4). Ling 
et al (1992) propose that the presence of 6-TG in the template strand of DNA blocks 
polymerase extension. Balajee and Geard (2004) identified Replication protein A 
(RPA) and y-H2AX foci at the site of replication blockage. These proteins are 
involved in the repair of double stranded breaks (DSBs), a highly cytotoxic lesion. 
Therefore, it is possible that their presence as foci indicates that DSBs are a possible 
outcome of replication blockage by 6-TG. In addition to DSBs as a method of cell 
killing by 6-TG; Yan et al (2003) propose that mismatch repair (MMR) has a role. 
The authors questioned the role of futile MMR processing in introducing persistent 
single stranded breaks, which lead to G2-M triggered apoptosis. The authors found 
significant increases in ssDNA breaks occurred in MMR+ cells than in MMR- 
following treatment of 6-TG. This model of 6-TG toxicity has important implications. 
This agent would only suffice as a selective agent if the host cell was proficient in 
MMR and G2-M checkpoint control. The ability to counter select for wildtype or 
HPRT mutant strains has allowed investigators to calculate reversion rates at this 
locus (Yang et al, 1988), however this hasn’t been determined in AHH-1 cells. 
Selection strategies are summarised in Figure 3.5.
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C ell death C ell death
MM R induced 
ssD N A  breaks
Replication blockage 
causing dsDNA breaks
D N A
GMP AMP
6 T G M P
XMP
Hprl IMP
6TG
PRPP
D e novo  purine synthesis
Figure 3.4. Metabolism o f  6-thioguanine (6-TG) in HPRT wildtype cells. 6-TG is 
converted into its monophosphate form, 6-TGMP. that inhibits de novo  purine 
synthesis and is incorporated into DNA leading to cell death. Cells deficient in HPRT 
will not metabolise 6-TG and will survive. Modified from Aubrecht et al (1997).
Population of cells with mixed HPRT proficiency
HPRT -/oHPRT +/o
Purine analogues 
ye.g. 6-ThioguanineHAT
Uniform culture of wildtype HPRT (+/o) cells Unifomi culture of mutant HPRT (-/o) cells
Figure 3.5. A schematic o f  the selective agents used to unify a population based on 
the cell 's  HPRT proficiencies.
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3.1.6. Alternative HPRT proficiency selection strategies.
Supplemented media is the easiest and most effective way of HPRT selection. 
However, other methods exist. Dorman et al (1978) report the positive selection 
through autoradiographic analysis following tritium labelled hypoxanthine 
([ H]hypoxanthine) incorporation into cells proficient in HPRT.
3.1.7. Outline of HPRT assay methodology.
The HPRT assay has been described in AHH-1 cells by Crespi and Thilly (1984). The 
assay has three important stages; mutant cleansing, treatment with test article, 
followed by selection for mutants and quantitation. A schematic is shown in Figure 
3.6.
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3.1.7.1. Stage 1-Mutant cleansing, Reducing the background HPRT-/o mutants.
The mutagenic potential of a test article is only realised once the mutant frequency 
(MF) at a certain dose is compared to that of the untreated control, as previously 
stated. The untreated control is vitally important. It infers the background level of MF 
that occurs, the result o f spontaneous DNA damage, under the conditions o f the assay. 
If the background is high then an increase in MF may not be significant and a 
mutagen could be misclassified. It is therefore essential that the assay has a low and 
stable background level. This is achieved through use of HAT supplemented media. 
See section 3.1.4.1. Only cells capable of salvage synthesis of purines (HPRT+/o) will 
survive, mutant cells (HPRTVo) cannot survive. This lowers the existing level of 
mutants, lowering the background to 1-100 mutant cells in a population of 105 cells 
(this is further discussed in section 3.3.1). Thus, increasing the sensitivity of the 
assay. Cells are then given four days growth under normal conditions to ensure 
sufficient cell numbers for treatment.
3.I.7.2. Stage 2-Treatment with test article and sub-culturing.
Cells are diluted and exposed to a range of concentrations of the test article under the 
instructions given in OECD guideline 476 (1997). These being;
1. Concentrations should not be more than 2 to VlO units to a maximum of 
5000mM, solubility limit or 50% cytotoxicity ( L D 5 0 )  measured by replicative 
plating efficiency (RPE) for the HPRT assay
2. An appropriate diluent (solvent) as given in the Merck index or in the 
manufacturer’s recommendations. The solvent used must; “be compatible 
with the survival of the cells,” not induce mutations giving an increase in MF 
over the spontaneous MF and it must not react with the test article
3. Cells are left in the presence of test article for up to 24hr. Shorter exposure 
strategies are adopted if an enzyme/rat liver (S9) mix is used. This mix is 
highly mutagenic after 4hr but it is necessary for metabolism of the test article 
into its respective end products for testing. Genetically modified cell lines like 
MCL-5, a derivative o f AHH-1, possess limited metabolism to overcome the 
use of S9.
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Following removal of the test article after the appropriate exposure strategy, the cells 
are cultured for 13 days. The initial cell divisions fix the resulting DNA damage into 
permanent mutations if not repaired prior to cell division, possibly changing the 
structure and/or function of the resulting HPRT protein. The remainder o f the 13 days 
gives time for the mutant non functional HPRT to replace the wildtype HPRT within 
the cell, effectively becoming HPRT-/o. Diamond et al (1982) identified an optimal 
expression period of 4-5 days post treatment only in Syrian hamster embryo cells. 
Grosovsky and Little (1983) state that a maximum mutation frequency was reached 9 
days post treatment, which remained stable up until 17 days. At alternating days the 
cells are diluted in fresh media, to replenish the nutrients, giving a cell concentration 
that will repopulate but not outgrow the culture.
3.1.7.3. Stage 3-Selection for mutants and quantitation.
The population at this stage contains wildtype (HPRT+/o) and mutant 
(HPRT-/o) cells, resulting from spontaneous mutagenesis and induced damage 
following genotoxin exposure. The next process is to isolate HPRT-/o cells for 
propagation and colony counting. This is achieved through use of 6-TG that becomes 
toxic when catalysed by HPRT in HPRT+/o cells. (See section 3.1.4.2). Cells are 
diluted and pipetted into 96 well plates in the presence of 6-thioguanine. Each well 
represents an independent observation. Increasing the number o f observations greatly 
increases the statistical power required for threshold analysis (Doak et al, 2007). A 
colony represents a HPRT-/o cell as one colony is derived from one cell and only 
HPRT-/o mutant cells will grow.
3.1.8. Why use the HPRT assay?
3.I.8.I. Alternative in vitro mutation assays.
There are a number of mutation assays that quantify MF at different loci. 
Consequently, each has a unique way of distinguishing mutant from wildtype cells. 
Sensitivity and specificity depend on the stability of the host cell genome. In a report 
by Kirkland et al (2005), the bacteria based mutation assay (Ames assay) is only
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sensitive enough to detect 58.8% of known genotoxins, far inferior to a combination 
of three mammalian cell based assays (73.2%). However the reverse is true if 
specificity of the assay is examined. The Ames assay correctly identified 73.9% of 
non-carcinogens as negative compared to 39% in mammalian cell based assays. 
Therefore one test does not give sufficiently robust sensitivity and specificity. A 
battery of three assays is used to predict genotoxicity by regulatory bodies. However, 
in our mechanistic studies only one assay needs to be used because the results will not 
be used to predict genotoxicity in a regulatory sense (Kirkland, et al, 2007). Table 3.1 
highlights the most popular alternatives to the HPRT assay and their relative 
advantages and disadvantages.
Table 3.1. Some alternative assays to the HPRT assay available for genotoxicity 
testing.
Assay Description Advantages Disadvantages
Ames A bacteria-based assay that measures 
reversion mutations that restores the 
host’s ability to synthesise certain 
amino acids, which are lacking from the 
culture media.
Included in the battery 
o f in vitro tests used.
Has a well-defined 
OECD guideline.
Only applicable in bacterial hosts.
Can only evaluate base substitutions or 
frameshifts.
Cannot mimic genomic organisation or 
metabolism found in eukaryotes.
Pig-a Fluorescently labeled antibodies 
identify wildtype cells as GPI linked 
surface marker (CD58) positive. 
Knockout mutants cannot synthesise 
CD58 and do not fluoresce.
Rapid screening by 
flow cytometry.
Rapid turnaround of 
results.
Can be used ex vivo.
Not yet OECD validated.
Source o f PigA mutants have not been 
identified (point mutations, deletions etc).
Tk
Assay
Same principle as the HPRT assay but 
at the thymidine kinase (TK) locus 
involved in pyrimidine biosynthesis. 
Trifluorothymidine (TFT) is used for 
mutant selection in an analogous way to 
6-thioguanine.
Detects larger effects 
such as
recombination, 
nondisjunction and 
large deletions.
Can be used ex vivo.
Higher background than HPRT assay in 
our laboratory (Doak et al, 2007).
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3.1.9. HPRT assay in mutation research.
Simple and effective procedures to discriminate and quantify HPRT mutants from 
HPRT wildtype cells have lead to the assay being employed in mutation research. 
Three features o f HPRT biology have attracted scientists for its use in mutation 
quantification. These being;
1. The gene is present as only one true or functional copy in males or females, 
respectively, making this locus sensitive to recessive mutagenesis.
2. It is a non-essential enzyme in cell culture as purines can be provided through 
de novo synthesis meaning cells can survive with both HPRT copies lost.
The HPRT assay is able to quantify point mutations and small deletions or insertions 
at the HPRT  locus. More drastic changes to the X chromosome are lethal and mutants 
will not be recovered. However, only missense or nonsense point mutations that cause 
amino acid substitutions to adversely affect HPRT function will be detected. Methyl 
nitrosourea (MNU), used in this thesis, induces pre-mutagenic adducts including 
0 6MeG a miscoding lesion that leads to GC->AT point mutations that will be 
detected in the HPRT assay if it alters HPRT function. Silent mutations will not be 
recovered, a commonality between all mutation assays that rely on phenotypic 
alterations. This is acceptable because silent mutations are not biologically relevant
Biomonitoring and long exposure studies have used HPRT in human blood cells as an 
in vivo sensor for mutations, predicting cancer and genetic disease (Albertini et al, 
1993).
The HPRT  locus has proved useful in identifying mutations arising;
• Spontaneously and between individuals (Lichtenauer-Kaligis et al, 1995)
• Over many population doublings in various cell lines with varying proficiency 
o f MMR (Glaab and Tindall, 1997)
• From occupational/environmental exposure (da Cruz and Glickman, 1997) and 
lifestyle factors such as smoking (Curry et al, 1999)
• Following disasters such as the Chernobyl incident (Moore et al, 1997)
• As a side effect of cancer treatment (Dempsey, Seshadri and Morley, 1985; 
Ammenheuser et al, 1991)
• During leukaemogenesis (Finette et al, 2001)
• From exposure to test chemicals in stage 1 and stage 2 genotoxicity tests.
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Lymphocytes isolated from blood sampled from individuals are models for the in vivo 
condition. They are easy to isolate but are short lived in vitro. To overcome this 
problem, scientists use the clonal assay whereby cells are stimulated to divide by an 
appropriate mitogen such as phytohaemagglutinin (PHA) that stimulates T cell 
mitosis (Pistoia et al, 1982). This has been useful in biomonitoring studies but not so 
useful in stage 1 genotoxicity testing, where the demand for cells would exceed 
supply. Here, the use of continually growing immortal cell lines is required. It is 
advantageous to carry out in vitro work using cell lines of human origin 
(Hawksworth, 1994). For this reason human lymphoblastoid cell lines such as AHH-1 
and TK6 are used in the HPRT assay.
3.1.10. HPRT assay has been used to determine the dose-response of alkylating 
agents.
Methyl-iV-nitrosourea (MNU), ethyl methanesulfonate (EMS) methyl 
methanesulfonate (MMS) and ethyl nitrosourea (ENU) are four representative 
alkylating agents in use to elucidate low dose genotoxoicity. Alkylating agents are 
mutagenic by adding alkyl groups to a variety o f nucleophilic centres in DNA 
(nitrogen and oxygen o f the bases and phosphate of the backbone). Thus, producing 
an array of alkyl adducts (adduct spectra). The predominant adducts are O6- 
methylguanine ( 0 6MeG), N7-methylguanine (N7MeG) and N3-methyladenine 
(N3MeA). Each adduct has different consequences to DNA. For example, a 0 6MeG 
has miscoding potential and causes GC->AT transitions unless repaired by MGMT. 
Whereas N7MeG and N3MeA, are clastogenic and responsible for EMS induced low 
dose micronuclei frequencies (Zair et al, 2011). The proportion of each adduct in the 
adduct spectra is determined by the electrophilic potential of the alkylating agent and 
is indicative of the likely mode of action (mutagenic or clastogenic). MNU used in 
this study, produces 20 times more 0 6MeG than MMS and is consequently, 20 times 
more mutagenic (Singer, 1980).
It was previously thought that alkylating agents elicited a linear dose-response even at 
low doses since they abide by the “one-hit” hypothesis as discussed in Chapter 1. 
Recently, with the contamination of Viracept® with low levels of EMS (Gerber and 
Toelle, 2009), there has been renewed impetus for strong scientific evidence to 
establish low dose effects of model alkylating agents as representatives of structurally
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and mechanistically similar genotoxic impurities (Muller et al, 2006). Although, 
currently, each chemical is assessed on a case-by-case basis. Concluding a safe-level 
of exposure requires substantial data, robust statistical modeling and evidence of an 
underlying biological mechanism. The work conducted at Swansea University by 
Doak et al (2007) established an in vitro NOEL for EMS for mutation and 
micronuclei induction. A further study by Zair et al (2011) identified DNA repair as 
the potential mechanism behind the NOEL. This data, together with necessary in vivo 
evidence has been used to clarify an acceptable level of EMS exposure with 
no/negligible risk (Gocke and Muller, 2009;Gocke et al, 2009;Pozniak et al, 
2009;Muller et al, 2009;Gocke and Wall, 2009). The aim of this study is to assess the 
low dose effects o f MNU, to elucidate a NOGEL at concentrations 10-fold lower than 
previously tested in the laboratory (Doak et al, 2007). In vitro work alone is not 
appropriate to justify safe exposure levels, due to the uncertainty factors from in vitro 
to in vivo extrapolation. However, in vitro studies can provide:
• Initial characterisation o f the dose-response prior to in vivo work
• Invaluable mechanistic data to determine the mechanism of genotoxic action 
o f carcinogens.
It is hoped that with ever-increasing evidence from in vivo studies (Lynch et al, 2011) 
the true low dose effect o f MNU exposure can be ascertained, which would have 
implications in assessing risk to direct-acting genotoxins of similar chemistry to 
MNU.
3.2. Results.
The HPRT assay was performed in AHH-1 cells to examine low dose effects of MNU 
at 10-fold lower concentrations than previously tested by Doak et al (2007). The 
dose-response was constructed and the shape determined by sophisticated statistical 
modelling described by Johnson et al (2009) and Gocke and Wall (2009).
3.2.1. MNU dose-response.
Plating efficiency (PE) o f treated cultures normalised to control was used as the 
standard measure o f toxicity in the HPRT assay (Duthie et al, 1995; Kulling et al, 
1997) based on colony forming ability of cells when inoculated into a 96 well plate 
without 6-thioguanine (non-selective conditions). The dose-range utilised here, was
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limited by the dose of chemical that caused 50%+/-5% reduction in cell viability 
compared to the negative control. The highest concentration of 0.075pg/ml MNU 
induced 40+/-5% toxicity (Figure 3.7). This is within the acceptable range for testing, 
as dictated in the OECD guideline 486 (OECD, 1997). A two-tailed t-test compared 
PE of each dose to PE of solvent control. The only statistically significant difference 
was a decrease in PE at 0.075 pg/ml (p=0.007), which was expected.
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Figure 3.7. Plating efficiency relative to control was used to assess the ability of cells 
to grow in 96 well plates alongside plates to assess mutant frequency. The solvent 
control (DMSO) is shown here. In comparison, the untreated control showed 92.3+/- 
18.2% PE. Therefore, DMSO had no great effect on PE. n=3, error bars signify 
standard deviation (SD), * p=<0.01.
The frequencies of HPRT mutants were plotted against increasing concentrations of 
MNU (Figure 3.8). It was noted that the mutant frequency (MF) of the solvent 
control is indistinguishable from the untreated control. The MF being; 1.4xl0'5+/- 
1.8xl0"6 (Mean +/-standard deviation) and 1.4xl0’5+/-3.2xl0"6, respectively. A One- 
Way ANOVA revealed that they were not significantly different (p=0.952). Since 
DMSO is not known to be mutagenic, they both represent the spontaneous HPRT MF 
in a wildtype AHH-1 population.
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Figure 3.8. Non-linear dose-response of MNU in AHH-1 cells quantified through the 
HPRT assay (solid line). n=3, error bars indicate SD, *p=<0.001.
The dose-response (Figure 3.8) resembles that of a J-shaped curve, indicative of 
hormesis where the lowest doses have the opposite effect to higher doses (Davis and 
Svendsgaard, 1990). The MF remains constant up to O.OOlpg/ml MNU, but is 
significantly lower at 0.0025pg/ml, an average of 5.52x10 '6+/-2.1x10'7 of three 
replicates. This was significantly lower than the spontaneous level (p=0.003) using 
the t-test as recommended by Gaylor, Lutz and Conolly (2004). Using the author’s 
terminology, 0.0025 pg/ml MNU is the dose showing minimum response (dm). Square 
root transformation of the data accounted for the heterogeneity of the variance, which 
became normally distributed under the Kolmogorov-Smirnov test. A two-sided 
Dunnett’s test on transformed data revealed that 0.0025g/ml (p=0.005) and 
0.005pg/ml (p=0.000) were significantly lower than the solvent control. The MF 
increases to the zero equivalent dose at approximately 0.0075pg/ml. At O.Olpg/ml 
and above, there are statistically significant increases in MF over the spontaneous 
frequency at higher doses of MNU.
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3.2.2. Statistical analysis.
Calculation of the MF is based upon the assumption that the variance in number of 
colonies between replicate plates is equal to the mean, thus conforming to a poisson 
distribution (Luria and Delbruck, 1943; Leonhardt et al, 1999) and statistical analysis 
was performed accordingly. On guidance from Johnson et al (2009), the raw data 
across the entire dose response was tested for best of fit between linear (null 
hypothesis) and quadratic (alternative hypothesis), the simplest non-linear model. The 
output o f SPSS is shown in Figure 3.9. Comparing the goodness of fit values for both 
models using the F-distribution (See appendix 3 for detailed instructions), the null 
hypothesis o f linearity could not be rejected (p=0.58). However, the dose-response 
did not appear linear in Figure 3.8. It is possible that the decrease in MF at 
0.0025pg/ml obscures regression analysis. The statistical approach was originally 
developed for analysis o f threshold dose-responses not J-shaped curves and so the 
approach by Gocke and Wall (2009) was modified for the current analysis.
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Figure 3.9. Initial regression analysis of HPRT full data set (0.00075pg/ml to 
0.075pg/ml MNU) suggested a linear dose-response. Open circles=observed data, 
solid line=linear fit and broken line=quadratic fit.
Due to this, attempts to identify the no observed and lowest observed genotoxic effect 
levels (NOGEL and LOGEL) were made as described by Doak et al (2007). A post
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hoc Dunnett’s analysis was performed on the raw data to compare all treatment MF 
with control (DMSO and untreated). It was found that the NOGEL was 0.0075 pg/ml 
(p=0.99) and the LOGEL being O.Olpg/ml (p=0.001). Log transformation of the data 
and re-analysis confirmed this. For further confidence, a two-tailed t-test was used to 
determine significance by comparing individual treatments to control values, which 
would overcome confusion caused by the initial decline in MF at lower doses of 
MNU. Under the t-test the conclusions were the same (NOGEL=0.0075pg/ml, p=0.19 
and LOGEL=0.01pg/ml, p=0.01). Gocke and Wall (2009) recommended regression 
analysis on the dose-response at doses below the statistical NOGEL of 0.0075pg/ml 
MNU. The data has a negative linear relationship substantiating the decrease in MF at 
lower doses of MNU. The gradient of the slope shown (Figure 3.10) is -0.00075 (to 
5d.p) with 95% confidence limits of -0.00133 to -0.00017 (calculated in the 
appendix). A true NOGEL that supports a broken stick dose-response would have a 
gradient of 0 (Lutz and Lutz, 2009).
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Figure 3.10. The dose-response up to the NOGEL (0.0075pg/ml MNU) shows a 
quadratic relationship. The gradient o f the slope is negative, indicative of hormesis. 
Open circles=observed data, solid line=linear fit and broken line=quadratic fit.
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From Figure 3.10, it is evident that the dose response below NOGEL doses of MNU 
fit a quadratic model (p=0.01), substantiating the appearance of a J-shaped dose- 
response.
3.3. Discussion.
The aim o f this chapter was to elucidate the dose-response relationship of mutation 
induction by MNU. Previous studies in our group have shown a linear dose response 
for MNU induced mutations in AHH-1 cells, but this may have been due to the higher 
doses tested (Doak et al, 2007). Therefore, we have used 10-fold lower concentrations 
using the same standardised methodology and cell line as Doak et al (2007). I have 
used the following term “no observed genotoxic effect level” (NOGEL) to 
discriminate from the opposite “effect” observed at 0.0025 pg/ml MNU.
3.3.1. HPRT assay methodology.
The methodology for HPRT assay has standardised OECD guidelines for testing of 
chemicals (number 486, OECD, 1997), which have been followed here (with the 
exception o f freezing cultures during the expression period) and in previous 
publications by our research group (Doak et al, 2007). However, there is some debate 
as to the optimum HPRT methodology and the variation and uncertainty it can cause 
in determining mutant frequencies. For example, the density of cells within the wells 
when plating up under selective conditions, will manipulate the ratio of cells: 
nutrients: selective agent. Thus, impacting on the recovery of clones resistant to the 
selective agent (6-TG). There is some debate as to what effects high cell densities 
have on the MF in the HPRT assay. If a high density of wildtype cells exist in a well, 
it may negatively impact the growth of mutant cells by depleting nutrients in the 
initial few days before 6TG is metabolised into a toxin (Khaidakov and Glickman,
1996). However, a higher cell density may more rapidly deplete 6-TG and enhance 
survival o f cells, which would overestimate MF. Wildtype cells may also metabolise 
6-TG and leak the genotoxic metabolite into the media, potentially affecting HPRT 
mutant cells. Hallahan et al (1989) state that with the eventual 6-TG induced death of 
wildtype cells, debris from dead cells may impact on the survival of mutants leading 
to an underestimation of MF. Many studies have incorporated 12-0-
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tetradecanoylphorbol-13-acetate (TPA) to prevent metabolic cross talk between 
mutant and wildtype cells (Raveh and Huberman, 1983) by inhibiting intercellular 
gap-junctions (Walder and Lutzelschwab, 1984). However, TPA is a tumour- 
promoting agent with published clastogenic abilities (Emerit and Cerutti, 1983). The 
HPRT assay shares similarities with the TK assay, which served as validation when 
establishing the HPRT assay in our laboratory (Doak et al, 2007). One difference it 
holds is that HPRT occupies a larger region of the genome, approximately 40Kb 
whereas the TK gene is 13Kb. Therefore, the HPRT loci could be considered more 
representative o f global genomic mutation frequencies and would serve as a more 
sensitive mutation sensor. Additionally, Chen et al (2002) concluded that both loci 
were similar in their response to ENU. Monroe et al (1998) compared HPRT, L a d  
and cll/cl as mutational sensors in Big Blue B6C3F1 mice and found that HPRT  
offered superior sensitivity due to the low background mutant frequency at this loci, 
making it an appropriate reporter gene for low dose mutagenicity studies. Dr George 
Johnson and Dr Shareen Doak have optimised the methodology used here, with 
careful consideration of aforementioned caveats. Comparison of mutant frequencies 
in response to increasing concentrations of MMS gave identical responses at both 
HPRT and TK loci (Doak et al, 2007). Thus, the HPRT assay has been validated 
against the TK assay and provides a sensitive method for detecting mutagenic events 
at low doses of genotoxin. Such a testing strategy, based on low dose exposures is 
accumulating more credence given the caveats of high dose to low dose 
extrapolations in predicting risk of likely human exposures (Pottenger and Gollapudi, 
2009). For sufficient confidence in the results, 10080 wells were scored in total for 
each dose. The inner 60 wells of each of 56 plates were scored (60x56=3360 per 
replicate). The perimeter wells were omitted for fear of confounding effects due to 
evaporation of media. Such numbers gave sufficient sample size for 80% power for a 
significance level of p=0.05. Under the conditions specified in Chapter 2, the 
spontaneous mutant frequency was inferred from the solvent and untreated control, 
being an average of 1.4x1 O'6. This is comparable to published mutant frequencies at 
the HPRT locus in a range of cell types (Table 3.2).
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Table 3.2. Frequency of spontaneous HPRT mutants in various populations of cells 
at the HPRT locus. The spontaneous values reported in this study are more 
comparable to other studies than previously reported frequencies from our laboratory.
HPRT MF (xlO 6) Source population Reference
2+/-0.6 (SE) Big Blue B6C3F1 mice Monroe et al (1998)
6+/-0.41 (SD) Adult T lymphocytes
McGinniss et al 
(1990)
0.6+/-0.1 (SD)
T lymphocytes Male 129/ola and 
C57B1/6 normal mice
Bol et al (1998)
3.6+/-1.1 (SD)
TK6 1
Steen, Meyer and
5.2+/-1.5 (SD)
TK6 3
Recio (1997)
3.78 TK6 lymphoblastoid cells Sussman et al (1999)
2-10.8
H2EI (derivative of AHH-1 
lymphoblastoid cells)
Chiang et al (1997)
1.4+/-1.8(SD) AHH-1 in this study -
3.3.2. MNU treatment strategy.
Cells were treated by lOOpl addition of MNU in DMSO, at the appropriate working 
concentration; to 10ml culture of AHH-1 asynchronous cells and incubated for 24hr. 
This method mimicked that o f Doak et al (2007) for direct comparison. It was felt that 
the use o f asynchronous cells would better reflect cycling cells in vivo (Cheshier et al, 
1999) than would a synchronised population created by cell cycle arrest, such as 
serum starvation and inhibition of DNA replication (Pedrali-Noy et al, 1980). The 
half-life of MNU shows considerable variation between studies owing to the 
differences in buffer pH and temperature. For example, Druckery et al (1967) report a 
half-life of 1.2hr at 37°C pH 7, compared to 0.35 s in aqueous buffer at pH 4. 
Reaction with DNA is thought to occur rapidly after administration. However, Baker 
and Topal (1983) showed the formation of methyladenine products from the in vitro 
reaction of MNU and dATP (deoxyribose adenine triphosphate) nucleotide continued 
for 24hr increasing from 43% yield at 2hr to 77% at 24hr without MNU becoming
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limited. It should be noted that adenine is a lesser-targeted nucleophilic centre than 
guanine and so reaction with DNA in situ may be shorter than 24hr. Nevertheless, 
exposure to MNU for 24hr maximises the likelihood for DNA reaction.
3.3.3. MNU dose-response.
Doak et al (2007) report that, at the doses tested, MNU did not exhibit a NOGEL and 
every dose caused an appreciable level o f DNA damage, with significance achieved at 
0.0075pg/ml (the LOGEL). This finding was confirmed as a linear dose-response by 
Johnson et al (2009), using the statistical model by Lutz and Lutz (2009). The authors 
postulated the appearance of a NOGEL for mutation induction at lower doses, since 
MNU is 20 times more mutagenic than MMS (Beranek, 1990), an alkylating agent 
which the authors showed to have a NOGEL. However, many reports provide 
evidence of a NOGEL for mutation induction by MNU in various assays. Pottenger et 
al (2009) demonstrate a NOGEL of 0.69pM (0.071 pg/ml) of MNU using Dunnetts 
test on log transformed data, which was confirmed as the threshold dose (td) using 
broken stick modelling (Lutz and Lutz, 2009). A study by Lynch et al (2011) 
examined MNU induced mutagenesis in vivo at the Pig-a locus in primary rodent 
reticulocytes. There is evidence of a threshold like dose response for gene mutations 
after a 28 day repeat dosing chronic study. This substantiated the findings of 
Pottenger et al (2009). Both data sets are currently being analysed using the statistical 
framework of Gocke and Wall (2009) by Dr George Johnson, which is of interest to 
the ILSI-HESI working group to better inform on the quantitative relationship of low 
dose exposure and human risk. The reader is referred to 
http://www.hesiglobal.org/files/public/Factsheets/2010/IVGT 2010.pdf. Such
datasets, as produced in this chapter, have important implications in human exposure 
risk assessment. Additionally, a threshold dose for MNU induced chromosomal 
aberrations has been found in TK6 cells in the in vitro micronucleus assay (MNvit) at 
0.75pg/ml (Bryce et al, 2010). Similarly, Doak et al (2007) found a NOGEL of
O.lpg/ml MNU in AHH-1 cells using MNvit assay, although the dose-response was 
found to be linear using the broken stick model. The discrepancy potentially 
highlights differential sensitivities of endpoint; differential repair capacities between 
cell lines or differences in methodology (manual vs automated scoring). MNU is 
considered more mutagenic than clastogenic, which explains the -fold increase in
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concentrations at the NOGEL for chromosome break endpoints. However, MNU has 
been found to be a potent inducer o f chromosomal aberrations (Lynch et al, 2011). 
However, these studies were over a protracted length of time where chromosomal 
aberrations were possibly caused by MMR processing of 0 6MeG and not just 
depurination o f N7MeG or N3MeA, the predominant cause o f chromosomal 
aberrations up to 24hr after a single acute exposure (Zair et al, 2011).
3.3.4. Hormetic dose-response for MNU.
This study correlates with those discussed that have found a NOGEL for MNU 
induced gene mutations. However, in this study, using sufficient sample size for 80% 
power for p=0.05, the doses below the NOGEL (0.00075pg/ml to 0.0075pg/ml) 
showed a negative slope with confidence limits that do not pass 0. Therefore the MF 
values were not randomly distributed around the negative control values, as would be 
expected of a true no effect level. The data presented here, showed a reduction in 
mutant frequency compared to the negative (spontaneous) level, contrary to previous 
work by Doak et al (2007) and Pottenger et al (2009). Data presented in this chapter 
reported a background MF of 1.4xl0'5, this is 6.8-fold lower than in L1587Y mouse 
lymphoma cells used in Pottenger et al (2009). A higher background MF may 
compromise the assay’s sensitivity to detect a decrease in MF at sub-NOGEL doses of 
MNU. The identified NOGEL by Pottenger et al (2009) of 0.69pM (0.071 pg/ml) 
MNU at the TK locus in L1578Y mouse lymphoma cells is 9.5-fold higher than the 
NOGEL reported in this study (0.0075pg/ml). Within a cell type, the TK and HPRT 
loci are concordant in the shape of the dose-response (Doak et al, 2007) and 
mutational spectra in response to a similar alkylator, ENU (Chen, Harrington-Brock 
and Moore, 2002). The increased sensitivity to MNU in AHH-1 human cells may 
reflect differences in DNA repair capacities between the cell populations or a function 
of differential MNU purity used in the experiments. The most likely repair protein is 
MGMT shown to be important in mutagenic thresholds (Gocke, Tang and Singer, in 
press). The quadratic shape to the sub-NOGEL dose-response (Figure 3.10) further 
emphasises a hormesis dose-response. Gocke and Wall (2009) have also concluded 
this after statistical analysis o f micronuclei frequency in the bone marrow of EMS 
treated mice, however, this was likely due to an outliar in the data set (Gocke et al,
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2009). For further emphasis of low dose benefit, a two-tailed t-test revealed a 
statistically significant decrease in MF compared to controls at 0.0025pg/ml 
(p=0.003) and 0.005pg/ml MNU (p=0.034), an appropriate method to identify 
hormesis (Calabrese, Stanek and Nascarella, 2011). Further statistical analysis 
revealed two doses that were significantly lower than the control, substantiating the 
argument that the observed reduction in MF is a true effect. It must be noted that the 
present experiments were not designed to identify hormesis (Conolly and Lutz, 2004) 
and so caution should be urged in promulgating this finding. However, the data does 
satisfy the concerns of Calabrese (2008), which states “There does not appear to be a 
means to prove, in an absolute sense, that hormesis has occurred in a specific case. 
Firm, statistically based conclusions, however, can be drawn that hormesis has 
occurred if the studies are well designed, with adequate numbers of doses, proper 
dose spacing, and sufficient statistical power and replication of findings.”
3.3.5. Biology behind hormesis.
There are many manifestations of hormesis across many disciplines (Calabrese, 
2008). In toxicology, a J-shaped or hormesis dose-response has been shown for a 
number of endpoints, such as glutathione-s-transferase (GST)-positive foci in hepatic 
carcinogenesis (Fukushima et al, 2005). In toxicity studies, low dose beneficial 
effects are attributed to overcompensation to restore the balance in homeostasis 
(Calabrese and Baldwin, 2001). When mutations are the measured endpoint, hormesis 
(non-monotonic dose-response) has been attributed to the stimulation of DNA repair 
processes (Feinendegen, 2003) or removal of cells with damaged/mutated DNA by 
apoptosis (Feinendegen, 2005). Hormesis is usually applied in the adaptive response 
to chemical and physical mutagens (Calabrese and Blain, 2005). Ugazio, Koch and 
Recknagel (1972) provide an early example of adaptation to environmental 
carcinogens where a small (“priming”) dose is given prior to treatment with damaging 
concentrations of the same agent (challenging dose). This has been well-established in 
E.coli, which harbours two MGMT genes (ogt and ada), in response to O6- 
methylating agents, such as N-methyl-N-nitroso-guanidine (MNNG). The priming 
dose increased expression of MGMT at a second, inducible locus (ada), and increased 
the number of MGMT proteins from a basal level of 13-60 MGMT molecules per cell 
(from the constitutive ogt gene), to 3000 per cell (Mitra et al, 1982). This conferred a
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6000-fold increase in resistance to future challenging doses (Cairns, 1980). The 
adaptive response also occurs in V79 rodent cells, reducing the sum toxicity and 
aberration frequencies from priming and challenging doses of MNU or MNNG 
(Kaina, 1982). The adaptive response has also been shown under the same conditions 
using the HPRT assay (Kaina, 1983), where a priming dose of MNNG protected 
against MNU or MMS clastogenicity. However, it didn’t adapt V79 cells to their 
mutagenic potential. Therefore, multiple adaptive response pathways may exist 
(Kaina, 1983). Despite the evidence of an adaptive response in V79 cells to O6- 
methylating agents, they were shown to have no detectable MGMT in northern blot 
hybridisation studies (Fritz et al, 1991). This study needs to be revised using real time 
PCR that offers superior sensitivity. Alternatively, the adaptive response could be 
mediated by another repair process. The adaptive response to 0 6-methylating agents 
is hypothetically mediated by an upregulation of MGMT as seen in E.coli. However, 
induction in mammalian cells is cell type specific. In cells where it has been identified 
(rodent cells), upregulation occurs to a lesser extent than in microbial hosts (Fritz et 
al, 1991). Doak et al (2008) provide evidence that MGMT is induced in AHH-1 
human lymphoblastoid cells upon genotoxin exposure but other examples in humans 
are lacking. However, the results reported couldn’t be categorised as an adaptive 
response o f AHH-1 cells to MNU because only a single acute dose of MNU was 
administered rather than a chronic exposure strategy (Gocke et al, 2009) or a priming 
dose to adapt a cell to future exposures. Data showing hormesis following acute 
exposures to ionising radiation and chemicals exist (Professor Edward Calabrese, 
personal communication).
3.3.6. Hypothesised mechanism to explain hormesis.
The reduction in MF observed at 0.0025pg/ml maybe an artefact o f the calculation of 
MF. The PE is included in the calculation o f MF (equation 2.6, Chapter 2) and has an 
inverse effect, whereby a higher PE lowers the MF. This could account for the 
observed reduction in MF. However, the dose showing minimum response (dm) 
(0.0025pg/ml) causes significantly fewer HPRT mutants as compared to solvent 
control (p=0.01) (Figure 3.11).
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Figure 3.11. A reduction in the number of HPRT mutant colonies was observed at
0.0025fj,g/ml MNU (dm). n=3. Error bars=SD. * p=<0.05, ** p=<0.001 as compared 
to solvent (DMSO) control.
The PE of each replicate at 0.0025pg/ml was substituted for the PE of each replicate 
o f the solvent control and the MF calculated. The actual MF at 0.0025pg/ml was 
5.52x10‘6+/-2.lxlO '7. This changed to an average of 6.1 lxlO*6 +/-1.6xl0‘6, which still 
remained significantly lower than the control (p=0.005). Therefore, it is likely that the 
increased PE did not cause the decrease in MF at 0.0025pg/ml. Since the hormetic 
response is not dose-dependent it seems likely that this is not a true reduction in the 
MF and may be an artefact of poor mutant recovery following freezing/thawing 
cultures during the expression period. Nevertheless, It is interesting to speculate that 
there is a biological mechanism responsible for the reduction in MF. Toxicity 
assessment over the treatment period suggests that sub-NOGEL doses o f MNU do not 
cause cell death, which is a mechanism to reduce the number of mutants within a 
population. Conolly and Lutz (2004) postulate a number of explanations to account 
for the reduction in spontaneous MF following genotoxin exposure. Assuming that;
1. Endogenous (background) adducts are formed at a zero-order rate
2. MNU ellicits adducts proportional to dose (linear dose-response as shown by 
Swenberg et al, 2008). This is tested in Chapter 4.
3. A basal level of DNA repair is upregulated by exogenous MNU
4. Exogenous adducts by MNU are capable of saturating repair mechanisms at 
higher concentrations (hypothesis o f this thesis)
5. Repair capacities act on exogenous MNU adducts and background adducts,
It could be hypothesised that 0.0025pg/ml causes an upregulation o f DNA repair 
capacities or detoxification mechanisms that remove or prevents damage from MNU
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and endogenously generated genotoxins (e.g. from mitochondrial processes). p53 may 
play a role as it is implicated in reducing mutant frequency (Morris, 2002), but there 
is no evidence showing upregulation by MNU. Base excision repair (BER) is a known 
inducible repair mechanism to protect against spontaneously occurring oxidative 
damage induced mutations (Cabelof et al, 2002).
Hormesis is recognised to have a temporal component; therefore, the extent of 
reduction in spontaneous mutation frequency would depend upon the efficiency of 
induction of DNA repair mechanisms (may explain the lack of reduction in MF at 
doses below 0.0025 pg/ml), the speed of repair and even duration of the upregulation 
(Conolly and Lutz, 2004). The data presented here suggest that 24hr exposure to 
MNU upregulates DNA repair, presumably within the treatment period (Doak et al, 
2008). However, it is difficult to determine when the reduction in MF occurred in the 
inherent post-treatment incubation periods of the HPRT assay. To give more 
confidence, MF should be measured at different post-treatment incubation periods but 
this cannot be performed in the HPRT assay.
3.3.7. MNU mechanism of action (MOA).
f\ • f\Point mutation induction by MNU has been attributed to O Methlyguanine (O MeG). 
This adduct constitutes 5.9-8.2% of the adduct spectra of MNU, approximately 20- 
fold more than the adduct spectra o f MMS (Beranek, 1990). Suter et al (1980) found 
that MNU was 20-fold more mutagenic than MMS in V79 cells. Therefore, one would 
expect a MNU LOGEL to exist at a 20-fold lower concentration than MMS. Pottenger 
et al (2009) found the LOGEL of MNU to be only 2.5-fold lower than the LOGEL for 
MMS in L1578Y mouse lymphoma cells. In this study, the LOGEL for MNU is
O.Olpg/ml (0.097pM), which is 117-fold lower than the LOGEL of MMS (1.25pg/ml,
11.35pM) (Doak et al, 2007).
This drastic difference emphasises;
1. Other mutagenic MNU adducts to which AHH-1 cells are sensitive
2. Increased sensitivity to 0 6MeG in AHH-1 cells compared to V79 and L1578Y 
rodent cells
3. Differences in adduct spectra at lower doses compared to the higher doses 
used to obtain adduct spectra in Beranek (1990).
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The mutability of each MNU adduct has been established. It is well known that 
0 6MeG is the main cause of MNU mutagenesis, causing GC->AT transitions. The 
following chapters aim to determine the mechanism of mutation induction by MNU 
and the cytoprotective mechanism responsible for the NOGEL observed in this 
chapter. We hypothesise that DNA repair by MGMT is responsible for low dose 
protection by removing 0 6MeG before replication, when it becomes fixed as 
GC->AT mutations. The following chapter examines the formation of MNU adducts 
at increasing concentrations of MNU, to highlight the role of post-adduct DNA repair 
in the protection of DNA from mutation induction at doses below the NOGEL.
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Chapter 4
Adduct Analysis.
Assessment of DNA 
Damage Following 
Low Dose MNU 
Treatment Through 
Mass Spectrometry.
4.1. Introduction.
The following chapter examines the biological importance of adducts and their use in 
genetic toxicology as biomarkers of exposure to DNA damaging carcinogens 
(genotoxins).
4.1.1. Adduct formation is a critical carcinogenic event.
Adducts are chemical groups covalently added to cellular macromolecules such as 
DNA and proteins by electrophiles. In the following work, the term adduct refers to 
DNA adducts unless otherwise stated. All direct acting genotoxins are electrophiles 
capable of adduct formation, either as administered or through metabolic activation 
(Miller and Miller, 1971). Adduct formation is non-random occurring at nucleophilic 
(electron rich) centres such as oxygen and nitrogen of the bases and phosphate o f the 
DNA backbone (Nehls and Rajewsky, 1985). Electron loving electrophiles (Lewis 
acids) accept an electron pair donated from the nucleophilic centre (Lewis base) 
forming a covalent Lewis adduct by sharing the electron pair in a reversible covalent 
bond as defined by International Union of Pure and Applied Chemistry (IUPAC). 
Adducts are pre-mutagenic lesions that, if  not efficiently repaired, persist through 
replication, where they are fixed as permanent genetic mutations. Of interest to the 
current work are adducts caused by methyl nitrosourea, MNU a methylating agent 
that is classed as an alkylating agent, a group of genotoxins that add alkyl adducts to 
DNA (Figure 4.1).
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Figure 4.1. Sites of alkylation in double stranded DNA. O f importance to this study is 
methylation at Oxygen and Nitrogen (0 6Methlyguanine (0 6MeG) N7-Methylguanine 
(N7MeG), respectively), circled in red. Adapted from Jenkins et al (2005).
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4.1.2. Electrophile chemistry.
Adducts differ in location and structure owing to the chemical properties of the parent 
electrophile. Consequently, different adducts pose different mutagenic threats to the 
DNA. Alkylating agents have a defined DNA reaction mechanism and produce a 
spectrum of adducts shown (Table 4.1). Adduct formation is determined by;
1. The electrophilic potential of the agent, which is governed by the Swain Scott 
constant ( 5  value) (Swain and Scott, 1953)
2 . Reaction kinetics, S n I v  S n 2 .
3. Steric hindrance and nearest neighbour effects of the local nucleotide sequence 
within the double helix (Swenson and Lawley, 1978;Glickman et al, 
1987;Mathison, Said and Shank, 1993).
MNU shows a low 5-value, which is associated with a SnI reaction mechanism. 
Conversely, MMS has a higher 5-value, which is associated with a Sn2 mechanism. 
This difference in electrophilic potential leads to the differences in adduct spectra. 
However, it is likely that these were determined at high doses of alkylating agent and 
the distribution could be different at low doses should the kinetics of DNA reaction 
depend upon concentration. The most abundant adducts are 0 6-methylguanine 
(0 6MeG), N7-methylguanine (N7MeG) and N3-methyladenine (N3MeA). The 
critical differences are in the proportions of methylation at 0 6G and N7G (Table 4.1). 
MNU produces more 0 6MeG that has miscoding properties through replication and 
causes GC->AT transitions. As a result, MNU is considered to be more mutagenic 
than agents that have a lower 0 6MeG:N7MeG ratio. Additionally, methylating agents 
are more DNA reactive than their ethylating equivalents (ethyl- nitrosourea, £NU) but 
are subject to better repair (Singer, 1985).
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Table 4.1. Comparative adduct spectra between two model methylating agents. A low 
s value (e.g. MNU) shows higher propensity for alkylation at exocyclic oxygen of 
guanine ( 0 6G), forming a potent miscoding adduct responsible for GC->AT 
transitions. Taken from Beranek (1990).
Proportions of adduct 
spectra (%)
Adduct site MMS MNU
5-value >0.83 0.42
N7G 81-83 65-70
0 6G 0.3 5.9-8.2
N3A 10.4-11.3 8-9
N3G 0.6 0.6-1.9
N7A 1.8 0.8-2
N3C <1 0.06-0.6
0*C Nd 0.1
N3T 0.1 0.1-0.3
o 2t Nd 0.1-0.3
o 4t Nd 0.1-0.7
4.1.3. Some genotoxins require activation into an electrophile to cause DNA 
damage.
There are many examples where genotoxic carcinogens require “bioactivation” into 
an electrophile that is capable of reacting with DNA and forming adducts 
(Guengerich, 1992). Cytochrome P450s (CYPs) typically perform reduction or 
oxidation reactions converting the pro-carcinogen into an electrophile in a redox 
reaction dependent on nicotinamide adenine dinucleotide phosphate (NADPH) 
generating systems, hence the use of enzyme extracts such as S9 in in vitro toxicology 
(Maack et al, 1986). Chesis et al (1984) provide a role for flavoenzymes such as 
NADPH-cytochrome P450 reductase in activating quinones (an environmental 
carcinogen). Stern et al (1993) and Degawa et al (1994) identify the role o f CYPs 2C, 
3A4 and 1A1 enzymes in polyaromatic hydrocarbon (PAH) activation to produce
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adducts identified in laryngeal tumours of smokers. Conversely, the cell is also 
equipped with detoxifying metabolism to rid the cell of potentially damaging agents. 
These include, glutathione S-transferase (GST), which conjugates pro-carcinogens 
and endogenously generated DNA reactive species to glutathione, a biosynthetic 
defensive antioxidant, to detoxify the cell and protect from mutagenesis. Shupe and 
Sell (2004) substantiate this by showing increased adduction by aflatoxin B1 in cells 
with low GST concentration. However, an increased intracellular thiol concentration 
increases adduction by alkylating agents (Lawley and Thatcher, 1970). Metabolism 
of aromatic and heterocyclic amines by arylamine A-acetyltransferases (NATs) can 
either serve to detoxify or promote their metabolic activation into DNA damaging 
agents (Hein, 2002). The balance of these processes determines risk o f DNA damage 
and carcinogenesis (Androutsopoulos et al, 2009). The potency of pro-carcinogens 
can be enhanced;
• By inter-individual polymorphisms within the CYP encoding genes that 
improves pro-carcinogen activation (Bartsch et al, 2000; Katoh, 1995)
• In tissues showing over-expression of activating enzymes (Perin-Roussel et al,
1997).
• By an imbalance in detoxification mechanisms
• Polymorphisms within GST that reduces its detoxifying capacity (Mohr et al, 
2003).
The risk of damage from pro-carcinogens is dependent on the phenotype of the cell or 
individual. MNU used in this study does not require metabolic activation. 
Nevertheless, extrapolating safe levels of exposure to genotoxins across a 
heterogeneous human population requires careful consideration of polymorphisms in 
detoxifying and activating pathways, which has been correlated to cancer 
susceptibility (Coles et al, 2003).
4.1.4. Endogenous electrophiles cause adducts that contribute to spontaneous 
mutagenesis.
Miller and Miller (1971) recognise adduct formation as a critical event in chemical 
carcinogenesis that is common between all genotoxins. The study of DNA adducts 
has accelerated in recent years with the discovery that adducts are caused not only by
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environmental carcinogens but also from endogenous electrophiles from normal 
cellular metabolism. Adduction of DNA by endogenous electrophiles contributes to a 
spontaneous level of DNA damage and mutation responsible for background tumour 
incidence o f 35-40% of a human population over a 75 year life span (Lutz, 1990). The 
most studied culprit o f endogenous damage is reactive oxygen species (ROS) from 
mitochondrial metabolism, such as superoxide (O2") and hydrogen peroxide (H2O2). 
Oxidative stress (when the level of ROS exceeds antioxidant capacities) has been 
shown to contribute to chemical carcinogenesis (Klaunig et al, 1998). Incidentally, 
exogenous agents such as dieldrin, an organochlorine pesticide, has been shown to 
cause a state of oxidative stress and subsequent liver cancer in rodent subjects. It can 
be considered as an indirect genotoxic carcinogen. ROS species (e.g. O2*) oxidise 
guanine bases forming adducts like, 8-hydroxydeoxyguanosine, a pro-clastogenic and 
pro-mutagenic adduct but useful oxidative stress biomarker in urine (Loft et al, 1999; 
Collins et al, 1996; Chiou et al, 2003). Humans accumulate 104 oxidative lesions per 
cell per day, 10 fold lower than rats (Cathcart et al, 1984;Ames, 1989).
Oxidative stress is not the only source of endogenous damage. Electrophiles are also 
produced from lipid peroxidation and endogenous oestrogens (De Bont 2004). 
Products from lipid peroxidation react with metals to form epoxides and aldehydes 
and form a variety of ethano and propano guanine adducts with varying mutagenic 
potential (Hecht et al, 2001). Redox cycling of oestrogens can cause oxidative DNA 
damage. Oestrogens themselves can cause DNA damage via a cytochrome-mediated 
activation into electrophilic quinone intermediates (Liehr, 2000;Cavalieri et al, 2000). 
Of interest here is the endogenous methylation of bases that can contribute to the 
naturally occurring adductome.
4.1.4.1. Endogenous methylation regulates gene expression and can be 
mutagenic.
Endogenous DNA methylation coupled with histone acetylation/phosphorylation play 
an important role in the epigenetic regulation of gene expression (Geiman and 
Robertson, 2002). Aberrant methylation causes inappropriate gene regulation causing 
genomic instability implicated in a number of human cancers (Jones and Baylin, 
2002;Esteller and Herman, 2002). Methylation at CpG dinucleotides at gene 
promoters suppresses transcription and temporarily silences the gene. Methylation is
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achieved by three DNA methyltransferases (DNMT); DNMT1, DNMT3a and 
DNMT3b. They have roles in epigenetic methylation, genetic imprinting and 
embryonic development (Chen and Li, 2004). Knowledge of how these are regulated 
in normal cells is lacking. DNMT’s are not electrophilic but catalyse the transfer of 
methyl groups from a donor, S-adenosylmethionine (SAM) to cytosine in DNA 
forming 5-methylcytosine. 5-methylcytosine is not miscoding like 0 6MeG but does 
cause spontaneous methylC->T transitions through deamination of 5-methylcytosine 
(Coulondre et al, 1978). To substantiate the mutability of 5-methylcytosine, Shen et al
1 3(1992) showed a higher rate of 5-methylcytosine deamination (5.8 x 10' /s) compared
n  t
to un-methylated cytosine (2.6 x 10' /s) at physiologically relevant conditions. This 
has been shown in human germline (Rideout et al, 1990) and somatic cells (Cooper 
and Youssoufian, 1988). Cooper and Krawczak (1990) estimated that 32% of point 
mutations responsible for human genetic disease resulted from spontaneous 
deamination of 5-methylcytosine to thymine. SAM has been shown to methylate 
DNA at sites other than CpG islands non-enzymatically. This has received much 
attention due to the mutability of methyl adducts. The in vitro adduct spectra o f SAM 
(Rydberg and Lindahl, 1982) showed that N7-MeG was the predominant adduct with 
lesser amounts of N3-Methyladenine (N3MeA) and 0 6MeG (constituting >1% of 
N7MeG formed). This adduct spectra mimics that for exogenous MMS. Rydberg and 
Lindahl (1982) extrapolated the in vitro adduct to the in vivo condition and estimated 
that an intracellular SAM concentration o f 4xlO'5M would cause 4000 N7MeG, 600 
N3MeA and 10-30 0 6MeG per cell per day. This suggests that the cells can tolerate a 
higher level of N7MeG than either N3MeA or 0 6MeG. Posnick and Samson (1999) 
increased intracellular SAM concentration but saw no increase in spontaneous 
mutagenesis. The authors confirm, “that SAM is not a major contributor to the 
endogenous formation of 0 6-methylguanine lesions in E. co lir  Endogenous 
generation of 0 6MeG, and also N7MeG, has been attributed to the in vivo generation 
of DNA reactive TV-nitroso compounds (NOC). NOC’s include; the nitrosamides 
(MNU and ENU) and the nitrosamines (DMN and DEN). Their adduct spectra show 
predominance of N7AlkylG and lesser amounts o f 0 6AlkylG at varying ratios 
(Beranek, 1990). NOC’s are formed from nitrosylation of digestion products (amino 
acids such as glycine and proteins) of ingested red meat in the gastrointestinal tract 
(Tricker, 1997; Lewin et al, 2006; Kuhnle and Bingham, 2007; Winter et al, 2011). 
This being the hypothesized link between colon cancer and red meat consumption
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(Hebels et al, 2009; Hebels et al, 2010; Hebels et al, 2011) although, other 
carcinogens in red meat also contribute such as heterocyclic amines (HCA) and 
polyaromatic hydrocarbons (PAH) (Chen et al, 1998).
4.I.4.2. Endogenous levels of 0 6MeG, N7MeG and N3MeA.
The occurrence of 0 6MeG, N7MeG and N3MeA in the natural adductome has been 
shown to contribute to spontaneous mutagenesis in yeast cells (Xiao and Samson, 
1993). Levels of endogenously formed N3MeA is lacking and cannot be commented 
upon. Quantification of 0 6MeG come from studies quantifying this adduct in human 
tissues o f individuals with no known exposure to methylating agents. Such studies are 
labile to recall bias and suffer from a lack of sensitivity; employing antibody based 
techniques and enzyme activity inference to quantify levels of 0 6MeG. Table 4.2 
shows a summary of reported spontaneous adduct levels.
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Table 4.2. Levels of endogenous alkylation damage. It is considered that 0 6MeG is 
naturally formed at lower levels than N7MeG. HPLC=high performance liquid 
chromatography, RIA=radio-immuno assay.
Vlethod of quantitation
Quantity of 
N7MeG 
(peri O'8 
nucleotides)
Quantity of 
0 6MeG
(peri 0~s
nucleotides)
Human tissue Reference
12P post-labelling 25 - Pulmonary alveolar cells
Petruzzelli et al 
(1996)
rIPLC/32 P post-labelling 31-7900 - Liver Kang et al (1995)
12P/TLC/HPLC 29 - White blood cells Zhao et al (1997)
12P/AEC 34 - White blood cells
Mustonen and 
Hemminki (1992)
32P/AEC 135 - Lymphocytes Mustonen and Hemminki (1992)
3refractionation/32P post­
label 1 ing/I mmunoprecipitation 
[PREPI)
- 11-67 Liver Kang et al (1995)
PREPI - 0.7-4.6 Peripheralblood Kang et al (1995)
3REPI - 0.1-1.6 Peripheralblood Kang et al (1992)
(>REPI - 11-42 Liver Kang et al (1993)
1
PREPI - 6.78-4.6 Leukocytes Kang et al (1993)
dPLC/RIA/immunoprecipitation - 0.4-4.4 Maternal blood Georgiadis et al (2000)
dPLC/RIA/immunoprecipitation - 4.8 Chord blood Georgiadis et al (2000)
^LISA - 0.65 Maternal blood Georgiadis et al (2010)
ELISA - 0.38 Chord blood Georgiadis et al (2010)
Spontaneous levels o f N7MeG tend to be higher than 0 6MeG (De Bont, 2004). This 
could reflect differences in;
1. Cellular tolerance to these adducts. It is known that N7MeG is relatively 
innocuous; Tudek, Boiteux and Laval (1992) showed naturally high levels 
after conversion to its imadazole ring-opened derivative; 2,6-diamino-4-
100
hydroxy-5N-methyl-formamidopyrimidine (Fapy-7-MeG) without severe 
mutagenesis. Whereas, 0 6MeG is highly mutagenic (Kaina et al, 2007).
2. Formation of each adduct. It is known that the major endogenous methylating 
agent, SAM causes more N7MeG than 0 6MeG.
3. Repair capacities, this influences the tissue specific half-lives (ti/2) o f the 
adducts (Jackson et al, 2000; Herron and Shank, 1981). Liver shows the most 
rapid half-life of 0 6MeG (Kleihues and Bucheler, 1977) this is attributed to 
the higher level o f its repair protein (0 6-methylguanine-DNA 
methyltransferase, MGMT) in liver samples (Souliotis et al, 1996). Beranek 
(1990) quote the in vitro half-life of 0 6MeG as 2 days and N7MeG as 4.4-8 
days. However, estimates of ti /2 0 6MeG range from lhr (Sklar and Strauss,
1981) to 14 days (Kleihues and Bucheler, 1977).
4. Ease of measurement (discussed later).
Due to the different methods of measurement, adduct levels are difficult to compare. 
However, Shields et al (1990) directly compared N7MeG to 0 6MeG and found 
approximately 10-fold higher levels of N7MeG (140-720 N7MeG per 108 
nucleotides) than 0 6MeG (10-70 0 6MeG per 108 nucleotides). There are notable 
differences between levels in liver and lymphocytes. This could reflect target organ 
specificity o f the endogenous NOC’s. Additionally, Souliotis et al (1996) found that 
liver MGMT is most rapidly and significantly depleted, compared to lymphocytes, 
which accounts for the higher level of 0 6MeG in these samples.
The ratio of N 7M eG /06MeG are consistent with the adduct spectra of endogenous 
NOC’s and SAM, hypothesized to contribute to spontaneous DNA methylation. It can 
be concluded that chemical damage to DNA is a natural occurrence, necessary for 
genetic variation, and may not contribute a substantial risk to hereditary mutation and 
cancer. However, endogenous damage can be mimicked and substantiated by 
exogenous electrophiles. Therefore the risk of genetic damage is much greater and 
exposure to exogenous genotoxins must be limited hence the need for genotoxicity 
testing.
4.1.5. Exogenous electrophiles.
Adducts, and adduct spectra, caused by exogenous electrophiles can mimic those 
formed from endogenously generated electrophiles. As previously discussed w ith /^ N ^ N
SAM and MMS. However, there is a distinction, endogenous damage is unavoidable 
but exposure to exogenous electrophiles can be limited to prevent further damage. 
Exogenous electrophiles are thought to have an additive effect on already existing 
endogenous adducts (Zito, 2001). At low levels, it seems that endogenous damage 
predominates. For example, Lu et al (2011) showed that 0.7ppm formaldehyde will 
produce 0.039+/-0.019 A2-hydroxymethyl-dG/107G but endogenous adducts naturally 
exist at 3.62+/-1.33 A2-hydroxymethyl-dG/107G. At this concentration, exposure risk 
seems negligible.
4.I.5.I. Exogenous adducts have a linear dose-response.
It is widely reported that, at low doses under first order kinetics, adduct formation 
from exogenous carcinogens accrues in a linear fashion proportional to dose (Zito, 
2001). This has been shown for acrylamide and MMS (Swenberg et al, 2008). By 
distinguishing between endogenous and exogenous adducts by administering 
radiolabelled genotoxins, exogenous adducts accrue linearly from zero at increasing 
doses. However, if  total adducts are analysed the level must have a nonzero 
background level of naturally occurring adducts, this is exemplified by Lu et al 
(2011). The authors quantified N  -hydroxymethyl-dG resulting from formaldehyde 
exposure and distinguished adducts on the origin of formation by administering radio­
labelled formaldehyde, which can be separated by mass from endogenously formed 
(non-radio-labelled) formaldehyde adducts. Despite an increase in exogenous adducts 
at increasing doses, if  this is combined with the endogenous levels, the increase is 
hidden within the background level particularly following administration o f 2 to 
9.1 ppm formaldehyde (Figure 4.2).
20.0
Formaldehyde (ppm)
Figure 4.2. The levels of A2-hydroxymethyl-dG adducts resulting from formaldehyde 
exposure (diamond). The increase from 2 to 9.1ppm is hidden when total (endogenous 
and exogenous) adducts were calculated (columns). Data taken from Lu et al (2011).
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Swenberg et al (2008) report that under linear adduct relationships; the resulting 
mutation dose-response for these compounds observe thresholds. This is the case for 
MMS (Figure 4.3) and has also been shown for MNU (Pottenger et al, 2009).
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Figure 4.3. N7MeG adducts induced by MMS (solid diamonds) show a linear dose- 
response. Mutation induction by this agent is non-linear with a NOGEL at lpg/ml 
(empty circles). At the NOGEL there are approximately 300 more adducts compared 
to Opg/ml without an increase in mutant frequency. Taken from Swenberg et al 
(2008).
This holds true for different endpoints such as tumour formation (Poirier, et al, 2004). 
Dragan et al (1995) report that an anti-oestrogen drug, toremifen, does not induce 
hepatic neoplasms even though DNA adducts in liver tissue have been detected (Li et 
al, 1997). Otteneder and Lutz (1999) state that this is because “the limit of detection 
(LOD) of DNA adduct levels can be much lower than the limit of detection for a 
statistically significant increase in tumour incidence.” Conversely, Groopman and 
Kensler (1999) highlight the correlated risk of hepatocellular carcinoma and presence 
of urinary aflatoxin B1 adducts and metabolites. It was recently concluded that 
adducts cannot be used to inform of cancer risk (HESI, 2010) and are not biomarkers 
of effect. It is considered that low doses of carcinogens can cause DNA damage but 
not all the damage causes mutation. For this reason adducts are considered biomarkers 
of exposure and not biomarkers o f effect (Swenberg et al, 1987).
103
4.1.6. Adducts as biomarkers of exposure
The presence of adducts unequivocally demonstrates the presence of an electrophile. 
Adducts confer information about extent to which an individual or population is 
exposed to endogenously generated and exogenous carcinogens and are, therefore 
termed biomarkers o f exposure. These are used to inform the Environmental 
Protection Agency (EPA) and other governing bodies as to the extent of 
environmental pollution. Detection of a carcinogen or its metabolites in bodily fluids 
quantifies the internal dose. Furthermore, detection of protein and DNA adducts in 
whole tissue give more relevant data on the biological effective dose which is more 
informative than administered dose (Ehrenberg and Osterman-Golkar, 1980). The 
ability to detect adducts depend on assay sensitivity and prior knowledge of route of 
exposure (Lehman-McKeeman, 2010). For example, Lu et al (2010) investigated N - 
HOCH2-dG adducts as biomarkers o f inhalation of formaldehyde. Exogenous adducts 
were only detected in nasal cavity and not liver and bone despite efforts to increase 
sensitivity. Protein adducts, as well as DNA adducts serve as “exposure monitors” 
(Farmer, 2004). Tomqvist et al (1988) investigated methyl adducts on amino acids in 
haemoglobin as potential biomarkers. The advantage of using haemoglobin as an 
exposure sensor is non-invasive sampling from patients. It is known that cyanate, a 
decomposition product of MNU (Melzer et al, 1983) is a carbamoylating agent and 
reacts with amine groups in guanine but also in proteins such as glutathione (GSH) 
(Trezl et al, 1987). Many other protein adducts have been useful as biomarkers 
(reviewed in Farmer, 1999). The time period following an acute exposure is essential 
when using adducts as biomarkers of exposure. Over time, a variety of adduct-dose 
relationships have been observed (Talaska et al, 1996; Herron and Shank, 1981). 
Following an acute dose of genotoxin, adduct levels initially rose but returned to a 
steady state level, reflecting a balance o f endogenous formation and removal. 
Kleihues and Bucheler (1977) found that, in rat brain, an initial increase in 0 6MeG 
following MNU injection took 180 days to plateau but only 28 days for N7MeG. A 
naturally higher level of N7MeG would explain this. A protracted curve for 0 6MeG 
reduction was also observed by Medcalf and Lawley (1981). DNA adducts have 
received more attention due to their mutability but they are more difficult to measure 
than protein adducts and their location in the nucleotide sequence cannot be 
determined. Determining adduct location particularly in proto-oncogenes and tumour
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suppressor genes or even coding regions of the genome, would increase their impact 
in cancer risk assessment. Despite this inability, with ever more increasing sensitivity 
in DNA adduct measurement, they are becoming an important biomarker but their 
risk to cancer is under contention and has been established for only a few carcinogens 
e.g. aflatoxin B l.
4.1.7. Biological effect of adducts is determined by cellular processing.
Once adducts have formed, their mutagenic potential is dependent on;
1. Adduct half life, which is determined by efficacy of cellular repair capacity
2. Adduct structure
3. The genomic location of adduct
4. Mis-coding potential
5. DNA replication (rate of cell division)
Different adducts have different mutagenic and carcinogenic potencies. For example, 
aflatoxin Bl is almost 40 times more carcinogenic than DMN adducts (Otteneder and 
Lutz, 1999) this can be explained by propensity for mutation and poor repair 
capabilities for aflatoxin B l and other bulky adducts (Hang, 2010).
If an adduct is fixed as a mutation, there may not be a phenotypic change in the 
protein, if;
1. The adduct and resulting mutation occurs in non-coding DNA
2. The mutation is silent, coding for the same amino acid due to redundancy of 
the genetic code. In the HPRT assay, and other mutation assays, silent 
mutations will not be detected which would compromise the sensitivity of 
mutation detection assays.
Therefore, many possibilities exist whereby an adduct does not pose an adverse effect 
to DNA and may be irrelevant to mutagenesis. This may explain the presence of 
adducts but absence of mutations found in a number of studies that postulate a no 
observed mutagenic and carcinogenic effect level (Swenberg et al, 2008; Waddel, 
Fukishima and Williams, 2006) although the difference in limit o f detection of each 
endpoint has a role (Jenkins et al, 2005).
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4.I.7.I. DNA repair plays a crucial role in adduct removal, which prevents 
mutation.
DNA repair is the most heavily cited mechanism that prevents mutations by repair of 
adducts. A number o f enzymes constitute a cell’s inventory of DNA repair processes. 
This means a variety of structurally diverse adducts can be repaired, this represents 
“first line defence” from adduct induced mutation and cancer (O’Connor et al, 2000). 
The efficiency of repair is determined by the affinity an enzyme has for the adduct. 
For example, in a wildtype cell, methylating agents are less mutagenic than their 
ethylating equivalents, this is due to more effective repair capacities for removing 
methyl adducts (Beranek, 1990). The location of adducts within the genome affects 
the rate at which they are repaired given differential genome wide repair capacities 
(Madhani, Bohr and Hanawalt, 1986;Wasserman, Kohn and Bohr, 1990). Measuring 
pan-genomic repair efficiencies is currently being investigated (Teng et al, 2011). The 
repair of adducts is often without any permanent damage to DNA, excluding 
erroneous base excision repair (BER). Therefore, certain repair deficient cells are 
unable to repair specific adducts and are more vulnerable to mutations. However, 
some repair deficiencies actually confer resistance to genetic alterations (such as 
chromosomal aberrations, as previously discussed with mismatch repair (MMR) 
deficient cells conferring a methylation tolerant phenotype. Multiple studies comment 
on the increased mutagenicity of a variety o f adducts in different repair deficient cell 
lines when compared to repair proficient cells following exposure to a variety of DNA 
damaging chemicals. For example, cisplatin induced mutations in xeroderma 
pigmentosa (XP, an NER deficient) cell line (Zhen et al, 1993), and mitomycin C 
(MMC) induced micronuclei in XP and fanconi anaemia (FA, cross-link repair 
deficient) cells (Speit et al, 2000). O f interest to the present study, O’Connor et al 
(2000) showed a higher level of 0 6MeG in DNA of cells lacking MGMT, the error 
free repair protein capable of removing 0 6MeG. 20hr following exposure, 0 6MeG 
levels were measured at 10p,molO6MeG/mole guanine in MGMT deficient cells 
compared to only 0.4^imolO6MeG/mole guanine in MGMT proficient cells. With a 
higher level of unrepaired 0 6MeG persisting in DNA through replication there is a 
higher likelihood of mutation, these being GC->AT changes after two replications of 
0 6MeG. These in vitro studies reflect intra-population polymorphisms in DNA repair
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genes. With altered DNA repair capacities, altered susceptibility to mutation by the 
same adducts impacts in differential cancer risk (Terry et al, 2004) and also in 
applying a DNA repair mediated threshold dose-response to the human population 
(Jenkins et al, 2009).
4.1.8. Analytical methods for measuring DNA adducts.
Early adduct detection methods administered radioactive carcinogens to animal 
models. Upon sacrifice, the DNA is harvested from organs of interest. An increase in 
radioactivity of isolated DNA from treated animals compared to untreated controls 
gave support to the formation of DNA adducts (Phillips et al, 2000). This technique 
gave no chemical information about the adduct or conclusive proof of formation nor 
does it permit the bio-monitoring of humans or study of endogenous damage. Since 
then, technological advancements permit the highly accurate detection of specific 
chemical adducts on macromolecules. If an adduct is induced below the limit of 
detection it does not mean it is not there, therefore, the sensitivity of the method is 
critical and can change the shape of the dose-response relationship. The technique that 
offers the lowest limit of detection is favoured. Methods for adduct detection and 
quantification include:
P-postlabelling-The most sensitive technique requiring only 1-1 Opg DNA 
(Randerath et al, 1981) to achieve detection limits of 1 adduct/109 nucleotides 
(Farmer, 2004). It overcame the obstacle of using pre-labelled radioactive 
carcinogens, which prevented detection in humans. The technique radiolabels adducts 
after exposure to carcinogens. Isolated DNA is digested and the free nucleotides are 
labelled by [y-P32-ATP] at the free 5’-OH group (formerly a phosphodiester link of 
the DNA backbone). Labelled adducted bases are separated from unmodified bases by 
polarity using variations o f chromatography to enhance sensitivity. The adducts are 
then resolved and quantified by autoradiography. The technique, however does not 
provide information about the structure of the adduct and its lack of specificity cannot 
resolve exogenous from endogenous (termed indigenous) adducts (Randareth et al, 
1983;Gupta et al, 1999).
Antibody based methods-Include immunoassays and immunohistochemistry 
(Poirier, 1981; Strickland and Boyle, 1984) but recently Georgiadis et al (2011)
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developed an enzyme linked immunosorbent assay (ELISA) type technique for 
detecting 1.5 adducts/109 nucleotides using lOpg of DNA. Mass spectrometry would 
require more than lOOpg DNA for similar sensitivities (Dr Rajinder Singh, personal 
communication). The assay was used to correlate endogenous 0 6MeG levels with 
NOC’s in nitrite rich diets and was shown to have similar sensitivities as 
HPLC/RIA/immunoprecipitation (Georgiadis et al, 2000) but with higher throughput. 
However, this technique is not routinely used. Other attempts to quantify 0 6MeG with 
antibodies was coupled with P-postlabelling but only achieved a sensitivity o f 1 
O6MeG/108 G (Cooper, Griffin and Povey, 1992).
Electrochemical-De Groot et al (1994) describe a technique for the analysis of O6- 
and N7 ethyl and methyl guanine. The authors quote a LOD of 0.5 methyl adducts/106 
nucleotides and 1 ethyl adduct/106 nucleotide. The discrepancy in LOD’s between 
ethyl and methyl adducts is unclear.
Enzyme inactivation studies-Measuring the decrease in MGMT activity following 
repair o f 0 6MeG has been correlated to the presence of 0 6MeG due to the 
stoichiomtery of the reaction. Authors refer to it as the competitive repair assay for 
0 6MeG (Souliotis et al, 1991; Georgiadis et al, 2000). Souliotis et al (1989) quote a 
LOD of 0.8pmol adduct/mol guanine. This equates to a LOD of 200
o
adducts/10 nucleotides. The technique would require careful monitoring of MGMT 
transcription and translation levels to ensure a decrease in activity was not due to a 
decrease in expression.
Adduct induced polymerase blockage assay- Moore and Strauss (1979) developed 
the “stop assay.” This technique allows the user to infer the location of adducts on 
plasmid DNA based on replication blockage. The “stop assay” has been used to 
identify bulky acetylaminofluorene (AAF) DNA adducts (Mah et al, 1991). However, 
these adducts only temporarily slow replication and are bypassed (Schorr et al, 2010) 
and so the “stop assay” may miss adducts. Jenkins, Burlinson and Parry (2000) report 
the successful detection of MNU, ENU and UV-C adducts. However, the assay lacks 
sensitivity.
Mass spectrometry-provides unequivocal evidence of the presence o f adducts. 
Recent developments have improved the sensitivity of the technique to greater than 
P-postlabelling without the need for radio -labelled substrates. The method has been 
used in this chapter and will be discussed further.
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4.1.9. Mass spectrometry in DNA adduct analysis.
Mass spectrometry has been used in macromolecular adduct detection. Analysis o f the 
unique molecular mass o f an ion from an adduct using spectrometry coupled with 
prior chromatographic separation of the analyte, offers enhanced specificity and 
signal/noise ratio providing conclusive evidence of DNA binding by specific chemical 
groups. However it has limited sensitivity. Advances in mass spectral techniques have 
improved sensitivity. For example, Accelerator mass spectrometry (AMS) offers 
unrivalled sensitivities (1/101 ’) but uses radioactive isotopes (Turteltaub et al, 1990). 
Many variations of chromatographic and mass spectral technologies exist for use in 
detection of different adducts (Farmer and Sweetman, 1995). Pieles et al (1993) used 
matrix assisted laser desorption-time of flight (MALDI-ToF) to analyse adducts 
within an oligonucleotide with the possibility o f determining adduct location. Liquid 
chromatography tandem mass spectrometry (LC-MS/MS) with electrospray ionization 
(ESI), used in this chapter, surpasses gas chromatography (GC) MS that is restricted 
to the analyses of volatile and non-polar adducts. Swenberg et al (2010) quoted a 10- 
to 1000- fold increase in sensitivity achieved through LC MS-MS over traditional 32P 
post-labeling techniques. However, Singh et al (2005) quote a LOD of 0.6 N7EtG 
adducts in 10 nucleotides which is approaching sensitivities of P post-labeling.
4.I.9.I. Liquid chromatography electrospray ionization tandem mass 
spectrometry multiple reaction monitoring (LC-ESI-MS/MS-MRM).
Below is a brief account of the theory of LC-ESI-MS/MS-MRM used for the current 
detection of N7MeG (nucleo)base. LC-ESI-MS/MS has been used to detect 
macromolecular monomers (Banoub and Limbach, 2009). Alkyl adducts such as 
N7MeG and 0 6MeG are released from DNA as adducted bases or nucleosides by 
thermal/acid-induced hydrolysis or enzymatic digestion, respectively. DNA digestion 
generates a high quantity of purine nucleosides that interferes with downstream 
analysis (Mallet, Lu and Mazzeo, 2004). Kato et al (2011) gave enzyme conditions 
for the removal of 0 6MeGuanosine but these proved ineffective when repeated at 
Leicester University (Dr Rajinder Singh, personal communication). Additionally, 
Muller et al (1997) found that using acid caused genomic depurination that 
suppressed ionisation further in the method. Therefore, in the present study, thermal
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hydrolysis is the preferred method allowing detection o f  N7M eG bases only and not 
0 6MeG nucleosides unfortunately. Following thermal depurination. the NT- 
methylated base is separated from unmodified DNA by filtration for purification. The 
filtrate (adducted base) is applied to the LC column for isolation (Singh et ah  2003). 
The adducted base (analyte) is retained in the column by the stationary phase while 
other molecules are eluted to waste. At the retention time (unique for each analyte), 
the analyte gains affinity for the liquid mobile phase (containing solvents and acids 
(such as formic acid, to enhance ionization) and is eluted into the electrospray for 
positive ionisation (protonation). A combination o f  nitrogen gas (nebulizing gas), 
heated nitrogen (drying gas) and high voltage is applied to the eluent at the source o f  
the electrospray generating an aerosol spray o f  positive ions. The spray undergoes 
solvent evaporation (desolvation) producing a stream o f  gas phase ions into the mass 
spectrometer. The mass spectrometer has three quadrupoles designated Q1 (M SI), 
Q2 (collision cell) and Q3 (MS2). In Q l ,  the gaseous ions are filtered according to 
their mass to charge ratio (m/z) by an oscillating electric field within the quadrupole. 
m/z  is defined as [M+/7H]"+//7. where M is the molecular mass o f  the analyte, n is the 
number o f  protons it can accept and H is the mass o f  the proton. Ions with the 
equivalent m/z  o f  the major product ion o f  the analyte (precursor ion) will be detected 
and passed to Q2. In Q2. an inert gas at high collision energy fragments the precursor 
ion in a collision-induced dissociation (CID). forming the product ion. detected in Q3 
as in Ql (Sleno and Volmer. 2004). For N7M eG. the major precursor ion has an m/z  
[(M+H) ] o f  166. following CID, the product ion has an m/z  [(B+H)+] o f  149 
indicating the loss o f  exocyclic amine, stabilised by a proton; N H 3 (Figure 4.4) 
(Tuytten et a l , 2006).
N7M eG Precursor ion Product ion
Protonation CID
a a m  — r >=*?
H ^ N  H ^ N
c „h 7n 50  c 6h 8n 5o  c 6h 5n 40
Mr= 165 Mr=l 66 Mr= 149
c=o
H
Figure 4.4. The structure o f  N7M eG base (precursor ion) and product ion following 
CID (collision-induced dissociation). With thanks to Dr Ed Dudley. Structures drawn 
using freeware at ww w .em olecules.com .
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Identifying the specific product ion following CID in tandem mass spectrometry 
confirms the identity of the precursor ion and adds confidence to the data. There are 
three methods of detecting ions in Q l and Q3 in tandem mass spectrometry;
1. Multiple/selective reaction monitoring (MRM/SRM)- Q l and Q3 are set to the 
desired m/z and will only detect those ions.
2. Constant neutral loss (CNL) Ql and Q3 scan a range of masses with a signal 
only being detected if Q3 detects a product ion of the desired m/z.
3. Single ion monitoring (SIM) either the product or precursor ion is detected. 
With multiple reaction monitoring (MRM) the user specifies the m/z to detect in Ql 
and Q3, being 166 and 149 for N7MeG, respectively. MRM offers the greatest 
sensitivity for use in LC-ESI-MS/MS (Ravanat et al, 1998; Singh and Farmer, 2006). 
The sample can be spiked with a base isotope that acts as an internal standard for 
quantification. An internal standard that is routinely used is [15N5]7MeG (Hu et al, 
2011), which is distinguishable from the sample analyte. [15Ns]7MeG is 5 mass units 
more than sample N7MeG, therefore, the precursor ion has a m/z of 171, following 
CID the subsequent product ion has a m/z o f 153. MRM monitors this on a separate 
channel to the sample. Song (2011), when analysing chlorophenoxy herbicides, found 
interference when detecting analytes through MRM on two channels caused by the 
time in alternating between channels. To overcome this, the author ran samples and 
standards separately, which hinders quantitation.
4.1.10. Measuring N7MeG as a biomarker for MNU exposure.
Several questions are raised given the non-linear dose response for MNU induced 
point mutations in chapter 3. The threshold at low dose region may be due to the 
inability to detect an increase in mutant frequency as an artefactual high background 
frequency exists due to limited sensitivity in the HPRT assay. The following work 
aims to identify DNA adducts at increasing concentrations of MNU and produce an 
adduct dose-response as performed by Marsden et al (2009) for ethylene oxide (EO) 
adducts. Identifying exposure biomarkers at doses below the NOGEL would 
demonstrate MNU-DNA interactions, thereby, substantiating our hypothesis of adduct 
formation followed by DNA repair as a mechanism of low dose threshold for MNU. 
The following depicts the use of N7MeG as a biomarker for low dose MNU exposure
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by LC-ESI-MS/MS-MRM analyses performed in Leicester University funded by a 
UKEMS transfer of knowledge bursary.
4.2. Materials and method.
4.2.1. Treatment of AHH-1 cells with MNU.
lxlO7 AHH-1 cells in 10ml cultures were treated with DMSO, 0.00075pg/ml and 
0.025 pg/ml MNU (details given in general materials and methods). This represented 
the negative control, below NOGEL and above LOGEL doses, respectively. After lhr 
exposure, the cells were washed twice in PBS and pelleted for storage in -80°C for 
transport to Leicester University where the following analysis took place.
4.2.2. Isolation of genomic DNA from AHH-1 cells.
DNA was extracted using Blood and Cell culture DNA midi kit' (Qiagen, Sussex, 
UK). Cell pellets were resuspended in 2ml of PBS and vortexed. 1 volume (2ml) of 
ice-cold buffer Cl and 3 volumes (6ml) of ice-cold distilled, filtered water were added 
and the tube inverted until solution became translucent. This was incubated on ice for 
lOmins for sufficient cell lysis. The lysed cells were centrifuged at 3000rpm for 
15min at 4°C and the supernatant discarded. The pelleted nuclei were digested using 
5ml of Buffer G2 and vortexed until completely re-suspended. To this, 18.1 pi (50U) 
of Bovine pancreatic ribonuclease (RNase) A (cat. R4642 Sigma-Aldrich, Poole, UK) 
and 5pi (5U) o f RNase Ti from Aspergillus oryzae (Cat. 10109193001 Roche, Sussex, 
UK) was added, briefly vortexed to mix and incubated at 37°C for 30min. The 
combination o f two RNases sufficiently digests RNA into small alcohol soluble 
fragments that can be washed from the sample. Stock of RNase Ti was provided at 
100000U in 1ml (lOOU/pl) and diluted 1:100 to lU /pl in phosphate buffered saline 
(PBS, Lonza, Slough, UK). After 30min incubation, lOOpl of proteinase K (at 
20mg/ml in water) was added and incubated at 37°C for a further 2hr to digest 
histones and other nuclear proteins. The genomic tip was equilibrated with 4ml buffer 
QGT and allowed to empty by gravity flow. The sample was applied and allowed to 
flow through by gravity. The column was washed twice with 7.5ml buffer QC. The
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DNA was eluted using 5ml buffer QF and precipitated with 3.5ml ice-cold 
isopropanol with slow inversion until the DNA precipitate became visible. The 
sample was stored overnight at -20°C. The samples were centrifuged at 4000rpm for 
30min at 4°C. The supernatant was discarded and the pelleted DNA washed with 
500pl o f absolute ethanol and centrifuged at 4000rpm for 15min. The supernatant was 
aspirated and the pellet air-dried to allow excess ethanol to evaporate. To dissolve the 
DNA pellet, 200pl of distilled, filtered water was added and gently vortexed. The 
concentration of DNA was determined by measuring the absorption at 260nm using a 
nanodrop 1000 spectrophotometer.
4.2.3. Preparation of the internal standard [15Ns]N7MeG.
[15N5]7MeG base was synthesised as per Chao et al (2005). 2pg Dimethyl sulfate 
(DMS, Sigma-Aldrich, Poole, UK) and lmg ,5N 5-deoxyguanosine monophosphate 
(Sigma, Poole, UK) were dissolved in 20pl N,N-dimethylacetamide and left stirring 
for 6hr at room temperature. To remove impurities, lmg celite was added to the 
mixture and centrifuged at 13000rpm for 30min. The supernatant was retained and pH 
increased to 8.0 by addition of ammonium hydroxide. The volume was increased to 
lOOpl with acetone. The white precipitate of l5N5-N7-methyldeoxyguanosine 
monophosphate was collected by centrifugation at 13000rpm for lhr. The supernatant 
was discarded and washed with lOOpl ice-cold absolute ethanol with repeat 
centrifugation. lOOpl absolute ether was added and the sample was dried overnight in 
a savant DNA 110 concentrator speedvac at ambient temperature. Acid hydrolysis 
with 1M hydrochloric acid (HC1) and incubation at 80°C for 30min on a heating block 
(Stuart Scientific, Staffordshire, UK), depurinated the nucleoside, releasing the 
methylated base. Ammonium hydroxide was added drop-wise until [15N5]N7MeG 
base precipitated. The sample was air dried and reconstituted in 400pl 0.1M formic 
acid. The purity of the sample was analysed at 250nm by UV coupled 
chromatography using a Varian Prostar 210 HPLC system with Varian Prostar 310 
UV detector (Varian CA, USA) connected to a phemomenex, synergi column (4pm, 
250mmx4.6mm). A 40pi aliquot of the standard was injected onto the column using a 
Varian Prostar 410 autosampler. The column was eluted at lml/min with a gradient of
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solvent A, 0.05M ammonium formate and solvent B absolute methanol. The gradient 
being; 98% A (2% B) 15min, 80% A 5 min then 98% A for lOmin.
4.2.4. Preparation of the positive control.
With an easily detectable level of naturally occurring N7MeG, calf thymus DNA was 
used as the positive control. A length of un-sheared genomic DNA from calf thymus 
(Sigma-Aldrich, Poole, UK) was dissolved in distilled water. The concentration was 
determined via absorbance at 260nm using a nanodrop 1000 spectrophotometer. The 
positive control was subjected to the same procedure as experimental samples detailed 
below.
4.2.5. Preparation of DNA for LC-ESI/MS-MS-MRM analysis.
For each dose, four samples were pooled into two to increase the amount o f DNA 
sufficient for mass spectrometry. Each sample, and positive control, were spiked with 
26.668pl (1333.4 fmol) of [l5N5]7MeG, (50fmol/pl) to be used as an internal standard 
in quantifying the amount of adduct in sample DNA. The samples were vortexed to 
mix and centrifuged for lhr to dryness using a savant DNA 110 concentrator 
speedvac at ambient temperature. After drying, lOOpl of HPLC-grade water 
(18.2MQcm) was added and incubated for lhr at 70°C in a heating block (Stuart 
Scientific, Staffordshire, UK) to release N7MeG from DNA. 80pil of ice-cold absolute 
ethanol was added to precipitate unwanted double stranded DNA. The adduct was 
filtered from unwanted DNA based on molecular weight by centrifuging at 14000rpm 
for lh r through an Amicon Ultra 3,000 MWCO centrifugal filter (cat. UFC500396, 
Millipore, Watford, UK) pre-conditioned with 200pl HPLC grade water by 
centrifuging for 15min at 14000rpm. Following drying of the filtrate, 20pl of 0.1% 
formic acid was added to dissolve the base. 15 pi of this was used for analysis. The 
5 pi loss of sample was taken into account when calculating the amount of DNA 
loaded on column (equation 4.0, overleaf).
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4.2.6. Measuring N7MeG using LC-ESI/MS-MS-MRM.
A Waters Alliance 2695 separations module with a lOOpJ injections loop and 
automated column-switching device was coupled to a Micromass Quattro Ultima Pt. 
tandem quadrupole mass spectrometer. The electrospray source was at 110°C. 
Nitrogen gas (650L/h) was used as the desolvation gas (350°C) and the cone gas 
(25L/h). The capillary was set at 3.20kV while the cone was 42V, the RF1 lens at 15V 
and the photomultiplier at 950V. To tune the mass spectrometer, N7MeG standard 
solution (lp,g/ml) in 0.1% formic acid/methanol solution (9:1 v/v) was continuously 
infused (lOpl/min) by a Harvard model 22 syringe pump (Harvard Apparatus Ltd, 
Edenbridge, UK).
The LC system consisted of a trap column to purify the signal and an analytical 
column. The trap was composed of Phenomenex Synergi Fusion RP 80A (4pM, 
2.0mm x 30mm) and a waste KrudKatcher (0.5pM) column whereas the analytical 
column consisted of a Phenomenex Synergi Fusion RP 80A column (4pM, 2.0mm x 
250mm), KrudKatcher and guard column. The trap column was eluted with 0.1% 
formic acid/2% methanol (9:1 v/v) at 120ql/min. At this flow rate, the analyte 
remained in the trap column for 1.96+/-0.01min. To limit the volume of unwanted 
molecules entering the mass spectrometer and increase signal over noise, the trap 
column was diverted to waste until 1 Amin, switched online into the analytical column 
until 3.2min then diverted back to waste. The analytical column was eluted at 
120pl/min with 0.1% formic acid/5% methanol, which gave minimum background 
peak. The collision gas, argon, was set at 2.0 x 10'3 mbar and the collision energy at 
12eV. The dwell time was set to 200ms and the resolution at two m/z units at peak 
base. The samples were analysed in positive electrospray ionisation in 
multiple/selected reaction monitoring (M/SRM) on two channels. One for the 
transitions o f m/z 166 to 149 for N7MeG and a second channel monitored the 
transition m/z 171 to 153 for the internal standard [15Ns]7MeG (Chao et al, 2005). 
MassLynx 4.0 software was used to obtain the area under the peak at 1 l.l+/-0.2m in 
that corresponded to N7MeG or [15Ns]7MeG of the resulting chromatograms. This 
was used to calculate the amount of adduct in DNA (equation 4.0).
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4.2.7. Calculation of DNA adduct levels.
The following calculation was used to determine the moles of adduct:
Equation 4.0 Q adduct=  (A adduct/A std) x Q std
Where;
Q a d d i ct  = the amount (fmol) of adduct detected
A adduct = the peak area of the DNA adduct
A std = the peak area of the internal standard
Qstd = the amount (fmol) of the internal standard loaded onto the column
4.2.8. Conversion of mole DNA adduct to adducts/108 nucleotides.
o
Using Q a d d u c t  from equation 4.0, the number of adducts/10 nucleotides was 
determined:
Equation 4.1
o o
Number of adducts per 1 0  nucleotides= ( Q a d d u c t / Q sa m ple) / !  x  10 '
Where;
Q adduct = the amount (mol) of adduct detected being amount in fmol x lx l O'15.
Q sam ple = the amount (mole) sample DNA loaded onto LC column for analysis.
This was derived assuming that l|rg  of DNA=3240pmol (Tauteltaub et 
al, 1990).
Therefore; Q sam ple=  amount of DNA (|rg) on column x 3.240x1 O'9
4.3. Results.
The results presented in this chapter quantify the levels of N7MeG in genomic DNA 
isolated from AHH-1 cells following treatment with 0.00075pg/ml MNU (below 
NOGEL) and 0.025pg/ml MNU (above LOGEL).
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4.3.1. Purity of the internal standard [15Ns]N7MeG.
The purity of the internal standard preparation was assessed by UV coupled HPLC, 
the resulting chromatogram (Figure 4.5). The methodology used to synthesise 
[15N5]N7MeG is taken from Chao et al (2005). The authors state a purity of 99% 
assessed by diode array detection.
3 e .c tce—
Figure 4.5. HPLC-UV chromatogram of the internal standard preparation. The peak 
represents [,5N5]N7MeG showing absorbance at 250nm as a function of elution time 
using a solvent gradient at a flow rate o f lml/min. Kindly provided by Jodie Sandhu 
with permission from Dr Rajinder Singh.
4.3.2. DNA extraction.
AHH-1 cells were treated for lhr with DMSO, 0.00075|ig/ml and 0.025pg/ml MNU 
to represent solvent control, below NOGEL and above LOGEL doses, respectively, 
and the DNA extracted. Table 4.3 shows the purity and suitability of each DNA 
sample for mass spectrometric analysis.
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Table 4.3. DNA yields from lx l0 7cells using Blood and Cell culture DNA midi kit*. 
Each letter represents a different replicate for the specified treatment group. For each 
treatment, sample A and B were pooled into one and so was C and D. The amount of 
DNA on column is shown. This was the final amount of DNA used for analysis. 
Values were calculated after the samples were pooled and accounted for the 
unavoidable loss of sample. This occurred following filtration of adduct from 
unwanted DNA (15pl was retained in the filter) and on injection into the LC system 
(15pl of20pl was used). These values were also used for equation 1.1. An absorbance 
ratio of 1.8-2.2 for 260/280 indicates no protein contamination and for 260/230 
indicates no ethanol or solvent carryover.
Sample ID
DNA YEILD 
(ng/pl) 
@260nm
260/280
ratio
260/230
ratio
Amount of DNA 
(jig) on column
DMSO
A 152.6 1.91 2.20
53.42
B 203.5 1.91 2.10
C 189.3 1.90 2.20
52.32
D 159.5 1.90 2.20
0.00075
(pg/ml)
A 163.7 1.91 2.20
53.03
B 189.8 1.91 2.20
C 199.1 1.92 2.20
60.84
D 206.5 1.92 2.20
0.025
(pg/ml)
A 181.6 1.83 2.09
46.13
B 125.9 1.90 2.12
C 171.5 1.89 2.20
49.31
D 157.2 1.89 2.20
4.3.3. LC-ESI-MS/MS-MRM chromatograms.
Ion chromatograms are shown in Figure 4.6 for DNA extracted from AHH-1 cells 
following lhr treatment with DMSO, 0.00075pg/ml and 0.025pg/ml MNU.
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Figure 4.6. Typical LC-MS/MS chromatograms A.) 0.1% DMSO B.) 0.00075pg/ml 
MNU and C.) 0.025 pg/ml MNU with respective internal standards. The numerical 
output for each DNA sample is shown in Table 4.4.
The area under the peaks (Table 4.4) was used to calculate the number of moles of 
adduct using equation 4.0. This was normalised against the amount o f DNA loaded 
onto the column used for analysis (equation 4.1) to calculate number of adducts per 
108 nucleotides (Figure 4.7).
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Table 4.4. The area under the peaks and retention time for each sample is given. The 
peak area for N7MeG was normalised against the corresponding peak area o f the 
internal standard (equation 4.0). The retention time for N7MeG is typically 0.1 min 
later than for [15Ns]7MeG. The mass spectrometer preferentially identifies higher 
mass ions first.
m/z 166 to 149 
(N7MeG)
m/z 171 to 153 
([,5N5]7MeG)
Sample ID
Peak
Area
Retention 
time (min)
Peak
Area
Retention 
time (min)
DMSO
A+B 3129 11.0 115536 10.9
C+D 4965 10.9 140578 10.9
0.00075
(pg/ml)
A+B 5551 11.0 144684 10.9
C+D 1922 11.1 71719 10.9
0.025
(pg/ml)
A+B 3140 11.0 66643 10.9
C+D 2065 11.2 55702 10.9
Calf thymus DNA 
(+ve control)
132357 11.6 107827 11.6
4.3.4. N7MeG levels below and above the mutation NOGEL for MNU.
The level of N7MeG was quantified in DNA from cells exposed to DMSO,
0.00075|iig/ml or 0.025pg/ml MNU and the dose-response obtained (Figure 4.6). The 
solvent control has similar adduct levels to low dose MNU being 18.2+/-3.7 (mean+/- 
standard deviation) N7MeG/108 nucleotides and 18.0+/-6.2 N7MeG/108 nucleotides
o
respectively with an increase of 27.4+/- 5.9 N7MeG/10 nucleotides at 0.025pg/ml 
MNU.
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Figure 4.7. AHH-1 cells were treated with increasing concentrations of MNU for lhr. 
DNA was extracted and N7MeG adducts quantified. N=2, error bars=s.d.
4.4. Discussion.
The aims of this chapter are to quantify N7MeG adducts as exposure biomarkers 
following MNU treatment through use of LC-MS/MS. 0 6MeG would have been the 
preferred analyte since it is the hypothesised adduct behind the observed MNU- 
induced mutation dose-response in the HPRT assay. However, due to the difficulties 
in releasing the adducted guanine base/nuceloside/nucleotide from DNA, N7MeG was 
chosen as an appropriate biomarker (Swenberg et al, 2008). The adducted base of 
N7MeG is readily and selectively released from DNA by thermal hydrolysis meaning 
that other sites of methylation that are not heat labile, but require enzymatic or acid 
hydrolysis (Shuker and Bartsch, 1994), will not interfere with the analysis.
4.4.1. Assay methodology.
Since N7MeG constitutes 69% of the adduct spectra, it is the predominant adduct 
formed by MNU and all other methylating agents (Beranek, 1990). Due to this, it may 
be a more sensitive biomarker than lesser formed adducts (Pottenger et al, 2009). 
There is a well-established protocol in use at Leicester University for the quantitation 
of N7MeG using LC-MS/MS. The method described here, has been able to achieve
O 1-1
sensitivities of 0.6 adducts/10 nucleotides with 100p,g DNA, similar to P-
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postlabeling techniques (Singh et al, 2005). Assay sensitivity was compromised by 
poor DNA yields (Table 4.5) meaning only a maximum of 60|ig of DNA was 
available for analysis but this proved to be sufficient. The method of DNA extraction 
is vitally important in downstream mass spectral analysis of adducts. For example, 
Clay camp (1992) concluded that DNA extraction by phenol-chloroform could 
overestimate 8-hydroxy guanine (oxidative damage adduct) by 2- to 20-fold. Qiagen’s 
Blood and Cell culture DNA midi kib was chosen for DNA extraction because the 
reagents do not react with DNA. The chromatograms (Figure 4.6) show 
miscellaneous peaks in all outputs for experimental samples. The output for calf 
thymus DNA showed an absence o f miscellaneous peaks. The sample was prepared 
by Sigma using a different extraction method, therefore we hypothesise that the peaks 
are evidence o f salts and trace impurities introduced throughout the DNA extraction 
method. This could be responsible for suppressing ionisation at the electrospray 
source, further compromising sensitivity. Sampling time post exposure is critical 
when determining adduct levels. An initial experiment quantified adduct levels at 
these doses after 24hr exposure, but there was no increase at 0.025pig/ml over 
background levels (Figure 4.8).
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Figure 4.8. 50pg genomic DNA was assessed for the quantity o f N7MeG adducts in 
AHH-1 cells treated with MNU for 24hr. This allowed time for repair, DNA 
replication and spontaneous depurination of chemically unstable N7MeG, which 
reduces the level o f N7MeG. n=2.
The findings in Figure 4.8 substantiate a study by Doniger et al (1985). The authors 
show a reduction in N7MeG over 24hr. Initial levels, following treatment with 
lOOpM (10.308pg/ml), was reduced from 1550 adducts/108 nucleotides to 625
o
adducts/10 nucleotides, a reduction of 59%. A reduction in exogenous adduct levels
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by 59% would not be detected in the current study and accounts for a lack o f dose- 
response at 24hr. This is comparable to the findings of Warren, Crathom and Shooter 
(1979) who found a half-life of 22hr for N7MeG in V79 cells treated with 1.2mM 
MNU (123.70pg/ml). The reduction could potentially involve spontaneous 
depurination. Additionally, the authors report a similar reduction in 0 6MeG. Since 
0 6MeG is not spontaneously labile, the reduction could also be caused by dilution 
through DNA replication or removal by repair, which occurs more rapidly than 
spontaneous hydrolysis (Singer, 1985). Commonly, there is a reduction in adducts 
over time following a single, acute exposure until a balance of endogenous formation 
and removal is reached. The time to reach this differs drastically between different 
adducts, studies and tissues (Singer, 1985). A study by Shibata et al (1994) showed 
persistence of adducts 72hr post-MNU injection in rats. While, Medcalf and Lawley 
(1981) showed persistence of MNU adducts 180 days post-exposure. Conversely, a 
chronic exposure regime in vivo shows an accumulation of adducts as exposure 
continues over several weeks. Previously shown for BAP adducts (Talaska et al, 
1996). In this study, N7MeG levels were determined after lh r post-treatment with 
MNU. This gave sufficient time for DNA reaction and adduct formation and limited 
the time for removal by mechanisms previously discussed. Since DMSO is not DNA 
reactive and does not cause N7MeG adducts (Fischer et al, 2008), the levels in Figure 
4.7 and Figure 4.8 reflect background levels of N7MeG adducts being 18.2+/- 
3.7adducts/10 nucleotides. This is comparable to in vivo background levels Table
4.2. For example, Petruzzelli et al (2006) quote a level of 25 N7MeG/108 nucleotides 
in DNA of blood cells using P-post labelling.
4.4.2. Postulating a no observed genotoxic effect level for adducts.
The data presented in Figure 4.7 gives the appearance of a no observed genotoxic 
effect level (NOGEL) of adduct formation. At 0.00075 pg/ml MNU, there is a lack of 
increase in adducts over the spontaneous level in the solvent control. There are two 
explanations for the lack of increase at 0.00075pg/ml MNU:
1. Assay sensitivity, adducts are formed but are below the limit o f detection o f 
the mass spectrometric analysis
2. Biological mechanism to prevent DNA reaction and adduct formation.
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4.4.2.1. Assay sensitivity.
This is the most likely conclusion from the available data. This possible lack of 
sensitivity could account for the similarity in adduct levels between the negative 
control and low dose MNU (0.00075(Ag/ml) giving the appearance o f a potential 
NOGEL (Figure 4.7). For further confidence, more replicates and doses would be 
needed for full dose-response characterisation. Marsdon et al (2009) and Swenberg et 
al (2008) believe exogenous genotoxins produce adducts proportionally to dose, any 
no observed effect level can be explained by the assay’s limit of detection rather than 
lack of DNA reactivity at the NOGEL. Swenberg et al (2008) distinguished 
endogenous from exogenous adducts by use of radio-labelled genotoxins. The linear 
response they found could only be applied to exogenous adducts which can be linear 
to the LOD. Without experimentally distinguishing between endogenous and 
exogenous adducts, a high level of endogenous damage may mask the appearance of 
MNU induced adducts (Professor James Swenberg, personal communication). 
However, one would expect that exogenous N7MeG adducts to be additive to 
endogenous N7MeG to give a linear response down to the endogenous (control level). 
The assay would need conclusive evidence that the endogenous level was true and not 
artefactually high due to poor assay sensitivity. Pottenger et al (2009) found a 
NOGEL of MNU induced N7MeG up to 6.9pM (0.7pg/ml MNU) but the endogenous
o
level was much higher than the present study (1200 N7MeG adducts per 10 
nucleotides) and may require higher concentration o f MNU to cause an observable 
increase. At low doses, the limit of detection of the assay and also variability in the 
data plays critically in the appearance of a NOGEL.
4.4.2.2. Biological mechanism to prevent DNA reaction.
Another explanation is that MNU does not react with DNA at such low concentrations 
and a true NOGEL exists for adducts, However, This cannot be concluded in this 
study because more biological replicates and doses would be needed. To exemplify,
0.025p,g/ml equates to 242.5301nM (mol/L, Mr of MNU is 103.08), where the 
number of moles is 2.425301x10‘10 [moles=Molar concentration (M/L) x volume (L)] 
being, 2.425301xl0‘10x0.001). Employing Avagadro’s number of
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6.0221415xl023/mol, the number of molecules of MNU in 0.025p,g/ml is 
1.46055x1014. Assuming that 1 molecule is capable of forming one DNA adduct, 
predicted by a linear extrapolation, 0.025pg/ml is capable of 1.46055xl014 adducts. 
N7MeG constitutes 69% of the adduct spectra (Beranek, 1990), therefore, 0.025 pg/ml 
theoretically produces 1.0078x1015 exogenous N7MeG adducts. The human genome 
contains 3 1 64.7x106 nucleotides (taken from
http://www.ornl.gov/sci/techresources/Human Genome/home.shtml). In the 
experiment reported here, lx l 07 AHH-1 cells were treated giving a total o f 
3.1647x1016 nucleotides. Assuming that all guanine nucleotides (approximately 40% 
of the human genome (Lander et al, 2001). Equates to 1.2659xl016 guanines therefore 
guanines are in excess) are substrates for DNA adduction, then there can be a total of 
3.18450xl05 N7MeG adducts per 108 nucleotides (3.1647xl016/ lx l0 8=31647xl04, 
therefore; 1.0078xl015N7MeG adducts/31647xl04=3.18450xl05 exogenous N7MeG 
adducts per nucleotide). Assuming that the maximum of amount o f DNA extracted 
from lxlO7 AHH-1 cells, reported in Table 4.5, is the total amount of genomic DNA 
in lx l0 7 AHH-1 cells i.e. 3.1647x1016 nucleotides then a comparison can be made 
between this theory and the data (Figure 4.7). Given that this study detected an 
average of 9.1 exogenous N7MeG adducts/108 at 0.025p,g/ml (quantity at solvent 
control subtracted from quantity detected at 0.025 pg/ml), the theoretical ratio is far 
too high for the “one molecule=one adduct” interpretation o f linear hypothesis. 
Although, the instability of N7MeG to spontaneous depurination is also a 
consideration and may lead to underestimation of the levels through loss of adduct 
during sample handling. When considering individual molecules, the linear 
hypothesis that states, one molecule of genotoxin forms one adduct, cannot hold true. 
It is, therefore, reasonable to hypothesise that adducts can display a NOGEL. A 
NOGEL has been found for 8-hydroxy-2'-deoxyguanosine adducts in murine liver 
DNA following exposure to increasing concentrations o f 2-amino-3,8- 
dimethylimidazo[4,5-/]quinoxaline (MelQx) (Fukushima et al, 2002). At such low 
doses, it is possible that carcinogens do not react with DNA. There are several 
explanations; membrane exclusion (Speit et al, 2000) or reaction with other 
macromolecules such as RNA (ubiquitously present in the cytoplasm) or components 
of cell culture media (proteins in supplements like horse serum) due to 
carbamoylation, which would not be detected in this assay. Woolley and Pinsky
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(1981) show that MNU shows substantial propensity for methylation of sub-cellular 
organelles and modifications like methylation, carbamoylation and guanidination of 
nuclear proteins such as histone H2A, H3 and H I, respectively (Pinsky, Lee and 
Woolley, 1980; Jump et al, 1980). Since histones are ubiquitous throughout the 
genome they represent an abundant target for reaction with MNU and other alkylating 
agents, thereby preventing DNA adducts. However, this does not disprove linearity 
concerning the fraction of molecules that actually reach the DNA. This could only be 
proven with naked DNA in a chemically inert buffer. Suffice to say that at higher 
doses, with more MNU molecules there is a higher likelihood of reaction with DNA. 
The kinetics of spontaneous MNU decomposition are dependent upon buffer pH and 
temperature (Golding et al, 1997). Donovan et al (2010) state a X\a o f 0.34hr at pH8.4 
but can be extended to 24hr at pH6 (Druckrey et al, 1967). The major decomposition, 
DNA reactive product of MNU is methyldiazonate. This has a half-life of 0.5-2min 
(Jensen, 1983), which was accelerated by bicarbonate, a constituent of buffering 
systems in cell growth media. It is plausible that rapid decomposition o f MNU, and its 
subsequent mutagenic products, prevent reaction with DNA, which explains the 
elucidated NOGEL. In the in vivo situation, MNU can be metabolised into methanol 
and excreted as CO2 and in urine (Swann, 1968). 15min following an intravenous 
injection of lOOmg [,4C] MNU/kg body weight into the rat the levels were 
undetectable with radioactivity detected in excretory products. It could be possible 
that MNU is metabolised to prevent DNA reaction and adduct formation, further 
substantiating the NOGEL hypothesis despite recent efforts to suggest a linear 
response. The data presented here cannot substantiate a biological mechanism 
responsible for the observed NOGEL.
4.4.3. Adducts and HPRT mutant frequency.
The results o f this chapter has been combined with the mutation indution dose- 
response obtained in chapter 3 (Figure 4.9).
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Figure 4.9. The adduct-dose relationship mimics that for mutation induction by MNU 
this suggests that the NOGEL is dependent upon adduct formation.
The observations o f  Figure 4.9 suggest that adduct formation is the critical event in 
mutagenesis. The lack o f  adducts is responsible for the lack o f  increase in mutant 
frequencies observed below the NOGEL (0.0075g/ml). This has been previously 
observed by Pottenger et al (2009) when quantifying 0 6MeG adducts at below 
NOGEL doses o f  MNU in mouse lymphoma cells. This is predominately due to a lack 
o f  mass spectrometric sensitivity since MNU specific N7M eG adducts were identified 
at the same doses. Incidentally, these doses were higher than those reported in the 
present study. The findings presented in this chapter would have implications in 
defining the mechanism behind the shape o f  the dose-response o f  M NU in wildtype 
AHH-1 cells. The mutational NOGEL could be explained by a lack o f  DNA reaction, 
which has been discussed, as opposed to adduct formation and repair. However, the 
dose tested here is 10-fold lower than the NOGEL. Adduct quantitation would need to 
be determined at more sub-NOGEL doses before this was concluded.
4.4.4. Concluding rem arks.
The data obtained in this study, shows that 0.025pg/ml induces 9.1 exogenous 
N7M eG adducts/108 nucleotides over background levels. We can infer the num ber of  
O^MeG adducts. which constitutes 8% o f  adducts according to the spectra o f  MNU. 
This is based on data from Beranek. (1990) obtained at high doses MNU exposure 
and so this may not hold true at low doses. If. 69% o f  adducts induced were N7M eG, 
being 9.1 adducts/108 nucleotides, 8% equates to 1.1 adducts/108 nucleotides (to 1
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d.p). We hypothesise that 1.1 0 6MeG adducts/108 nucleotides are sufficient to cause 
MGMT inactivation in AHH-1 cells and contribute to an increase in mutagenesis. It is 
likely that poor assay sensitivity prevented adduct detection at low doses of MNU. 
Therefore, this study does not provide conclusive proof of adduct induction at doses 
below the NOGEL (0.0075 pg/ml MNU) found in chapter 3. In the following chapter, 
HPRT mutants resulting from MNU treatment were sequenced and the results 
contradict the findings presented here and show that MNU is capable o f DNA 
reaction at doses below the NOGEL. An important question is raised; is DNA 
sequencing more sensitive at detecting changes than adduct quantitation?
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Chapter 5. 
Mutation Analysis.
Comparison Of 
Mutation Spectra At 
Increasing 
Concentrations Of
MNU.
5.1. Introduction.
This chapter will discuss sequencing of HPRT mutants following MNU exposure. 
Sequencing is required for construction of mutation spectra and interpretation of 
changes in mutation induction. Therefore, changes in mutation induction from low, 
non-mutagenic doses to higher, mutagenic doses of MNU will be examined.
5.1.1. Establishing a mutation spectrum.
Mutation induction is observed as an increase in mutant frequency over background 
levels when quantified through the HPRT forward mutation assay. Like other assays 
at different loci (such as TK assay), the HPRT assay positively selects for mutants, 
facilitating downstream analysis o f the mechanism of mutation induction. Mutations 
are important biomarkers of effect following mutagen exposure (Au, 2007). In 
chemical carcinogenesis, mutations are dependent upon adduct formation; adduct 
miscoding potential during DNA replication and cellular processing of the damaged 
base (Figure 5.1). This reflects cellular repair capacity and DNA replication rate 
(Swenberg et al, 2008). Downstream DNA sequence analysis of HPRT mutants 
allows construction of a mutation spectrum. Mutation spectra identify the frequency 
and location of mutations over a DNA sequence, in this example over the HPRT gene. 
Patterns of mutation induction are mutagen specific, as exemplified by analysis of 
mutations induced by ethyl nitrosourea (ENU) and Benzo-a-pyrene (B[a]P) (Kohler 
et al, 1991). However, mutation spectra at low doses of mutagen have not been 
previously analysed. The spectrum of mutations at the HPRT locus reflects the 
mechanism of action of mutation induction, in relation to the requisite steps in Figure
5.1.
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Figure 5.1. Mutations are biomarkers of effect;a combination of adduct formation and 
cellular processing. Image is taken from Swenberg et al (2008).
Mutation induction at the HPRT locus can act as a surrogate for mutation induction at 
other genomic sites relevant to cell growth control and cancer progression, such as 
p53 (Aidoo, Morris and Casciano, 1997). HPRT mutation spectra also allows:
1. Comparison of mutation induction in vitro to the same locus in vivo
2. Comparison of mutation induction in repair deficient and proficient cells 
(Yang et al, 1994)
3. Comparison of mutation induction between different mutagens (Casciano et 
al, 1999)
4. Analysis of spontaneous mutation induction (Zhang et al, 1992)
5. Identification of mutagen specific hotspots
Methyl nitrosourea (MNU) produces an array of DNA adducts (Beranek, 1990). 
Examining the mutation spectra will identify the location and likely type of adduct 
responsible for specific mutations (Van Zeeland et al, 1989). The biological relevance 
of different adducts can also be ascertained. In this study, we are comparing mutation 
spectra at increasing concentrations of mutagen to elucidate the mechanisms of 
mutation induction, at doses below and above the NOGEL of MNU.
5.1.2. Point mutations caused by MNU induced adducts.
The three major DNA adducts resulting from treatment with MNU are 0 6MeG (O6- 
methylguanine), N7-methylguanine (N7MeG) and N3-methyladenine (N3MeG). 
These form 5.9-8.2%, 65-70% and 8-9% of the MNU specific adduct spectra, 
respectively (Beranek, 1990). Their conversion into point mutations has been
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investigated. These adducts are also clastogenic lesions, responsible for sister 
chromatid exchanges (Quiros, Kaina and Roos, 2010) and chromosome aberrations 
(Zair et a l , 2010). However, such chromosomal alterations will not be detected in the 
mutation spectra and will not be discussed.
5.1.2.1. 0 6MeG is miscoding.
0 6MeG is a miscoding lesion and has a well-defined fixation mechanism in 
G :C->A :T  transitions, unless 0 (1MeG is repaired by methylguanine methyltransferase 
(MGM T). As discussed in Chapter 1, unrepaired 0 (’MeG is mispaired with thymine, 
forming 0 ('M eG:T mispairs, following the first post-treatment DNA replication. The 
0 6MeG is then converted to adenine following a second S phase (Figure 5.2).
0 6*Alkyl 0 6-Alkyl
G Replication G R e p lic a tio n _____A __  i z z z r  2 ___
C T T
Figure 5.2. Fixation o f  CfM eG into G C -> A T  transitions is a well-understood 
mechanism, requiring two rounds o f  replication. Image adapted from O 'Neill (2000).
5.1.2.2. N7MeG and N3MeG are not miscoding.
Methylated purines (N7M eG and N3M eA) are not directly miscoding (Mhaskar et al, 
1981). However, these adducts can be processed into point mutations following 
hydrolysis into non-coding apurinic (AP) sites (Figure 5.3).
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Figure 5.3. Enzymatic removal and unstable properties o f  methylpurines (as well as 
other mechanisms) lead to apurinic sites. These are substrates for repair to restore the 
original DNA sequence or can lead to point mutations and chromosome aberrations. 
Image taken from Boiteux and Guillet (2004).
Hydrolysis into an apurinic site can be caused:
• Spontaneously, due to the weakening o f  the glycosidic link following 
methylation
• Through enzymatic removal by DNA glycosylases.
The genome contains 10000 AP sites per mammalian cell per day (Lindahl and 
Nyberg, 1972), although only a small percent are lethal in double stranded DNA 
(Lafleur. Woldhuis and Loman, 1981). AP sites are substrates for repair that can 
restore the original guanine, or can contribute to mutagenesis should an incorrect base 
be inserted. N7M eG and N3M eA are substrates for repair, initiated by specific 
glycosylases o f  base excision repair (BER), an important protective mechanism from 
alkylpurine-induced carcinogenesis (Wirtz et al. 2010: Kondo et a l, 2010). The 
glycosylases are N3-M eA DNA glycosylase/alkyladenine glycosylase (AAG) for 
removal o f  N3M eA (Engelward et al. 1996) and N-M ethylpurine-DNA glycosylase 
(MPG) for the removal o f  N7M eG. These glycosylases cleave the glycosidic bond 
between the base and DNA backbone, thereby removing the base and leaving an AP 
site. Over-expression o f  these repair genes sensitises cells to methylpurine 
mutagenesis by creating more AP sites (Ibeanu et al. 1992). Replication can proceed
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over an apurinic site at the expense of genome fidelity (Vos and Rommelaere, 1987; 
Schaaper, Kunkel and Loeb, 1983). Upon recognition o f an AP site, the replicating 
polymerase (polymerase s) is displaced and replaced through “polymerase switching” 
in the “replisome” to a polymerase (Lehman et al, 2007; Lovett, 2007) capable of 
translesion synthesis (TLS). These polymerases are polymerase X, p and r\ (Villani et 
al, 2011), as identified in human cells. Polymerase p preferentially incorporates 
adenine opposite an AP site, although all dNMPs are substrates for incorporation 
opposite an AP site (Efrati et al, 1997). Whereas, polymerase X incorporates guanine 
(Shtygasheva et al, 2008). Therefore, through translesion synthesis, N-methylpurines 
can give rise to a number of transversion and transition mutations. This pathway may 
account for the variety o f mutations seen for Sn2 alkylators, e.g. MMS, which target 
N7MeG to a higher extent. The different patterns of mutations induced by alkylating 
agents (Table 5.1) can be attributed to the differences in adduct spectra. Due to the 
similarity in amount of 0 6AlkG induced by ENU and MNU (7.8-9.5% and 5.9-8.2% 
of total alkylations, respectively) and the differences in GC->AT transitions (26% and 
92% of total mutations, respectively), other adducts or mechanisms may cause 
G C ^A T  transitions. ENU causes more 0 2Thymine (0 2T) and 0 4Thymine (0 4T) than 
MNU, shown to cause AT->TA and AT->GC substitutions, respectively (Tosal, 
Comendador and Sierra, 1998).
Table 5.1. Mutation induction at the HPRT locus by three alkylators. The differences 
in proportions of substitutions likely reflect different mechanisms of action and 
adduct spectra. Taken from Jenkins et al (2005).
Mutation type ENU SNi % MNU SN, % MMS SN2 %
G O A T 206 26 112 92 129 69
AT>GC 164 21 5 4 19 10
AT>TA 255 33 2 2 8 4
AT>CG 106 14 0 0 10 5
GC>TA 39 5 3 2 14 7
GC>CG 14 2 0 0 8 4
Totals 784 100 122 100 188 100
Transitions 47 96 79
Transversions 53 4 21
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5.1.3. HPRT mutation spectra database.
HPRT has served as an important reporter gene for induced mutations following 
genotoxin exposure. As a result, there is a wealth of knowledge of mutation induction 
at the HPRT locus. Cariello (1994) compiled information from different hosts and 
different mutagens. Information is also available on the Mammalian Gene Mutation 
Database (MGMD). This facilitates the comparisons listed previously in section 5.1.1. 
There is an added impetus for mutation analysis o f HPRT as missense mutations in 
HPRT cause Lesch-Nyhan syndrome (Puig et al, 2001). Therefore, DNA sequence 
analysis has received much attention. Tomita-Mitchell et al (2003) report significant 
concordance between mutational patterns found in vitro and in vivo at the HPRT 
locus, emphasising its suitability as an in vitro mutation detector.
5.1.4. Methods for mutation detection.
There are a variety of methods available for determining the type and location of 
mutations in DNA sequences (Reviewed by Nollau and Wagener, 1997). The 
following is a brief account of techniques used to identify genetic alterations. 
Denaturing gradient gel electrophoresis (DGGE) coupled PCR. This technique is 
based on sequence specific denaturation of double stranded DNA (dsDNA) and 
subsequent mobility shifts on a low percentage denaturing acrylamide gel. A single 
base pair difference can be resolved using this method but its identity remains 
unknown. Cariello and Skopek (1993) have used this technique to identify the 
replicating fidelity of DNA polymerases and to purify mutant DNA from wildtype 
DNA, at heterozygous loci. A modification known as constant DGGE is able to 
determine the location o f a mutation on an oligonucleotide (Hovig et al, 1991). This 
technique can accommodate as many samples as the size of the gel permits and can be 
useful for comparing multiple samples simultaneously. DGGE permits the analysis of 
mutations on strands less than lkilobase (kb) with analysis taking up to lOhr. 
However, the “technique reveal(s) little about the nature or position of that mutation” 
(Cariello et al, 1988).
Single strand conformational polymorphism (SSCP). This assay is very similar to 
DGGE but is more robust (Hori et al, 2006). dsDNA is denatured a priori to single 
stranded DNA (ssDNA). The conformation of the secondary structures of ssDNA
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formed upon self-annealing is sequence specific and will influence migration 
throughout a gel (Orita et a l, 1989). This allows the user to identify ssDNA o f  
different sequences. As with DGGE, the mutation type is not identified but only 
200base pair (bp) fragment is optimal. DGGE and SSCP can only ascertain the 
proportion o f  samples that are mutated. Both techniques have been applied in analysis 
o f  mutations in exon 8 o f  the HPRT gene o f  rodent splenic lymphocytes following 
ENU treatment (Mittelstaedt and Heflich. 1994).
Restriction site mutagenesis (RSM) assay. RSM has been validated in our 
laboratory to identify ENU and M NU induced mutations in murine tissues (Jenkins, 
Takahashi and Parry et al, 1999; Suzen, Jenkins and Parry, 1998). The theory o f  this 
technique is shown in Figure 5.4.
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Figure 5.4. Theory o f  restriction site mutagenesis (RSM) assay. Image taken from 
Jenkins et al, (1999).
Mutations at a restriction site will prevent endonuclease cutting and the target will be 
amplified, giving a band on a DNA gel. The technique is similar to restriction 
fragment length polymorphism (RFLP), where PCR is performed before digestion. 
RSM will not detect mutagenic events outside o f  the restriction sites. In addition, 
further PCR and sequencing are required to determine the type o f  mutation.
Northern (DNA) and Southern (RNA) blotting. Labelled oligonucleotide probes 
will specifically bind to regions o f  interest, allowing the identification o f  nucleic acid 
sequences in a sample. Nucleic acid blotting can be used to detect deletions and 
insertions in genomic DNA, or exons in mRNA. This has been used in analysis o f  
mutations at the TK locus following ethyl methanesulfonate (EM S) and mitomycin C 
(M M C) treatments (Davies, Phillips and Rumsby, 1993). Alternative RNA splicing 
causes a loss o f  exons throughout the HPRT m RN A  (O 'Neill et al, 1998). that would
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be detected by Northern blotting. Single point mutations in the region of probe 
binding are unlikely to affect hybridisation and so will not be detected. Southern 
blotting has been used to detect 2-40kb deletions at the HPRT locus (Bradley et al, 
1987). However, Southem-blot detectable genetic alterations account for only 10-20% 
of HPRT mutations (Recio et al, 1990).
Hybridisation to detect point mutations. With interests in disease genotyping, there 
is incentive to detect single base changes and point mutations within genes of interest. 
One approach hybridises sample ssDNA to wildtype ssDNA, forming a homoduplex 
or a heteroduplex if mutations are present in the sample DNA. The mismatches in the 
heteroduplex can be detected by a number of methods; a diminished electrocatalytic 
signal o f methylene blue (Boon et al, 2000), a downward deflection of a cantilever in 
a cantilever-based optimal deflection assay (Hansen et al, 2001) and a change in 
frequency of a quartz resonator, upon mismatch repair (MMR) mediated recognition 
(Su et al, 2004). These techniques are designed to be highly specific but are expensive 
and laborious.
Differential amplification of mutant transcripts by real time PCR. Morlan, Baker 
and Sinicropi (2009) describe a technique that preferentially amplifies mutant 
transcripts. This would require prior knowledge of hotspots for appropriate primer 
design and is not appropriate for establishing mutation spectra over a large gene. 
Direct sequencing of PCR-amplified targets. This technique has been used in this 
chapter as it provides unequivocal evidence of the location and type of mutation at a 
gene of interest, using computer software to compare to the wildtype.
5.1.5. DNA sequencing.
A variety of sequencing methodologies exist. These include mass spectrometry 
(Murray, 1996) and more recently, next-generation sequencing (NGS) (Metzker,
2010). NGS is offered commercially as a higher throughput method than traditional 
Sanger’ chain termination-based methods and can achieve longer read lengths 
(Schuster, 2008), allowing the sequencing of entire cancer genomes (Aburatani,
2011). The most common methodologies for small-scale sequencing reactions are 
based on Sanger’s method, but with automation for higher throughput and lower cost. 
The method replicates the sample DNA using deoxynucleotides spiked with equal 
volumes of each of the four dideoxynucleotides (ddATP, ddCTP, ddGTP and ddTTP),
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each with a different fluorescent tag. These all lack a 3’-OH group and, as a 
consequence, block chain extension upon incorporation into the growing DNA strand. 
This results in a mixture of oligonucleotides of different sizes depending on where the 
chain terminator has been incorporated. They are separated based on fragment length, 
fluorescence emissions determined and order of bases starting from the shortest 
oligonucleotide.
5.1.6. Experimental approaches to sequence HPRT.
The HPRT gene occupies 47542 base pairs (bp) of the long arm of the X 
chromosome, designated Xq26. A significant portion of this region consists of 
intronic regions with the protein-coding region of 654bp over 9 interspersed exons 
(Figure 5.5), which are spliced together forming a mRNA of 1435bp.
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Figure 5.5. HPRT schematic showing intron/exon organisation. Adapted from 
http://www.ncbi.nlm.nih.gov/nuccore/NG_012329.1 ? fro m = l& to = 5 1601 &report 
=graph&content=5. Values taken from O 'N eill et al (1998).
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PCR amplification or cloning of HPRT into bacterial hosts, is needed to give 
sufficient yield for sequence analysis. As the length of template increases, the 
efficiency of cloning and PCR amplification diminishes. There have been several 
experimental approaches to overcome this problem. Edwards et al (1990) 
deconstructed the entire gene into a M l3 library composed of overlapping contigs. 
Williams, Rainville and Nicklas (2002) devised a method, termed inverse PCR 
(iPCR), to sequence break sites, within the HPRT gene, of deletion or insertion 
mutants that gave an altered hybridisation pattern on a Southern blot. The advantage 
being that not all the gene needed to be sequenced. However, alterations such as point 
mutations, that are undetectable by Southern blot, would be excluded from further 
analysis. One approach used by Jenkins et al (2005) was to sequence one exon of 
interest, where known mutation hot spots exist. The authors sequenced exon 3 of 
HPRT following MMS exposure. However, mutations occurring at flanking exons 
will not be identified. Liu et al (2003) have avoided this. The authors used 18 primers 
in multiplex PCR to amplify each exon, with the advantage of easy detection of exon 
deletion on a DNA gel. However this technique is expensive and laborious. To 
overcome this, van Zeeland et al (1989) amplified cDNA (complementary DNA), 
synthesised from mRNA, via reverse transcription using reverse transcriptases from 
retroviruses (Simpson, Crosby and Skopek, 1988). HPRT has four reported 
homologous sequences present in human genomes; two on chromosome 11, one on 
chromosome 3 and another on chromosome 5 (Patel et al, 1984). Fuscoe et al (1983) 
demonstrated that these sequences are “unexpressed intronless pseudogenes”. As 
pseudogenes are not represented in the transcriptome, these sequences are not 
amplified in mistake. cDNA will be shorter than the genomic region and has all 9 
exons spliced together, containing the protein-coding region. cDNA is easier to clone 
and amplify (Jolly et al, 1983). Harbach et al (1995) was able to amplify 780bp 
including the protein coding region. In this chapter we report the successful 
development of PCR and sequencing methodology, with improved coverage (83%) of 
HPRT mRNA.
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5.1.7. PCR and sequencing method optimisation.
Two methods of PCR were tested:
1. Nested PCR
2. Overlapping PCR primers
5.I.7.I. Nested PCR.
Following mRNA conversion into cDNA using Oligo(dT) primers, an initial strategy 
of PCR amplification used nested primers to copy cDNA in one contiguous sequence. 
This required the use of two primer sets, in two separate PCR reactions. The primers 
are shown in Table 5.2.
Table 5.2. Details of the nested PCR primers.
PCR
reaction
number
Primer name Sequence
Primer 
binding site 
(bp in 
HPRT 
mRNA)
Length of
product
(bp)
1 Outer Forward 5'-CGGGGCCTGCTTCTCCTC-3' 3 1374
Outer Reverse 5 '-GGG AACT GCT G AC A A AG ATT C AC-3' 1376
2 Inner Forward 5'-CCTCCGCCTCCTCCTCTG-3'
92 1146
Inner Reverse 5'-CTTACTTTTCTAACACACGGTGG-3' 1238
As can be seen in Figure 5.6A, the optimal annealing temperature that produces 
ample product with minimal miscellaneous bands, for PCR reaction number 1, is 
61.5°C.
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Temperature
(°C):
Tem perature
Figure 5.6. Temperature gradient for PCR reaction number 1 (A) and PCR reaction 
number 2 (B). Left most lane is 100bp-1500bp DNA ladder.
A 2pl aliquot o f  the product obtained at 61.5°C, in PCR reaction 1, was used in PCR 
reaction 2. using the nested primers. For reaction 2, 58.5°C was the optimal annealing 
temperature (Figure 5.6B). To improve yield, increasing volumes o f  PCR reaction 
number 1 product was used in PCR reaction 2 (Figure 5.7).
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Volume of 
tem plate (pi):
 >
Figure 5.7. Concentration gradient. Optimal volume o f  product from PCR reaction 1 
(template) for use in PCR reaction 2 is 5pl. Right most lane is 300-1500bp.
5 pi was found to give the greatest yield. However, nested PCR was not reproducible. 
It is likely that the success o f  PCR was limited by the efficacy o f  cDNA conversion, 
which diminishes as the length o f  the target sequence increases. Therefore an 
alternative, more successful approach was to divide the amplicon into two shorter 
fragments by using overlapping primers (Figure 5.8).
5.1.7.2. Overlapping PCR prim ers.
 ,   —- - i - > ___________________ _ ___________ ,______--------------------------------------  < ..■l-M.I..—--------------------------------- <  "
Figure 5.8. Schematic o f  the technique o f  splitting HPRT m RNA into two 
overlapping oligos to shorten the length o f  amplicon and improve PCR success. Red 
primers are designated “D” and green are designated "K ".
14 combinations o f  forward and reverse primers were designed using Beacon 
software (Premier Biosoft, Palo Alto. USA) and tested (at the optimal final 
concentration o f  0.04pM  in each 50pl reaction, Figure 5.10) and their annealing 
temperature experimentally determined. The two primer sets (one for each half  o f  the 
gene) with identical annealing temperatures were further optimised: this meant that
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both fragments of the gene could be amplified simultaneously, thereby saving time 
and running costs. These primer sets were designated D and K, targeting a fragment 
of 537bp and 714bp respectively.
5.1.8. Optimisation strategy.
The initial recipe for PCR reaction mixture was obtained from Dr Sarah Prior 
(personal communication). The annealing temperature, primer concentration, 
magnesium chloride concentration and number of cycles were manipulated to 
improve sensitivity, while maintaining specificity. The following is a stepwise 
account of how the technique was optimised;
1. An annealing temperature range from 51 -58°C was performed (Figure 5.9A)
2. A 10-fold reduction in primer concentration over the same temperature range 
gave better specificity; further primer dilutions were unsuccessful (Figure 
5.9B).
3. The optimal annealing temperature for D and K primers was 52.6°C (Figure 
5.10).
4. Magnesium chloride dissociates into free positive magnesium ions to improve 
annealing of primer to target sequence, both of a negative charge. Therefore, 
3-7pl (final concentration 0.5mM to 3.5mM) MgCb was added per 50pl 
reaction (Figure 5.11 A and 5.1 IB). It was later found that 3 pi of MgCb for D 
primers gave inconsistent yields and so 4pl was used.
5. To further increase the yield, the number of cycles was increased to 40. 
However this gave miscellaneous bands o f higher bp (Figure 5.12).
6. To overcome this the extension time was reduced to 10s (Figure 5.13).
7. Finally, both primer sets were added to one reaction mixture, as in multiplex 
PCR. However, primer dimers were evident which later interfered with 
sequencing (Figure 5.14).
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Figure 5.9. Optimal concentration o f  primers. (A) A temperature gradient with 2pM  
primers was too concentrated. (B) 1 in 10 dilution was sufficient. Leftmost lanes are 
100bp-1500bp DNA ladder.
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Tem perature
Figure 5.10. Optimal temperature for D and K primer sets is 52.6°C.
A).
Volume of MgCl2 per ^
50|xl reaction (|al): ^  K <, a ^
Figure 5.11. Magnesium chloride (M gC b) concentration gradients for D (A) and K 
(B) primer sets.
146
Figure 5.12. To increase yield, the number o f  cycles were increased to 40 and tested 
with RNA extracted from four HPRT mutant colonies. Once optimised, all RNA 
samples were tested for DNA contamination using RNA in PCR (-RT (without 
reverse transcription) control) and the PCR reagents were tested for contamination 
using water as a control (no template control. NTC).
Extension tim e
Figure 5.13. Halving the extension time to 10s reduced the appearance o f  high 
molecular weight bands.
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Prim er
Dimer
Figure 5.14. For convenience, both primer sets were added to one reaction tube to 
mimic multiplex PCR. Plowever, primer dimers were evident and interfered with 
downstream sequencing, so D and K reactions were performed in separate tubes.
5.2. Materials and methods.
The finalised PCR and sequencing methodology is given in Chapter 2.
5.2.1. Principal com ponent analysis.
To compare the inter-relationships between different spectra, multivariate principal 
component analysis (PCA) was performed using R software version 2.9.0 
downloaded from http: ■Avww.r-proiect.org/index.html on 7/9/2009. Detailed 
instructions and coding is given in appendix 6 .
5.2.2. A dam -Skopek  test.
To reject the null hypothesis o f  no difference between spectra, the Adams-Skopek test 
was used in a pair-wise manner. Analysis was performed using FIYPRG software 
downloaded from ftp://sunsite.unc.edu/pub/academic/biology/dna-mutations/hyperg 
on 13/2/2012 (Cariello et al, 1994).
5.3. Results.
This chapter constructs mutation spectra to comment on changes in mutation 
induction, over the hormetic dose-response observed in the previous chapter. The 
doses chosen for sequence analysis were 0, 0 .00075pg/ml and 0.025pg/ml MNU 
(Figure 5.15). We hypothesise the involvement o f  0 (1-methylguanine-DNA 
methyltransferase (M GM T) in preventing mutations, by repairing 0 6MeG at 
0 .00075pg/ml MNU and doses up to the NO GEL (0.0075pg/ml MNU). Real time 
PCR analysis o f  M G M T transcripts and analysis o f  M G M T activity was performed to 
assess the response at this locus over the transition from ‘“non-mutagen to mutagen” .
7 .00E -05
6 .00E -05
=  5 .00E -05  
cr
z  4 .00E -05
LOGE3  3 .00E -05
2.00E-05 NOGE
~  1.00E-05
0 .00E +00
0 .0 0 0 7 5 0 .025 0 .05  0 .0750 .001  0 .0 0 2 5  0 .005  0 .0 0 7 5  0.01
MNU ( M g / m l )
Figure 5.15. Data from Chapter 3 showing the doses (outlined in red) selected for 
sequence analysis at the H P R T  locus.
5.3.1. Proportion of mutations identified.
Three treatments were chosen for further analysis o f  mutants. These were; DM SO 
which represents the solvent control (spontaneous mutagenesis), 0 .00075pg/ml MNU 
and 0 .025pg/ml M NU, representing below NOGEL and above LOGEL respectively. 
This allowed characterisation o f  differences in mutation induction over the dose- 
response observed in Chapter 3. For each treatment, 40 HPRT mutants were isolated 
and propagated at the end o f  the HPRT assay for sequence analysis. The proportions 
o f  all possible substitutions resulting from each treatment are shown in Table 5.3.
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Table 5.3. Proportions of substitutions at the HPRT locus observed at increasing 
concentrations of MNU. The values in bold represent the most predominant 
substitution at each dose. n=22 for Opg/ml, n=40 for 0.00075pg/ml, and n=36 for 
0.025pg/ml (see text for details). Pairwise comparisons = <1x1 O'60 for each treatment.
Percentage of total mutations (%)
Substitution type Opg/ml MNU 0.00075pg/ml MNU 0.025 pg/ml MNU
GC->AT 15.0 12.5 45.9
AT->CG 29.0 7.8 5.1
AT->GC 9.3 7.8 8.9
GC->TA 9.3 7.8 3.0
AT->TA 22.4 14.1 16.2
CG->GC 15.0 50.0 20.7
Total number of 
mutations found 112 64 135
18 mutants of the solvent control and 4 mutants following treatment with 0.025pg/ml 
were found to contain a contiguous sequence o f changes found to occur elsewhere in 
the HPRT sequence. Whether this is a translocation or duplication cannot be resolved. 
These mutants were excluded from further analysis and only base substitutions (the 
main mutagenic mechanism of MNU) were considered. An interesting observation 
was the lack of this rearrangement in mutants resulting from treatment with 
000075pg/ml. The proportions changed drastically over the dose range, suggesting 
the involvement of different mutational pathways at increasing concentrations of 
MNU. Pair-wise comparisons using a Chi2 test on actual numbers and not percentages 
were performed. Each were highly significant. 0 vs 0.00075 ;p=2.3x 10‘61, 0 vs 
0.025;p=4.7xl0'65, 0.00075 vs 0.025;p=1.0xl0'154. In the solvent control, a total of 
112 mutations were found in 40 mutants. The most prominent spontaneous 
substitutions were AT->TA transversions, constituting 38.1% of the spontaneous 
mutation spectra. Following treatment with 0.00075pg/ml, CG->GC transversions 
were the most abundant, constituting 32 of 64 (50%) substitutions observed. The 
spectrum changed upon treatment with 0.025 pg/ml MNU, where GC->AT transitions 
were the predominant alterations, as expected from MNU exposure, forming 43.9% of
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the mutation spectrum. The increase in G C ->A T transitions most closely reflected the 
increase in mutant frequency observed in Chapter 3 (Figure 5.16). The change in 
proportion o f  G C -> A T  transitions was accompanied by a change in the number o f  
mutants found to harbour a G C -> A T  transition, from 52.5% (21/40) mutants in the 
spontaneous spectrum, to 17.5% (7/40) mutants at 0.00075pg/ml, to 72.5% (29/40) 
mutants at 0 .025pg/ml. Therefore, results were not biased by a mutant containing 
many G C -> A T  transitions.
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Figure 5.16. The proportion o f  G C -> A T  changes increases in concordance with the 
increase in HPRT mutant frequency observed in Chapter 3.
5.3.2. M utation spectra
The spectrum o f  base substitutions along the HPRT m RN A  sequence is shown for 
each treatment in Figure 5.17. As expected the vast majority o f  mutations occurred in 
the protein-coding region o f  the mRNA. from position 167bp to 824bp. The spectrum 
at 0 .00075pg/ml M NU showed a different spectrum o f  mutations to the solvent 
control. A GC~>TA transversion at 747 seems specific to M NU treatment, regardless 
o f  concentration. However, many o f  the G C ->A T transitions are only present 
following treatment with 0.025pg/ml MNU. Each spectrum was significantly 
different (p=0.000). adjudged through pair-wise comparisons o f  each spectrum, using 
the Adams-Skopek test (Adams and Skopek, 1987) through HYPERG software
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(Cariello et al, 1994). MNU specific hot spots were defined as mutations occurring at 
>5% of the total mutations for each spectrum. At 0.00075pg/ml one hotspot (shown 
in bold) occurred at 747; 5’TGA->TCA. This was also found at 0.025pg/ml with 
additional hotspots at 551; 5’AGA->AAA, 555; 5’TGT->TAT and 556; 
5’GTC->GAC.
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Figure 5.17. Summation o f  all mutations found along the non-transcribed strand o f  
HPRT sequence, from 40 HPRT mutants for each treatment. For example, mutation at 
747 in B). occurred in 27 mutants. Spectra were composed using iMARS software 
(Morgan and Lewis, 2006).
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5.3.3. Principle component analysis (PCA) of mutation spectra
Principle component analysis (PCA) was conducted to reveal differences in mutable 
sites between spectra. The data was explained by two components, PCA 1 (correlation 
factor=0.9) and PCA2 (correlation factor=0.1). Therefore, 90% of the data is 
explained by PCA1 and PCA2 explains 10% of the data. The data is presented as a 
scatterplot in Figure 5.18, which allows the user to identify the differences between 
the spectra.
o
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o
<ua.
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Figure 5.18. Scatterplot to visualise the differences in mutable sites between the 
spectra resulting from different doses of MNU.
Referring to Figure 5.18, PCA1 (x-axis) separates MNU treated from solvent control 
spectra. The second component (y-axis) separates the two MNU treatment groups 
suggesting different mutational mechanisms at increasing concentrations of MNU. 
Most notably, o f the sites clustering at 0.025 pg/ml, 67.7% were GC->AT transitions 
and equal proportions (11.1%) were TA->AT, GC->CG and AT->GC substitutions. 
These mutations were absent at 0.00075pg/ml MNU and the most prominent mutation 
occurred at 747, which was GC->TA transversion.
Above LOGEL, 
0.025pg/ml MNU
M20G
Solvent control
Below NOGEL 
0.0007S|ig/ml MNU
PCA axis 1
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5.3.4. Measuring the effect of MNU treatment on MGMT.
5.3.4.I. MGMT activity in AHH-1 cells.
To test our hypothesis of 0 6MeG induced MGMT activity saturation, the activity of 
MGMT was measured at increasing concentrations of MNU in AHH-1 cells. This was 
performed at the Institute of Toxicology, University of Mainz, by Professor Bemd 
Kaina and Karl-Heinz Tomaszowski, to whom I am incredibly grateful. Cells were 
treated for lh r with MNU and left to recover for 90mins to allow for MGMT reaction. 
MGMT was undetected in AHH-1 cells but high quantities were detected in Caco-2 
and Hela S3 cells, kindly provided by Mrs Margaret Clatworthy and Dr Sian-Eleri 
Owens respectively. These cells are known expressers of high level MGMT and were 
chosen as positive controls (Foote and Mitra, 1984) (Table 5.4). The limit of 
detection (LOD) of the assay is 1000 MGMT molecules/cell (Kaina et al, 1991). 
Given that 255 molecules/cell=0.16fmol/mg protein (Bobola et al, 2007), the LOD of 
1000 molecules/cell equates to 0.63fmol/mg protein. It is possible that MGMT exists 
at a level below 0.63fmol/mg protein in AHH-1 cells and lack of assay sensitivity 
prevents detection.
Table 5.4. MGMT activity in AHH-1 cells was not detected (ND), but the positive 
controls were successful. It is possible that MGMT in AHH-1 cells is below the limit 
of detection or AHH-1 cells are MGMT deficient.
Dose MNU (pg/ml) MGMT activity (fmol/mg protein)
0 ND
0.00075 ND
0.025 ND
HeLa S3 (positive control) 655.50
Caco-2 (positive control) 2,952.96
5.3.4.2. Expression analysis of MGMT in AHH-1 cells.
Real-time PCR quantified the fold changes in MGMT transcripts in response to 
increasing concentrations of MNU, at four time points over 24hr post-exposure 
(Figure 5.19).
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Figure 5.19. Real time PCR analysis o f  M G M T transcripts showed no statistically 
significant increase in expression in response to M NU exposure.
There seems to be a slight increase in expression 4hr following treatment with
O.Olpg/ml. However, no treatment resulted in a statistically significant change (lowest 
a  value being p=0.07 at 24hr treatment with 0.05pg/ml). Attempts to sequence the 
amplicon proved unsuccessful and so the product could not be verified.
S.3.4.3. MGMT prom oter methylation analysis.
To assess M GM T promoter methylation status; methylation specific PCR (MS-PCR) 
was performed at the Institute o f  Toxicology. University o f  Mainz, by Professor 
Bernd Kaina and Karl-Heinz Tomaszowski, to whom I am incredibly grateful. Figure
5.20 shows that, in AHH-1 cells, the M G M T promoter is methylated. This suggests 
that M GM T is not expressed, however, M G M T  m RNA can be detected by real time 
analysis.
Figure 5.20. Methylation specific PCR (M S-PCR) suggests that M G M T promoter in 
AHH-1 is methylated. MZ160 is the unmethylated control and MZ227 is the 
methylated control.
AHH-1 MZ160 MZ227 H20
U M U M U M U M
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5.4. Discussion.
The aim o f  the present chapter is to establish understanding o f  mutation induction by 
MNU, to determine a biological mechanism responsible for the observed dose- 
response in Chapter 3. The observed differences in treated mutation spectra can be 
explained by saturation o f  M G M T at 0.025pg/ml, due to increased concentration o f  
0 (1MeG at higher doses o f  MNU. To test this; M G M T activity, the response at the 
M GM T promoter and M GM T status o f  AHH-1 cells were investigated.
5.4.1. Mutagenesis at the HPRT locus.
Jinnah et a l (2000) compiled Lesch-Nyhan disease (LND) causing point mutation 
along the HPRT gene (Figure 5.21). There is substantial spread in deleterious 
substitutions, which is replicated in Figure 5.17. Providing evidence that all exons o f  
HPRT should be included in mutation analysis.
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Figure 5.21. Base substitution along the protein-coding region o f  HPRT gene (black) 
shows substantial spread in the location o f  deleterious mutations. (Taken from Jinnah 
et a l  2000).
5.4.2. Spontaneous mutagenesis at the HPRT locus.
Mutagenesis in the absence o f  exogenous genotoxic treatment is referred to as 
spontaneous. DMSO, used here, is a solvent control in many mutation assays without 
causing mutagenesis (also observed in Chapter 3). Therefore, at the final 
concentration used here (0.01%) there is no evidence to suggest DM SO is mutagenic. 
Mannan et al (2010) showed that DM SO generated reactive oxygen species (ROS) 
only in rooted Artem isia  annua shoots. ROS are capable o f  DNA reaction and 
mutagenesis. However, in animal cells, DM SO is a well-known scavenger o f  ROS 
(Yu and Quinn. 1994). O f  course, without conclusive proof by comparing with the 
mutation spectra o f  untreated controls, we cannot be certain that D M SO  treated
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cultures reflect the spontaneous spectrum. However, given what is known of DMSO, 
this assumption may be valid. In the present study it is more value to compare to 
DMSO treated than untreated cultures in order to determine MNU specific effects. 
The importance of spontaneous mutagenesis is realised in ageing and carcinogenesis 
(Ames and Gold, 1991; Loeb, 1989). There are many well-known sources of 
endogenously generated genotoxins that can contribute to the spontaneously occurring 
mutation spectra. This is discussed in relation to alkylating agents in Chapter 4. At the 
HPRT locus, exon deletions are common due to mutations that abrogate appropriate 
splicing at intron-exon junctions during pre-mRNA maturation prior to translation 
(O’Neill et al, 1998). This did not occur in the present study but has been reported 
previously as a mechanism for spontaneous deletions in HPRT mRNA. Sources of 
spontaneous mutations include;
• DNA adduction by reactive oxygen species (ROS) from media components 
and intracellular metabolism (Wiseman and Halliwell, 1996). Each nucleotide 
is susceptible to oxidative damage, causing a variety of substitutions
• Replication over abasic sites from chemically unstable bases, hypothesised to 
cause a range of transversions and transitions as discussed
• Spontaneous deamination of 5-methylcytosine at CpG dinucleotides leading to 
GC->AT transitions
• Mistakes by the replicating polymerase in DNA synthesis (Tippin, Pham and 
Goodman, 2004)
• Transcription associated mutagenesis, which has been shown to cause 
GC->AT, TA->GC and AT->TA substitutions (Hudson, Bergthorsson and 
Ochman, 2003).
The mutational mechanisms above could account for the spontaneous substitutions 
observed at the HPRT locus. However, it is likely that another mechanism is 
involved, which would better explain the rearrangement seen in 18/40 mutants from 
positions 490 to 517 of the mRNA sequence (indicated with a line Figure 5.17) in , 
than would chemical alteration to individual bases. A colleague has also reported this 
in a separate experiment in untreated AHH-1 cells (Mrs Kulsoom Shah, personal 
communication). There is substantial variation in spontaneous mutagenesis between 
cell types. Lewis and Parry (2002) confirmed this at the SupF locus, which is also 
used as a mutation sensor. This variability is also evident at the HPRT locus (Figure
158
5.22). Different rates of spontaneous damage and genotypic variation in the repair 
capacities would account for the differences between cell lines. Additionally, 
variability is also observed between laboratories in the same cell lines. For example, 
de Jong et al (1988) report a high proportion (22/28, 79%) of spontaneous base 
substitutions to be GC-> AT transitions at the HPRT locus of Chinese hamster ovary 
(CHO) cell lines. Phear et al (1989) on the other hand, while working with the same 
cell line, found that these transitions accounted for only 40% of spontaneous base 
substitutions found at the HPRT locus. The observed variability reflects differences in 
cell handling, laboratory protocols and between batches of cells. This may explain the 
differences observed between AHH-1 and the derivative, MCL-5, which would be 
expected to have similar mutation spectra (Figure 5.22). Additionally, Corso and 
Parry (1999) found genetic differences between the two cell lines upon comparative 
genomic hybridisation (CGH) and fluorescent in situ hybridisation (FISH). AHH-1 
cells were derived from RPMI 1788 cell line (Freedman et al, 1979), isolated from a 
healthy male donor and immortalised using Epstein-Barr virus (EBV) (Crespi et al, 
1991). This method of transformation has been shown to increase genomic instability 
and DNA damage (Kamranvar et al, 2007), which would be implicated in 
spontaneous mutagenesis. Genetic drift within a population is a major source of 
population divergence in in vitro cell culture systems. As a result, over time and 
between laboratories, the genotypes and genomic stabilities of cells will change 
(Anderson et al, 1984) Hence the effort o f the International Workshop on 
Genotoxicity Testing (IWGT) workshop to standardize cell culture (Pfuhler et al, 
2011). It is therefore essential that spontaneous mutagenesis be considered in such 
studies, as featured in this chapter.
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Figure 5.22. Comparison o f  spontaneous mutation spectra in different cells taken 
from M ammalian Gene Mutation Database (MGM D). Top to bottom: AHH-1 (own 
data), Chinese Hamster Ovary cell line (CHO), Human T lymphocyte. Cynom olgus 
Monkey T lymphocyte. Murine macrophage. Murine splenic T lymphocyte, T K 6 and 
Chinese Hamster Lung cell lines (CHL). Axes are described in Figure 5.17.
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5.4.3. Comparison of mutation spectra.
This study is the first to construct mutation spectra in order to analyse mutation 
induction at low doses of genotoxin. In addition, it is also the first study to comment 
upon the genotoxic transition around the NOGEL. Visual inspection of the mutation 
spectra in Figure 5.17 shows drastic differences in mutation distribution. This is 
further emphasised through statistical analysis. The Adams-Skopek test is a robust 
statistical model widely used for pair-wise comparison of mutation spectra. PCA is a 
multivariate analysis first applied to mutation spectra by Benigni, Palombo and 
Dogliotti (1992) as a “reliable and sensitive tool” for analysing the inter-relationships 
between multiple spectra. PCA has been used in exploratory analysis to reveal 
unknown commonalities in mutation induction; between different treatments at the 
supF  locus (Lewis and Parry, 2002) and between spectra from chemical treatments 
and spectra from tumours (Lewis et al, 2008). This study uses PCA as an explanatory 
tool to highlight differences in mutation induction at different doses o f MNU.
The dissimilarity between solvent control and 0.00075pg/ml MNU highlights the 
cellular presence and effect of MNU. We could postulate that low dose of MNU 
upregulates cytoprotection, which would perturb spontaneous mutagenesis. However, 
the present study cannot confirm this and further investigation is needed. Further 
evidence is provided in Table 5.5.
Table 5.5. Analysis of the strand specificity of GC->AT transitions. The number of 
G->A transitions occurring on the non-transcribed strand (mRNA) are higher 
compared to C->T transitions following MNU treatment, which is indicative of the 
mechanism of action (MO A) of MNU.
MNU (pg/ml)
Number of 
G -»A
Number of 
C -»T
Proportion of GC-^ AT transitions that 
are G-^ A on non-transcribed strand (%)
0 9 9 50.0
0.00075 7 1 87.5
0.025 52 10 83.8
Referring to Table 5.5, there is a clear difference in the strand specificity of G->A 
transitions following MNU treatment. The sequence of mRNA, which has been used 
in the present study, is identical to the anti-sense/non-transcribed strand. Therefore,
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the mutations identified in the mRNA, indicate mutagenesis in the non-transcribed 
strand of the double helix, but also take into account transcription-associated 
mutagenesis (TAM). The majority of spontaneously occurring GC~>AT transitions 
observed were C->T transitions in the non-transcribed strand. This has been 
attributed to the strand-biased deamination of 5-methylcytosine into thymine (Beletski 
and Bhagwat, 1996). Although none of the observed C->T changes occurred at CpG 
islands, they are still targets for epigenetic methylation (Lister et al, 2009). In 
presence of MNU, the majority of GC->AT transitions were G->A changes in the 
non-transcribed strand. This is indicative of the MOA of MNU (Zhang and Jenssen, 
1991) and is not the effect of transcription-coupled repair as this strand biased was 
independent of transcriptional status (Palombo et al, 1991). This potentially highlights 
the reactivity of MNU with DNA at doses below the NOGEL. The question whether 
MNU is still a hazard at this dose because of the change in mutagenic profile at a dose 
that does not increase MF over background levels still exists (Professor Bhaskar 
Gollapudi, personal communication). Although, this is the first study to show this for 
direct acting genotoxins, it has been reported for phenobarbitol, a non-genotoxic 
carcinogen. In a study by Shane et al (2000), changes in the mutation spectrum at a 
non-mutagenic, non-tumourigenic dose of phenobarbitol was attributed to oxidative 
stress through the induction o f cytochrome P450 following exposure. Of interest, at
0.00075pg/ml MNU, is the absence of the suspected rearrangement observed in the 
negative control. This substantiates the hormesis argument developed in Chapter 3, 
whereby a small dose of MNU prevents endogenous damage from causing 
spontaneous mutations, through upregulation of DNA repair machinery. However, the 
present study cannot confirm this. Furthermore, at 0.00075pg/ml, the most 
predominant mutations were GC->TA transversions. This has been found in previous 
studies with MNU (Van Zeeland et al, 2008) and has been attributed to mutagenesis 
across apurinic sites, following hydrolytic release of N7MeG and insertion of adenine 
opposite the resulting gap (Loeb and Preston, 1986). The effect of a higher 
concentration of MNU was the increase in GC->AT transitions from 12.5% to 43.9% 
of the respective mutation spectra. The dose-dependency of GC->AT transitions was 
also evidenced in the PCA scatterplot (Figure 5.18), which accounted for the 
separation of the treated spectra. Incidentally, the vast majority o f GC->AT mutations 
(76%) observed at 0.025pg/ml MNU occurred at guanines preceded by a purine 
(5’Pu-G-N), which is to be expected (Zhang and Jenssen, 1991). The GC->AT
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hotspots identified in the present study were 551 and 555 in exon 5. A study by 
Tomita-Mitchell et al (2003) identified GC->AT hotspots in exon 3 by A-methyl-A’- 
nitro-A-nitrosoguanidine (MNNG), a similar alkylator to MNU. The increase in 
GC~>AT transitions, we hypothesise, is due to the persistence of 0 6MeG in the DNA 
following saturation of MGMT that possibly occurs at doses o f MNU higher than the 
LOGEL of O.Olpg/ml MNU. To substantiate this, MGMT depletion by MNU has 
been observed in rodents (Kyrtopoulos, 1998). In light of this, we performed further 
analysis of MGMT.
5.4.4. Real time PCR methodology.
In this study, Taqman® probes were used to measure MGMT and housekeeper 
transcripts, as opposed to SYBR® green technology used in previous studies (Doak et 
al, 2008). Taqman® probes offer enhanced specificity over SYBR® green because of 
the use of an additional probe, in conjunction with forward and reverse primers. 
Therefore, there are three points of sequence recognition in mRNA detection. A 
comparison of both technologies is shown in Table 5.6
Table 5.6. Comparison of two fluorescence technologies for use in real time PCR.
Assay
technology Advantages Disadvantages
Enhanced specificity A different probe is needed for detection of 
different loci thereby increasing costs
Taqman®
probes
High level of fluorescence emission 
upon probe degradation during strand 
synthesis overcomes the inherent high 
background fluorescence
Use of different dyes on probes permits 
analysis of two or more genes in one 
sample well.
Many inventoried assays exist but 
custom probes can be made
SYBR®
green
Cost effective Fluorescence upon binding to non-specific 
PCR products (primer dimers) thereby giving 
false positives
Can be applied to the detection of all 
dsDNA
Melt curve required
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The use o f  Taqman" probes permits the reverse transcription o f  mRNA into cDNA 
and subsequent real time detection in one-step in each reaction well, thereby 
simplifying setup time and labour. However, variability is introduced due to differing 
efficiencies o f  cDNA synthesis. It is, therefore, recommended that measurement o f  
target gene and housekeeper transcripts are made from the same cDNA sample to 
minimise variation. This is termed two-step real time PCR. Analysis o f  the PCR 
reaction products on 6% polyacrylamide gel electrophoresis (PAGE) revealed that 1 
step PCR gave miscellaneous bands (Figure 5.23).
RNA sample:  1 2
MGMT
Figure 5.23. Amplification efficiencies o f  one-step PCR varied between samples.
The results presented in Figure 5.19 suggest that M NU does not cause induction o f  
M GM T expression. This is in agreement with popular opinion that states a lack o f  
induction at the M G M T promoter in response to genotoxic insult (Professor Bernd 
Kaina. personal communication). Doak et al (2008) provided the first example o f  
upregulation o f  M GM T in human cells in response to genotoxin; following 4hr 
treatment with 1 pg/ml MMS. M NU is a more potent inducer o f  C)(1MeG and reacts 
with DNA with faster kinetics than MMS. Therefore, it was expected that M NU 
would cause a more prominent M G M T induction at lower doses. The M G M T 
promoter contains multiple regulatory elements for transcriptional control including 
NF-kB (Lavon et al, 2007), activator protein-1 (A P-l) ,  glucocorticoid response 
elements (GRE) and Sp-1 (Harris et al, 1991). Induction has also been shown in HeLa 
S3 cells in response to protein kinase C activators (Boldogh et al, 1998). Therefore, it 
would be reasonable to assume that M GM T promoter is inducible, particularly in
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response to 0 6-methylating agents, however substantial evidence is lacking (Kaina et 
a l , 2007). Sequencing attempts were made to provide further confidence in the results, 
but these proved unsuccessful. It is possible that the PCR purification procedure was 
unsuccessful in removing the fluorescent dye and this interfered with downstream 
sequencing.
5.4.5. Method of expression quantitation.
CTThe 2 'aa method (Livak and Schmittgen, 2001) was chosen over the method 
developed by Pfaffl (2001). The methods are very similar but where the Pfaffl method 
calculates the actual efficiency o f  amplification, the Livak method assumes 100% 
efficiency, giving a 2-fold increase in target after each round o f  amplification. When 
using Taqman" probes this is a valid assumption to make, as all assays have 100% 
(+/-10%) amplification efficiencies. (The reader is referred to the following 
application note;
http://www3.app 1 iedbiosystems.com/ems/groups/meb marketing/documents/generald 
ocuments/cms 040377.pdf). Determining the actual amplification efficiencies 
required for the Pfaffl method requires construction o f  a standard curve over a 3-5 log 
sample dilution series for each replicate, thus requiring extra reagents and costs. 
Where the level o f  fluorescence exceeds the user defined threshold value, the sample 
is given a threshold cycle value (Ct). This indicates the number o f  cycles needed to 
exceed baseline fluorescence. The Ct is inversely proportional to target abundance. 
This study revealed that M GM T had a Ct o f  34 in all samples, suggesting a low? un­
inducible level o f  constitutive expression. This also made construction o f  a dilution 
series, for use in the Pfaffl method, impossible (Figure 5.24).
Dilutions:
Resulting Ct: 34  36 N/A N/A
Figure 5.24. Tow abundance o f  M G M T m RNA in AHH-1 cells means dilutions for a 
standard curve for use in the Pfaffl method are impossible.
1 /1 0 0Neat
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To overcome this, the target gene could be induced to increase abundance, as has 
been shown by Doak et al (2008) following 4hr incubation with lpg/nil methyl 
methanesulfonate (MMS). This was attempted but upregulation was not observed. 
Alternatively, the mRNA sequence can be cloned using a vector transfected into a 
microbial host and amplified to create a stock o f  concentrated amplicons, as 
performed for MPG by Zair et al, (2011). Other cell lines were tested to assess 
whether the Ct was an artefact o f  the assay. T K 6 human lymphoblastoid cell lines had 
a Ct o f  34 for MGM T. whereas, virus transformed human bronchial epithelial cells 
(Beas-2b) showed a Ct o f  21. Therefore, it seems AHH-1 cells have a comparatively 
lower expression level. To substantiate this, M G M T protein levels were compared 
between cell types in our laboratory (Figure 5.25).
Beas 2b AHH-1 TK6 HEK 293T Heraklio Ishikawa
p-actin 1
MGMT
Figure 5.25. Western blot using 40pg protein from various cell types was analysed 
for M G M T protein. There was a no band for AHH-1 or T K 6 cells demonstrating 
inter-cellular variation in M GM T levels.
Western blot analysis revealed obvious differences in M GM T protein levels between 
AHH-1 and T K 6. Beas-2b (kindly provided by Mr Abdullah Al-Ali), HEK 293T 
(Human embryonic kidney cells, kindly provided by Dr Jo Forde), Heraklio and 
Ishikawa cells (Human endometrial adenocarcinomas, kindly provided by Miss 
Natalie De-Mello). AHH-1 cells showed the smallest amount o f  M GM T protein 
compared to other cell lines analysed. Inter-cellular differences in levels o f  M GM T 
between cell types is a well-known phenomenon (Fritz et al, 1991).
5.4.6. Prom oter methylation analysis.
Promoter methylation at CpG islands is associated with gene silencing (Razin and 
Cedar. 1991). It was considered that M G M T  promoter hypermethylation, and 
subsequent loss o f  M GM T expression, sensitises tumours to alkylating chemotherapy 
(Estellar et al, 2002) and M GM T promoter methylation status predicts patient
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response to alkylating chemotherapy (Everhard et al, 2006). Therefore, MGMT 
promoter methylation status has received much attention. The results shown in Figure
5.20 show that MGMT promoter is methylated. However, MGMT mRNA can be 
detected using real time PCR Taqman® probes, suggesting that the gene is expressed. 
There are several explanations:
• Methylation specific PCR (MS-PCR) used here lacks precision (Mikeska et al,
2007) and needs to be confirmed through bisulfite sequencing (Kitange et al, 
2009).
• There are 97 CpG islands within the promoter region and each can 
differentially influence transcriptional activity of MGMT (Everhard et al,
2009). Shah et al (2011) suggest that promoter wide methylation analysis 
needs to be conducted for accurate determination of methylation status of the 
MGMT promoter.
• Sites downstream of the promoter are subjected to epigenetic modification that 
can influence expression status (Nakagawachi et al, 2003).
• The axiom of epigenetic transcriptional regulation does not hold true at the 
MGMT promoter. Treatment with 5-azacytidine causes global 
hypomethylation, which increases gene transcription of methylation-induced 
silenced genes. However, Pieper et al (1991) found that this reduced MGMT 
transcription.
Additionally, promoter hypermethylation is not correlated to a lack of protein in brain 
(Lavon et al, 2007). Similarly Della Puppa et al (2012) found that 41.5% of 
glioblastoma samples did not display the expected relationship between MGMT 
methylation and expression levels. The effects of MGMT promoter methylation are 
still poorly understood.
5.4.7. Concluding remarks: Mechanism for the observed dose-response.
The difference in spectra between 0.00075pg/ml MNU and the solvent control in 
Figure 5.17 and evidence of MNU specific strand bias (Table 5.5) strongly suggest 
that MNU reacts with DNA below the NOGEL for point mutations. The difference 
between 0.00075pg/ml and 0.0025pg/ml MNU were GC->AT transitions, which are 
well-documented to be caused by 0 6MeG following MNU exposure, and prevented 
by MGMT, which repairs 0 6MeG. Attempts were made to measure the inactivation of
167
MGMT but these were unsuccessful. Real time PCR analysis of MGMT transcripts 
suggests MGMT is un-inducible and has a very low constitutive expression level in 
AHH-1 cells. At low levels of exposure to MNU, basal level MGMT is sufficient to 
repair 0 6MeG, thus accounting for the NOGEL. However, MGMT is present in very 
small, finite amounts and can become limited following exposure to higher 
concentrations of MNU and other 0 6-methylating agents. It is possible that saturation 
of MGMT occurs at the LOGEL, where mutation induction and GC->AT transitions 
are significantly increased over the control.
The data presented in this chapter strongly suggests that the biological effect of 
0 6MeG is observable once a threshold concentration of MNU, sufficient to cause 
MGMT inactivation, has been surpassed. The direct role o f MGMT in the NOGEL 
will be discussed in the following chapter.
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Chapter 6.
DNA Repair 
Analysis.
Biological 
Mechanism For Low 
Dose MNU 
Mutagenesis.
6.1. Introduction.
It is known that GC->AT transitions are the major mutation induced by MNU (Zhang and 
Jenssen, 1991). The data in previous chapters supports this and shows that the proportions of 
GC->AT transitions mimic the hormetic dose-response observed for overall mutation 
induction by MNU in the HPRT assay (Figure 4.15). MNU induces GC->AT transitions 
predominantly through 0 6MeG adducts that mispair during replication. We hypothesise that a 
lack o f GC->AT transitions observed at doses below the LOGEL is due to repair of 0 6MeG 
by 0 6-methylguanine-DNA methyltransferase (MGMT). We aim to test this by MGMT 
knockdown in AHH-1 cells because a MGMT deficient AHH-1 strain is not commercially 
available. If  our hypothesis holds true, MGMT deficiency, will cause;
1. An increase in mutant frequency at and below the NOGEL for MNU (0.0075pg/ml).
2. An increase in GC->AT point mutations in MGMT deficient AHH-1 cells compared 
to MGMT proficient AHH-1 cells at and below the NOGEL for MNU.
6.1.1. Methods of MGMT knockdown.
Various MGMT deficient cell lines are commercially available. MT1, human T Lymphocyte 
cell line, has been used as an in vitro model for MGMT deficiency without adequate 
validation (Goldmacher, Cuzick and Thilly, 1986). It has been found that these cells are not 
deficient in MGMT but mismatch repair (MMR) processing (Dr Zoulikha Zair, personal 
communication). It is likely that they are deficient in MMR processing because the authors 
conclude MT1 cells are “highly resistant to killing but hypermutable by MNNG,” this is the 
methylation tolerant phenotype indicative of MMR impairment. In order to compare with 
previous findings in AHH-1 cells, it was decided to knockdown MGMT in AHH-1 cells, thus 
minimising confounding effects by using two cell lines. Creating MGMT deficient cells has 
received much attention due to the implications in sensitising MGMT expressing tumours to 
alkylating chemotherapy. The most researched alkylating chemotherapeutic is temozolomide 
(TMZ) in the treatment of glioblastoma (Friedman, Kerby and Calvert, 2000). It has been 
shown that MGMT deficiency potentiates the cell killing and mutagenic effect o f 0 6MeG 
induced by TMZ (Hansen et al, 2006). Therefore, MGMT knockout strategies could be used 
as an adjuvant to improve patient response to chemotherapy. There are several methods that 
can create MGMT deficient cells; gene knockdown or pharmacological inhibition. Some 
studies propose a method of gene disruption that abrogates the protein coding function of the 
gene (Tsuzuki et al, 1996).
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6.1.1.2. Gene knockdown.
The most widely used method of gene knockdown is RNA interference (RNAi), the sequence 
specific RNA induced post-transcriptional silencing of genes (Figure 6.1). Double stranded 
(ds)RNA oligonucleotides, homologous to the gene of interest (GOI), guide the degradation 
of homologous mRNA thereby suppressing protein translation and achieving gene specific 
knockdown. The advantage of this technique is that knockdown can be validated by reduced 
GOI mRNA through real time PCR and also a distinct lack of protein in western blot. There 
are two sources o f the dsRNA oligonucleotides;
shRNA-short hairpin RNA. Cells are transfected with an expression vector which expresses 
desired dsRNA that forms a hairpin structure which act as substrate for DICER, an 
endoribonuclease (Figure 6.1). With continuous expression of double stranded RNA, 
knockdown is permanent. This is advantageous because it allows selection and propagation 
of successful transfectants creating a stable homogenous population. This was the method of 
MPG knockdown by Zair et al (2011).
siRNA-small interfering RNA. Cells are transfected with dsRNA 19-21 nucleotides in length. 
Since transfection is easier, this method is more achievable than shRNA. However, it is only 
temporary, lasting for up to 7 days. This method is recognised as crude knockdown, giving 
rise to a heterogenous population of varying knockdown successes. Successful transfectants 
can show up to 98% gene knockdown. However, transfection into lymphoid type cells, like 
AHH-1 is difficult.
Rosati et al (2008) describe down regulation o f MGMT by Interferon p (IFN-p) to sensitise 
MGMT expressing cell lines to TMZ, used in clinical chemotherapy. The down regulation of 
MGMT by IFN-p has been attributed to up-regulation of p53 (Natsume et al, 2005; Natusme 
et al, 2008). Since IFN-P has pleiotropic effects on the cell, this method of knockdown is 
unfavourable.
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Figure 6.1. Schematic o f  siRNA mediated gene knockdown. siRNA molecules associate with 
proteins such as TRBP (transactivating response binding protein) forming RISC (RNA
and Behlke (2007).
Incidentally, M GM T expression modulation by p53 has been reported (Grombacher, Eichorn 
and Kaina, 1998), but the mechanics are not well understood. It seems that when p53 levels 
are artificially high (following transfection o f  a wildtype p53 expression vector), M G M T is 
down regulated (Harris e/ aL 1991; Grombacher, Eichorn and Kaina, 1998). However, a 
decrease  in p53 levels by gene knockout has the same inhibitory effects (Blough. Zlatescu 
and Cairncross, 2007). It has been shown that wildtype p53 sequesters specificity protein 1 
(SP1) transcription factors, preventing their binding to M G M T promoter and inhibiting 
transcription (Bocangel et a l , 2009). AHH-1 are p53 heterozygotes, expressing a mutant p53 
(Guest and Parry. 1999). Whether the same effect in AHH-1 cells is observed is unknown. A 
better understood method o f  M GM T knockdown uses pharmacological inhibitors to 
inactivate MGMT.
6.1.1.3. MGMT has a broad range of affinity for structures at the O6 position of 
guanine.
M G M T (EC 2.1.1.63) is a protein o f  21kDa composed o f  207 amino acids encoded over 5 
exons located at chromosome 10 (10q26.3). M GM T, also called alkylguanine
alkyltransferase (AGT), is able to remove a variety o f  alkyl structures covalently bound to 
oxygen at position 6 o f  guanine (O^AlkylG); the result o f  reaction with highly nucleophilic
induced silencing complex) that degrades hom ologous m RNA sequences. Taken from Peek
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methylating agents (forming 0 6MeG) or chemical synthesis (Moschel et al, 1992). Examples 
are shown in Figure 6.2.
H
J .HH
Figure 6.2. Examples of base substrates acted upon by MGMT. Each a guanine base with 
different adducts at O6 A.) 0 6-methylguanine (0 6MeG). B.) 0 6-benzylguanine (0 6BG). C.) 
Allylguanine. D.) 0 6-(p-methylbenzyl)guanine. From Moschel et al (1992). Structures drawn 
using freeware at www.emolecules.com.
Alkyl adducts fit into the active site of MGMT and are pseudosubstrates for repair where they 
inactivate MGMT by causing the suicidal inactivation (as with 0 6MeG), hence their use as 
inhibitors of MGMT activity. MGMT acts on these substrates with differing affinities 
(Moschel et al, 1992), governed by steric effects within the active site (Daniels et al, 2000). 
Poor affinity correlates with poor MGMT inhibition (Pegg et al, 1993). Alkylation damage 
can be removed from mononucleotide guanine in the nucleotide pool and also when in 
dsDNA; this broad range activity enhances the efficacy of MGMT in protecting DNA from 
the carcinogenic effects of various endogenous and exogenous alkylating agents. It also gives 
the opportunity to manipulate MGMT activity by administering these agents.
Depleting the cells protection through MGMT inactivation potentiates the DNA damaging 
and cell killing effects of 0 6alkylating agents (Dolan et al, 1990; Rabik et al, 2006; Fukuchi 
et al, 1997). Due to this, these pharmacological inhibitors have been extensively studied for 
their use in sensitising MGMT proficient tumours to 0 6guanine alkylating chemotherapy 
(Gerson, 2002), particularly in the treatment o f glioblastoma multiforme (GBM; Kato et al,
2010). They also have uses in studying the mechanism of mutation induction by alkylating 
agents (Kaina et al, 1991) and in assessing the role of MGMT in protecting against 0 6alkylG 
induced carcinogenesis (Dolan et al, 1990). Many in vitro studies have evaluated the 
effectiveness of a variety of pseudosubstrates as pharmacological inhibitors of MGMT 
(Kaina, Margison and Christmann, 2010). They conclude that 0 6-benzylguanine (0 6BG, 
Figure 6.2B) is a potent and simple pharmacological inhibitor of human MGMT (Dolan et al, 
1985) and will be discussed further.
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6.1.2. Effective inhibition of MGMT by 0 6BG.
MGMT inactivation by 0 6BG is ubiquitous in published literature. For example, a study by 
Pegg et al (1993) reports complete and selective decrease in human MGMT activity in the 
presence of 0 6BG in cell free extracts (Figure 6.3).
—o -  Ada AGT 
—O - Yeast AQT 
— OgtAGT 
— Human AGT
0 20Q 400 600 600
nM 0 *-benzy(9uanine
Figure 6.3. The inactivation of human AGT (MGMT) with low dose 0 6BG. The difference 
in inter-species inactivation is explained through bioinformatics by Daniels et al (2000) 
which suggests that 0 6BG is unable to bind at the active site of the respective species specific 
MGMT. Graph taken from Pegg et al (1993).
The efficacy of 0 6BG as a pharmacological inhibitor is attributed to the following properties;
1. MGMT has higher affinity for 0 6BG than it’s natural substrate, 0 6MeG as a free base 
(Zang et al, 2005). This is further emphasised by Moschel et al (1992), they 
concluded that the concentration of 0 6BG used to achieve complete inhibition was far 
less than other alkylguanines used. Incidentally, MGMT has highest affinity for 
0 6MeG when in an oligonucleotide complex (Moschel et al, 1992).
2. Dolan et al (1990) compared the inactivating effects of 0 6BG and 0 6MeG in HT29 
(human colorectal adenocarcinoma) cells. lOmin incubation with 2.5pM 0 6BG 
achieved 90% inactivation whereas lhr with 0.2mM of 0 6MeG was needed to achieve 
the same level.
3. O BG is a “low molecular weight substrate lacking polynucleotide structure” (Pegg et 
al, 1993) allowing passive diffusion into the cell (Reinhard et al, 2001).
4. It inhibits cytoplasmic and nuclear MGMT (Ueno, 2006).
5. It is not a substrate for DNA synthesis, it is not incorporated into DNA and does not 
cause mutations (Ueno, 2006).
174
I
*
100
so
60
40
20
0
6. 0 (1BG is more efficient at M GM T inhibition than other conjugated forms (Reinhard et 
al, 2001). The authors show that 0.62pM  OhBG causes 50% M GM T inhibition. The 
conjugates tested caused 50% M GM T inhibition at concentrations (IC50) ranging from
0.009pM  to 25 pM. However, 0 (1BG was non-toxic at these doses compared to other 
conjugates.
6.1.3. How MGMT inactivation is achieved.
The reaction is a covalent transfer o f  adduct from O pposition  in guanine to M G M T and 
proceeds with the same stoichiometry where 0 6M eG  is the substrate. Cysteine at position 145 
(Cys 145) in the active site o f  M GM T is evolutionarily conserved through E .coli, rats and 
humans (Tano et al, 1990) and acts as the acceptor residue for the abstracted alkyl group (Xu- 
Welliver and Pegg, 2002). this being the benzyl group from 0 6BG. This irreversibly forms S- 
benzylcysteine within the active site o f  M GM T with the stoichiometric release o f  guanine. 
Formation ofS-benzylcysteine  in the active site renders M G M T inactive (Pegg et al, 1993) 
(Figure 6.4).
Synthesis  Degradation
IGM
iysteine  
145 .
'Cysteine
145
HjN N p}
0 6Benzylguanine Guanine
Figure 6.4. Reaction o f  0 6BG with MGMT. Direct transfer o f  alkyl group from 0 6BG to 
cys 145 restores guanine but inactivates the protein and targets it for degradation. Adapted 
from Kaina. Margisson and Christmann (2010).
Daniels et al (2000) and Rasimas et al (2003) suggest that a conformational change in the 
tertiary structure o f  M GM T is brought about by the disruption o f  complex hydrogen bonding
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upon benzylation of Cys 145. This causes protein instability (Crone et al, 1996) and renders 
the benzylated protein more labile to ubiquitination (Srivenugopal et al, 1996; Liu et al, 
2002) followed by proteolysis by the 26S proteasome (Xu-Welliver and Pegg, 2002) leading 
to its degradation (Glickman and Ciechanover, 2002). The lack of induction of MGMT 
observed in AHH-1 cells (Chapter 5) and in human cells in response to genotoxic exposure 
(Fritz et al, 1991) suggests the existence of a basal and finite amount of MGMT within the 
cell, which is depleted once it has repaired the equivalent amount o f 0 6alkylated guanine. 
This means that MGMT molecules can become limited with increasing concentrations of 
0 6alkylated guanines (Pegg and Byers, 1992). The suicidal reaction mechanism, lack of 
induction in humans and sometimes-slow regeneration can deplete a cell’s MGMT 
proficiency and is a viable target for inactivation by pharmacological inhibitors.
6.1.4. Measuring the inactivation of MGMT.
The concentration of 0 6BG required for 50% MGMT inactivation (IC50) is a measure of 
0 6BG efficacy. This can be measured through various experiments, these are:
1. Increased mutagenesis and cytotoxicity from exposure to alkylating agents following 
MGMT. However, this is not a direct measurement with confounding factors
2. Loss of MGMT protein through western blot analysis, although western blotting is not 
sufficiently sensitive to detect MGMT in AHH-1 cells
3. Lower rate of removal of 0 6MeG from DNA using mass spectrometric analysis. 
However, 0 6MeG is extremely hard to identify through mass spectrometry (Dr 
Rajinder Singh, personal communication). This has been further discussed in chapter 
4
4. Loss of activity using activity assays involving radiolabelled substrates, this being the 
most direct measurement but it is costly and hazardous and is not sufficiently 
sensitive to detect MGMT in AHH-1 cells.
The quoted I C 5 0  in the literature differs between studies. This may be due to the different 
measurements but also differences in sensitivity between cell lines used due to differential 
MGMT proficiences. We have previously discussed the lack o f sensitivity of protein assays 
for MGMT detection in AHH-1 cells, these being western blot and activity detection (Chapter 
5). Therefore, the most applicable method o f validation of MGMT inactivation would be 
increased sensitivity to 0 6MeG-induced toxicity following alkylating agent exposure.
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6.1.5. Cellular influences on 0 6BG efficacy.
A one-hour pre-treatment with 0 6BG was shown to deplete MGMT for one cell cycle in Raji 
cells, a human male B lymphocyte cell line (Sklar et al, 1981). However, the efficiency and 
duration o f 0 6BG mediated inactivation differs between cell lines. It is noted that degradation 
rates of benzyl-inactivated MGMT differ between tumour and primary cells (Liu et al, 2001) 
(Figure 6.5) and also between cell lines (Ayi et al, 1994; Dolan et al, 1991).
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Figure 6.5. Time course showing more rapid degradation of MGMT post 0 6BG treatment in 
tumour biopsies (diamonds) compared to peripheral blood mononucleocytes (PBMC’s, 
circles). Taken from Liu et al (2001). Expressing the data as % control circumvents well- 
documented inter-tissue differences in MGMT levels (Gerson et al, 1986).
The differences highlighted in Figure 6.5 reflect cellular differences in;
1. Ubiquitin dependent proteolysis (Gunn et al, 1977)
2. Initial MGMT levels (Dolan et al, 1991; Bobola et al, 1996; Heighway et al, 2003). 
Chen et al (1993) found that 0 6BG had no effect on sensitivity in HeLa MR (MGMT 
deficient Human cervix cell line) but drastically increased toxicity of BCNU in HeLa 
S3 (MGMT proficient) cells.
3. Differential rates of basal level expression and therefore protein regeneration. Sklar et 
al (1981) found that it takes 49hr (one cell cycle) for Raji cells to regain full 
protection against 0 6alkylating agents following complete removal by 0 6BG.
4. Protein turnover which seems to be dependent on cell division (Gerson, 1988)
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5. Polymorphisms within M GM T gene, which alters the affinity for protein 0 (1BG and 
also affecting degradation rates (Remington et a l , 2008).
6.1.5.1. Polymorphism within MGIV1T can modify affinity for 0 ()BG.
Single-nucleotide polymorphisms (SN P‘s) within the coding region o f  the M GM T gene that 
change the amino acid sequence give variant forms o f  M G M T with altered functions and 
responses to 0 6BG (Bacolod et a l, 2004). In addition to polymorphisms, 0 6BG resistant 
forms o f  M G M T can also arise through mutations in M G M T occurring in cell lines and 
through clonal expansion within tumours; noted by Bacolod et al (2004) as a reason for 
development o f  O 'B G  resistant tumours. In D283 MED. D341 MED. and Daoy (human brain 
tumour cell lines) 0 6BG resistant daughter cells evolve from M GM T proficient/O^BG 
sensitive parental cells. Three mutations were identified (one in each cell line). Some o f  
which have also been identified in other studies. G lycine->cysteine at position 156 o f  the 
primary sequence (Crone et a l, 1994; Loktionova and Pegg, 1996; Xu-welliver and Pegg,
1996), tyrosine->phenylalanine at 114 and Lysine->threonine at 165 confer resistance to 
0 ('BG. Other point mutations are shown in Figure 6.6 and Table 6.1. Measuring resistance is 
the fold increase in the IC50 for mutant M G M T over the IC50 o f  the respective wildtype 
M GM T (typically <0.3pM ). The higher the fold increase in IC50 the higher the resistance.
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DNA BINDING SITE
Figure 6.6. A schematic o f  the primary structure o f  M GM T. The coloured circles represent 
published mutations that de-sensitise cells to 0 (’BG. They all fall into the active site 
preventing 0 6BG from binding and inactivating the enzyme (Daniels et a l, 2000). The 
colours correspond to the mutations in Table 6.1. Mutations shown cause the most drastic 
difference.
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Table 6.1. Fold change is given to negate differences in the IC50 for inhibition o f  wildtype 
M G M T in different cell types.
Mutation/
polymorphism
Fold increase in IC50 
0 (’BG over wildtype 
MGMT protein
Reference
T yrl14P he nd Bacolod et a l (2004)
Pro 140 Ala/Lys 20/12000
Crone et a l (1993); Loktionova and Pegg 
(1996)
P ro l40A la  with 
P ro l38L ys
116 Crone et al (1994)
P ro l40A la  with 
Gly 156Ala
1200 Crone et al (1994)
Cysl 50Phe/Tyr/Glu/Leu 3-26 Xu-Welliver and Pegg (2000)
Gly 156N <40
Crone et al (1994); Loktionova and Pegg 
(1996); Xu-W elliver and Pegg (2000)
Tyrl 58His 7750 Xu-Welliver et al (1999)
Seri 591 le 110 Xu-W elliver and Pegg (2000)
Gly 160Arg 20
Edara et al (1996); Imai (1995); Wu et al 
(1999)
Lysl65Ser 600 Xu-Welliver and Pegg (2000)
L ysl65A la 100 Xu-Welliver and Pegg (2000)
L eu l69G lu 860 Xu-Welliver and Pegg (2000)
The polymorphism, G ly l60A rg , causes a 20-fold increase in the IC50 o f  0 6BG compared to 
wildtype (Edara et a i  1996) without hindering the repair o f  0 6MeG compared to controls 
(Wu et al, 1999). Individuals with this polymorphism had similar cancer incidence to 
matched controls (Kaur et al, 2000). G ly l60A rg  was found in 15% o f  the Japanese 
population (Imai et al, 1995) but Gerson et al (1999) suggest that it is at much lower 
frequency in the wider population. Imai et al, (1995) found G ly l60A rg  at much higher 
frequency (25%) in cancer patients. Since the majority o f  cell lines are derived from cancers, 
it is reasonable to assume that some cell types would be 0 6BG resistant. C/'BG resistance in 
cancers cause problems in chemotherapy.
6.1.6. 0 6BG in chemotherapy.
MGMT provides a pivotal role in protecting against mutagenesis and cytotoxicity caused by 
replication o f 0 6AlkylG. MGMT deficiency is an initiating event in carcinogenesis (Graham 
et al, 2010) and many human primary tumours (Gerson et al, 1986). However, in cancer 
treatment, patients with MGMT deficient tumours respond better to chemotherapy (Hegi et 
al, 2005; Esteller et al, 2000). Some human cancers over-express MGMT, making 
chemotherapy ineffective. Examples are;
1. Colon cancer (Zaidi et al, 1996)
2. Pancreatic carcinoma (Kokkinakis et al, 1997)
3. Melanoma (Lee et al, 1992)
4. Gliomas in the brain (Bobola et al, 2001)
Due to the protective effect that MGMT exerts, such malignancies are “4- to 10-fold more 
resistant” to alkylating chemotherapy (Liu and Gerson, 2006). Coincidentally, it is recognised 
that tumours with low levels of MMR proteins are more resistant to alkylating chemotherapy 
(Middlemas et al, 2000). This is understandable since MMR is responsible for 0 6AlkylG 
toxicity. The importance of MGMT inhibitors, like 0 6BG, in sensitising MGMT positive 
tumours to the cytotoxic effects of alkylating chemotherapy is realised. Since the in vitro 
mechanism of 0 6BG mediated MGMT inactivation was elucidated by Pegg et al (1991). 
Several in vivo studies were then performed using murine models with human tumour 
xenografts. This circumvents the differences between human and murine MGMT (Liu et al, 
1996). Gerson et al (1993) used a human colon cancer xenograft model and report 98% 
MGMT inhibition by 0 6BG, reduced tumour growth rates at 3- to 4-fold lower BCNU 
concentration than without 0 6BG. The usefulness o f 0 6BG is further substantiated by Wedge 
et al (1997) who report “a very significant increase in (melanoma) tumour growth delay” 
after 40mg/kg/day temozolomide with 0 6BG over 5 days in a murine human melanoma 
xenograft model. These studies help to realise;
1. 0 6BG alone is non-toxic at therapeutic doses.
2. It sensitises tumours to cell killing through MGMT depletion and not through 
additional toxicity (Wedge and Newland, 1996).
3. High level inactivation of MGMT could be achieved
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4. A combination of alkylating agent with 0 6BG had the desired toxic effect at lower 
concentrations than alkylating agent on its own (Gerson et al, 1993) potentially 
reducing unwanted toxicity in healthy tissues caused by excessive concentrations.
The studies led to clinical trials of 0 6BG to potentiate cell killing by alkylating agents in the 
treatment o f glioblastoma and in tumours of the central nervous system in children (Gerson 
2002; Quinn et al, 2009). The consequence o f using MGMT inhibitors is severe 
myelosuppression caused by increased toxicity in haematopoietic stem cells (Verbeek et al,
2008). Gene therapy represents one solution by introducing 0 6BG resistant MGMT into 
haematopoietic stem cells as protection (Sorg et al, 2007). These complications have 
hindered the clinical use of 0 6BG in chemotherapy. Since the advent of RNAi technology, 
new methods of MGMT inhibition in chemotherapy are being investigated (Kato et al, 2010).
6.1.7. 0 6BG and low dose alkylating agent.
It is well documented that MGMT depletion enhances mutagenesis, toxicity and other 
genotoxic endpoints caused by 0 6MeG (e.g. base substitutions and sister chromatid 
exchanges, SCE’s) by a variety of SnI, 0 6-alkylating agents (Dolan et al, 1991; Kaina et al, 
1991). However, this has only been ascertained for high doses of alkylating agent. The 
following chapter provides evidence to suggest low doses of MNU that are non-mutagenic, in 
MGMT proficient cells, become mutagenic following MGMT depletion. Thus, implicating 
MGMT in protection from low dose MNU mutagenesis. The following chapter details the use 
of siRNA and 0 6BG as methods to create AHH-1 MGMT deficient cells to be used in the 
HPRT assay. A dose-response was obtained, in the HPRT assay, for direct comparison to the 
previous chapter in AHH-1 wildtype cells. For further evidence of the potential role of 
MGMT, the proportion of GC->AT transitions were calculated from HPRT mutant colonies 
treated with 0.0075pg/ml MNU (the NOGEL dose in AHH-1 wildtype cells for mutation 
induction) and compared between MGMT proficient and deficient AHH-1 cells.
6.2. Materials and method.
6.2.1. Preparation of 0 6-benzylguanine stock.
0 6BG (Cas number 19916-73-5) was purchased from Sigma (Poole, UK) as a 50mg powder 
with 2:98% purity. Addition of 5ml 100% analytical grade methanol (Fisher Scientific, 
Loughborough, UK), gave a stock concentration of lOmg/ml. The stock was discarded after 
use.
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6.2.2. 0 6BG pre-treatment.
For all treatments with MNU, 1 flask of AHH-1 cells at sufficient volume was treated with 
2.4jll1 o f lOmg/ml 0 6BG per 10ml media to obtain a final concentration of 10pM, for 
sufficient MGMT inhibition (Professor Bemd Kaina, personal communication). AHH-1 cells 
were exposed to 0 6BG for lhr at 37°C, 5% CO2 . At this time, the 0 6BG treated cell stock 
was divided into 10ml cultures, one for each dose of MNU. This minimised pipetting errors 
of adding 0 6BG to individual treatment flasks. Time 0 was taken after lhr pre-treatment with 
0 6BG. At time 0, the appropriate solvents were added and immediately sampled.
6.2.3. HPRT assay.
Following lhr pre-treatment with 0 6BG, the procedure was performed as detailed in Chapter
2. However, 1800 wells per dose were sufficient for this mechanism of action analysis (Zair 
et al, 2011).
6.2.4. Cytotoxicity.
To assess the effect of 0 6BG on MNU toxicity, RPD measurements were performed 
according Chapter 2. MNU without 0 6BG (M NU-06BG) was compared to M NU+06BG at 
equal MNU doses, performed as discussed. Two dose ranges of MNU were performed. One 
being; 0.0075pg/ml, O.Olpg/ml and 0.05pg/ml (Table 2.2, Chapter 2) with relevant controls 
to assess toxicity of MNU in presence of 0 6BG over the dose range in chapter 3. And the 
second dose range used toxic doses of MNU, which was prepared as follows. The stock of 
O.lg/ml MNU (Chapter 2) was further diluted 1:100 to 1 mg/ml in dimethyl sulfoxide 
(DMSO). This was used in Table 6.2.
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Table 6.2. Dilutions of MNU used to cause cytotoxicity in AHH-1 cells.
Final Concentration MNU 
(Pg/ml)
Volume of DMSO 
(pl)
Volume of MNU stock at lmg/ml 
(Pi)
0 500 0
2 100 400
4 200 300
6 300 200
8 400 100
10 500 0
6.2.5. Negative controls for 0 6BG and MNU in the HPRT assay and cytotoxicity studies.
The negative controls were;
• 100^1 DMSO solvent control for MNU
• Methanol + DMSO lhr pre-treatment with 2.4pl methanol (final concentration
0.024%) in 10ml cell culture (0.00024% methanol) followed by lOOpl of DMSO, to 
assess the contribution of respective 0 6BG and MNU solvents
• Methanol lhr pre-treatment with 2.4pl methanol used as the solvent control of 0 6BG
• 0 6BG-MNU lhr pre-treatment with 2.4pl (lOpM) 0 6BG only assessed the effects of 
just 0 6BG
• 0 6BG + DMSO lhr pre-treatment with 0 6BG followed by lOOpl DMSO allowed 
comparison with the solvent control in Chapter 3.
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6.2.6. Calculation of the RPD and RPE for the negative controls.
DMSO=population doubling (PD) or plating efficiency (PE) of DMSO treated cultures
PD of untreated cultures 
Methanol and DMSO= PD or PE of Methanol + DMSO treated cultures
PD or PE of untreated cultures 
Methanol= PD or PE of Methanol treated cultures 
PD or PE of untreated cultures 
Q6BG-MNU= PD or PE of Q6BG-MNU treated cultures 
PD or PE of methanol treated cultures 
0 6BG + DMSO= PD or PE of Q6BG + DMSO treated cultures
PD or PE of untreated cultures
6.2.7. Calculation of the RPD of treated control cultures 
MNU-Q6BG= PD or PE of MNU-Q6BG treated cultures
PD or PE DMSO treated cultures 
MNU+Q6BG= PD or PE of MNU+Q6BG treated cultures 
PD or PE Methanol+DMSO treated cultures
6.2.8. Preparation of cells for MGMT activity analysis.
To validate inactivation of MGMT by 0 6BG, AHH-1 cells were harvested at six time points 
over 48hr post-treatment and assayed for activity. For sufficient yields, lx l0 6cells/ml were 
treated with lOpM 0 6BG and divided into 10ml cultures for each time point and incubated at 
37°C, 5% CO2 . Time of treatment was taken as time 0 and cells were harvested at 1,4,6,12,24 
and 48hr post-treatment. Methanol was used for time-matched controls. Upon harvest, cells 
were washed twice in phosphate buffered saline (PBS, Lonzo, Slough, UK) and the pellet 
snap-frozen in liquid nitrogen for 30s. Samples were stored at -80°C awaiting shipment.
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Assay for activity took place in University of Mainz, Germany with the help o f Professor 
Bemd Kaina and Karl-Heinz Tomaszowski to whom I am incredibly grateful.
6.2.9. siRNA oligonucleotides
6.2.9.I. MGMT siRNA oligonucleotides.
The sequence of 3 MGMT siRNA oligonucleotides was obtained from Kato et al (2010). 
(Table 6.3).
Table 6.3. The sequences of the siRNA used in MGMT knockdown from Kato et al, (2010) 
including overhangs necessary for efficient transfection and silencing (Bellemin et al, 2007).
siRNA Sense sequence Antisense sequence
1 5'GAGCAGGGUCUGCACGAAdTdT3' 5'P-UUUCGUGCAGACCCUGCUCdTdT3'
2 5 'CC AG AC AGGUGUU AU GG A AdT dT3' 5'P-UUCCAUAACACCUGUCUGGdTdT3'
3 5'GGACUGGCCGUGAAGGAAUdTdT3' 5'P-AUUCCUUCACGGCCAGUCCdTdT3'
6.2.9.2. siRNA controls.
All control siRNA were purchased from Dharmacon (ThermoScientific, Loughborough, UK). 
GAPDH was targeted for knockdown as a positive control for optimisation using ON- 
TARGET plus GAPDH control siRNA number D-001830-01-05. The negative control was 
ON-TARGET plus non-targeting siRNA number D-001810-01-05.
6.2.9.3. Reconstitution of MGMT siRNA.
Upon delivery, tubes containing MGMT siRNA oligonucleotides were briefly centrifuged, 
and reconstituted to 40pM by addition of 1ml RNase free water per tube. The solution was 
pipetted up and down 4 times and vortexed on an orbital shaker for 30mins at room 
temperature. The tubes were centrifuged and the concentration determined by measuring 
absorbance at 260nm on a nanodrop 1000 spectrophotometer. Single use (lOpl) aliquots were 
made and stored at -20°C.
6.2.9.4. Transfection optimisation.
Reverse transfection offered the most reliable method (Dr James Cronin, personal
communication) and was performed in Nunc 24 well plates (Fisher Scientific, Loughborough,
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UK) according to instructions provided with the transfection reagent, 
Lipofectamine™RNAiMAX (Invitrogen, Paisley, UK). For GAPDH, a range of 0.6pmol to 
30pmol ON-TARGETplus siRNA was used per well with 0.5pl to 5pl 
Lipofectamine™RNAiMAX. For maximum effect on MGMT knockdown (Kato et al, 2010), 
all 3 MGMT targeting siRNAs were used in combination. The amount of siRNA added per 
well ranged from 1.8pmol (0.6pmol per siRNA) to 150pmol (50pmol per siRNA) and the 
volume of Lipofectamine ™ RNAiMAX ranged from 0.5pl to 5pl per well o f a 24 well plate. 
The same amount of each siRNA was diluted in lOOpl Opti-MEM’ I medium without serum 
(Invitrogen, Paisley, UK) in one well o f the culture plate. Lipofectamine ™ RNAiMAX was 
added to the well, mixed and incubated at room temperature for 20min to allow siRNA to be 
enveloped in liposomes. AHH-1 cells were diluted to lx l0 5cells/ml and 500pl added to each 
well (5xl04cells/well). The plate was incubated at 37°C, 5% C02 for 24hr for RNA 
extraction to assess knockdown by real time PCR.
6.2.9.5. Real time analysis of siRNA treated cells.
Real time analysis was performed as detailed in Chapter 2. Each siRNA treatment was 
performed in triplicate and real time PCR performed in triplicate on three separate occasions. 
However, to save on cost o f real time PCR master mix reagents, each sample was only 
assayed once per plate. GAPDH specific probes (Applied Biosystems, Warrington, UK assay 
ID; Hs99999905_ml) were used to assess knockdown following treatment with GAPDH 
specific siRNA, which was used as the positive control for transfection optimisation.
6.3. Results.
The results of this chapter report on the two methods used to create an AHH-1 MGMT 
deficient phenotype, through knockdown of MGMT using siRNA and the use of 0 6BG to 
inactivate MGMT, with subsequent validations. The HPRT assay was repeated using MGMT 
knockdown cells. In comparison to wildtype AHH-1 cells, (Chapter 3) a change in dose- 
response and mutation spectra was observed which implicates MGMT in low dose alkylation 
exposure.
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6.3.1. siRNA and 0 6BG in creating a MGMT deficient phenotype.
6.3.I.2. siRNA trial.
siRNA experiments were set up as detailed but with limited success. To validate gene 
knockdown, RNA was extracted 24hr following treatment with gene specific siRNA. 
GAPDH (positive control) or MGMT mRNA was measured by real time PCR using TBP as 
the reference housekeeping gene for MGMT and GAPDH quantitation. TBP was shown to be 
constitutively expressed in AHH-1 (supplementary figure Zair et al, 2011) and is an 
appropriate housekeeper. The fold change in GAPDH (Figure 6.7 and Figure 6.8) and 
MGMT (Figure 6.9) mRNA levels, between treated and control, is recorded as a function of 
increasing concentrations of transfection reagents.
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Figure 6.7. The first attempt at GAPDH knockdown using siRNA. 20pmol siRNA with 1.5pl 
Lipofectamine™RNAiMAX showed greatest fold decrease. n=3. Error bars represent 
standard deviation (SD), **p=<0.01*** p=<0.001, ****p=<0.0001, *****p=<0.00001.
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From Figure 6.7, treatment using 20pmol of ON-TARGETplus GAPDH siRNA with 1.5pl 
Lipofectamine ™ RNAiMAX significantly decreases the fold change to an average of 0.36 
(p=0.0007), giving an average of 64% (1-0.36=0.64; 0.64x100=64%) GAPDH knockdown 
compared to the untreated control. Using higher amounts of reagents (Figure 6.8) a 
maximum average knockdown of 80% was achieved using 20pmol o f siRNA with 5 pi 
Lipofectamine ™ RNAiMAX (p=0.0005). Although, neither Figure 6.7 nor Figure 6.8 shows 
a dose-response (an increase in efficacy) as would be expected with increasing concentration 
of siRNA reagents until toxicity is reached.
* * * *
siRNA treatment
Figure 6.8. Fold change in GAPDH at higher concentrations of siRNA reagents. n=3. Error 
bars are SD *p=<0.05, ***p=<0.001, ****p=<0.0001.
The treatment conditions used in Figure 6.8 were repeated using a combination of all three 
MGMT targeting siRNA’s. Four of ten treatments analysed gave threshold cycle values for 
MGMT at the end of real time PCR. O f these four samples, not one treatment method was 
found to reduce MGMT expression (Figure 6.9).
The following treatments gave no Ct values in one or more replicates for MGMT;
1. 1 Opmol each siRNA 4pl Lipofectamine
2. 20pmol each siRNA 1.5pl Lipofectamine
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3. 20pmol each siRNA 5 pi Lipofectamine
4. 30pmol each siRNA 2 pi Lipofectamine
5. 30pmol each siRNA 5 pi Lipofectamine
6. 50pmol each siRNA 4pl Lipofectamine
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Figure 6.9. There was no decrease in MGMT mRNA level following siRNA transfection. 
n=3, error bars are SD.
Six treatments did not yield Ct (threshold cycle) values, suggesting 100% knockdown since 
the mRNA could not be detected. This was not reproducible with at least one replicate per 
treatment showing no change in fold change compared to control.
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6.3.2. 0 6BG.
6.3.2.1. Assessing the cellular presence of 0 6BG through increased toxicity by MNU.
An alternative method o f  M GM T knockdown using 0 6BG as a pharmacological inhibitor was 
investigated. To provide evidence o f  the cellular presence o f  0 6BG, we compared the toxicity 
o f  high dose MNU with and without 0 (1BG pre-treatment. Relative population doubling 
(RPD) was used as a measure o f  toxicity. RPD compares the num ber o f  cells at 24hr and 48hr 
post-MNU treatment to the number o f  cells before treatment. In Table 6.4, the T D 50 (dose o f  
M NU that causes 50% reduction in RPD. i.e. 50% toxicity) is shown for each time point and 
treatment.
Table 6.4. Pre-treatment with 0 6BG reduces the dose o f  M NU needed to achieve 50% 
cytotoxicity at both time points. n=2 .
Time Point (hr post MNU treatm ent) Treatm ent group Average TB 50 (jug/ml)
24 M N U -0 '’BG 3
24 m n u + o 6b g 2
48 M N U -0 '’BG 2
48 m n u + o 6b g 1
Referring to Table 6.4, at comparative time points, treatment with 0 6BG reduces the TDso 
suggesting that MNU toxicity is potentiated by Cf’BG. For example, at 24hr the T D 50 was 
reduced from 3pg/ml MNU to 2pg/ml M NU following lhr  pre-treatment with lOpM 0 6BG. 
used to inactivate MGM T. 0 (’BG further potentiated MNU toxicity when cell counts were 
measured at 48hr post MNU treatment, reducing its TD 50 from 2pg/ml to 1 pg/ml. For both 
treatment groups, M NU was more toxic 48hr post treatment than when toxicity is assessed 
24hr post exposure. For M N U -0 6BG, the T D 50 o f  MNU was reduced from 3pg/ml to 2pg/ml, 
with a similar reduction over 48hr in the presence o f  0 6BG.
6.3.2.2. Does 0 6BG render low dose MNU toxic?
MNU was assayed for cytotoxicity following pre-treatment with 0 6BG and compared to 
toxicity o f  M NU alone over the dose range used in the HPRT assay (0.00075g/ml to 
0.075g/ml). The results are shown in Figure 6.10.
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Figure 6.10. Toxicity curves for the dose of MNU used in the HPRT assay in absence and 
presence of 0 6BG showing that 0 6BG. Key; M NU-06BG (Dashed line), M NU+06BG (solid 
line), 24hr (squares) 48hr (circles). n=3.
Weak toxicity was observed over the MNU dose-range over 48hr. At 24hr, the top dose of 
0.5pg/ml used here, gave maximum toxicity, an average of 13.2% (86.8% RPD) of 2 
replicates. This was only slightly enhanced following 0 6BG pre-treatment to an average of 
18.6% toxicity (81.4% RPD). Toxicity at 48hr was higher at all doses than at 24hr post­
treatment. The toxicity of the solvent controls was also assessed over 48hr (Table 6.5).
Table 6.5. The contribution of the respective solvent controls to the observed toxicity of 
MNU and 0 6BG. It can be seen that the solvent treatments did not cause a substantial 
reduction in RPD. n=2.
Average RPD (%)
Control treatment 24hr 48hr
DMSO 97.7 98.7
Methanol and DMSO 95.7 98.2
o 6b g -m n u 100.0 102.1
Methanol 96.8 98.4
o 6b g +d m s o 102.4 96.0
It is evident that the solvent controls did not cause a drastic reduction in RPD highlighting 
their suitability in the assay.
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6.3.3. The effect of MGMT inactivation on the shape of the dose-response.
The HPRT assay was performed as detailed in Chapter 2 following lhr pre-treatment with 
lOpM 0 6BG to inactivate MGMT prior to addition of MNU. The cells ability to form a 
colony in 96 well plates, under non-selective conditions (without 6-thioguanine) was assessed 
using plating efficiency (PE) shown in Figure 6.11. At the higher doses there was a general 
decrease in cell viability particularly at O.Olpg/ml MNU, where the lowest was 77.3 +/- 
13.7% at 0.025pg/ml MNU which was comparable to Doak et al (2007). All values were 
normalised to the PE of cultures treated with lh r methanol, and then 1 OOjlxI DMSO, which 
represented the solvent control. The PE of all control treatments is shown in Table 6.6. All 
were normalised against the untreated PE with the exception of 0 6BG that was divided by the 
PE of methanol, the solvent control for 0 6BG.
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Figure 6.11. Plating efficiency as a measure o f AHH-1 cell viability following MGMT 
inactivation with 0 6BG at increasing concentrations of MNUover the HPRT assay. The 
solvent control represents DMSO+methanol compared to untreated controls. n=3 error bars 
represent standard deviation.
A number o f solvent treatments were used to ensure the experiment was appropriately 
controlled and to assess the contribution of each treatment on mutant frequency (MF) at the 
HPRT locus (Table 6.6).
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Table 6.6. The effects of solvent controls and 0 6BG on mutant frequency and plating 
efficiency compared to untreated cultures as calculated using equations in materials and 
method. n=3.
Treatment type Average mutant 
frequency (xlO'5)
Standard 
deviation (xlO'5)
Relative plating 
efficiency (%)
Standard
deviation
Untreated (chapter 3) 1.41 0.31 100 -
o 6b g 1.00 0.78 155.36 47.19
Methanol + DMSO 1.49 0.59 87.46 20.99
DMSO + 0 6BG 1.33 1.52 83.18 22.75
Methanol 1.86 0.36 80.74 25.82
The MFs and PE of each solvent were not significantly different compared to the untreated 
control using a one-way ANOVA (lowest p=0.475 and lowest p=0.343, respectively). 
Therefore, a valid comparison can be made between AHH-1 cutures pre-treated with 0 6BG 
and those without in chapter 3. The mutant frequencies, over the same dose range in chapter 3 
(0.00075pg/ml to 0.075pg/ml MNU) of 0 6BG treated cultures are shown in Figure 6.12.
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Figure 6.12. Linear increase (p=0.15) in HPRT mutant frequencies following 24hr exposure 
to MNU in AHH-1 cells pre-treated with 0 6BG. The solvent control (at 0.00) represents the 
MF of cells treated with Methanol and DMSO. n=3.
The dose-response shows high variability between MNU doses. However, curve estimations 
reveal that the dose response was linear (p=0.15) which is in contrast to the results of Chapter 
3 in wildtype AHH-1 cells. Statistical analysis using a two-tailed t-test, revealed the lowest 
observed genotoxic effect level to be O.OOlpg/ml MNU (p=0.04).
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6.3.4. Comparisons of dose-response with MGMT active AHH-1 cells in Chapter 3.
0 6BG is known to specifically inhibit MGMT activity and so cells treated with 0 6BG are 
assumed to represent MGMT inactive cells. A comparison of mutation induction by MNU is 
made between MGMT inactive AHH-1 cells and MGMT active AHH-1 cells. There was a 
marked increase in mutagenicity by MNU in 0 6BG treated cells, particularly at sub-NOGEL 
doses. For example, the previously observed NOGEL dose of MNU (0.0075 pg/ml) gave 
1.03x10‘5+/-3.2lxlO '5 HPRT mutants, whereas cultures pre-treated with 0 6BG gave a 3-fold 
increase in MF to 3.62 xlO'5 +/-1.60 xlO’5. This suggests that 0 6BG sensitises AHH-1 cells to 
MNU mutagenesis. In addition, there is a 10-fold reduction in the LOGEL from 0.01pg/ml 
MNU (p=0.015) in wildtype AHH-1 cells to 0.001 pg/ml (p=0.04) in 0 6BG treated cells as 
adjudged by a two tailed t-test between control and treatment mean MF’s. Comparison of the 
dose-response at sub-NOGEL doses in presence and absence of 0 6BG is shown in Figure 
6.13.
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Figure 6.13. HPRT data comparing the dose-response at sub-NOGEL MNU doses 
(<0.0075pg/ml) in presence (A) and absence (B) o f 0 6BG.
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Pre-treatment with 0 6BG to inactivate MGMT has drastically changed the shape o f the dose- 
response up to 0.0075fig/ml MNU, which was the statistical NOGEL found in Chapter 3. 
Previously, a quadratic model was the better fit of Figure 6.14B (p=0.01). However, the 
linear model better explained the data following inactivation of MGMT in Figure 6.14A 
(p=0.4). The change in MNU dose-response is further evident in Table 6.7.
Table 6.7. Numerical values for the slopes of Figure 6.13.
Treatment Gradient of the slope 95% confidence limits
-o 6b g -0.000749 -0.001327 to -0.000748
+o 6b g 0.003012 0.004801 to 0.001223
For both treatments, the confidence limits of the gradient do not pass 0, which is the gradient 
expected if the dose-response observed a true NOGEL, where the slope would run parallel to 
the x-axis, therefore, there was definite deviation from the control value (Gocke and Wall,
2009). However, where the gradient was negative in absence of 0 6BG, it was positive in the 
presence of 0 6BG. This highlights the change from a reduction in MF (-0 6BG) to an increase 
in MF (+ 06BG).
6.3.5. Comparison of benchmark dose (BMD).
The benchmark dose (BMD) is a more sophisticated model than NOGEL and has been used 
in risk assessment (EFSA, 2009) and is used in an analogous way. Gollapudi et al (2012) and 
Filipsson et al (2003) suggest that BMD should be the first choice in dose-response 
modelling of all continuous data where a significant response is seen compared to the control. 
The authors of the ILSI-HESI quantitative subgroup, further emphasise the use o f BMDLjo 
(lower limit of the BMD) as a point of departure (PoD) over NOGEL and threshold dose 
(Td). There is current debate as to which parameter should be used to define the PoD. Here, 
using PRO AST software, the BMD was determined for both dose-responses (+ 0 6BG and -  
0 6BG) and are shown in Table 6.8.
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Table 6.8. The benchmark dose (BMD) that marks the critical event in a dose-response, 
analogous to the NOGEL/LOGEL approach. 90% confidence limits are given either side of 
the BMD. The BMD is lower following 0 6BG pre-treatment.
90% confidence limits
Treatment BMD Lower (BMDL) Upper (BMDU)
-o 6b g 0.00956 0.00667 0.00981
+o 6b g 0.00020 0.00006 0.00112
The data in Table 6.8 importantly shows that AHH-1 cells without prior MGMT inactivation 
(-0 6BG) can tolerate 50-fold higher concentration of MNU before a significant response is 
seen compared to cells with MGMT activation (+ 0 6BG). The BMD and the lower confidence 
limit (BMDL) of MNU in MGMT inactivated cells are extremely low (0.0002pg/ml and 
0.00006pg/ml MNU, respectively) and are below the level of doses tested, therefore we could 
not state that a point of departure (PoD) exists for this data set, further highlighting the 
increased potency of MNU in MGMT inactivated cells.
6.3.6. Fold difference in MF.
The fold change in MF between AHH-1 cells differing in MGMT proficiency was calculated 
by dividing the MF in presence of 0 6BG (MGMT inactive) by the MF in absence of 0 6BG 
(MGMT active) at each dose (Figure 6.14).
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Figure 6.14. The fold difference in MF between + 0 6BG and - 0 6BG is greatest at doses 
below the statistical LOGEL of O.Olpg/ml. Plotted on Log-Linear axis.
A maximum 5-fold increase in MF in MGMT inactivated cells was observed at doses below 
the LOGEL (0.01pg/ml MNU, identified in Chapter 3). There was very little difference in 
MF fold change at the LOGEL and higher doses of MNU. This suggests that the effects of 
MGMT loss are more noticeable at doses below the LOGEL. This is further emphasised by
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statistics (Table 6.9), which compares the MF at each concentration of MNU. Since the MF 
of solvent controls did not differ significantly to the untreated control, the MF in presence 
and absence of 0 6BG was compared at each dose using a two-tailed t-test. Significance was 
only seen at doses below the LOGEL.
Table 6.9. A two-tailed t-test compared each dose for significance to see the effect of 0 6BG 
on MF. Significance (show in bold) was only achieved at doses below the NOGEL. p=<0.05 
except 0.005 pg/ml where p=<0.01.
HPRT Mutant Frequencies (MF)
MNU Oig/ml) Replicate 1 Replicate 2 Replicate 3 p-value
0.00075-06BG 9.56E-06 1.14E-05 1.53E-05
0.00075+06BG 2.84E-05 6.27E-06 6.11E-06 0.852
0.001-0<>BG 1.04E-05 1.68E-05 1.45E-05
o.ooi+o 6b g 5.25E-05 2.01E-05 1.60E-05 0.251
0.0025-06BG 5.66E-06 5.61E-06 5.14E-06
0.0025+0(’BG 4.61E-05 2.58E-05 2.11E-05 0.029
0.005-0<’BG 1.06E-05 7.96E-06 6.07E-06
0.005+06BG 5.08E-05 1.70E-05 3.09E-05 0.067
0.0075-06BG 4.55E-06 1.39E-05 9.58E-06
0.0075+0‘BG 5.37E-05 3.26E-05 2.24E-05 0.049
o.o i-o 6b g 2.51E-05 2.63E-05 2.03E-05
o.o i+o 6b g 2.95E-05 1.28E-05 4.79E-05 0.583
0.025-06BG 4.29E-05 3.63E-05 3.47E-05
0.025+0('BG 2.44E-05 7.49E-06 6.24E-05 0.713
0.05-06BG 3.02E-05 3.14E-05 3.22E-05
0.05+06BG 4.81E-05 6.79E-05 2.89E-05 0.205
0.075-06BG 6.51E-05 5.30E-05 4.66E-05
0.075+06BG 6.90E-05 2.79E-05 3.99E-05 0.524
6.3.7. Fraction of lesions unrepaired by MGMT.
Gocke, Tang and Singer (in press) divided the MF in MGMT active cells (-0 6BG) by the MF 
in MGMT inactive cells (+ 06BG) to infer the fraction of unrepaired lesions by MGMT. This 
mathematical model assumes that the only difference between these two conditions is the
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efficiency o f repair of DNA adducts. This has been applied to the data presented here (Figure 
6.15).
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Figure 6.15. Fewer adducts are unrepaired at doses below the LOGEL of 0.01 pg/ml. Values 
approaching 1 at higher doses suggest that all adducts are unrepaired. Plotted on Log-Linear 
axis.
As shown in Figure 6.15, at doses below the LOGEL (O.Olpg/ml MNU) there was a lower 
fraction of unrepaired adducts for example, at 0.001 pg/ml MNU (10-fold lower than the 
LOGEL found in Chapter 3) four in every ten adducts were unrepaired (4x10 '1). At,
0.0025pg/ml (which caused a significant reduction in MF in chapter 3) one in every ten 
( lx l0 '1) adducts were unrepaired suggesting a higher efficiency of DNA repair. Ratios at 
doses above the LOGEL (<0.01pg/ml MNU) were close to 1. There was no difference in 
repair efficiency between AHH-1 cells in absence and in presence of 0 6BG at higher doses of 
MNU.
6.3.8. Real time analysis of MGMT transcripts over MNU dose range with 0 6BG.
To assess the response at the MGMT promoter to 0 6BG and MNU treatment, MGMT 
expression analysis was conducted over 24hr at increasing concentrations o f MNU following 
1 hr pre-treatment with 0 6BG (Figure 6.16).
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Figure 6.16. M G M T m RNA was analysed at different time points following treatment with 
MNU in M G M T inactivated ceils.
Due to the high variability o f  data, gene expression was found not to differ significantly from 
the solvent control (lowest p=0.07, a decrease in expression at 0.05pg/ml following 24hr 
exposure). There seemed to be a dose response at 24hr where expression increases to a peak 
at 0.0075pg/ml (previously found to be the N O GEL in wild type AHH-1 cells) and then 
declines at higher doses.
6.3.9. M utation spectra at the HPRT locus following M GM T inactivation.
M G M T has a well-established role in preventing G C ->A T transitions by removing O 'M eG . 
formed in comparatively high quantities by M NU and other Sn I alkylating agents. To further 
emphasise the role o f  M GM T in the dose-response for MNU mutation induction, we 
sequenced HPRT mutants treated with 0.0075pg/ml MNU and compared proportions o f  
G C -> A T  transitions in cultures pre-treated with Cf’BG to inactivate M GM T (Table 6.10).
MNU (pg/ml)
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Table 6.10. A comparison of the mutation spectra at the HPRT locus in AHH-1 cells 
following treatment with 0.0075pg/ml MNU (NOGEL, chapter 3), with and without pre­
treatment with 0 6BG and the spontaneous mutation spectra following pre-treatment of 0 6BG 
which has been shown to inactivate MGMT.
Percentage o f total mutations
Substitution type Opg/ml MNU  
n=22
o+ o 6b g
n=8
NOGEL - 0 6BG 
n=6
NOGEL + 0 6BG 
n=7
G C -^A T 15.0 1.0 28.6 45.8
A T ^ C G 29.0 28.3 0.0 25
A T ^ G C 9.3 24.2 24.5 14.5
G C -^TA 9.3 4.0 6.1 0.0
A T -»T A 22.4 14.1 40.8 4.2
C G -»G C 15.0 26.3 0.0 10.4
Single nucleotide 
deletion
0.0 2.0 0.0 0.0
Total number o f  
substitutions
112 198 49 48
A total of 12 mutants were sequenced following MGMT inactivation and 0.0075pg/ml MNU 
(NOGEL + 0 6BG). O f these, 5 were found to contain the rearrangement to the HPRT gene as found in 
chapter 3. Likewise, these were removed from analysis and only base substitutions are shown. An 
interesting finding was that 0 6BG drastically changed the spontaneous mutation spectra 
where only 1% of mutations were GC->AT transitions compared to 15.0% found in the 
spectrum of the negative control in chapter 3 (Opg/ml M NU-06BG). The most predominant 
change, AT->CG transversions, constituted 29.0% of this mutation spectra. A deletion o f a 
single adenine at 303 occurred in 2/8 mutants. These changes did not occur in the treated 
samples as can be seen in their respective spectra in Figure 6.17. The important finding in 
MNU treated cells was the increase in GC->AT transitions in samples pre-treated with 0 6BG 
from 28.6% to 45.8% at the same doses of MNU (0.0075pg/ml). This increase is not biased 
by a heavily mutated colony at 0.0075pg/ml MNU + 0 6BG, since the number of mutants 
harbouring GC->AT transitions also increased from 3/6 (50%) to 5/7 (71%) following 
MGMT inactivation by 0 6BG.
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6.4. Discussion.
6.4.1. siRNA as a method for MGMT knockdown.
RNAi is a widely used technique for reducing gene function, and can be used in all aspects of 
research. siRNA is a crude method of RNAi whereby, addition of sequence specific dsRNA 
oligonucleotides to culture medium is sufficient for knockdown. However, this requires 
robust optimisation and validation (Cheng, Magdaleno and Vlassov, 2011). Many studies use 
real time PCR and western blot to confirm knockdown on mRNA and subsequent protein 
levels, respectively. Knockdown by siRNA is only temporary and so a gene of interest 
deficient cell species cannot be stably passaged which introduces variation between 
experiments. We describe a method of chemical transfection using 
Lipofectamine™RNAiMAX transfection reagent to deliver siRNA oligonucleotides into 
cells. This method is routinely used by colleagues in our laboratory and was found to be the 
most convenient method of siRNA delivery compared to electroporation, which has been 
used by Zair et al (2011) for delivery of shRNA expression vectors into cells. Chemical 
transfection achieved a maximum knockdown of 80% in GAPDH mRNA levels using 
20pmol GAPDH ON-TARGETplus with 5pl Lipofectamine RNAiMAX. This level of 
knockdown is lower than manufacturers’ expectations. However, 3pi of Lipofectamine and 
above caused increasing cytotoxicity after 24hr when examined under the microscope and the 
cells were not viable after 3days. This may be due to off target effects by siRNA 
oligonucleotides (Fedorov et al, 2006) or lipofectamine-induced toxicity (Zhong et al, 2008). 
A more comprehensive cytotoxicty study was not undertaken due to limited reagents. This 
reduction in fold change importantly demonstrated the success of siRNA delivery into the 
cells and so the experiment was repeated with MGMT specific siRNA oligonucleotidess 
(Figure 6.9). Real time PCR analysis o f cultures treated for 24hr with concentrations 
exceeding lOpmol of each siRNA and 4pl Lipofectamine revealed that MGMT mRNA was 
not detectable. This suggests 100% knockdown, which was not reproducible across the 
replicates. Upon closer inspection of the raw real time data, amplified MGMT cDNA had a 
threshold cycle (Ct) value of approximately 34 cycles and TBP has a Ct value of 
approximately 19 cycles in AHH-1 cells. At the same concentration of RNA starting material, 
where a lack of Ct value for MGMT was observed, it was accompanied by an increase in 
TBP Ct, up to Ct 24. For genes with very low expression (a high Ct value) like MGMT, 
siRNA knockdown validation using real time PCR and western blotting is difficult, because 
o f this, and the induced toxicity, another method of MGMT knockdown was sought.
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6.4.2. 0 6BG as a method of MGMT inhibition.
The use of 0 6BG in MGMT inactivation is the more widely researched in vitro method to 
produce MGMT deficiency than gene disruption (Tsuzuki et al, 1996) or siRNA (Kato et al, 
2010).
6.4.2.1. Assessing the toxicity of MNU with 0 6BG.
Referring to the toxicity curves (Figure 6.10), relative population doubling (RPD) was used 
based on recommendations in OECD test guidelines 487 for the micronucleus assay (OECD,
2010). It is a measure of cell proliferation, calculated from cell counts obtained before and 
after treatment. RPD has an inverse relationship with toxicity. For example, 80% RPD 
indicates (100-80=) 20% toxicity. A study by our group suggests that RPD offers the most 
reliable estimation of acute toxicity (Johnson et al, 2010). A more accurate assessment can be 
made through apoptosis assays. For example, the caspase assays that detect the activity of 
caspases, a class of proteases that elicit the apoptotic response. However, this would involve 
cost.
6.4.2.2. Ensuring the experiment was appropriately controlled.
The solvents used for dilution of MNU and 0 6BG are DMSO and methanol, respectively, in 
accordance with manufacturers instructions. DMSO is acknowledged as causing low toxicity 
and is used as a solvent for water-insoluble chemicals (Brown, Robinson and Stevenson, 
1963). Methanol is a strong solvent but many studies report high level-toxicity caused by 
100% methanol in humans and non-human models. The reader is referred to 
http://ntp.niehs.nih.gov/index.cfm?objectid=E8820866-BDB5-82F8-F588ACF109C14CE2 
for a comprehensive list o f methanol toxicity studies. It was necessary to determine solvent 
specific effects on RPD (shown in Table 6.5) to ascertain their contribution in the observed 
toxicity of the test substance. For M NU-06BG, DMSO was used as the solvent control 
causing very minor toxicity giving 97.7% and 98.7% RPD at 24hr and 48hr post-treatment. 
The solvent control for M NU+06BG treatments required lhr pre-treatment with methanol 
(final concentration of 0.00024%) followed by lOOpl addition of DMSO (final concentration 
of 0.001%). This mimicked the treatment protocol for the test substances and was the 
appropriate strategy. The PD was compared to that of untreated controls to determine the 
effects of both solvents on RPD. This being, 95.7% at 24hr and 98.2% at 48hr post treatment, 
which suggested that the solvent controls caused insubstantial toxicity and had no substantial
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bearing on the results. Elucidation of the toxic potential of 0 6BG had important implications 
that are discussed later. The RPD was calculated by dividing the PD of 0 6BG treated 
cultures, with the PD of cultures treated with methanol, it’s solvent control. This gave RPD 
values of 100% at 25hr and 102.1% at 49hr (given the additional lh r during pre-treatment) 
compared to control suggesting that 0 6BG is not toxic. Incidentally, methanol was used as 
the solvent control, which was not significantly toxic, compared to untreated controls.
6.4.2.3. Assessing the cellular presence of 0 6BG through increased MNU toxicity.
The toxicity of MNU is attributed to 0 6MeG because it is formed in higher levels than other 
toxic adducts such as N7MeG and N3MeA reviewed by Shiravstav et al (2010). Cells 
deficient in MGMT would therefore show increased toxicity to MNU due to ineffective 
repair of 0 6MeG. This has been inferred by a decrease in the TD50 (Table 6.4). TD50 is 
defined as the dose that causes 50% toxicity observed as a 50% reduction in cell viability 
(50% RPD). TD50 is a standard measure used to compare cell sensitivities, toxic potencies of 
chemicals and concordance of methodologies (Johnson et al, 2010). TD50 is documented in 
various databases throughout genetic toxicology, e.g. the national toxicology programme 
(NTP) found at http://ntp.niehs.nih.gov/. The decrease in TD50 of MNU following pre­
treatment with 0 6BG suggests increased sensitive to the toxic effects of MNU. This is in 
concordance with other studies. For example, Wagner et al (2007) report the concentration of 
TMZ required for 50% growth inhibition of neuroblastoma tumours (IC50) alone is 41pM, 
which is reduced to 3.4pM when used with 0 6BG. Furthermore, Table 6.5 shows that 0 6BG 
was, by itself, non-toxic. Many reports support this (Batts et al, 2007; Berg et al, 1998). 
Therefore, the additional toxicity of M NU+06BG is not due to additive toxicity but 0 6BG 
potentiation o f MNU toxicity. The well-documented explanation is the inactivation of 
MGMT by 0 6BG rendering the protein unable to repair 0 6MeG, from alkylating agent 
exposure that can cause cell death. Determining the causative adduct is difficult since 
multiple adducts are formed. Increased sensitivity to MNU toxicity as a result o f MGMT 
deficiency has been reported in mice (Glassner et al, 1999). The authors report a dramatic 
decrease in TD50 from 107mg/kg to 9mg/kg. Such a significant difference is not represented 
in this study. Wildtype AHH-1 have only a low natural level of MGMT and so removing 
what little protection they have only produces a modest difference. Konduri et al (2009) 
suggest that 0 6BG by itself causes repression of MGMT expression. The authors used 
207pM 0 6BG for 48hr exposure, far more than featured in this study. In a luc reporter gene 
construct, under the control of MGMT promoter, the authors report a significant reduction in
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luciferase activity upon treatment with 0 6BG. However the authors fail to produce real time 
data confirming this.
6.4.3. 0 6MeG toxicity.
0 6MeG requires MMR processing and two rounds of replication to exert toxic effects (Kaina 
et al, 1997; Roos and Kaina, 2008; Shrivastav, Li and Essigmann, 2010), hypothesised to be 
via apoptosis. There are two mechanisms for apoptosis induction:
• Futile MMR processing of 0 6MeG:Thymine mispairs, from the first post treatment S 
phase, leading to pro-apoptotic secondary lesions such as double strand breaks in the 
second post-treatment S phase (Roos et al, 2009).
• Direct apoptotic signalling by MMR proteins upon recognition of mispairs.
Presumably, the second possibility would not require two S phases to convert 0 6MeG into a 
cell-killing event and may explain the observed increase in toxicity at 24hr in presence of 
0 6BG. Given the cell cycle time of AHH-1 as 22-24hr (Crespi et al, 1991), one would expect 
AHH-1 to be in the second cell cycle by 48hr, the last time point in this experiment. In both 
treatment groups, the TD50 is comparatively lower at 48hr than at 24hr suggesting that MNU 
is more toxic in the second cell cycle. This is consistent with the toxic mechanism of action 
of 0 6MeG (Kaina et al, 2007). However, MNU is toxic in the first cell cycle given the TD50 
of 3pg/ml at 24hr, this is reduced to 2pg/ml following 0 6BG pre-treatment. Assuming that, 
this decrease is the effect of increased persistence of 0 6MeG, the result of MGMT 
inactivation by 0 6BG. The contribution of 0 6MeG to the toxicity observed in first cell cycle 
cannot be ignored. The data presented importantly demonstrates the cellular presence of 
0 6BG in AHH-1 cells following addition to culture media by the increased toxicity of MNU.
6.4.4. Effect of MGMT inactivation on HPRT mutant frequencies.
The HPRT assay was repeated in AHH-1 cells following pharmacological inactivation of 
MGMT by 0 6BG. This allows direct comparison with HPRT data in Chapter 3 to test the 
hypothesised involvement of MGMT in protection from low dose MNU.
6.4.4.I. Comparing background mutant frequency + /-0 6BG.
MGMT inactivation can only be inferred from the experiments and without conclusive 
evidence of decreased activity, it is assumed that AHH-1 cells treated with 0 6BG are MGMT 
deficient. Wildtype AHH-1 cells have a spontaneous mutant frequency (MF) of 1.4xl0"5+/-
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1.78x1 O'6 HPRT mutants in a population as discussed in Chapter 3. MGMT deficient cells 
have a comparative spontaneous MF of 1.3x10'5+ /-l.05x1 O'5. This suggests that MGMT does 
not play a major role in protecting cells from background mutagenesis. This is logical since it 
is known that 0 6BG is not mutagenic (Ueno, 2006) and 0 6MeG does not form a large 
proportion of endogenously formed damage and so MGMT may not be “needed” in 
unexposed individuals but is essential in protecting against exposure to exogenous alkylating 
agents (Nakatsuru et al, 1993). However, in microbial hosts, deficiency at both MGMT loci 
(<ada and ogt) renders the cell sensitive to increased spontaneous mutagenesis, which is 
correlated to a 10-fold increase in GC->AT transitions (Mackay, Han and Samson, 1994). 
However, in mammalian hosts, spontaneous MF at a lacl reporter gene was 1.5-fold lower in 
liver o f MGMT deficient mice compared to wildtype mice (Sandercock et al, 2004). 
However, this could be the result o f lacl integration at a locus of improved repair capacities 
or reduced endogenous damage. Similarly, MGMT deficiency did not have any effect on 
spontaneous tumour rates (Bugni, Meira and Samson, 2009). This suggests that MGMT loss 
is not a causal event in spontaneous carcinogenesis o f unexposed individuals. Contrary, 
Rydberg and Lindahl (1982) showed that S-adenosyl methione (SAM) is a weak endogenous 
DNA methylator that may cause 10-30 sporadic 0 6MeG molecules per cell, although this was 
not experimentally determined. One would expect this to contribute to the spontaneous 
mutation spectra in absence of MGMT. Incidentally, MGMT loss is thought to be a critical 
early carcinogenic event, causing “field cancerisation” of tissue in sporadic colon cancer 
(Shen et al 2005; Graham and Leedham, 2010), where alkylating agents from digestion 
products are in high concentration. Without an increase in spontaneous mutagenesis in 
MGMT deficient cells, there may be a compensatory mechanism potentially involving MMR 
but this has not been substantiated. Interestingly, Glassner et al (1999) found residual 
transferase activity in MGMT knockout mice. This could be the limit of detection of the 
activity assay, although, there may exist MGMT paralogues or an alternative repair 
mechanism. Given the lack of MGMT activity in AHH-1 cells (Chapter 5), this isn’t the case 
in AHH-1 cells. Also, It can be assumed that 0 6BG would inactivate all potential MGMT 
paralogues if they share same activity kinetics. Therefore, MGMT paralogues would not 
affect results observed in this study. It has been shown that MGMT deficiency may not be 
important in spontaneous mutagenesis but has important implications in chemical exposure 
(Nakatsuru et al, 1993). The data presented in this chapter supports this notion.
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6.4.4.2. 0 6BG sensitises AHH-1 cells to (below LOGEL doses) MNU mutagenesis.
The evidence provided in Chapter 5 postulates that MNU mutation induction is attributed to 
0 6MeG, the main mutagenic lesion formed by MNU. We hypothesise that this adduct is 
formed at all doses of MNU but is repaired by MGMT at doses below the NOGEL of 
0.0075pg/ml MNU. At higher doses, MNU produces more 0 6MeG that saturates MGMT and 
mutation induction accrues linearly because the protection is lost. We tested this hypothesis 
by creating MGMT deficient AHH-1 cells (+ 0 6BG) and comparing mutant frequencies to 
MGMT proficient AHH-1 cells (-0 6BG) over increasing concentrations of MNU over the 
hormetic dose range. The role of MGMT in low dose protection is evidenced by the drastic 
change in the shape of the dose response (Figure 6.13) due to an increase in sensitivity to low 
dose MNU when MGMT is inactivated. This is emphasised by the 10-fold decrease in the 
LOGEL from O.Olpg/ml in MGMT proficient AHH-1 cells to 0.001 pg/ml in MGMT 
deficient cells. There is considerable variation in the data of Figure 6.13A, this may reflect 
differences in independent observations made between Figure 6.13A and Figure 6.13B, 
where increasing the number of wells scored from 600 to 10033 may reduce the error bars. 
Alternatively, this may be a true representation o f the heterogeneity in MGMT activity 
between the AHH-1 populations following administration of 0 6BG.
Evidence is provided to support our hypothesis o f MGMT saturation at doses above the 
NOGEL. Such as:
1. The fold increase in sensitivity in MGMT deficient cells is greatest at doses below the 
NOGEL (0.0075pg/ml). 0 6BG had no effect at doses above the LOGEL (O.Olpg/ml) 
since MGMT has been potentially saturated by increased dose of MNU (Figure 6.14; 
Table 6.9).
2. The fraction of unrepaired lesions (Figure 6.15) shows that MGMT repairs more 
adducts at doses below the LOGEL than above. This is based on the logical 
assumption that cells treated with 0 6BG are MGMT deficient and the only 
consequence is defective lesion repair. 0 6MeG levels would need to be determined 
for substantiation of this statement.
Referring to Table 6.9, at O.Olpg/ml MNU and above, the MF seems to plateau giving the 
appearance of a supra-linear dose response. Real time expression analysis of MGMT 
transcripts was undertaken to investigate whether induction at the MGMT promoter was 
responsible for this (Figure 6.16). A student’s paired t-test of deltaCT values (Doak et al,
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2008) revealed that there was no statistically significant increase in fold change of MGMT 
mRNA (lowest p=0.07). A likely explanation of the observed supra-linearity is the increased 
toxicity observed as a decrease in plating efficiency (PE) (Figure 6.11) observed at 
O.Olpg/ml and above, this would remove the cells carrying the most genetic damage thereby 
reducing the number of mutant colonies. The lack of increase at 0.00075pg/ml MNU in 
0 6BG treated cells suggests that lOpM 0 6BG is not sufficient to inactivate all MGMT and a 
residual amount remain to remove 0 6MeG induced at this dose and it’s the combination of 
higher dose of MNU and 1 OpM 0 6BG that are required for complete inactivation. Increasing 
concentrations of 0 6BG with 0.00075pg/ml MNU would have supported this but this was not 
undertaken due to the time consuming and labour intensive nature o f the HPRT assay. This 
finding correlates to the lack of increase in N7MeG adducts at this dose compared to the 
solvent control, as concluded in Chapter 5. But it cannot be concluded that MNU does not 
react with the DNA because the mutation spectra at this dose is significantly different to the 
solvent control.
6.4.5. Real time MGMT analysis.
Doak et al (2008) found an increase in MGMT expression that peaks at the NOGEL dose of 
MMS (lpg/m l) 4hr after exposure. The pattern is similar here although there was no 
significant increase in expression. MGMT expression is highest at 24hr post-exposure with 
the NOGEL dose of MNU (0.0075 pg/ml). MNU reacts with DNA and produces more 
0 6MeG via a SnI reaction mechanism, which has faster kinetics than Sn2 reaction mechanics 
o f MMS. Therefore, one would expect more emphatic and rapid MGMT induction following 
MNU exposure. The discrepancy in time for MGMT induction is not known.
6.4.6. Spontaneous mutant spectra + /-0 6BG.
MGMT loss is associated with increased GC->AT transitions (Esteller et al, 2001). This is 
most notable upon exposure to 0 6-methylating agents (Nakatsukri et al, 1993; Sandercock et 
al, 2008). The effects of MGMT deficiency on spontaneous mutation spectra are less well 
defined. An increase in spontaneous GC->AT transitions is generally observed, however the 
extent is possibly dependant on;
• Original MGMT levels
• Intracellular S-adenosylmethionine (SAM) concentration.
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The study by Sandercock et al (2004) found a modest increase in GC->AT transitions from 
49% to 56% in the liver of MGMT deficient mice. Whereas, Aquilina et al (1992) found a 
greater increase from 8.3% to 25% in MGMT deficient Chinese hamster ovary (CHO) cells. 
These studies were not carried out at the HPRT locus. In this study, analysis of 40 
spontaneously occurring mutants in a wildtype AHH-1 population, found that GC->AT 
transitions constitute 28% of the mutation spectra. There is a dramatic decrease in GC->AT 
transitions to 1% of the spontaneous mutation spectra in MGMT deficient AHH-1 cells 
(Table 6.10). However, only eight mutants were analysed and so this may not be a true 
reflection. It is hypothesised that the majority of spontaneous GC->AT transitions occur 
through deamination of 5-methylcytosine into thymine and not through 0 6MeG. Therefore, 
MGMT loss would not dramatically change the proportion of these spontaneous transitions. 
Interestingly however, the only spontaneous GC->AT transitions to occur in MGMT 
deficient cells, found at position 1229. This mutation was also found in the spectra treated 
with 0.0075pg/m l+06BG and also in 0.025pg/ml in Chapter 3. This evidence suggests that 
this mutation is only found in samples where MGMT has been inactivated. Aquilina et al 
(1992) found concordance of spectra between MGMT proficient and deficient CHO cells 
with the differences being the increase in GC->AT transitions and decrease in GC->TA 
transversions. This is in contrast to the results found in this study. We found that the 
spontaneous mutation spectra of MGMT deficient AHH-1 cells are drastically different to 
that of MGMT proficient AHH-1 cells in Chapter 3. The array of mutations at 241 to 300 all 
occurred in unison in 50% of the mutants analysed. Individual damage to each base is 
unlikely to account for this change of 49 base substitutions and more likely that they share a 
common mutagenic pathway and the loss of MGMT in AHH-1 cells causes dysregulation of 
DNA maintenance. Further mutants would need to be screened before firm conclusions can 
be made.
6.4.7. The effects of MGMT inactivation on MNU induced mutations.
Comparing the mutation spectra from MNU treated mutants (Figure 6.17) revealed that some 
mutations are only present following 0 6BG induced MGMT inactivation. O f these, the 
majority are GC->AT changes caused by 0 6MeG from MNU that are not repaired once 
MGMT has been inactivated. When reviewing the mutation spectra, caution is urged due to 
the differences in the number of mutants sequenced for each treatment, which may bias the 
spectra. The drastic increase in proportions o f GC->AT transitions was accompanied by an 
increase in number of mutant harbouring these transitions from 50% to 71% following
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M G M T inactivation. This shows that the increase was not due to a heavily mutated colony 
that would misrepresent the data. The observed increase in M GM T deficient cells, at the 
same concentration o f  M NU (0.0075 pg/ml), supports our hypothesis o f  the involvement o f  
M GM T in low' dose protection. The use o f  0.0075 pg/ml was appropriate here since we are 
examining the effects o f  M GM T deficiency. However, this dose is not recommended for use 
to examine the effects o f  different concentration o f  M NU because 0.0075pg/ml was the 
highest dose tolerated, since this “tolerance'* is an average response o f  the population it may 
be possible that individual cells may have different responses to this dose. Multivariate 
analysis was not performed on these data to due lack o f  statistical power (requiring n=40 
mutants per spectra as used in Chapter 3). However, the numbers were sufficient for visual 
comparison o f  spectra. An interesting comparison was made between the spectra o f
0.0075pg/ml M N U + 0 6BG and 0.025pg/ml M NU (analysed in Chapter 3), both o f  which we 
hypothesise to have inactivated M GM T (Figure 6.18).
A).
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Figure 6.18. Mutation spectra for 0.0075pg/ml M N U + 0 (1BG (A) and 0.025pg/ml MNU (B). 
Similarities unique to these spectra are circled. They also share the rearrangement at 490bp. 
Axis given in Figure 6.17.
There are striking similarities between the two spectra that are absent in all other spectra. 
Most notable are G C ->A T transitions (circled in Figure 6.17). These mutations are not found 
in any other spectra; therefore, it is reasonable to state that 0 .0075pg/ml M NU in 
combination with M GM T inactivation resembles mutation induction seen at a higher dose o f  
M NU, which is sufficient to cause M GM T inactivation.
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6.4.8. Conclusion: Evidence for the role of MGMT.
The cellular presence of 0 6BG was confirmed through toxicity studies that showed an 
increase in MNU induced toxicity at high doses (Table 6.6). Since it is well established that 
0 6BG has no other mechanism of action than to inhibit MGMT, we can confidently assume 
that the increased toxicity is due to MGMT inactivation and as a result, increased persistence 
of 0 6MeG in DNA following MNU treatment. Therefore 0 6BG treated cultures are deficient 
in MGMT. This causes the increased sensitivity to low dose MNU evident in Figure 6.13. 
The J-shaped curve becomes more linear with a 10-fold lower LOGEL and 50-fold lower 
BMD. Further evidence of the role of MGMT is also provided by the increase in proportions 
of and number of mutants with GC->AT transitions seen in MGMT deficient cells treated 
with 0.0075pg/ml MNU. We noted an increase from 28.3% to 48.1% in MGMT proficient 
and deficient cells, respectively. In conclusion, the experimental evidence provided in this 
chapter implicates MGMT in the NOGEL for MNU mutation induction that is summarised in 
Figure 6.19.
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Figure 6.19. Inactivation of MGMT by 0 6BG causes increases in MF (A) and G C ^A T  
transitions (B). Error bars in A) represent standard deviation, * p=<0.05.
Following the inactivation of MGMT the 0.0075pg/ml MNU causes 3.5-fold increase in MF 
(Figure 6.19A). This is accompanied by a 68.5% increase in GC->AT transitions (Figure 
6.19B) and a 66% increase in the number o f mutants harbouring a GC->AT transition. The 
data presented in this chapter strongly defines the role o f MGMT in creating the NOGEL for 
MNU induced point mutations.
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Chapter 7.
General Discussion.
7.1. General Discussion.
The purpose of the project was to clarify the in vitro biological mechanism of point 
mutation induction at low doses of methyl nitrosourea (MNU). This has important 
implications because:
1. MNU is the most mutagenic of the four model alkylators (MNU, 
ethylnitrosourea (ENU), ethyl methanesulfonate (EMS) and methyl 
methyl sulfonate (MMS). Therefore, describing low dose effects sets 
precedence for lesser mutagenic alkylating agents.
2. There is real impetus for defining the mechanism of mutation induction given 
the biological relevance of point mutations in carcinogenesis.
In addition, this study provides evidence for the applicability of in vitro tests for use 
in mechanism of action studies and dose-response modelling to provide more 
quantitative information than the dichotomy of genotoxic/non-genotoxic (Gollapudi et 
al, 2012). This is particularly pertinent with the 7th amendment to the EU cosmetics 
directive that puts emphasis on in vitro toxicology as a replacement for animal models 
in cosmetic testing (Tweats et al, 2007). An addendum written by Pottenger et al 
(2011) discuses 6 key events (KE) in MO A analysis and relevant endpoints for each. 
These including:
KE1: Internal Dose (Portine adducts) not relevant to in vitro studies.
KE2: Dose to critical target (DNA adducts)
KE3: Altered homeostasis (gene expression)
KE4: Genotoxic stress (increase in unrepaired adducts)
KE5: Cell replication (Mitotic index)
KE6: Mutation (Genotypic change).
With these in mind, this study is a comprehensive study into the MOA of mutation 
induction by MNU.
7.2. Findings of this thesis.
The following is an account of the main findings of this thesis and their implications 
in dose-response modelling. The conclusions from each of the results chapters are:
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• MNU has a No-Observed Genotoxic Effect Level (NOGEL) for point 
mutation (Chapter 3) and an apparent J-shaped dose-response.
• MNU reaches and damages DNA without an increase in HPRT mutant 
frequency at doses <NOGEL (Chapter 4 and 5)
• GC->AT transitions caused by 0 6MeG are the major mutagenic event 
responsible for the increase in MF at doses >NOGEL (Chapter 5)
• MGMT is responsible for repair of 0 6MeG until it is saturated by increased 
concentrations o f MNU, thereby creating the NOGEL (Chapter 6)
These will be discussed in turn.
7.2.1. NOGEL for MNU induced point mutations (Chapter 3).
A NOGEL for mutations has previously been found for two alkyl sulfonates; EMS 
and MMS but not for the alkyl nitrosoureas; ENU and MNU at the doses tested (Doak 
et al, 2007). MNU is known to be 20 times more mutagenic than MMS, which has 
been attributed to 0 6-methylguanine (0 6MeG), which is the major mutagenic lesion 
(Doak et al, 2007). It was therefore hypothesised that a NOGEL for MNU would exist 
but at lower doses. A NOGEL has since been found for MNU using the TK assay in 
L1587Y mouse lymphoma cells (Pottenger et al, 2009) and the in vivo Pig-a assay 
(Lynch et al, 2011). Chapter 3 of this thesis reports a NOGEL for MNU in the same 
test system as Doak et al, (2007), this being; AHH-1 cells using the HPRT assay to 
quantify Mutant Frequency (MF) within a population (Figure 3.9). The NOGEL 
occurred at 0.0075pg/ml MNU, 117-fold lower than MMS. At such low doses, the 
adduct spectra of MNU and MMS may be different to that found in Beranek (1990) 
and such a drastic fold difference in NOEL may be expected.
7.2.2. Hormesis of low dose MNU on mutation induction (chapter 3).
Using curve estimations, the shape of the dose-response in chapter 3 (Figure 3.9) was 
J-shaped. There was a statistically significant and reproducible decrease in MF at
0.0025pg/ml compared to the control, potentially owing to the induction of DNA 
repair. This is indicative of hormesis, whereby MNU had a beneficial effect in 
reducing the frequency of HPRT mutants in a wildtype AHH-1 population. Such a
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finding was not expected but it importantly demonstrates that current statistical 
analysis of Gocke and Wall (2009) and Johnson et al (2009), designed to identify a 
NOGEL, can detect a variety of dose-responses. Hormesis as a concept of low dose 
effects is a controversial area o f genotoxicology, particularly for MNU, which is a 
very potent genotoxic carcinogen. Proponents state that hormesis better predicts low 
dose exposures to carcinogens (Calabrese and Baldwin, 2001). While on the other 
hand some argue that there is a lack of supportive evidence of hormesis (Calabrese 
and Baldwin, 2000). Gocke and Wall (2009) identified hormesis through statistical 
analysis of mutation induction by EMS at the lacZ locus in vivo. The same analysis 
has been used in this thesis (Figure 3.11). Additionally, a colleague has also reported 
the reduction in micronuclei frequency in the mononuclear micronucleus assay after 
acute exposure to MNU in TK6 human lymphoblast cells (Kate Chapman, personal 
communication). Whether the same effect at low dose MNU is observed in vivo has 
not been established. Currently, hormesis is not an accepted dose-response model 
used for risk characterisation of genotoxins, primarily due to lack of applicability 
across populations and genotoxins and firm mechanistic understanding. However, the 
model is gaining credence and this study may aid in the recognition of hormesis as a 
legitimate model for low dose exposure to MNU and similar alkylating agents. This 
would require substantial evidence across a broad range of studies.
7.2.3. MNU interacts with DNA at doses below the NOGEL (Chapter 4 and 
Chapter 5).
It was important to test for MNU induced DNA damage (adducts) at doses below the 
mutagenic NOGEL. This implicates DNA repair in the removal of the damage to 
account for the lack of increase in MF in chapter 3. Adducts are well known to have a 
linear dose-response, in situations where mutations have a non-linear dose-response 
(Swenberg et al, 2008). Adduct detection by mass spectrometry provides unequivocal 
evidence of DNA damage, which is used as a biomarker of exposure (Swenberg et al, 
2008). Levels of N7-methylguanine (N7MeG), a relatively innocuous adduct formed 
in large quantities naturally and by MNU, was quantified in AHH-1 cells following 
exposure to MNU at doses below (0.00075pg/ml) and above (0.025pg/ml) the 
NOGEL (Figure 4.6). A lack of sensitivity and biological replicates overestimated the
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levels of N7MeG in absence of MNU treatment, gave the impression of a NOGEL for 
adduct formation. However, given the statistically significant difference in mutation 
spectra between solvent control (DMSO treated) and following MNU treated 
(0.00075 pg/ml) (Figure 5.17) suggests that MNU had an effect on the DNA sequence 
at doses below the NOGEL.
7.2.4. MNU induced 0 6MeG causes GC-^ AT transitions that are increased 
above the NOGEL (Chapter 5).
Referring to chapter 5, mutation spectra analysis of HPRT mutants resulting from 
spontaneous (inferred through the solvent control), 0.0075pg/ml and 0.025pg/ml 
MNU treatments reveal significant differences in mutation induction. There was an 
increase in proportions of GC->AT transitions from 12.5% to 43.9% as the NOGEL 
was surpassed (Table 5.3). The dose-dependency of GC->AT changes was further 
emphasised using multivariate principle component analysis (PCA). 67% of the 
differences between treated spectra were GC->AT changes (Figure 5.18). GC->AT 
transitions are caused by replication over 0 6MeG, formed following MNU exposure. 
0 6MeG is stoichiometrically repaired by MGMT. At low doses of MNU, there are 
sufficient MGMT molecules per cell for successful repair, creating the NOGEL for 
mutation induction at 0.0075pg/ml MNU. At increasing concentrations of MNU, 
demand for repair exceeds the number o f MGMT molecules per cell, 0 6MeG remains 
in the DNA and causes GC->AT transitions. The data obtained in chapters 4 and 5 
shows that 0.025pg/ml induces 9.1 exogenous N7MeG adducts/108 nucleotides over 
background levels. We can infer the number of 0 6MeG adducts, which constitutes 8% 
of adducts according to the spectra of MNU. This is based on data from Beranek, 
(1990) obtained at high doses MNU exposure and so this assumed to hold true at low
o
doses. If, 69% of adducts induced were N7MeG (9.1 adducts/10 nucleotides), 8%
o /
equates to 1.1 adducts/10 nucleotides (to 1 d.p). We hypothesise that 1.1 O MeG
o
adducts/10 nucleotides are sufficient to cause MGMT inactivation in AHH-1 cells 
and contribute to a 15.8% increase in GC->AT mutations observed at 0.025pg/ml 
over the background level.
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7.2.5. MGMT protects DNA from GC-^ AT changes below the NOGEL (Chapter 
6).
Evidence is provided in chapter 6 that implicates MGMT in the protection of DNA at 
doses below the NOGEL. In the absence of MGMT, following inactivation with 
0 6BG, MNU is more mutagenic.
This is observed as:
1. A 10-fold decrease in the Lowest Observed Genotoxic Effect Level (LOGEL) 
(0.01 pg/ml compared to 0.001 pg/ml without priori inactivation) and a 
reduction in benchmark dose (BMD) (Table 6.8).
2. A 3-fold increase in MF at 0.0075pg/ml MNU in MGMT inactivated cells 
(Figure 6.19A)
3. An increase in GC->AT transitions 28.6% to 48.1% at 0.0075pg/ml MNU 
(Table 6.10)
4. An increase in the number of mutants with GC->AT transitions at
0.0075pg/ml from 50% (3/6) to 83% (10/12) (Figure 6.19B).
0 6BG did not potentiate mutagenicity of doses higher than the NOGEL 
(0.0075pg/ml). This can be explained by inactivation of MGMT by increasing 
concentrations of 0 6MeG at higher doses of MNU, which is a well-documented 
phenomenon (Daniels et al, 2000) thus rendering 0 6BG ineffective once MGMT has 
been inactivated by high dose MNU. We have found that MGMT is present at 
comparatively low levels in AHH-1 cells and its level does not increase in response to 
MNU treatment (Figure 5.26 and Figure 5.19). This is in agreement with the 
majority of published data (Fritz et al, 1991). Therefore, AHH-1 cells have a basal 
number of MGMT molecules that decrease upon repair of 0 6MeG. Replenishment is 
dependant upon a low level of constitutive expression and has been shown to require 
one cell cycle in Raji cells (Sklar et al, 1981). As a result, the levels of MGMT can 
become limited at higher concentrations of 0 6MeG at higher doses o f MNU. Thus 
accounting for the increase in MF and increase in GC->AT transitions observed. 
These main conclusions are summarised in Figure 7.1. We can reason that the level 
of MGMT in AHH-1 cells, although low, is sufficient to protect against a 10-fold 
increase in MNU concentration (from 0.00075pg/ml to the NOGEL of 0.0075pg/ml). 
It must be said that other DNA repair proteins could contribute to cellular tolerance to
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6 z
O MeG particularly MMR proteins, which have an emerging role in 0  MeG repair 
(Kaina, 2007).
1. MNU reacts with DNA
5. 0 6MeG remains in the DNA causing increased MF 
and GC*>AT transitions7.00E-05 -i
2. Forms adducts, o f  
significance is 0 6MeG
6.00E-05 -
9s 5.00E-05 -
£  4.00E-05 -
3. 0 6MeG is removed by 
MGMT-no increase in MF
LOGELg  3.00E-05 -
2.00E-05 - 4. Cellular MGMT molecules 
diminished with increased 
demand for repair
NOGEL
1.00E-05 -
0.00E+00
0 0.00075 0.001 0.0025 0.005 0.0075 0.01 0.025 0.05 0.075
MNU (fig/ml)
Figure 7.1. Representation of the conclusions of this thesis.
7.3. Linear dose-response model challenged; implications in hazard 
identification.
Dose-response modelling is an integral part of hazard identification and 
characterisation and plays critically in determining safe exposure margins (NRC, 
1983). Establishing a safe-level o f exposure requires extrapolations from high dose, 
necessary to elicit a statistically significant increase in genotoxicity over the control, 
to low doses that are relevant for human exposure levels. Various mathematical 
models exist for extrapolation to low dose. The method employed depends upon the 
mode of carcinogenic action and potency of chemical. There is an accepted distinction 
between non-genotoxic carcinogens (e.g. hormones) (and indirect genotoxins (e.g. 
aneugens)) and genotoxic carcinogens (Bolt et al, 2004). Due to the redundancy in the 
number of targets, non-genotoxins and indirect genotoxins have been shown to have 
threshold dose-responses, where extrapolations are based upon NOGELs. Genotoxic 
carcinogens (e.g. MNU), however, are thought to abide by the single hit, single target
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hypothesis, where every dose has potential to cause an adverse effect. This is 
governed by the linear (no threshold) model. As such, safe exposure margins for, 
genotoxic impurities, are determined using the As Low As Reasonably Practicable 
(ALARP) principle (Figure 7.2).
Chemical carcinogen,
causing tumors in humans and/or experimental animals
Non-genotoxicGenotoxic
DNA reactive,
causing mutations
Genotoxidty only on chromosome 
level (e.g. spindle, topoisomerase)
Clearly 
DNA-reactive 
& initiating
 i "
Borderline
cases
T
Weak genotoxin, 
secondary mecha­
nisms important
A: No threshold,
LNT model to apply
B: Situation not clear
LNT as default
Cl  Practical/apparent] Dl True/perfect 
threshold likely 1 threshold likely
Numerical risk assessment, 
technical feasibilities ?
—» ALARA principle
NOAEL
health-based exposure limit(s)
Figure 7.2. Current thinking in genotoxicology distinguishes carcinogens based on 
their MOA (non-genotoxic/genotoxic potential) as to the mathematical model for 
extrapolations to low dose. LNT=linear no threshold, ALARA=As Low As 
Reasonably Achievable, NOAEL=no observed adverse (genotoxic) effect level.
Evidence from Koana et al (2004) found a threshold for X-ray induced point 
mutation. Radiation was used as the model genotoxin, which defined the linear model. 
Together with work published from our laboratory (Doak et al, 2007), there has been 
a paradigm shift in the accepted dose-response relationship for genotoxins 
(particularly with increasing evidence using the four alkylators, as previously 
discussed). Thus having substantial implications in setting safe exposure levels for 
genotoxins with proven thresholds (Jenkins et al, 2005) (evident in Figure 7.2). 
Currently, this is assessed on a case-by-case basis, however, with the work presented 
in this thesis, it is plausible that hazards are assessed based on the adducts induced 
(Jenkins et al, 2005) and mechanism of action. Dose-response modelling has 
implications in assessment of genotoxic impurities (Figure 7.3). Genotoxic impurities
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exist throughout drug research and development e.g. EMS in Viracept* (Muller and 
Singer, 2009), food manufacturing e.g. N-nitroso compounds (MNU) in heat 
processed foods (Tricker and Preussmann, 1991) and in the environment from 
agricultural and industrial sources.
NoYes
No
Yes
No
Yes
No
Yes
YesNo
Does estimated intake 
exceed TTC* of 
' " \ 1 . 5  p g /d a y ? ^ ^
Intake level x - 
>1.5 Mg/day acceptable?
Calculate PDE* 
(NOEL/UP analysis): 
k. Safe exposure?^
^  Level as low as 
reasonably practicable?
Presence of 
genotoxic impurity 
unavoidable?
Reduce to 
safe level
No further 
action
Reduce to as 
low as reasonable 
level
Negligible risk
Use alternative 
w/o genotoxic 
impurity
Restrict or 
reject applied 
use
Negligible/
acceptable
risk
Test data indicate concern, e.g. 
Ames test positive/DNA reactive
Sufficient evidence for 
threshold-related mechanism 
of genotoxicity
Genotoxic impurity
Figure 7.3. Schematic of a decision tree to evaluate the most appropriate method to 
deal with low levels o f genotoxic impurity once ALARP has been applied. 
Abbreviations: PDE=Permitted Daily Exposure, UF=Uncertainty Factors,
TTC=Threshold of Toxicological Concern. Taken from EMEA (2006).
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As can be seen from Figure 7.3, impurities with established NOGELs are permitted at 
given concentrations. However, contaminants with insufficient evidence of a NOGEL 
are assumed to have a linear dose-response and may prevent the product from 
entering the market. While this is logical if  it was perceived to cause harm, if the 
assumption o f linearity was disproved, this may be unnecessary.
7.4. Concluding remarks.
To overcome the default linear assumption for genotoxins, there must be “convincing 
evidence to support a proposed thresholded mechanism of action” (Henderson, 2000). 
The data presented provide strong in vitro mechanistic evidence in support of a non­
linear dose-response for mutation induction by MNU, which is dependent upon repair 
of DNA adducts. While sufficient evidence is not provided to challenge the 
hypothesis o f “one molecule causes one adduct” we do challenge the latter part o f the 
theory that states “one adduct causes one mutation.” The evidence provided in this 
thesis will contribute to weight of evidence (WOE) (Kirkland, 2005) to help 
determine low dose effects of MNU. This has been performed with EMS using data 
generated from our research group (Doak et al, 2007:Zair et al, 2011) that has been 
used in conjunction with in vivo work (Muller and Singer, 2009:Muller et al, 2009) to 
draw firm conclusions on low dose EMS genotoxicity.
This thesis has clarified a robust mechanism of action for MNU induced point 
mutations that can support a non-linear dose-response.
7.5. Future Work.
For further understanding of mutation induction by MNU, the mechanism responsible 
for the reduction in MF at 0.0025pg/ml MNU needs to be elucidated. We hypothesise 
the upregulation of DNA repair enzymes involved in repair of endogenous damage. In 
addition, there is a lack of understanding of MGMT protein turnover and regulation. 
This has important implications in chemotherapy. The difficulty in administering 
alkylating agents and observing mutagenic effects is that a number of adducts are
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induced. The relative MOA of each adduct and relative repair mechanims e.g. 
N7MeG and MPG. The findings of this thesis would be strengthened if:
1. The same conclusions were found by studies using prolific expressers of 
MGMT where validation o f knockdown would be easily achievable.
2. Transfection of a MGMT expression vector (e.g. TET-on inducible system) 
into AHH-1 cells proffered increased tolerance to MNU and shifted the 
NOGEL to the right on the x-axis.
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Appendix 2:Raw HPRT data (Chapter 3).
Replicate A 6-TG (selective conditions) -6-TG (non-selective conditions)
Dose MNU  
(pg/ml)
Number of  
wells without 
colonies
Total 
number of 
wells scored
Number of 
wells 
without 
colonies
Total 
number of 
wells scored
Dilution
Factor
Mutant
Frequency
(MF)
Average
of
replicates
Standard
deviation
0 3009 3360 22 1824 0.0005 1.25E-05 1.40E-05 3.22E-06
DMSO 3052 3360 34 1920 0.0005 1.19E-05 1.40E-05 1.82E-06
0.00075 2946 3360 2 1920 0.0005 9.57E-06 1.21E-05 2.90E-06
0.001 2943 3360 3 1920 0.0005 1.03E-05 1.39E-05 3.33E-06
0.0025 3152 3360 7 1920 0.0005 5.69E-06 5.53E-06 2.20E-07
0.005 3038 3360 17 1920 0.0005 1.07E-05 8.93E-06 1.50E-06
0.0075 3000 3360 2 1920 0.0005 8.25E-06 1.05E-05 2.99E-06
0.01 2570 3360 9 1920 0.0005 2.50E-05 2.40E-05 2.98E-06
0.025 2243 3360 17 1920 0.0005 4.27E-05 3.79E-05 4.28E-06
0.05 2013 3360 6 1920 0.0005 4.44E-05 3.60E-05 7.30E-06
0.075 2522 3360 181 1920 0.0005 6.07E-05 5.15E-05 8.00E-06
Replicate B 6-TG (selective conditions) -6-TG (non-selective conditions)
Dose MNU 
(pg/ml)
Number of 
wells 
without 
colonies
Total number 
of wells scored
Number of  
wells 
without 
colonies
Total number 
o f wells scored
Dilution
Factor
Mutant
Frequency
(MF)
0 2999 3360 16 1920 0.0005 1.19E-05
DMSO 2890 3360 12 1920 0.0005 1.48E-05
0.00075 2987 3360 11 1920 0.0005 1.14E-05
0.001 2782 3360 7 1916 0.0005 1.68E-05
0.0025 3174 3360 12 1920 0.0005 5.61E-06
0.005 3116 3360 17 1920 0.0005 7.97E-06
0.0075 3004 3360 34 1916 0.0005 1.39E-05
0.01 2612 3360 16 1919 0.0005 2.63E-05
0.025 2603 3360 57 1920 0.0005 3.63E-05
0.05 2788 3360 98 1920 0.0005 3.14E-05
0.075 2571 3360 112 1920 0.0005 4.71 E-05
Replicate C 6-TG (selective conditions)
-6-TG (non-selective 
conditions)
Dose MNU 
(pg/ml)
Number 
o f wells 
without 
colonies
Total 
number of 
wells scored
Number of 
wells without 
colonies
Total 
number of  
wells 
scored
Dilution
Factor
Mutant
Frequency
(MF)
0 2995 3360 75 1920 0.0005 1.77E-05
DMSO 2936 3360 23 1920 0.0005 1.52E-05
0.00075 2885 3360 13 1920 0.0005 1.53E-05
0.001 2943 3360 20 1920 0.0005 1.45E-05
0.0025 3220 3360 34 1920 0.0005 5.28E-06
0.005 3132 3360 26 1920 0.0005 8.17E-06
0.0075 3033 3360 8 1920 0.0005 9.34E-06
0.01 2800 3360 23 1920 0.0005 2.06E-05
0.025 2722 3360 92 1920 0.0005 3.47E-05
0.05 2836 3360 138 1920 0.0005 3.22E-05
0.075 2550 3360 100 1920 0.0005 4.67E-05
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Appendix 3:Ra\v HPRT plating efficiency data (Chapter 3).
Rep A Rep B Rep C
Dose MNU 
(Mg/ml)
PE
RPE
(% ) PE
RPE
(% ) PE
RPE
(% )
Average
cell
viability
S tandard
deviation TTEST
0 441.77 109.52 478.75 94.33 324.26 73.29 92.38 18.20 0.438
Solvent control 403.37 100.00 507.52 100.00 442.46 100.00 101.96 11.89 .
0.00075 686.69 170.24 516.22 101.71 499.51 112.89 128.28 36.76 0.742
0.001 646.15 160.19 561.21 110.58 456.43 103.16 124.64 31.01 0.387
0.0025 561.42 139.18 507.52 100.00 403.37 91.17 110.12 25.56 0.013
0.005 472.69 117.18 472.69 93.14 430.20 97.23 102.52 12.87 0.073
0.0075 686.69 170.24 403.16 79.44 548.06 123.87 124.51 45.40 0.343
0.01 536.29 132.95 478.70 94.32 442.46 100.00 109.09 20.86 0.025
0.025 472.69 117.18 351.70 69.30 303.83 68.67 85.05 27.83 0.045
0.05 576.83 143.00 297.51 58.62 263.28 59.50 87.04 48.46 0.202
0.075 236.16 58.55 284.16 55.99 295.49 66.78 60.44 5.64 0.001
Appendix 4:Instructions for dose-response modeling (C hapter 3 and C hapter 6).
The following are detailed instructions detailing the statistical analyisis for does- 
response modelling perfomed on data from the HPRT assay.
Step 1. Test for differences in controls using one way AN OV A in SPSS.
1. Arrange data so that control treatments are in VAR00001 and MF in 
VAR00002
; V A R 0 0 0 0 1  V A R G 0 Q 0 2
.00
.00U ntrea ted
.00 .00
1.00 .00
Solvent
control
1.00 .00
1.00 .00
2. Click Analyze,
3. Compare means.
4. One-W ay ANOVA
5. VAR00001 in dependent list and VAR00002 in factor
6. Click OK
7. Output table opens in new window
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ANOVA
VAR00002
Sum of Squares df Mean Square F Sig.
Between Groups .000 1 .000 .004 .952
Within Groups .000 4 .000
Total .000 5
8. Sig. value >0.05 means control MF’s are not statistically significant.
9. All the control treatments can be labeled as 0 and can be used in further
analysis.
Step 2. Quadratic vs Linear fit over the entire dose-response.
1. Paste all doses in VAR00001 and corresponding MF’s in VAR00002
2. Click Analyze
3. Regression
4. Curve estimation
5. VAR00001 in variable and VAR00002 in dependent
6. Tick Linear, Quadratic and display ANOVA table
7. OK
8. Compare R values in Linear and Quadratic model summary, The model with 
greatest R value gives rough estimation that it is a better fit than the other.
Linear
Model Summary
R R Square
Adjusted R 
Square
Std. Error of 
the Estimate
.882 .779 .772 .000
The independent variable is VAROOOOl.
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Quadratic
Model Sum m ary
R R Square
Adjusted R 
Square
Std. Error of 
the Estimate
,884 .781 .766 .000
The independent variable is VAR00001.
9. For further confidence. Copy and paste into excel; AN OV A table for Linear 
and A N O V A  table for Quadratic
10. Paste required values into table as shown by colours;
A N O V A
Sum o f  Squares d f Mean Square F Sig.
Regression 000
Residual .000 31 .000
Total .000 32
The independent variable is VAR00001.
A N O V A
Sum o f  Squares d f Mean Square F Sig.
Regression .0 0 0 2 .0 0 0 L 4 8 9 .000
Residual .000 30 .000
Total .000 32
The independent variable is VAR00001.
A B C D E F G
Sum o f  Squares df Mean Square F Sig.
Quadratic Regression .000 2 .000 53.489 .000
Linear Regression .000 1 .000 109.059 .000
R2 change 0 .000000000016944398 1 1.69444E-I 1 0.31790188 0.0177062233
Residual .000 30 .000
Where;
C4=C2 minus C3 
D4=D2 minus D3
E4=C4 divided by D4 
F4=E4 divided by E5 
G4=Fdist(F4,D4,D5)
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If G4=<0.05 then null hypothesis of linearity is rejected and Quadratic is the best fit.
Step 3. If Quadratic, identify NOEL/LOEL by Dunnet’s in SPSS.
1. Set up data as for step 2 in SPSS
2. Click transform
3. Click compute variable
4. Type “Log” into Target variable
5. “Function group”: click Arithmetic
6. “Functions and Special variables”: double click LglO
7. Move VAR0002 to replace “?” in LG10(?) giving LG10(VAR00002) in 
“Numeric expression.
8. Log appears in column next to VAR00002
9. Repeat but type Log05 into target variable and type “+05” this appears in 
column next to log
10. Click analyze
11. Compare means
12. One-way Anova
13. VAR00001 in Factor, VAR00002, Log and Log05 in Depedent list
14. Click Post Hoc...
15. Tick Dunnett
16. Control category:first
17. Test click >control
18. Continue
19. OK
20. Output table opens in new window
21. Identify LOEL as lowest dose with Sig. <0.05 and NOEL as the dose below 
that. Ensure they are the same for VAR00002, Lohg and Log05 (test o f 
normality) if they do not correspond the data is not normally distributed and 
the assumed Poisson distribution is incorrect.
Step 4. Test linear vs quadratic best of fit below NOEL.
1. Repeat step 2 but only include NOEL and below doses for testing.
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Calculating the gradients 95% confidence limits.
1. In coefficients table, under quadratic from SPSS output;
A B C D E F
Coefficients
Standardized
U nstandardized C oefficients C oefficients
B Std. Error Beta t S , l:
1 VAROOOOl -.001 .000 -.503 -2.535 .0 2 0
2 (Constant) .000 .000 12.153 .000
2. Gradient o f  the slope is given in 1B.
3. 95% confidence limits = 1C x 1.96
4. lower limit = 1 B-95% Cl
5. Upper limit = 1 B+95% Cl.
Appendix 5 :Raw N7MeG adduct levels.
..............
Dose
MNU
(pg/ml)
Amount  
DNA 
yield 
used (pg)
Amount
adduct
detected
(fmol)
Number of 
adducts/l()s 
nucleotides
Amount  
DNA yield 
used (pg)
Amount
adduct
detected
(fmol)
Number of  
adducts/108 
nucleotides
DMSO 53.42 27.08 15.65 52.32 35.32 20.83
0.00075 53.03 38.37 22.33 60.84 26.80 13.60
0.025 46.13 47.12 31.52 49.31 37.07 23.20
Appendix 6:Raw sequence data (C hapter 5).
Due to the large num ber o f  pages required, the raw mutation spectra, data and 
instructions for analysis, are available at w w w .dropbox.com .
Using the login details:
Email:hprtseq@ hotmail. co.uk.
Password :HPRTSeq.
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Appendix 7: Coding for Principle component analysis (Chapter 5).
1. Save data as “name’\tx t file in the following format;
Nucleotide Sum of Sum of substitutions Sum of
sequence substitutions at at each nucleotide substitutions at
each nucleotide spectrum each nucleotide
spectrum 1 
(Opg/ml)
2(0.00075pg/ml) spectrum 3 
(0.025pg/ml)
2. In R,File->change d irec to rychoose  file where data is saved.
3. Type:
dat<-read.table('data.txt', header=T, row.names=l)
pca<-prcomp(t(dat))
summary (pea)
This brings up the following output and allows user to identify the number of 
components and their importance in explaining the data:
Importance o f components:
PCI PC2 PC3
Standard deviation 40.8948 13.9386 1.325e-13
Proportion of Variance 0.8959 0.1041 0.000e+00
Cumulative Proportion 0.8959 1.0000 1.000e+00
For construction of Scatter plots:
4. Type:
plot(pca$rotation[, 1 ], pca$rotation[,2],col-white') 
text(pca$rotation[,l], pca$rotation[,2], row.names(dat), cex=0.7)
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Appendix 8:Raw real time data (Chapter 5).
1 hour post MNU treatment.
Rep A
Dose
(pg/ml)
Mean MGMT  
Ct
Mean TBP 
Ct ACt AACt
Fold
change Average
Standard
deviation
DMSO 33.37 22.07 11.30 0.00 1.00 1.14 0.28
0.00000 33.57 21.89 11.68 -0.37 1.30 1.44 0.49
0.00075 33.84 22.77 11.07 -0.24 1.18 1.05 0.27
0.00750 33.99 22.64 11.35 0.05 0.97 0.66 0.42
0.01000 33.94 22.15 11.80 0.49 0.71 0.81 0.26
0.05000 33.84 22.23 11.61 0.31 0.81 1.31 0.46
Rep B
Dose Mean MGMT Mean TBP
ACt AACt Fold(Pg/ml) Ct Ct change
DMSO 34.11 22.26 11.85 -0.55 1.46
0 34.33 21.49 12.85 -0.99 1.99
0.00075 34.02 21.74 12.29 0.43 0.74
0.0075 36.09 21.79 14.30 2.45 0.18
0.01 34.44 21.87 12.57 0.72 0.61
0.05 32.97 21.89 11.08 -0.77 1.71
Rep C
Dose
(pg/ml)
Mean MGMT 
Ct
Mean TBP 
Ct ACt AACt
Fold
change
DMSO 33.49 22.24 11.24 0.06 0.96
0 33.31 22.02 11.29 -0.05 1.03
0.00075 33.29 22.35 10.94 -0.30 1.23
0.0075 33.75 22.22 11.53 0.28 0.82
0.01 33.21 22.11 11.09 -0.15 1.11
0.05 32.95 22.21 10.74 -0.50 1.42
4hr post MNU treatment.
Rep A
Dose
(pg/ml)
Mean 
MGMT Ct
Mean TBP 
Ct ACt AACt
Fold
change Average
Standard
deviation
DMSO 36.34 19.09 17.25 2.12 0.23 2.45 1.96
0 34.67 19.54 15.13 -2.12 4.35 2.19 1.87
0.00075 37.91 19.64 18.27 1.02 0.49 1.05 1.04
0.0075 34.69 19.30 15.39 -1.86 3.64 2.85 0.85
0.01 33.86 19.30 14.57 -2.69 6.44 3.50 2.72
0.05 33.18 18.13 15.06 -2.20 4.58 3.31 1.14
Rep B
Dose
(pg/ml)
Mean 
MGMT Ct
Mean TBP 
Ct ACt AACt
Fold
change
DMSO 35.25 19.67 15.58 -1.67 3.19
0 34.67 19.15 15.52 -0.06 1.04
0.00075 35.86 19.01 16.86 1.28 0.41
0.0075 33.51 18.89 14.62 -0.96 1.95
0.01 32.96 18.96 14.00 -1.58 3.00
0.05 33.46 19.12 14.33 -1.25 2.37
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Rep C
Dose
(pg/ml)
Mean 
MGMT Ct
Mean TBP 
Ct ACt AACt
Fold
change
DMSO 34.42 19.14 15.28 -1.97 3.93
0 34.18 19.14 15.04 -0.24 1.18
0.00075 33.25 19.14 14.11 -1.17 2.25
0.0075 32.85 19.14 13.71 -1.57 2.97
0.01 34.32 19.14 15.18 -0.10 1.07
0.05 32.85 19.14 13.71 -1.57 2.97
6 hour post MNU treatment.
Rep A
Dose
(pg/ml)
Mean 
MGMT Ct
Mean TBP 
Ct ACt AACt
Fold
change Average
Standard
deviation
DMSO 33.37 20.90 12.47 0.00 1.00 1.11 0.40
0 36.17 21.03 15.14 2.67 0.16 0.62 0.40
0.00075 34.50 21.76 12.74 0.28 0.83 1.07 0.53
0.0075 34.12 21.50 12.62 0.16 0.90 0.87 0.11
0.01 34.19 21.13 13.06 0.59 0.66 1.09 0.37
0.05 33.52 21.45 12.08 -0.39 1.31 1.36 0.10
Rep B
Dose
(pg/ml)
Mean 
MGMT Ct
Mean TBP 
Ct
ACt AACt Fold
change
DMSO 34.42 21.57 12.85 0.38 0.77
0 34.67 21.52 13.15 0.30 0.81
0.00075 33.05 20.95 12.10 -0.75 1.68
0.0075 34.31 21.06 13.25 0.40 0.76
0.01 33.61 21.08 12.53 -0.32 1.24
0.05 33.76 21.47 12.29 -0.56 1.48
Rep C
Dose
(pg/ml)
Mean 
MGMT Ct
Mean TBP 
Ct ACt AACt
Fold
change
DMSO 33.76 21.93 11.83 -0.63 1.55
0 33.83 21.82 12.02 0.19 0.88
0.00075 34.14 21.79 12.35 0.51 0.70
0.0075 34.05 22.17 11.87 0.04 0.97
0.01 33.62 22.22 11.40 -0.43 1.35
0.05 33.33 21.88 11.45 -0.38 1.30
24hour post MNU treatment
Rep A
Dose
(pg/ml)
Mean 
M GMT Ct
Mean TBP 
Ct ACt AACt
Fold
change Average
Standard
deviation
DMSO 34.52 21.65 12.88 -0.22 1.17 1.18 0.12
0 34.06 20.96 13.10 0.22 0.86 0.69 0.16
0.00075 35.07 22.28 12.79 -0.08 1.06 1.58 0.46
0.0075 34.03 21.77 12.26 -0.61 1.53 1.11 0.37
0.01 34.08 21.21 12.87 -0.01 1.01 0.92 0.13
0.05 33.53 21.65 11.88 -0.99 1.99 1.61 0.57
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Rep B
Dose
(jig/ml)
Mean 
MGMT Ct
Mean TBP 
Ct ACt AACt
Fold
change
DMSO 34.60 21.82 12.78 -0.09 1.07
0 34.80 21.11 13.68 0.90 0.54
0.00075 33.74 21.76 11.99 -0.79 1.73
0.0075 34.21 21.42 12.79 0.01 1.00
0.01 34.38 21.58 12.81 0.02 0.98
0.05 33.53 21.65 11.88 -0.90 1.87
Rep C
Dose
(Pg/ml)
Mean 
MGMT Ct
Mean TBP 
Ct ACt AACt
Fold
change
DMSO 33.72 21.22 12.50 -0.38 1.30
0 34.24 21.20 13.04 0.54 0.69
0.00075 33.52 21.97 11.55 -0.95 1.94
0.0075 34.31 21.51 12.80 0.30 0.81
0.01 34.08 21.21 12.87 0.37 0.77
0.05 34.00 21.43 12.56 0.06 0.96
235
Appendix 9: Real time PCR statistics (Chapter 5).
Statistics on Delta Ct values.
Calculated using the formula;
=TTEST(DMSOrepA:C,TREATMENTrepA:C,2,2)
1 h r A C t R e p  A A C t R e p  B A C t R e p  C TTEST
D M S O 11.30 11.24 11.85
0 11.68 11.29 12.85 0.40
0 .00 0 7 5 11.07 10.94 12.29 0.94
0 .0075 11.35 11.53 14.30 0.40
0.01 11.80 11.09 12.57 0.49
0.05 11.61 10.74 11.08 0.37
4 h r A C t R e p  A A C t R e p  B A C t R e p  C TTEST
D M SO 17.25 15.58 15.28
0 15.13 15.52 15.04 0 .27
0 .00075 18.27 16.86 14.11 0 .80
0 .0075 15.39 14.62 13.71 0.13
0.01 16.57 14.00 15.18 0 .46
0.05 15.06 14.33 13.71 0 .08
6 h r A C t R e p  A A C t R e p  B A C t R e p  C TTEST
D M SO 12.47 12.85 11.83
0 15.14 13.15 12.02 0.33
0 .00075 12.74 12.10 12.35 0 .97
0 .0075 12.62 13.25 11.87 0.71
0.01 13.06 12.53 11.40 0.93
0.05 12.08 12.29 11.45 0 .32
2 4 h r A C t R e p  A A C t R e p  B A C t R e p  C TTEST
D M SO 12.88 12.78 12.50
0 13.10 13.68 13.04 0 .08
0 .00075 12.79 11.99 11.55 0 .19
0.0075 12.26 12.79 12.80 0.65
0.01 12.87 12.81 12.87 0.33
0.05 11.88 11.88 12.56 0 .07
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Appendix 10:Raw data for real time validation of siRNA.
R e p  A
T r e a tm e n t
C t
G A P D H
C t
T B P
A C t A A C t
F o ld
c h a n g e
A v e ra g e
fo ld
c h a n g e
S ta n d a r d
d e v ia t io n
Untreated control 21.62 21.12 0.50 0.00 1.00 1.02 0.03
0.6pmol o f siRNA 0.5pl 
Lipofectamine
22.15 21.00 1.15 0.65 0.64 0.65 0.02
0.6pmol of siRNA 1.5pl 
Lipofectamine
20.53 20.99 -0.46 -0.96 1.94 1.98 0.16
5pmol o f siRNA 0.5pl 
Lipofectamine
18.99 19.15 -0.16 -0.66 1.58 1.60 0.04
5pmol o f siRNA 1.25pl 
Lipofectamine
20.86 21.38 -0.52 -1.02 2.02 2.38 0.43
lOpmol o f siRNA 1 pi 
Lipofectamine
20.42 20.55 -0.13 -0.63 1.55 1.38 0.15
20pmol o f siRNA 1.5jil 
Lipofectamine
21.93 20.34 1.59 1.09 0.47 0.36 0.09
30pmol o f siRNA 0.5pl 
Lipofectamine
22.24 20.95 1.29 0.79 0.58 0.56 0.02
30pmol o f siRNA 1.5pl 
Lipofectamine
19.94 21.64 -1.70 -2.20 4.61 2.24 2.07
R e p  B
T r e a tm e n t
C t
G A P D H
C t
T B P
A C t A A C t F o ld
c h a n g e
Untreated control 21.62 21.20 0.42 -0.08 1.05
0.6pmol o f siRNA 0.5pl Lipofectamine 22.06 20.99 1.07 0.65 0.64
0.6pmol o f siRNA 1.5pl Lipofectamine 20.52 20.98 -0.46 -0.88 1.85
5pmol o f siRNA 0.5pl Lipofectamine 19.86 20.09 -0.23 -0.65 1.57
5pmol o f siRNA 1.25pl Lipofectamine 20.78 21.87 -1.09 -1.52 2.86
lOpmol o f siRNA Ipl Lipofectamine 20.61 20.54 0.07 -0.36 1.28
20pmol of siRNA 1.5(0.1 Lipofectamine 22.10 19.99 2.11 1.69 0.31
30pmol of siRNA 0.5pl Lipofectamine 22.31 21.01 1.30 0.88 0.54
30pmol of siRNA 1.5pl Lipofectamine 20.89 20.00 0.89 0.46 0.73
R e p  C
T r e a tm e n t
C t
G A P D H
C t
T B P
A C t A A C t F o ld
c h a n g e
Untreated control 21.66 21.16 0.50 -0.01 1.00
0.6pmol of siRNA 0.5pl Lipofectamine 22.06 21.01 1.05 0.56 0.68
0.6pmol of siRNA 1.5pl Lipofectamine 20.49 21.11 -0.62 -1.11 2.16
5pmol o f siRNA 0.5pl Lipofectamine 18.77 19.00 -0.23 -0.72 1.65
5pmol o f siRNA 1.25pl Lipofectamine 20.99 21.68 -0.69 -1.18 2.27
lOpmol o f siRNA lp l Lipofectamine 20.73 20.61 0.12 -0.38 1.30
20pmol o f siRNA 1.5pl Lipofectamine 22.22 20.01 2.21 1.72 0.30
30pmol o f siRNA 0.5pl Lipofectamine 22.28 20.98 1.30 0.81 0.57
30pmol of siRNA 1.5pl Lipofectamine 19.04 19.03 0.01 -0.49 1.40
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R e p  A
T r e a tm e n t
C t C t
A C t A A C t
F o ld
A v e ra g e
fo ld
c h a n g e
S ta n d a r d
G A P D H T B P c h a n g e d e v ia t io n
Untreated control 16.84 19.82 -2.97 0.00 1.00 1.06 0.06
0.6pmol o f siRNA 2pl Lipofectamine 16.90 20.36 -3.46 -0.49 1.40 1.21 0.19
0.6pmol o f siRNA 4pl Lipofectamine 16.87 19.73 -2.86 0.11 0.93 0.97 0.08
5pmol o f siRNA 3pl Lipofectamine 17.34 19.15 -1.81 1.16 0.45 0.44 0.02
lOpmol o f siRNA 4pl Lipofectamine 17.62 18.33 -0.71 2.26 0.21 0.34 0.22
lOpmol o f siRNA lp l Lipofectamine 17.99 20.10 -2.11 0.86 0.55 0.66 0.16
20pmol o f siRNA 3 pi Lipofectamine 17.87 19.75 -1.87 1.10 0.47 0.40 0.07
20pmol o f siRNA 5 pi Lipofectamine 18.64 19.15 -0.50 2.47 0.18 0.20 0.05
30pmol o f siRNA 2pl Lipofectamine 17.24 18.46 -1.22 1.76 0.30 0.25 0.04
30pmol o f siRNA 5pl Lipofectamine 16.90 19.10 -2.20 0.78 0.58 0.52 0.07
R e p  B
T r e a tm e n t
C t C t A C t A A C t F o ld
G A P D H T B P c h a n g e
Untreated control 16.89 19.95 -3.06 -0.08 1.06
0.6pmol o f siRNA 2pl Lipofectamine 16.89 19.97 -3.08 -0.02 1.02
0.6pmol o f siRNA 4pl Lipofectamine 16.81 19.95 -3.14 -0.08 1.06
5pmol o f siRNA 3pl Lipofectamine 17.19 18.99 -1.80 1.26 0.42
lOpmol o f siRNA 4pl Lipofectamine 17.56 18.46 -0.91 2.15 0.23
lOpmol o f siRNA lp l Lipofectamine 17.72 20.00 -2.28 0.78 0.58
20pmol o f siRNA 3 pi Lipofectamine 18.08 19.82 -1.74 1.32 0.40
20pmol o f siRNA 5pl Lipofectamine 18.67 19.19 -0.51 2.54 0.17
30pmol o f siRNA 2pl Lipofectamine 17.38 18.24 -0.86 2.20 0.22
30pmol o f siRNA 5pl Lipofectamine 16.94 19.09 -2.15 0.91 0.53
R e p  C
T r e a tm e n t
C t
G A P D H
C t
T B P
A C t A A C t F o ld
c h a n g e
Untreated control 16.98 20.11 -3.13 -0.16 1.12
0.6pmol o f siRNA 2pl Lipofectamine 16.91 20.34 -3.42 -0.29 1.22
0.6pmol o f siRNA 4pl Lipofectamine 16.76 19.78 -3.02 0.12 0.92
5pmol o f siRNA 3pl Lipofectamine 17.21 19.17 -1.96 1.17 0.44
lOpmol o f siRNA 4pl Lipofectamine 17.73 20.10 -2.37 0.76 0.59
lOpmol o f siRNA lp l Lipofectamine 17.78 20.68 -2.90 0.24 0.85
20pmol o f siRNA 3pi Lipofectamine 18.11 19.65 -1.54 1.59 0.33
20pmol o f siRNA 5pl Lipofectamine 18.84 20.00 -1.16 1.97 0.26
30pmol o f siRNA 2pl Lipofectamine 17.31 18.33 -1.02 2.11 0.23
30pmol o f siRNA 5pl Lipofectamine 17.10 19.10 -2.00 1.14 0.45
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R e p  A
T r e a tm e n t
C t
G A P
D H
C t
T B P A C t A A C t
F o ld
c h a n g e
A v e ra g  
e fo ld  
c h a n g e
S ta n d a r d
d e v ia t io n
Untreated control 33.64 19.29 14.35 0.00 1.00 0.89 0.12
0.6pmol each siRNA 2pl 
Lipofectamine 33.13 19.11 14.02 -0.33 1.26 1.38 0.14
0.6pmol each siRNA 4pl 
Lipofectamine 33.86 19.62 14.24 -0.12 1.08 1.24 0.17
5pmol each siRNA 3pi Lipofectamine 33.68 19.61 14.08 -0.28 1.21 1.22 0.08
5pmol each siRNA 5pl Lipofectamine 33.85 20.19 13.67 -0.69 1.61 1.21 0.37
lOpmol each siRNA 4pl Lipofectamine N/A 22.17 _ _ _ _
20pmol each siRNA 1.5pl 
Lipofectamine N/A 23.62
20pmol each siRNA 3pi Lipofectamine N/A 24.40 _ _ - .
30pmol each siRNA 2pl Lipofectamine 34.01 20.38 13.63 -0.04 1.03 _
30pmol each siRNA 5pl Lipofectamine 33.86 19.18 14.68 _ _ - -
50pmol each siRNA 4pl Lipofectamine N/A 23.70 _ _ .
R e p  B
T r e a tm e n t
C t
G A P D H C t  T B P A C t A A C t F o ld  c h a n g e
Untreated control 3 3 .94 19.19 14.74 0 .39 0 .76
0.6pmol each siRNA 2pl Lipofectamine 33.19 19.07 14.12 -0.62 1.54
0.6pmol each siRNA 4pl Lipofectamine 34.07 19.61 14.45 -0.29 1.22
5pmol each siRNA 3pl Lipofectamine 34.22 19.67 14.54 -0.20 1.15
5pmol each siRNA 5pl Lipofectamine 34.73 19.81 14.92 0.18 0.88
lOpmol each siRNA 4pl Lipofectamine 34.79 20.70 14.09 -0.65 1.57
20pmol each siRNA 1.5pl Lipofectamine N/A 23.43 _ _ .
20pmol each siRNA 3pi Lipofectamine N/A 23.34 _ _ .
30pmol each siRNA 2pl Lipofectamine N/A 24.53 _ _
30pmol each siRNA 5pl Lipofectamine N/A 25.19 - - -
50pmol each siRNA 4pl Lipofectamine 34.81 19.76 15.05 - -
R e p  C
T r e a tm e n t
C t
G A P D H C t  T B P A C t A A C t F o ld  c h a n g e
Untreated control 3 4 .2 6 19.39 14.87 0 .13 0.91
0.6pmol each siRNA 2pl Lipofectamine 33.51 19.09 14.43 -0.44 1.36
0.6pmol each siRNA 4pl Lipofectamine 34.14 19.78 14.36 -0.51 1.42
5pmol each siRNA 3pl Lipofectamine 34.07 19.58 14.49 -0.38 1.30
5pmol each siRNA 5pl Lipofectamine 34.72 20.04 14.68 -0.19 1.14
lOpmol each siRNA 4pl Lipofectamine N/A 19.86 14.48 -0.39 1.31
20pmol each siRNA 1.5pl Lipofectamine 34.34 20.58 _ _ _
20pmol each siRNA 3pi Lipofectamine N/A 23.50 _ . .
30pmol each siRNA 2pl Lipofectamine N/A 23.26 . .
30pmol each siRNA 5pl Lipofectamine N/A 25.04 . . _
50pmol each siRNA 4pl Lipofectamine N/A 24.68 - - -
239
Appendix ll:R aw  relative population doubling data + /-0 6BG (Chapter 6).
B a s e lin e  =  2 4 0 0 0 0  ce lls .
M N U  - 0 6B G  24  R e p  A
D o se  (p g /m l) N u m b e r  o f  ce lls P o p u la t io n  d o u b l in g  (P D ) R P D  ( % )
0 520000 1.12 105.34
D M S O 500000 1.06 100.00
0 .0 0 0 7 5 528000 1.14 107.42
0.001 461 8 0 0 0 .94 8 9 .17
0 .05 451 6 0 0 0.91 86.13
M N U -0 6 B G  2 4 h r  R ep B
D o se  (p g /m l) N u m b e r  o f  ce lls P o p u la t io n  d o u b l in g  (P D ) R P D  ( % )
0 513800 1.10 99 .59
D M S O 515400 1.10 100.00
0 .0 0 0 7 5 484 6 0 0 1.01 9 1 .94
0.001 475 0 0 0 0 .98 89 .32
0 .05 4 7 3 4 0 0 0 .98 88.88
M N U  - 0 6B G  48 R e p  A
D o se  (p g /m l) N u m b e r  o f  cells P o p u la t io n  d o u b l in g  (P D ) R P D  ( % )
0 870000 1.86 102.12
D M S O 847000 1.82 100.00
0 .0 0 0 7 5 712200 1.57 86.25
0.001 737600 1.62 89.03
0 .05 711000 1.57 86 .12
M N U -0 6 B G  4 8 h r  R ep  B
D o se  (p g /m l) N u m b e r  o f  ce lls P o p u la tio n  d o u b l in g  (P D ) R P D  ( % )
0 722200 1.59 100.61
D M S O 717400 1.58 100.00
0 .00 0 7 5 651 0 0 0 1.44 91.13
0.001 629 7 0 0 1.39 88 .09
0 .05 625 0 0 0 1.38 87.41
M N U  + 0 6B G  24 R e p  A
D o se  (p g /m l) N u m b e r  o f  ce lls P o p u la t io n  d o u b l in g  (P D ) R P D  ( % )
0 6 B G -M N U 500000 1.06 96 .87
0 6 B G + D M S O 567600 1.24 120.60
0 .00075 4 8 7 4 0 0 1.02 99 .25
0.001 439 0 0 0 0 .87 84 .60
0.05 435 8 0 0 0 .86 83 .58
M E T H + D M S O 490 0 0 0 1.03 100.00
M ethano l 512000 1.09 106.15
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M N U + 0 6 B G 2 4  R epB
D o se  (p g /m l) N u m b e r  o f  ce lls P o p u la t io n  d o u b l in g  (P D ) R P D  ( % )
0 6 B G -M N U 500000 1.06 100.83
0 6 B G + D M S 0 489200 1.03 94 .33
0 .0 0 0 7 5 469 6 0 0 0.97 88.91
0.001 442 6 0 0 0.88 81 .07
0 .05 446800 0.90 82.32
M E T H + D M S O 510600 1.09 100.00
M e th an o l 497000 1.05 96 .42
M N U  + 0 6B G  48 R ep  A
D o se  (p g /m l) N u m b e r  o f  ce lls P o p u la t io n  d o u b l in g  (P D ) R P D  ( % )
0 6 B G -M N U 819 0 0 0 1.77 103.14
0 6 B G + D M S O 741000 1.63 92 .68
0 .00 0 7 5 609400 1.34 76.61
0.001 662000 1.46 83.41
0 .05 694 0 0 0 1.53 87 .29
M E T H + D M S O 810000 1.75 100.00
M eth an o l 789000 1.72 97 .84
M N U  + 0 6B G  48 B
D o se  (p g /m l) N u m b e r  o f  ce lls P o p u la t io n  d o u b l in g  (P D ) R P D  ( % )
0 6 B G -M N U 760 0 0 0 1.66 100.23
0 6 B G + D M S O 744 0 0 0 1.63 100.72
0 .00 0 7 5 724 6 0 0 1.59 98 .37
0.001 596 8 0 0 1.31 81 .09
0 .05 560400 1.22 75 .49
M E T H + D M S O 738 0 0 0 1.62 100.00
M eth an o l 758 0 0 0 1.66 102.38
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Baseline=262500 cells.
M N U  - 0 6 B G  R e i) A  2 4 h r c o u n t
D ose  (p g /m l) N u m b e r  o f  cells P o p u la tio n  d o u b lin g  (P D )
R P D
( % )
M eth + D M S O 660 0 0 0 1.33 100.00
2 4 5 5 0 0 0 0 .79 59 .66
4 4 7 0 0 0 0 0 .84 63.18
6 340 0 0 0 0 .37 28 .06
8 350 0 0 0 0.42 31 .20
10 2 5 5 0 0 0 -0 .04 -3 .14
M N U  - 0 6 B G  R e ij B  2 4 h r c o u n t
D ose  (p g /m l) N u m b e r  o f  ce lls P o p u la t io n  d o u b lin g  (P D )
R P D
( % )
M eth + D M S O 4 7 5 0 0 0 1.03 100.00
2 3750 0 0 0 .69 66 .79
4 400 0 0 0 0 .78 75.85
6 266 0 0 0 0 .19 18.54
8 246 0 0 0 0 .08 7.55
10 260 0 0 0 0 .16 15.33
M N U  - 0 6 B G  48  R e p  A
D ose (p g /m l) N u m b e r  o f  cells P o p u la tio n  d o u b lin g  (P D )
R P D
( % )
M eth+ D M S O 825000 1.82 100.00
2 4 5 5 0 0 0 0 .96 52.91
4 3 15 0 0 0 0.43 23.82
6 320 0 0 0 0 .46 25 .06
8 2 6 0 0 0 0 0 .16 8.63
10 2 4 0 0 0 0 0.04 2 .30
M N U  - 0 6 B G  48  R e p  B
D ose (p g /m l) N u m b e r  o f  cells P o p u la t io n  d o u b l in g  (P D )
R P D
( % )
M eth+ D M S O 750 0 0 0 1.51 100.00
2 387 5 0 0 0 .56 37 .10
4 305 0 0 0 0.22 14.29
6 310 0 0 0 0 .24 15.84
8 2 9 0 0 0 0 0 .14 9 .49
10 2 5 0 0 0 0 -0 .07 -4 .65
M N U  + 0 6 B G  R e p  A 2 4 h r  p o s t  t r e a tm e n t
D ose (p g /m l) N u m b e r  o f  cells P o p u la t io n  d o u b l in g  (P D ) R P D  ( % )
M eth+ D M S O 380000 0 .70 100.00
2 305000 0 .39 55 .00
4 265 0 0 0 0 .18 26.23
6 180000 -0 .37 -52 .93
8 150000 -0 .64 -90 .25
10 190000 -0 .30 -4 1 .8 6
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M N U  + 0 6 B G  R e p  B 2 4 h r  p o s t  t r e a tm e n t
D o se  (p g /m l) N u m b e r  o f  cells P o p u la t io n  d o u b lin g  (P D ) R P D  ( % )
M e th + D M S O 4800 0 0 1.04 100.00
2 300000 0 .36 34 .92
4 3 30 0 0 0 0 .50 4 8 .1 2
6 175000 -0.41 -39.71
8 150000 -0 .64 -61 .05
10 150000 -0 .64 -61 .05
M N U  + 0 6 B G  4 8 R e p  A
D o se  (p g /m l) N u m b e r  o f  ce lls P o p u la t io n  d o u b l in g  (P D ) R P D  ( % )
M e th + D M S O 7 80 0 0 0 1.57 100.00
2 2 5 0 0 0 0 -0 .07 -4 .48
4 190000 -0 .47 -2 9 .6 8
6 157500 -0 .74 -46.91
8 110000 -1 .25 -7 9 .8 7
10 100000 -1 .39 -88 .62
M N U  + 0 6 B G  4 8  R e p  B
D o se  (jug/m l) N u m b e r  o f  ce lls P o p u la t io n  d o u b lin g  (P D ) R P D  ( % )
M e th + D M S O 740000 1.50 100.00
2 2250 0 0 -0 .22 -1 4 .8 7
4 145000 -0 .86 -5 7 .2 7
6 135000 -0 .96 -6 4 .1 6
8 105000 -1 .32 -88.41
10 75 0 0 0 -1.81 -120 .8 8
Appendix 12:Raw HPRT data (Chapter 6).
R e p lic a te  A
6 -T G  (se lec tiv e  
c o n d it io n s )
-6 -T G  (n o n -  
se lec tiv e  
c o n d it io n s )
D o se  M N U  
O ig /m l)
N u m b e r  
o f  w ells 
w ith o u t 
co lo n ie s
T o ta l  
n u m b e r  
o f  w e lls  
sc o re d
N u m b e r  
o f  w ells  
w ith o u t  
co lo n ie s
T o ta l  
n u m b e r  
o f  w ells 
sc o re d
D ilu tio n
F a c to r
M u ta n t
F re q u e n c y
(M F )
A v e ra g e
o f
re p l ic a te s
S ta n d a r d
d e v ia tio n
0 560 600 3 480 0 .0005 6 .8 0 E -0 6 1.00E -05 7 .8 2 E -0 6
M e th + D M S O 544 6 00 4 480 0 .0005 1.02E -05 1.49E -05 5 .8 5 E -0 6
D M S O 567 600 4 480 0.0005 5 .9 1 E -0 6 1 .33E -05 1 .05E -05
M eth 512 600 4 480 0 .0005 1.66E -05 1 .86E -05 3 .5 5 E -0 6
0 .0 0 0 7 5 457 600 4 480 0 .0005 2 .84E -05 1 .36E -05 1.28E -05
0.001 385 600 7 480 0 .0005 5 .25E -05 2 .9 5 E -0 5 2 .0 0 E -0 5
0 .0025 427 600 12 480 0 .0005 4.61 E -05 3 .10E -05 1 .33E -05
0.005 419 600 14 480 0 .0005 5.08E -05 3 .29E -05 1.70E -05
0 .0075 381 600 7 480 0 .0005 5 .37E -05 3 .6 2 E -0 5 1 .60E -05
0.01 496 600 19 480 0 .0005 2 .9 5 E -0 5 3 .01E -05 1 .76E -05
0.025 501 600 12 480 0 .0005 2 .44E -05 3 .15E -05 2 .8 1 E -0 5
0.05 448 600 23 480 0 .0005 4.81 E -05 4 .83E -05 1 .95E -05
0.075 341 600 8 480 0.0005 6 .90E -05 4 .5 6 E -0 5 2.11 E -05
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R e p  B
6 -T G  (se lec tiv e  
c o n d it io n s )
-6 -T G  (n o n -  
se lec tiv e  
c o n d it io n s )
D o se  M N U  
(H g/m l)
N u m b e r  
o f  w e lls  
w ith o u t  
c o lo n ie s
T o ta l  
n u m b e r  
o f  w ells 
sc o re d
N u m b e r  
o f  w e lls  
w ith o u t  
co lo n ie s
T o ta l  
n u m b e r  
o f  w ells 
sc o re d
D ilu tio n
F a c to r
M u ta n t
F re q u e n c y
(M F )
0 572 600 2 480 0.0005 4 .3 6 E -0 6
M e th + D M S O 552 600 20 480 0.0005 1.31 E -05
D M S O 563 600 12 480 0 .0005 8 .6 3 E -0 6
M E T H 548 600 31 480 0 .0005 1 .65E -05
0 .00075 563 600 3 480 0 .0005 6 .2 7 E -0 6
0.001 468 600 1 480 0 .0005 2.01 E -05
0 .0025 452 600 2 480 0 .0005 2 .5 8 E -0 5
0 .005 505 600 3 480 0 .0005 1 .70E -05
0 .0075 431 600 3 480 0 .0005 3 .2 6 E -0 5
0.01 542 600 9 480 0 .0005 1 .28E -05
0 .025 567 600 11 480 0 .0005 7 .4 9 E -0 6
0 .05 331 600 6 480 0 .0005 6 .7 9 E -0 5
0 .075 538 600 68 480 0 .0005 2 .7 9 E -0 5
R e p  C
6 -T G  (se lec tiv e  
c o n d it io n s )
-6 -T G  (n o n -  
se lec tiv e  
c o n d it io n s )
D o se  M N U  
(H g/m l)
N u m b e r  
o f  w ells 
w ith o u t  
c o lo n ie s
T o ta l  
n u m b e r  
o f  w ells 
sc o re d
N u m b e r  
o f  w ells 
w ith o u t  
c o lo n ie s
T o ta l  
n u m b e r  
o f  w ells 
sc o re d
D ilu tio n
F a c to r
M u ta n t
F re q u e n c y
(M F )
0 516 600 9 480 0 .0005 1 .90E -05
M e th + D M S O 531 600 28 480 0 .0005 2 .1 5 E -0 5
D M SO 540 600 60 480 0.0005 2 .5 3 E -0 5
M eth 536 600 40 480 0.0005 2 .2 7 E -0 5
0 .00075 576 600 17 480 0 .0005 6.1 IE -0 6
0.001 510 600 3 480 0.0005 1 .60E -05
0 .0025 528 600 23 477 0.0005 2.11 E -05
0.005 527 600 59 480 0.0005 3 .09E -05
0.0075 478 600 3 480 0 .0005 2 .2 4 E -0 5
0.01 529 600 129 480 0.0005 4 .7 9 E -0 5
0.025 494 6 00 101 479 0.0005 6 .2 4 E -0 5
0.05 547 600 97 480 0.0005 2 .8 9 E -0 5
0.075 495 6 00 43 480 0.0005 3 .9 9 E -0 5
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Appendix 13:Raw HPRT plating efficiency data.
R e p  A R e p  B R e p  C
D o se  M N U  
(p g /m l)
P E
R P E
(% ) P E
R P E
( % ) P E
R P E
(% )
A v e ra g  
e cell 
v ia b il i ty
S ta n d a r
d
d e v ia t io n
T T E S
T
U n trea ted 441 .77 478 .75 324 .26 - _ _ -
0 + O 6 B G 507.52 106.01 548 .06 200 .04 397 .66
160.0
3 155.36 47 .19 0 .34
M e th + D M S
0 478 .75 108.37 317.81 66 .38 284 .1 6 87.63 87 .46 2 0 .9 9 0.51
D M S O 478.75 108.37 368 .8 9 77.05 207 .94 64.13 83.18 22 .75 0.53
M e th 478 .75 108.37 273 .98 57.23 248 .49 76.63 80 .74 25 .82 0 .40
0 .0 0 0 7 5 478 .75 100.00 507 .52 159.69 334 .06
117.5
6 125.75 30 .68 0 .74
0.001 422 .79 88.31 617 .38 194.26 507 .52
178.6
0 153.73 5 7 .19 0.24
0 .0 0 2 5 368 .89 77.05 548 .06 172.45 303 .20
106.7
0 118.74 48.83 0.93
0 .005 353 .47 73.83 507 .52 159.69 209 .62 7 3 .77 102.43 4 9 .5 9 0.58
0 .0 0 7 5 422 .79 88.31 507 .52 159.69 507 .52
178.6
0 142.20 47 .62 0 .30
0.01 322.93 67.45 397 .6 6 125.13 131.40 4 6 .24 79.61 40 .82 0.23
0 .025 368 .89 77.05 377 .5 9 118.81 155.66 54 .78 83.55 32.51 0 .26
0 .05 303.83 63 .46 43 8 .2 0 137.88 159.91 56 .27 85 .87 4 5 .1 9 0 .29
0.075 409 .43 85.52 195.43 61 .49 241 .26 8 4 .90 77.31 13.70 0.17
Appendix 14:Fraction of unrepaired adducts (Chapter 6).
D ose M N U  
(p g /m l) M F  - 0 6BG M F  + 0 6BG
F ra c tio n  o f 
u n re p a ire d  
lesions
0.001 1.39E-05 2.95E-05 4.71E-01
0.0025 5.52E-06 3.10E-05 1.78E-01
0.005 8.92E-06 3.29E-05 2.71E-01
0.0075 1.03E-05 3.62E-05 2.84E-01
0.01 2.40E-05 3.01E-05 7.98E-01
0.025 3.79E-05 3.15E-05 1.21E+00
0.05 3.62E-05 4.83E-05 7.49E-01
0.075 5.15E-05 4.56E-05 1.13E+00
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R e p  B
D o se  M N U  
(p g /m l)
C t  M G M T C t T B P A C t A A C t F o ld  c h a n g e
M E T H  +  D M S O 33 .94 21 .72 12.21 -0 .78 1.71
0 34.11 22.01 12.10 -0 .12 1.09
0 .0 0 0 7 5 3 3 .96 21 .66 12.30 0 .0 9 0 .94
0 .0 0 2 5 32 .76 21.55 11.21 -1 .0 0 2.01
0 .0 0 7 5 33.03 21.54 11.49 -0 .73 1.65
0.01 3 3 .57 21 .98 11.58 -0 .63 1.55
0 .025 33.33 21.44 11.89 -0 .3 2 1.25
0.05 33.52 21.75 11.77 -0 .4 4 1.36
R e p  C
D o se  M N U  
(p g /m l)
C t  M G M T C t T B P A C t A A C t F o ld  c h a n g e
M E T H  +  D M S O 33.33 21 .59 11.73 -0 .3 0 1.23
0 34 .50 2 1 .79 12.71 0 .98 0.51
0 .00075 32 .96 21.81 11.15 -0 .5 8 1.50
0 .0025 34 .40 21.63 12.76 1.03 0 .49
Appendix 15: Raw real time data +O BG (Chapter 6).
1 h o u r  p o s t  M N U  tre a tm e n t
R e p  A
D ose M N U  
(p g /m l)
C t
M G M T
C t
T B P
A C t A A C t F o ld
c h a n g e
A v e ra g e S ta n d a r d
d e v ia t io n
M E T H  + D M S O 33.21 21 .77 11.44 0 .00 1.00 1.31 0 .36
0 33 .96 21 .60 12.36 0.92 0.53 0.71 0.33
0 .00075 33.75 22 .28 11.47 0.03 0 .98 1.14 0.31
0 .0025 33.94 21 .72 12.21 0 .78 0 .58 1.03 0.85
0 .0075 33.94 21 .47 12.47 1.04 0 .49 0 .85 0 .69
0.01 33.55 22.62 10.93 -0.51 1.42 1.31 0.31
0.025 31.78 21 .30 10.48 -0.95 1.94 1.24 0 .70
0.05 33.93 21.31 12.62 1.18 0 .44 0 .75 0.52
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0 .0075 34 .70 2 1 .72 12.98 1.24 0 .42
0.01 33.55 21 .76 11.79 0 .05 0.97
0 .025 34.45 21.85 12.60 0 .87 0.55
0 .05 34.44 21 .59 12.85 1.11 0 .46
4 h r  p o s t M N U  tre a tm e n t.
R e p  A
T r e a tm e n t C t
M G M T
C t
T B P
A C t A A C t F o ld
c h a n g e
A v e ra g e
fo ld
c h a n g e
S ta n d a r d
d e v ia t io n
M E T H  + 
D M S O
32.65 21 .16 11.49 0 .00 1.00 1.17 0 .86
0 31 .97 21 .20 10.77 -0 .72 1.65 1.23 0 .36
0.00075 31.82 21 .02 10.80 -0 .69 1.61 1.86 1.38
0.0025 32.41 21.02 11.39 -0 .09 1.07 1.03 0 .44
0.0075 32.08 20.83 11.26 -0 .23 1.17 1.65 0.95
0.01 31.72 21 .86 9 .86 -1 .63 3 .10 1.68 1.29
0.025 36 .70 21.23 15.47 3.98 0 .06 0 .47 0 .40
0.05 33 .00 20.96 12.04 0.55 0 .68 0 .86 0 .69
R ep  B
T re a tm e n t C t  M G M T C t T B P A C t A A C t F o ld
c h a n g e
M E T H  +  D M S O 33 .76 21 .20 12.56 -1 .08 2.11
0 33.92 21 .34 12.57 0.01 0 .99
0 .00075 31 .70 20 .87 10.82 -1 .74 3 .34
0 .0025 32 .88 20 .84 12.03 -0.53 1.44
0 .0075 31 .97 20 .86 11.10 -1 .46 2.75
0.01 33.35 21.23 12.13 -0.43 1.35
0 .025 33 .79 21.03 12.76 0 .20 0 .87
0 .05 32 .76 2 0 .89 11.86 -0 .70 1.62
R ep  C
T re a tm e n t C t  M G M T C t T B P A C t A A C t F o ld
c h a n g e
M E T H  + D M S O 31 .09 20 .88 10.21 1.27 0.41
0 3 1 .44 21 .30 10.14 -0 .07 1.05
0 .00075 31 .78 2 0 .87 10.91 0 .70 0.62
0 .0025 32.05 2 1 .04 11.01 0 .80 0 .57
0 .0075 30.95 20 .80 10.15 -0 .06 1.04
0.01 32 .17 21 .20 10.97 0.75 0 .59
0 .025 32 .38 21.11 11.26 1.05 0 .48
0.05 3 2 .79 20 .77 12.02 1.81 0 .29
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6hr post MNU treatment.
T r e a tm e n t C t  M G M T C t T B P A C t A A C t F o ld
c h a n g e
A v e ra g e
fo ld
c h a n g e
S ta n d a r d
d e v ia t io n
M E T H  +  D M S O 32.25 21.71 10.53 0 .0 0 1.00 1.26 0 .24
0 3 2 .70 21 .29 11.41 0 .87 0.55 0 .67 0 .20
0 .00075 3 4 .06 2 1 .32 12.75 2 .22 0 .22 0.78 0 .72
0 .0025 34 .08 21 .30 12.77 2 .24 0.21 0.71 0.65
0 .0075 32 .52 21 .14 11.37 0 .84 0 .56 0.73 0 .19
0.01 3 2 .26 21 .39 10.87 0 .34 0 .79 0 .89 0 .26
0.025 33 .48 21 .06 12.43 1.89 0 .27 0 .46 0 .18
0.05 32 .88 20 .79 12.09 1.55 0 .34 0.85 0 .46
R ep  B
T r e a tm e n t C t  M G M T C t T B P A C t A A C t F o ld
c h a n g e
M E T H  +  D M S O 32 .67 21 .75 10.92 -0 .3 9 1.31
0 33 .19 21 .45 11.74 0 .82 0 .57
0 .00075 32 .84 21 .00 11.84 0 .92 0.53
0 .0025 33 .17 2 1 .14 12.04 - 1.12 0 .46
0 .0075 32.23 2 1 .20 11.03 0.11 0.93
0.01 32.01 21.33 10.68 -0 .24 1.18
0.025 33 .04 21.43 11.61 0 .69 0 .62
0.05 31.43 20 .82 10.61 -0.31 1.24
R e p  C
T re a tm e n t C t  M G M T C t T B P A C t A A C t F o ld
c h a n g e
M E T H  +  D M S O 32.51 21.43 11.08 -0 .55 1.46
0 32 .57 21.35 11.22 0 .14 0.91
0 .00075 3 1 .57 21 .16 10.41 -0 .67 1.60
0 .0025 31.73 21 .18 10.55 -0 .53 1.45
0.0075 32 .68 21.11 11.58 0 .50 0.71
0.01 3 2 .80 21 .18 11.62 0 .54 0 .69
0.025 33.43 21.33 12.10 1.02 0 .49
0.05 32 .14 21 .04 11.10 0 .02 0 .99
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24hr post treatment.
R e p  A
T r e a tm e n t C t  M G M T C t T B P A C t A A C t F o ld
c h a n g e
A v e ra g e
fo ld
c h a n g e
S ta n d a r d
d e v ia t io n
M E T H  + 
D M SO
34.97 21.13 13.83 0 .00 1.00 0 .84 0 .17
0 35.43 21 .16 14.27 0 .44 0 .74 1.03 0 .27
0 .00075 3 4 .56 21.04 13.52 -0.31 1.24 1.21 0 .04
0 .0025 35.55 21.91 13.64 -0 .19 1.14 1.61 0 .40
0 .0075 34 .96 21.38 13.58 -0 .26 1.19 1.66 0 .50
0.01 35.63 2 1 .74 13.89 0 .06 0 .96 1.10 0.71
0 .025 37.13 22 .22 14.91 1.08 0 .47 0 .94 1.06
0 .05 36.01 21 .69 14.32 0 .49 0.71 0 .42 0 .29
R ep B
T re a tm e n t C t
M G M T
C t  T B P A C t A A C t F o ld
c h a n g e
M E T H  + 
D M SO
3 4 .56 21 .34 13.22 0.61 0.65
0 34 .00 20 .88 13.12 -0 .10 1.07
0.00075 34 .79 21 .79 13.00 -0 .22 1.17
0.0025 34 .04 21 .69 12.35 -0 .87 1.83
0.0075 34.43 2 2 .34 12.09 -1.13 2 .19
0.01 36.03 21.71 14.32 1.10 0 .47
0.025 37.42 21 .80 15.61 2 .39 0 .19
0.05 36.72 22 .17 14.55 1.33 0 .40
R ep  C
T re a tm e n t C t
M G M T
C t  T B P A C t A A C t F o ld
c h a n g e
M E T H  + 
D M SO
34 .49 2 0 .86 13.62 0.21 0 .86
0 34.12 20 .85 13.28 -0 .35 1.27
0 .00075 34 .46 21.12 13.35 -0 .28 1.21
0.0025 34 .60 2 1 .86 12.73 -0 .89 1.85
0.0075 35 .06 22.11 12.95 -0 .68 1.60
0.01 34.54 21.81 12.72 -0 .90 1.87
0.025 34.21 21 .69 12.52 -1.11 2.15
0.05 37.58 21 .15 16.43 2 .80 0 .14
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Appendix 16: Accepted abstract for poster at UKEMS 2009 and ICEM, 2009.
Comparison and validation of the micronucleus assay with and without 
cytochalasin in mammalian cell lines
A d a m  D . T h o m a s , S h a re e n  H . D o a k , G a re th  J. J e n k in s  a n d  G e o rg e  E . J o h n s o n  
In s t i tu te  o f  L ie  S c ie n c e s  S c h o o l  o f  M e d ic in e , S w a n s e a  U n iv e r s i ty , S w a n s e a  S A 2  8 P P ,  
U K
A s a  c o n se q u e n c e  o f  th e  re d u c e d , re f in e d  a n d  u ltim a te  r e p la c e m e n t o f  a n im a l u sa g e  in  
g e n e tic  to x ic o lo g y , m o re  e m p h a s is  h a s  b e e n  p la c e d  o n  in  v itro  a s sa y s . T h e  in  v itro  
m ic ro n u c le u s  a s sa y  is o n e  su c h  te s t  sy s te m , a n d  w e  a re  w o rk in g  w ith  a  n u m b e r  o f  
E u ro p e a n  la b o ra to r ie s  to  s ta n d a rd ise  a n d  v a lid a te  th e  a ssa y , a s  re c o m m e n d e d  in  th e  
la te  2 0 0 7  v e rs io n  o f  th e  d ra f t  O E C D  T e s t G u id e lin e  4 8 7 . C y to c h a la s in  B  (C y to B )  is 
u se d  in  th e  c y to k in e s is  b lo c k  m ic ro n u c le u s  (C B M N ) a ssa y  is  w id e ly  u se d  to  a s se ss  
c h ro m o so m a l d a m a g e  in  c e lls  th a t  h a v e  u n d e rg o n e  o n e  c e llu la r  d iv is io n . T h e  
m ic ro n u c le u s  a s sa y  c a n  a lso  b e  c a rr ie d  o u t  w ith o u t C y to B  in  th e  n o n -C B M N  a ssa y , 
a lth o u g h  th is  is  le ss  w id e ly  c o n d u c te d  d u e  to  la c k  o f  c o n tro l o f  m ito tic  k in e tic s . In  th is  
c o m m u n ic a -  t io n  w e  c o m p a re  th e se  tw o  m e th o d o lo g ie s  b y  te s tin g  th e  k n o w n  sp in d le  
p o iso n s , v in b la s tin e  a n d  d ie th y ls ti lb o e s tro l (D E S ) in  b o th  te s t  sy s te m s  in  C H O  ce lls . 
R e la tiv e  p o p u la t io n  d o u b lin g  (R P D ), re la tiv e  in c re a se  in  ce ll c o u n t (R IC C ) a n d  
re la tiv e  ce ll c o u n ts  (R C C ) w e re  u se d  in  th e  n o n -C B M N  a ssa y  a n d  th e  r e p lic a tiv e  
in d e x  (R I) w a s  u se d  in  th e  C B M N  assa y . T h e se  m e a su re s  w e re  th e n  c o m p a re d  a n d  
th e ir  im p lic a tio n s  fo r  d o se  se le c tio n  a re  h ig h lig h te d . N o ta b ly , R I e x a g g e ra te d  to x ic ity  
a n d  lead  to  a  lo w e r  d o se  b e in g  se le c te d  to  g iv e  5 0 %  to x ic ity  (v in b la s tin e  0 .7  lg /m l; 
D E S  41g/m l), p o s s ib ly  d u e  to  te m p o ra ry  m ito tic  b lo c k . R C C  u n d e re s tim a te d  to x ic ity  
a n d  le a d  to  h ig h e r  d o se s  s e le c te d  (v in b la s tin e  .2 lg /m l; D E S  .6 
lg /m l). F a ilu re  to  d e te c t k n o w n  g e n o to x in s  (so  c a lle d  fa lse  n e g a tiv e s )  a t d o se s  se le c te d  
u s in g  R P D  is its  m a in  c r it ic ism  fo r  u se , h o w e v e r , in  th e  fo llo w in g  re p o r t , I h a v e  
sh o w n  th is  is  n o t th e  ca se . T h is  w o rk  su p p o r ts  th e  p re m ise  th a t R P D  a n d  R IC C  are  
a p p ro p ria te  m e a s u re s  fo r  th e  n o n -C B M N  a ssa y  in  v itro . W e a re  a lso  u s in g  th is  
in fo rm a tio n  to  h e lp  in  o u r  v a lid a tio n  o f  b o th  th e  C B M N  a n d  n o n -C B M N  a s s a y s  u s in g  
th e  M e ta sy s te m s  M e ta fe r  a u to m a te d  sy s te m .
250
Comparison and Validation of the  Micronucleus Assay with 
and  w ithout Cytochalasin B in Mammalian Cell Lines.
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^ R esu lts  and Discussion ______________
Current m icro n u c leu s  a s s a y  m e th o d o lo g y  is being standard ised  
in a co l laborative  effort to  e n s u r e  the  reduction of  fa lse  
posit ive  and fa lse  n e g a t iv e  resu lts .  The different toxicity  
m e a s u r e s  u sed  to  d e f ine  th e  d o s e  range for the  m icronucleus  
(Mn) a s s a y  w ithout  cy to k ine s is  block are currently under  
scrutiny.
Such  m e a s u r e s  be ing  RPD and RICC, are r e c o m m e n d e d  in 
draft OECD g u id e l ine  4 8 7  for u s e  in a b s e n c e  o f  C ytochalasin  B 
(CytoB ).  T h ey  are known to produce very different resu lts  to 
m o re  traditionally u sed  cy to to x ic  e n d -p o in ts  (RCC) and their  
in f luences  are  im plicated in risk a s s e s s m e n t .____________________
— A i m  ---------------------------------------------------------------------
Through quantif ication of Mn induction in r e s p o n s e  to  
Vinblastine w e  h o p e  to validate  the  u se  of  RPD and RICC for 
u se  in th e  Mn a s s a y  w ithout  cy tok ine s is  block with 
implications in th e  M e ta s y s t e m s  Metafer a u to m a te d  s y s t e m .
__ Materials and Methods
Cultures  
established to 
give 5 0 %  
confluency at 
tre a tm e n t
Cells counted  
for RPD, RICC 
and RCC 
calculation
Ratio of 
binucleates: 
m ono:m ulti 
(Fig 2 ) scored to  
give R I Mn 
' in d uction_______ ,,
Cyto B
- CytoB
Cells +
V inb lastine for 
3hrs, le ft in 
recovery for 
21hrs + / -  
C ytoB  _______
7v
Figure 1. S c h e m a t ic  o f  th e  exp er im en ta l  des ign .
Figure 2. C h in ese  h a m s te r  CHO cells. A) M ononucleated ,  
B) Binucleated  C) B inucleate  with m icronucleus.
Chemical.
Vinblastine (from C o v a n ce ,  Harrogate,  UK). 
C h em o th era p eu t ic  and m ode l  a n e u g e n ,  through inhibition 
of m icrotubule  a ss e m b ly .  Active at  0 . 5 - 5 p g /m l  in DMSO.
Toxicity endpoints m easured.
•Relative populat ion doubling (RPD)
•Relative in crea s e  in cell  c ou n t  (RICC)
•Relative cell c o u n t  (RCC)
•Replication Index  (RI)
-••%  Toxicity RPD 
% Toxicity RCC 
-*>'% Toxicity RICC
Toxicity RI ♦ Cyto-B
01CTl(0■M
CVu
k.Vo. 01
Vinblastine (p g /m l)
Figure 3. Illustration of  the  impact that  different toxicity  
e n d p o in ts  ha v e  on d o s e  se lec t io n ,  giving th e  s a m e  e x te n t  of  
toxicity.
•RICC leads to higher d o s e s  se le c te d  and RI leads  to lower  
d o s e s  s e le c te d  c o m p a red  to RPD for s a m e  e x te n t  o f  toxicity.
Cyto-B RI %MNBN
■  No Cyto-B RICC. %MNmono 
□  No Cyto-B RCC %MNmono
■  No Cyto-B RPD %MNmono
2 12
V in b la s t in e  ( ^ g /m l)
Figure 4. Mn induction with and w ithout  CytoB, coupled  
with toxicity using re levant  toxicity  endpoints .
* * *  Significant increase above control (p<0.001)
•There w as a positive response at all doses selected  
by RPD, RCC, RICC and RI giving appropriate ex ten t of 
toxicity .
^Conclusions ---------------------------------------
•RI g iv e s  over  e x a g g e r a t io n  of  toxicity  through mitotic arrest,  
and leads  to lower d o s e s  se le c te d  to g ive  LD50.
•RPD, RICC and RCC adequate ly identify  known  
aneugens as positive genotoxins and so could be used 
as a toxic ity  m easure in non-CBMN assay.
•T hese  resu lts  are in line with th e  rest  of  the  collaborative  
group in sh ow in g  that  all of  the  toxicity  m e a s u r e s  are  
su itable  and should  be included in the  OECD guidel ine  4 8 7 .
Appendix 18: Accepted abstract for poster at UKEMS 2010.
Low dose exposure to MNU in Human Lymphoblastoid cell line AHH-1.
A d a m  D . T h o m a s , G a re th  J. S. Je n k in s , S h a re e n  H . D o a k  a n d  G e o rg e  E . Jo h n so n .
In s t i tu te  o f  L ife  S c ie n c e , S w a n s e a  U n iv e r s i ty , S w a n s e a , U K , S A 2  8 P P .
B e fo re  p h a rm a c e u tic a ls  a re  a p p ro v e d  fo r  h u m a n  u sa g e , th e ir  p o te n tia l  to  c a u se  p o in t 
m u ta tio n s  a n d  c h ro m o so m e  d a m a g e  is  a s se s se d  a t in c re a s in g  d o se s  u s in g  in  v i t r o  c e ll 
c u ltu re  sy s te m s  a n d  a n im a l m o d e ls . T h e  re su ltin g  d o s e -re s p o n s e  is a  c r itic a l fa c to r  in  
e s ta b lis h in g  sa fe  e x p o s u re  lim its . I t  h a s  lo n g  b e e n  a s su m e d  th a t  D N A  re a c tiv e  
c h e m ic a ls  c a u se  a d v e rse  e f fe c ts  a t e v e ry  d o se . H o w e v e r , e x p e r im e n ta tio n  in to  th e  lo w  
d o se  re g io n  h a s  re v e a le d  a  th re s h o ld  m e c h a n is m  w h e re , u p  to  th e  th re s h o ld  d o se ,
D N A  re a c tiv e  c h e m ic a ls  c a n  b e  to le ra te d  w ith o u t in c u rr in g  m o re  d a m a g e  th a n  th a t  
n a tu ra lly  o c c u rr in g  w ith in  th e  ce ll. M N U , a  m o d e l a lk y la tin g  a g e n t  h a s  b e e n  sh o w n  to  
il l ic it  D N A  d a m a g e  in  a  l in e a r  fa s h io n  e v e n  a t lo w  d o se s , w h e re a s  s im ila r  a c tin g  
c o m p o u n d s  M M S  a n d  E M S  h a v e  b e e n  sh o w n  to  h a v e  th re s h o ld s  (1 ). In  th is  s tu d y  w e  
f in d  a  p u ta tiv e  th re s h o ld  d o se  fo r  p o in t  m u ta tio n  in d u c tio n  a t 0 .0 0 0 7 5 p g /m l M N U  
w h e n  q u a n tif ie d  th ro u g h  th e  H P R T  a ssa y  in  th e  A H H -1  H u m a n  L y m p h o b la s to id  c e ll  
lin e . S e q u e n c e  a n a ly s is  o f  th e  re s u lta n t m u ta n ts  w ill g iv e  m e c h a n is tic  in fo rm a tio n  
re g a rd in g  p o in t m u ta tio n  in d u c tio n  o v e r  th is  th re s h o ld e d  d o se  ra n g e . T h ro u g h  u se  o f  
th e  M e ta sy s te m s  m e ta fe r  so f tw a re  o p tim is e d  fo r  th e  m ic ro n u c le u s  a ssa y , w e  a im  to  
e v a lu a te  M N U s a b ility  to  in d u c e  c h ro m o so m e  b re a k a g e s  o v e r  a  w id e r  d o se  ra n g e  th a n  
p re v io u s ly  te s te d . F u r th e r  w o rk  w ill id e n tify  th e  m e c h a n is m  o f  th e  th re s h o ld  d o se -  
re sp o n se  fo r  g e n e tic  d a m a g e  h y p o th e s is e d  to  in v o lv e  D N A  re p a ir  o f  p re -m u ta g e n ic  
le s io n s .
R e fe re n c e s
D o a k , S .H ., Je n k in s , G .J .S ., J o h n so n , G .E ., Q u ic k , E ., P a rry , E . M . a n d  P a rry , J. M . 
(2 0 0 7 ) M e c h a n is tic  In f lu e n c e s  fo r  M u ta tio n  In d u c tio n  C u rv e s  a f te r  E x p o su re  to  D N A - 
R e a c tiv e  C a rc in o g e n s . C a n c e r  R e s e a r c h ., 6 7 :(8 ) , 3 9 0 4 -3 9 1 1 ,
252
Establishing a mutation spectrum for MNU over a threshold dose-response
in AHH-1 Human cells.
Swansea University 
Prifysgol Abertawe
-In trod u ctio n ----------------------------------------
•E xper im ents  into th e  g e n o to x ic  potential of low d o s e  
e x p o s u r e s  highlight a threshold  d o s e  r esp o n se .
•Evidence is accum ulating  to s u g g e s t  that  alkylating a g e n t s  are  
sa fe  at low d o s e s ,  w h ere  signif icant DNA d a m a g e  w as  o n c e  
th o u g h t  to occur.
•S afe  e x p o s u r e  levels  have  implications in drug d e v e lo p m e n t  
and ch e m o th e r a p e u t ic  ca n cer  trea tm en t .
•The cy to p ro te c t iv e  m e c h a n ism  respons ib le  is currently under  
invest iga t ion .
•We are hyp oth es is in g  that  DNA repair r e m o v e s  alkylation  
d a m a g e  (Fig 1) up until the  threshold  d o s e  w h ere  t h e s e  
m e c h a n i s m s  b e c o m e  o v e r w h e lm e d  and m utation  induction  
th e rea f ter  accru es  in a liner fash ion  (Fig 2)
Figure 1 DNA repair as  
a bodyguard  aga inst  
O0C X X X X X  alkylation d a m a g e .  MNU 
induces  0 6MeG that,  if 
not repaired by MGMT, 
b e c o m e s  replicated and  
fixed a s  GC-A1 point  
m utat ions
A d am  D. T h o m a s 1, G e o rg e  E. J o h n s o n ,  
S h a r e e n  H. D oak  a n d  G a re th  J. S. J e n k in s .
EPSRC
Engineering and Physical Sciences 
School o f  Medicine,  University  o f  Wales S w a n s e a ,  S ing le ton  Park, S w a n s e a  SA2 8PP. Research Council
P r e s e n t in g  author.
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Figure 2 Incorporating the  
DNA repair h yp oth es is  into the  
threshold  d o s e -r e s p o n s e .
S a tu ra t io n  of repair
DNA d am age .
Form ation
-K ey research questions--------------------------------
D o e s  MNU illicit a threshold  d o s e - r e s p o n s e  in AHH-1 hum an  
cells  using the  HPRT point m utat ion  a ss a y ?  (prev iou s  data  
s u g g e s t s  not (Doak e t at, 2007).
D o e s  the  spec trum  of point m uta t io ns  induced by MNU c h a n g e
at doses below end above a threshold?___________________
-Materials and M ethods_______________
Mutations and small de le t io ns  quantified through th e  HPRT 
a s s a y  a s  previously  detailed  (Doak e t a / ,  2 0 0 7 )  and resulting  
m u ta n ts  se q u e n c e d .
7'y" TV"
Endpoint
HPRT
AHH-1 m utant
co lon ies  RNA cDNA 
isolated and Iso lated  m a d e  
en u m e ra te d
PCR strategy:
5' _____
PCR S e q u e n c e  
o bta ined
3'
Two overlapping pairs o f  primers u sed  for 8 3 %  g e n e  
c o v e r a g e .
r-Results and Discussion --------------------
Figure 3 Low d o s e  e x p o s u r e  to MNU in AHH-1 in the  HPRT 
assay .  D o s e s  s e q u e n c e d  are  circled in red.
Figure 3 s u g g e s t s  th a t  AHH-1 cells can  to lerate  up to
0 .0 0 0 7 5 p g / m l  MNU w ithout  incurring m ore  d a m a g e  than  that  
occurring in th e  cell naturally.
Figure 4 proportions of  GC to AT transit ions at th e  resp ec t iv e  
d o s e s  of  MNU. Mutants recovered  at
O pg/m l w ere  found to  
contain  a ~ 7 0 b p  
delet ion,
At 0 .0 0 0 7 5 p g /m l the
pred om inan ce  of  
m u ta n ts  w ere  A-T 
point m uta t ions  at th e  
start  codon ,
0 .0 2 5 p g /m l MNU
induced m ore  GC-AT 
transit ions (3 7 % )  than  
any o ther  s ingle  
m utational e v en t .
The sp ec tru m  of m uta t io n s  induced c h a n g e s  over  the  threshold  
d o s e  re s p o n s e .
The proportion of GC-AT transit ions ,  characteristic  of  MNU 
e x p o su r e ,  increase  drast ically o n c e  th e  threshold  d o s e  is 
su r p a s se d .
r-Conclusions -----------------------------------------
W e have found th a t AHH-1 hum an cells can to le ra te  low  
doses of MNU in the HPRT assay, th e  resistance, w e  
believe is conveyed through DNA repair mechanisms.
Analysing th e  s e q u e n c e  a t  th e  HPRT locus revea ls  the  
sp ec tru m  of  m uta t io ns  induced by increasing c on cen tra t ion s  of  
MNU.
MNU produces 0 6MeG, a pre-m utagenic event th a t gives 
rise to GC-AT m utations unless it is repaired by MGMT. 
doses above the threshold saturate  MGMT and so the  
proportions of GC-AT events increase th erea fte r.
Reference:
Doak et al (2007)
Appendix 20: Accepted abstract for oral presentation (UKEMS, 2011) and 
poster (EEMS, 2011)
Can 0 6-Methylgaunine methyltransferase (MGMT) protect DNA from low doses 
of Methyl Nitrosourea?
A d a m  D . T h o m a s , G a re th  J. S. J e n k in s , S h a re e n  H . D o a k , P a u l D . L e w is  a n d  G e o rg e  
E . Jo h n so n .
In s t i tu te  o f  L ife  S c ie n c e , C o l le g e  o f  M e d ic in e , S w a n s e a  U n iv e r s i ty , S A 2  8P .
In  th e  h o p e  o f  d e c re a s in g  th e  c h a n c e  o f  h u m a n  c a n c e r  a n d  h e r ita b le  g e n e tic  d e fe c ts ; 
p h a rm a c e u tic a ls  a n d  fo o d  p ro d u c ts  a re  te s te d  fo r  th e ir  a b ility  to  c a u se  D N A  d a m a g e . 
A s  a  p re c a u tio n , it  h a s  b e e n  a s s u m e d  th a t c h e m ic a ls  k n o w n  to  in d u c e  D N A  d a m a g e  a t 
h ig h  d o se s  a lso  d a m a g e  D N A  a t lo w  d o se s . T h is  l in e a r  h y p o th e s is , d e r iv e d  f ro m  
e x tra p o la tio n  o f  h ig h  d o se  d a ta , c o u ld  p re v e n t b e n e f ic ia l  p ro d u c ts  f ro m  e n te r in g  th e  
m a rk e t i f  sh o w n  to  c o n ta in  v e ry  lo w  lev e l o f  g e n o to x in s .
O u r la b o ra to ry  h a s  id e n tif ie d  th re s h o ld  d o s e -re s p o n s e s  fo r  m o d e l a lk y la tin g  a g e n ts  
[m e th y l m e th a n e su lfo n a te  (M M S ) a n d  e th y l m e th a n e s u lfo n a te  (E M S )] in  th e  H P R T  
m u ta tio n  a ssa y  (D o a k  e t  a l , 2 0 0 7 ) . S in c e  th e n  th e re  h a s  b e e n  an  a c c u m u la tio n  o f  in  
v i t r o  a n d  in  v iv o  d a ta  fo r  c e r ta in  D N A  re a c tiv e  c o m p o u n d s  su p p o r tin g  th e  th re s h o ld  
h y p o th e s is .
N u c le o tid e  su b s titu tio n s , q u a n tif ie d  b y  th e  H P R T  a ssa y  c a n  b e  c a u se d  b y  th e  
m isc o d in g  p o te n tia l  o f  0 6m e th y lg u a n in e  ( 0 6M e G ), a  p re -m u ta g e n ic  D N A  a d d u c t 
p re s e n t in  lo w  a m o u n ts  fo llo w in g  e x p o su re  to  th e s e  a lk y la tin g  a g e n ts . I t is  re p a ire d  b y  
M e th y lg u a n in e  m e th y l tra n s fe ra s e  (M G M T ) b e fo re  it  c a u se s  G C -A T  tra n s itio n s , 
M G M T , is th e re fo re  p re d ic te d  to  p ro te c t  D N A  a t lo w  le v e ls  u n til it is  s a tu ra te d  a t th e  
th re sh o ld  d o se  a n d  a b o v e . T h is  is th e  h y p o th e s is e d  m e c h a n is m  b e h in d  th e  m u ta g e n ic  
th re sh o ld  d o se  re sp o n se .
D o a k  e t  a l  (2 0 0 7 )  sh o w e d  th a t  M N U  d id  n o t  h a v e  a  th re s h o ld  d o se  re sp o n se . T h e  
fo llo w in g  w o rk  re p o r ts  a  th re s h o ld  d o se -re sp o n se  w ith  a  N O E L  o f  0 .0 0 7 5 p g /m l. W e  
h a v e  in a c tiv a te d  M G M T  b y  0 6b e n z y lg u a n in e  a n d  th e  m u ta tio n  fre q u e n c y  a t  th e  
N O E L  in c re a se s  f ro m  9 .2 2 x 1  O'6 to  5 .37x1  O'5. T h e  H P R T  lo c u s  h a s  b e e n  s e q u e n c e d  to  
o b ta in  th e  m u ta tio n  sp e c tra  o v e r  th e  d o se  re sp o n se . W e  h a v e  o b se rv e d  12%  G C -A T  
m u ta tio n s  s u b - th re s h o ld  c o m p a re d  to  3 3 %  a b o v e  th e  th re sh o ld .
R e fe re n c e s
D o ak , S .H ., Je n k in s . G .J .S ., J o h n so n . G .E ., Q u ic k . E ., P a rry . E .M . a n d  P a rry . J .M . 
(2 0 0 7 ) M e c h a n is tic  in f lu e n c e s  fo r  M u ta tio n  In d u c tio n  C u rv e s  F o llo w in g  E x p o s u re  to  
D N A -R e a c tiv e  c a rc in o g e n s . C a n c e r  R e s e a r c h . 6 7 :1 -8 .
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DNA repair as the mechanism in 
genotoxic thresholds
A d am  D. T h o m a s , G a re th  J. S. J e n k in s ,
S h a r e e n  H. D oak, P au l  D. Lew is a n d  G e o rg e  E. J o h n s o n .
College o f M edicine, U n iversity o f Wales Swansea, Singleton Park, Swansea SA2 8 PP.
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Prifysgol Abertawe
n t r o d u c t i o n
nitrosourea (MNU) and o ther 
ylating agents are DNA reactive 
notoxins, a ssum ed  to  be mutagenic, 
en at low doses (linear dose-response) ;
p h a rm a ce u tic a ls  w ith  im p u r i t ie s  a s s u m e d  to  
have a  lin e a r  d o s e - r e s p o n s e  a r e  n o t  a p p r o v e d  
for hu m a n  u s e .
idence is accumulating suggesting 
t other alkylating agents (MMS) are not 
tagenic at low doses but exh ib it a
eshold d ose -resp on se  (Doak e ta /, 2007);
However, MNU is  2 0  t im e s  m o r e  m u ta g e n i c  th a n  
M M S (B aranek , 1 9 9 0 ) .
POTHESISED MECHANISM
e hypothesise th a t at low doses,
, repair mechanisms remove
remutagenic DNA d a m a g e  before it Responsi 
fixed into m utations.
he repair mechanism involved 
epends on the chemical's mechanism
faction (MOA)
EPSRC
Engineering and Physical Sciences 
Research Council
LINEA
THRESHOLD
Sa turation  of repair 
m echanism
dam age
Form ation  o f a d d u c ts  with 
su b se q u e n t rem oval th rough  
DNA repair
0A OF MNU AND DNA REPAIR;
F ig u r e  1 . I n c o r p o ra t in g  th e  DNA r e p a i r  h y p o th e s is  
in to  t h e  t h r e s h o ld  d o s e - r e s p o n s e .
Chemical 
reaches target PH3
X X X X X > X X X X X
X X M O 0 O O O O O C  XXXX
DNA
replication
and
permanent
genetic
damage
MNU induces
06m e th y ig u a n in e  
( 0 5MeG) a m u ta g e n ic  
ad d u c t
MGMT rep a irs  0 6MeG which 
p re v e n ts  GC-»AT po in t 
m u ta tio n s
1MGMT can  only rep a ir
1 0 6MeG
We p red ic t MGMT 
sa tu ra tio n  a t  h igh  d o ses
ims-  _______________________________
Quantify m utations induced by low doses of MNU through the HPRT
say,
Establish mutation spectra and quantify GC->AT mutations to 
ntify mutations below and above the NOEL.
M L  and quantify  GC->AT changes and MF at the NOEL.___
aterials and M ethods________________
r,, ,l0ns were Quantified through the HPRT assay as previously 
(Doak et at. 2007) and the resulting mutants sequenced.
E ndpoint
of
HPRT 
a ssa y  
1 strategy;
AHH-1 m u ta n t 
co lon ies 
iso la ted  and 
e n um era ted
RNA
Iso la ted
cDNA
m ade
PCR Sequence
obtained
J ^ 5r|apping pairs p f prim ers used fo r 83% gene coverage 
^MT inhibition was achieved through lh r  pre-treatm ent w ith
T3'
° bbenzylguanine fo llowed by HPRT assay and sequencing 
-PCR p e rfo rm e d  as d e ta ile d  in Z a ir  e t at. (2 0 1 1 )
_ Results and Discussion
Negative control _ '  '
1MNU THRESHOLD DOSE RESPONSE IN THE HRRT ASSAY
^.OOE-05
rr E_05
.& .00E-05
NOEL2 .50E -05
CO.50E-05
n.O O E-05
5.00E-06
0.00E+00
„ __   Dose MNlP(pg/ml)
2. MUTATION SPECTRA
n = 3 3 6 0 .  W h e r e  s td e v  b a r s  
s h o w n  n = 6 7 2 0
The cell can to le ra te  
up to  0 .0 0 7 5 p g /m l 
w ith o u t an increase
in m u ta tion  
frequency (MF) 
com pared to  th e  
negative  con tro l
G re e n  c irc le s  d e p ic t s  d o s e s  
s e le c te d  fo r  s e q u e n c e  a n a ly s i s
E ach  m u ta t io n  a s  a  p r o p o r t io n  o f  to ta l  
n u m b e r  fo u n d  fo r  e a c h  d o s e  e .g .  in 
n e g a t iv e  c o n tro l  G -»C  m u ta t io n = 1 3 %  
o f  to ta l .
From  th is , it is s e e n  th a t  th e  p ro p o rtio n  of GC->AT m u ta tio n s  ( a t tr ib u te d  to  
0 6MeG from  MNU ex p o su re )  m im ic th£ ,£ )iresho ld  d o s e  re s p o n s e ;
This h igh lig h ts  th e  ro le  for 
0 6MeG in th re sh o ld  d o s e -  
re s p o n s e . Is  it b e ing  rep a ire d  
by MGMT a t s u b - th re s h o ld  
d o s e s ?  T est th is  by MGMT 
inhibition
3. MGMT INHIBITION BY PRE-TREATMENT WITH O'BENZYLGUANINE
The e ffect of MGMT inh ib ition  on percentage GC-»AT m u ta tio n s  a t 
the  NOEL and M utation frequency (MF);
■+MGMT
■-MGMT Loss of MGMT 
in c re a s e s  both  
th e  p ropo rtion  of 
GC->AT c h a n g e s  
an d  th e  m u ta tio n  
freq u en c y  a t th e  
NOEL
I (0.0075 pg/ml MNU)
MGMT EXPRESSION OVER THRESHOLD DOSE-RESPONSE
T h e re  is no in c re a s e  in 
sy n th e s is  of new  
MGMT.
T h e re  is a  fin ite  
a m o u n t w ithin th e  cell 
an d  on ce  it is u se d  up 
it is n o t rep laced  an d  
b ec o m e s  SATURATED
average 1hour
O  2.00
Lowest p=0,08 nul 
hypothesis of no 
change cannot be
-C o n clu s ion s---------------------------------------
1. The HPRT assay quantifies mutations. We observed that 
MNU elicits a NOEL at 0 .0075|jg /m l for mutation induction
2. Sequence analysis at the HPRT locus shows a marked increase in 
GC->AT changes above the NOEL. This mutation is attributed to 
methylation at guanine ( 0 6MeG) which is repaired by MGMT.
3. Inhibition of MGMT increases MF and GC-»AT at sub­
threshold doses. This provides evidence that MGMT is the  
repair protein responsible for MNU threshold by repairing 
OeMeG, thereby preventing GC-»AT changes at low d oses but 
not at high doses.
References;
Doak e t a / (2007) Cancer R es. 67 ;3904-3911  
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Dethylstilboestrol
Ototoxicity
It vitro micronucleus test 
Vnblastine
The known aneugens vinblastine and diethylstilboestrol (DES) were tested in the in vitro  micronucleus 
assay, with and without cytokinesis block in Chinese hamster CHO cells, at the laboratories of Swansea 
University, Swansea, UK. These experiments were carried out to determine the suitability of the cell 
death and cytostasis measures used in the assay, as recommended in the draft OECD Test Guideline 487, 
2007. Both compounds were positive in the assay without cytokinesis block at concentrations giving 
approximately 50% or less cell death and cytostasis, using relative population doublings and relative 
increase in cell counts. Moreover, both compounds were positive in the assay with cytokinesis block at 
concentrations giving approximately 50% cell death and cytostasis, using replicative index. Vinblastine 
was also positive for mitotic slippage, causing micronuclei in mononucleate cells with cytokinesis block. 
Relative population doublings and relative increase in cell counts were appropriate measures of cell 
death and cytostasis for the non-cytokinesis block in vitro  micronucleus assay. In the cytokinesis blocked 
micronucleus assay, replicative index and cytokinesis block proliferation index were suitable cell death 
and cytostasis measures.
© 2009 Elsevier B.V. All rights reserved.
In tro d u c tio n
» This investigation is part of an inter-laboratory exercise to assess 
1 e  suitability of the cell death and cytostasis measures used in the 
m vitro micronucleus assay, as recommended in the draft OECD Test 
M Jideline 4 8 7 ,2 0 0 7  [ 1 ]. The main aim was to establish whether rel­
iv e  population doubling (RPD) and relative increase in cell count 
fl ICC) are appropriate [2],
In Swansea University w e tested the known aneugens vinblas- 
a n d  diethylstilboestrol (DES). Both compounds are mitotic 
I  indie poisons and they w ere both tested in CHO cells in the 
J e s e n c e  and absence of cytokinesis block using cytochalasin-B 
Jyto-B). RICC, RPD and relative cell counts (RCC) were used to 
Measure cell death and cytostasis in the absence of cytokinesis 
Dck while replicative index (RI) was used in the cytokinesis block 
M ic ro n u c le u s  (CBMN) assay.
Materials and methods
Avarice Laboratories Limited purchased and supplied the test chemicals for 
mg 'n Lhe in vitro micronucleus assay in the presence and absence of Cyto-B.
'383
do
Corresponding author. Tel.: +44 1792 295158. 
nai address: g.johnson@swansea.ac.uk ( G . E .Johnson).
2.1. Test chemicals
Vinblastine and DES were the test chemicals. Vinblastine was dissolved in 
dimethyl sulfoxide (DMSO) and DES was dissolved in 1% ethanol.
2.2. Cell line and culture conditions
Chinese hamster ovary (CHO) cells were obtained from HPACC (European Col­
lection of Cell Cultures, Health Protection Agency. Porton Down. Salisbury, Wiltshire, 
UK). The expected karyotype was hypodiploid, modal no. 20, and the average cell 
doubling time was approximately 14-17 h. Cells were cultured in Ham’s FI 2 (Gibco, 
Invitrogen UK), 2mM glutamine (Gibco, Invitrogen UK) 10% foetal bovine serum  
(FBS, Sigma-Aldrich) and maintained at 37 °C in a humidified atmosphere of 5% C02
2.3. Treatment with test chemicals
Six-well treatment plates were set up that contained 5 x  104 cells/mL in each 
well, suspended in 3 mL culture medium, and these were treated with vinblastine 
for 3 h followed by 21 h growth, or with DES for 24 h. Test chemicals and solvents 
were added to the cell cultures at 1% (v/v). Each test agent concentration and solvent 
control was repeated, with at least duplicate treatment flasks being prepared for 
each test concentration. 3 p,g/mL of Cyto-B was added to each treatment flask at the 
same time as the test chemical for DES treatment, and for the 21 h growth period 
for the vinblastine treatment in the CBMN assay. However, Cyto-B was omitted for 
the non-cytokinesis block method.
2.4. Preparation and scoring o f slides for micronuclei determination
Microscope slides were prepared by spinning 1.5 x  104 cells onto their surface 
in a Cytospin (ThermoShandon; 200 rpm for 8 min).They were air dried, fixed in 90%
10 i7n8/S ' See front matter ® 2009 Elsevier B.V. All rights reserved. 
' O16/j-mrgentox.2009.07.014
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ianol and stained with Giemsa (CAS number: 51811-82-6). Where possible, a 
of a t  l e a s t  1000 cell per replicate culture were examined for the presence of 
o nu dei. Fisher’s exact test was used to determine the significance of the com- 
;on b e tw e e n  treated cultures and negative controls, using p< 0.05 or p< 0.001 
reappropriate (Tables 1 and 2; Figs. 1 and 2).
M ethods used to determine cell death and cytostasis in the absence of
:halasin-B
Methods were as described by Lorge et al. [3] and Kirkland [2], namely:
■lative c e ll c o u n t  (R C C )
RCCwas determined as:
n a l  c o u n t  treated cultures ^ l0Q 
n a f c o u n t  control cultures 
;la t iv e  increase in cell count (RICC)
R1CC was determined as:
lcrease in number of cells in treated cultures (final -  starting) 
creases in number of cells in control cultures (final -  starting) *
la t iv e  population doubling (RPD)
RPD was determined as:
jm b erof population doublings in treated cultures  ^
amber o f  population doublings in control cultures
Mation doubling =
[log(post-treatment cell number/initial cell number)] 
log2
2 2 - 
20  ■ 
1 8 -
Cyto-B. Rl. %MNBN 
I No Cyto-B. RICC. %MNMONO 
] No Cyto-B. RCC. %MNMONO 
I No Cyto-B. RPD. %MNMONO
% Toxicity - Calculated as a 
percentage reduction from test article r -  
dose to concurrent control value
11 i I
3H: I 3
0.8 1 0 0.8 1 2 0 0.8 1 2 
Vinblastine (pg/ml)
o 0.8 1
Fig. 1. Vinblastine: 3 + 21 h, -S-9, micronucleus data. Toxicity, cell death and cytosta­
sis: RCC, relative cell count; RICC, relative increase in cell counts; RPD, relative 
population doubling: Rl, replicative index: “ ‘significant increase above control 
(p< 0.001).
I (Method u s e d  to determine cell death and cytostasis in the presence of
pasin-B
i,| R eplicative i n d e x  (Rl)_________________________________________________________ __
Method was described by Kirsch-Volders et al. [4]. 
was determined as:
No. binucleated cells +  2 x no. multinucleate cells)/total number of cells treated cultures 
No. binucleated cells +  2 x no. multinucleate cells)/total number of cells control cultures
and cytostasis, as measured by Rl in the cytokinesis block method. 
When testing vinblastine in CHO cells, RICC and Rl overestimated  
cell death and cytostasis.
100
H «esults
JtVinblastine
Insults for vinblastine are shown in Table 1 and Fig. 1. Signif- 
N  increases in the number of micronucleated cells were seen 
pneentrations giving approximately 30% or less cell death and 
tasis as measured by RPD, RCC and RICC, when assessed using 
'^on-blocked micronucleus assay. There were also significant 
ases in both the percentage of micronuclei in binucleate cells 
) and in mononuclear cells (%MNMONO) at 64% cell death
iblei
Inb lasi
3.2. D ie th y ls tilb o e stro l (DES)
Results for DES are shown in Table 2 and Fig. 2. Significant 
increases in the number of micronucleated cells were seen at 
concentrations giving approximately 50% or less cell death and 
cytostasis as measured by RPD, RCC and RICC, when assessed using 
the non-cytokinesis blocked method. However, RICC overestimated  
cell death and cytostasis, and RCC underestimated cell death and 
cytostasis. There was also a significant increase in %MNBN but not
fine, 3 + 21-h genotoxicity, cell death and cytostasis results.
With Cyto-B
RPD RCC RICC %MN MONO Rl %MN BN %MN MONO
0
1.43
1.35
1.58
0 0 0 1.35 0 2.01 1.47
0.8
1.09
1.21
18 21 29 7.29'” 64 9.84'" 3.51’’’
11
0.89 22 25 35 9.96'"
67 15.72"’ 3.44’”
2 1.28
0.72 49 48 65 10.28"’
81 13.97’" 5.05”*
0.80
3-9133 TrvT/         “ ~ ppn relative population doubling; Rl, replicative index (binucleates); MN, micronuclei;I  mon /m L  RCC. relative cell count; RICC, relative increase in  cell counts; RPD, relative popuid
i^8nifica°!1UC*eate ce**s: BN- binucleate cells; NS, not scored. 
n lncrease above control (p< 0.001).
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Table 2
DES, 24-h genotoxicity, cell death and cytostasis results.
Day 1 replicate cell counts (x l0 4/mL) Without Cyto-B With Cyto-B
RPD RCC RICC %MN/MONO Rl %MN/BN %MN/MONO
4.78
5.64
0 0 0 1.36 0 1.79 1.85
3.82
5.38
3.60
4.44
15 18 19 1.28 17 3.33“* 0.73
4.30
4.32
20 12 25 2.061 25 5.48"* 1.71
3.89
3.65
39 23 47 2.87“* 32 9.79*** 2.10
1.07
1.59
NS 78 NS 3.89“ * 97 9.31**’ 2.05
B a se lin e  = 2.5 x  104/mL RCC, relative cell count; RICC, relative increase in cell counts; RPD, relative population doubling; Rl, replicative index (binucleates); IVIN, micronuclei; 
dONO, mononucleate cells; BN, binucleate cells; NS, not scored, 
t p = 0 .0 5 .
Significant increase above control (p< 0.001).
Cyto-B: Rl %MNBN 
»  No Cyto-B: RICC: %MNMONO 
0 No Cyto-B: RCC. %MNMONO 
a  No Cyto-B: RPD %MNMONO
% Toxicity - C alculated a s  a  p e rc en ta g e  
reduction from  te s t article c lose to 
concu rren t control v b I u b
47* 23%
2 3 4  0 2 3 4 8
DES G/g/ml)
Fig. 2. DES: 24 h, -S-9, micronucleus data. Toxicity, cell death and cytostasis; RCC, 
relative cell count; RICC, relative increase in cell counts; RPD, relative population 
doubling; Rl, replicative index; “ ’significant increase above control (p < 0.001).
XMNMONO at concentrations giving 50% or less cell death and 
cytostasis as measured by Rl, in the cytokinesis block method.
4. Discussion
Both vinblastine and DES gave significant increases (p <  0.001)
■ roicronucleated mononucleated cells at concentrations that pro­
ceed approximately 50% cell death and cytostasis or less as 
calculated using RPD, RICC and RCC. Therefore, both vinblastine and 
BES were positive at an acceptable level of cell viability using any 
°ne of these measures of cell death and cytostasis, along with the 
n°n-cytokinesis block in v itr o  micronucleus assay. These data are 
a'so 'n line with previous publications which show that RCC gen- 
eral'y underestimates cell death and cytostasis, and RICC genei ally 
°Verestimates cell death and cytostasis when the three measures 
are compared to one another [3,5].
The tests w ere carried out both with and without cytokine- 
S's block in CHO cells, and both versions of the assay correctly 
' entified vinblastine and DES as genotoxic chemicals. However 
t0r DES (Table 2, Fig. 2) the lower doses of 2 and 3|xg/mL were 
nat significant for %MNMONO either with or without cytokinesis 
°^> but were significant at 4 |xg/mL w ithout cytokinesis block. 
s ^MNMONO w ith cytokinesis block are known to be a measure
I !T hFr»4 .:_  t .  . . . . . .  .1 _ n r r  Ar\c* c  n n f• i i n  t K i i  d i u l  d i  m i w v h  ^  -  —mitotic slippage [6], these findings indicate that DES does not 
''Ce mitotic slippage in CHO cells at the concentrations tested. 
°w level of %MNMONO w ithout cytokinesis block could also be
due to the nature of the assays, as it has been previously stated that 
“the frequency of MN per cell in binucleate cells is tw ice that w hich  
would be observed in the resulting cells if one allowed the binu­
cleate cell to complete cytokinesis” [7]. Therefore, w hen testing in 
the assay without cytokinesis block, “at least twice the number of 
mononucleate cells should be scored, to observe the same level of 
MN that would occur in binucleate cells scored in the assay w ith  
cytokinesis block" [7]. A further observation is with the Rl follow ­
ing treatment with vinblastine, where the level of cell death and 
cytostasis is overestimated compared to the measures used in the 
assay without cytokinesis block. This is most likely because by vin­
blastine blocks mitosis through aberrant centrosomes [8] resulting 
in an artifactual high level of mononucleate cells compared to bin­
ucleate cells. There was also a high level of mitotic slippage induced 
vinblastine, as seen by significant levels of %MNMONO at each test 
concentration presented in Table 1 and Fig. 1.
Our findings show that RICC and RPD were appropriate m ea­
sures of cell death and cytostasis for the non-cytokinesis blocked 
in v itro  micronucleus assay when testing the model aneugens vin­
blastine and DES in CHO cells.
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G lo s s a ry
Alkylating agents-A g ro u p  o f  h a z a rd o u s  c o m p o u n d s  in  th e  e n v iro n m e n t. U p o n  
re a c tio n  in  a q u e o u s  so lu tio n s , o r  to  D N A  o r  p ro te in s  tr a n s fe r  a n  a lk y l g ro u p  (e .g . 
M N U ).
Alkyl group-A fu n c tio n a l g ro u p  m a d e  o f  o n ly  c a rb o n  a n d  h y d ro g e n  p re s e n t  o n  
o rg a n ic  c o m p o u n d s  e .g . M e th y l CH3.
Alkylation-A c h e m ic a l re a c tio n  w h e re b y  an  a lk y l g ro u p  re p la c e s  h y d ro g e n  o f  a n  
o rg a n ic  s tru c tu re .
Assay-a s tru c tu re d  e x p e rim e n t.
Base substitution-A g e n e  le v e l m u ta tio n  th a t  c h a n g e s  th e  se q u e n c e  o f  DNA b y  
c h a n g in g  th e  n u c le o tid e . T h e  o p e n  re a d in g  fra m e  is  n o t  a ffe c te d . C a n  b e  c a u s e d  b y  
p o ly m e ra s e  e rro r.
DNA d a m a g e -R e v e r s ib le  c h e m ic a l o r  p h y s ic a l m o d if ic a t io n  to  a  n u c le o tid e  o f te n  
a f fe c tin g  its  b a se -p a ir in g  c a p a b ilitie s .
Hormesis (J-shaped)-A n o n - lin e a r  d o s e -re sp o n se  w h e re  lo w  d o se  h a s  th e  o p p o s ite  
e f fe c t  to  h ig h  d o se . T h is  c a n  b e  o b se rv e d  a s  lo w  d o se  b e n e f i t  a n d  h ig h  d o se  a d v e rs ity .
HPRT assay-A g e n o to x ic ity  a s sa y  u se d  to  q u a n tify  th e  n u m b e r  o f  HPRT m u ta n ts  in  a  
p o p u la t io n  a t in c re a s in g  c o n c e n tra tio n s  o f  te s t  c h e m ic a l.
Methyl nitrosourea (MNU)-A m u ta g e n ic  a lk y la tin g  a g e n t th a t  c a u se s  c o m p a ra tiv e ly  
m o re  0 6M e th y lg u a n in e  th a n  o th e r  a lk y la tin g  a g e n ts .
Methylguanine methyltransferase (MGMT)-A D N A  re p a ir  p ro te in  th a t  re m o v e s  
m e th y l g ro u p  f ro m  0 6M e G  s to c ih im o e tr ic a lly . T h e re b y  p re v e n tin g  G C -> A T  c h a n g e s . 
F o llo w in g  th e  a b s tra c t io n  o f  m e th y l g ro u p  to  a n  in te rn a l c y s te in e  ( c y s l4 5 )  ta rg e t  
M G M T  fo r  p ro te o ly tic  d e g ra d a tio n .
Mutation-A p e rm a n e n t c h a n g e  to  DNA e .g . base substitution, a n u e p lo id y  o r  
s tru c tu ra l a b e rra tio n
Mutation s p e c t r a - Id e n t i fy in g  th e  k in d s , f re q u e n c y  a n d  lo c a tio n  o f  m u ta tio n s  a t a  
d e f in e d  lo cu s .
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Non-linear dose-response-A d o se  re sp o n se  w h e re  re s p o n s e  (e .g . m u ta n t f re q u e n c y )  
d o e s  n o t  in c re a se  p ro p r tin a lly  w ith  d o se . e .g . Threshold dose response a n d  
hormesis.
N7-Methlyguanine (N7MeG)-A c la s to g e n ic  a n d  m u ta g e n ic  a d d u c t th a t is  fo rm e d  
n a tu ra lly  in  h ig h  le v e ls  a n d  fro m  a lk y la tin g  e x p o su re  w ith o u t a d v e rs e  c o n se q u e n c e . 
S e v e re s  a s  a  b io m a rk e r  o f  e x p o s u re  to  a lk y la tin g  a g e n ts .
0 6Methylguanine-A m is c o d in g  a d d u c t fo rm e d  b y  M N U  a n d , to  a  le s se r  e x te n t, o th e r  
a lk y la tin g  a g e n ts . C a u se s  G C -> A T  tra n s itio n s .
Pre-mutagenic le s io n -R e v e rs ib le  D N A  d a m a g e  th a t  r e q u ire s  D N A  re p lic a tio n  to  b e  
f ix e d  a s  p e rm a n e n t  m u ta tio n .
Threshold dose response-A th re sh o ld  in  c o n c e n tra t io n  n e e d s  to  b e  e x c e e d e d  fo r  a n  
in c re a se  in  a d v e rse  re sp o n se . R e p re se n te d  a s  a  s ta tis tic a l NO(A)EL.
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